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CHAPTER ONE
12
GENE RAL  INT RODU CTION   
Skeletal muscle tissue is of importance for ambulation, physical functioning, and overall 
metabolic health. Muscle mass maintenance is dictated by the net balance between muscle 
protein synthesis and muscle protein breakdown rates. Fluctuations in both basal and 
postprandial muscle protein synthesis rates seem to be key in the regulation of skeletal muscle 
maintenance throughout the lifespan. Physical activity and dietary protein intake are the two 
main anabolic stimuli that stimulate muscle protein synthesis [1]. Therefore, structural changes 
in physical activity and food intake can strongly affect muscle mass maintenance. Both a 
decline in physical activity level and a reduction in food intake can lead to a substantial decline 
in muscle mass [2-9]. Even a few days of physical inactivity and/or reduced food intake due to 
injury, hospitalization, and/or disease can strongly reduce muscle mass and strength [3-5, 9]. 
It has been proposed that the progressive loss of muscle mass throughout the lifespan can be 
largely attributed to the muscle and strength loss experienced during such short, successive 
periods of inactivity or muscle disuse [10, 11]. In support, older individuals generally do not 
fully regain all muscle tissue that is lost during such short periods of reduced physical activity 
and/or food intake [10, 12]. Skeletal muscle mass at hospital admission, as well as muscle mass 
loss during hospitalization are strongly associated with clinical outcome [13-16]. It thus seems 
clinically relevant to maintain skeletal muscle mass and strength in both health and disease. 
Intervention strategies to maintain muscle mass are warranted to attenuate muscle loss with 
aging and during acute and chronic disease. The present thesis focusses on nutritional 
strategies to support muscle mass maintenance in both healthy and more clinically 
compromised older populations. 
Muscle mass maintenance  
Skeletal muscle proteins are synthesized and broken down at a rate of approximately 1-2% 
per day. Consequently, maintenance, growth, and loss of skeletal muscle tissue is regulated 
via the balance between muscle protein synthesis and breakdown rates. When net muscle 
protein balance is positive over a sustained period of time, muscle mass increases [1, 11]. 
Conversely, a substantial loss of skeletal muscle mass must be attributed to a structural 
negative net balance with the rate of muscle protein breakdown exceeding the rate of muscle 
protein synthesis [1, 17]. To understand the proposed impairments in muscle protein 
metabolism leading to muscle loss with aging and disease, several research groups have 
assessed basal muscle protein synthesis and/or breakdown rates in both young and older 
subjects [18-20]. Studies assessing basal muscle protein synthesis rates show little or no 
differences between healthy young and older subjects [18-20]. However, it should be noted 
that even minor (undetectable) differences in basal muscle protein synthesis and/or 
breakdown rates may become clinically relevant when calculating their impact over one or 
more decades before sarcopenia becomes evident [1]. As physical activity and food intake are 
the key stimuli for muscle protein synthesis, more recent research has focused on whether 
 
derangements in the muscle protein synthetic response to those stimuli may be responsible 
for the greater loss of skeletal muscle mass with advancing age and chronic metabolic 
diseases.  
 
Figure 1 | A schematic representation of 24 h postprandial muscle protein synthesis rates in: A) a healthy 
condition; B) following a single bout of resistance exercise; C) during aging and/or anabolic resistance; and D) 
following a pre-sleep protein dose as a suggested strategy to increase overnight muscle protein synthesis rates.  
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Postprandial muscle protein synthesis 
Food intake, with dietary protein in particular, acutely increases muscle protein synthesis rates 
(Figure 1A) [1, 19, 21-23]. Following dietary protein ingestion, protein is digested and amino 
acids are absorbed by the gastrointestinal tract resulting in a rapid increase in plasma amino 
acid levels. The postprandial rise in circulating (essential) amino acids results in increased 
delivery to peripheral tissues, including muscle, resulting in increased tissue uptake and 
eventually increased muscle protein synthesis rates [23-25]. As such, protein digestion and 
amino acid absorption kinetics can have a major impact on the postprandial muscle protein 
synthetic response to meal ingestion. It has been well established that the muscle protein 
synthetic response to protein ingestion is dependent on multiple factors such as the amount 
[21, 26-29], type [30-32], source [27, 31, 33], and timing [34-36] of dietary protein ingestion.  
Whereas the ingestion of a meal-like amount of protein (20 g) can substantially increase 
muscle protein synthesis rates in young individuals [20, 28, 29], more protein seems to be 
required to substantially increase postprandial muscle protein synthesis rates in the older 
population [21, 23, 26, 37, 38]. Moreover, a dose-dependent relationship to stimulate muscle 
protein synthesis has been observed in older individuals following the ingestion of graded 
amounts of amino acids or dietary protein [21, 26, 37, 38]. Greater amounts of protein result 
in prolonged hyperaminoacidemia and, as such, may stimulate muscle protein synthesis for a 
more prolonged period [21, 26]. The type of protein that is ingested forms another important 
factor in the postprandial stimulation of muscle protein synthesis. The ingestion of whey 
protein, which is commonly referred to as a ‘rapidly digestible’ protein source, results in a more 
rapid increase in postprandial amino acid levels and subsequent increase in muscle protein 
synthesis rates when compared with the more ‘slowly digestible’ milk protein fraction, casein 
[30, 32]. Apart from the fact that differences in the postprandial muscle protein synthetic 
response to the ingestion of various protein sources is attributed to differences in protein 
digestion and amino acid absorption kinetics, the essential amino acid composition with 
leucine content in particular plays a key role. Essential amino acids do not only serve as 
precursors for muscle protein synthesis, but also act as signaling molecules that activate the 
mTOR signaling pathway, stimulating muscle protein synthesis [23, 24]. Previous work has 
shown that increasing the leucine content in a dose of protein/amino acids can augment the 
postprandial muscle protein synthetic response in older individuals [39-42]. For example, 
differences in the muscle protein synthetic response following the ingestion of animal-based 
protein vs plant-based protein sources or whey vs casein have been attributed to the lower 
essential amino acid/leucine content in these protein sources. In addition, the co-ingestion of 
free leucine with a single bolus of amino acids or protein has been shown to further increase 
muscle protein synthesis rates [39-41].  
More recently, the distribution and timing of protein ingestion throughout the day has been 
suggested to modify net muscle protein balance on a 24-hour basis [34-36, 43]. While some 
research groups showed increased muscle protein synthesis rates and attenuated lean mass 
loss following a more evenly distributed protein intake pattern [7, 34, 35], others have failed 
 
to observe such differences in muscle mass maintenance and net protein balance between a 
balanced and a more skewed protein intake pattern [44-47]. To compensate for a suboptimal 
protein synthetic response to the ingestion of the main meals throughout the day, the 
overnight phase has been suggested as a window-of-opportunity for the simulation of muscle 
protein synthesis (Figure 1D) [48, 49]. Administration of dietary protein during sleep 
effectively increases plasma amino acid concentrations and muscle protein synthesis rates in 
healthy, older subjects [48]. Furthermore, in younger subjects the ingestion of protein in the 
hour(s) prior to sleep has been shown to stimulate overnight muscle protein synthesis, as well 
as, increasing the muscle mass gains during training intervention, supporting its potential as 
a strategy for muscle mass maintenance [48-50]. 
Under normal circumstances dietary protein is mainly consumed as part of a product or meal. 
The macronutrient composition in a meal likely modulates protein digestion and absorption 
kinetics and, as such, postprandial muscle protein synthesis rates [51]. The co-ingestion of 
carbohydrate and fat with protein delays protein digestion and amino acid absorption [52, 53]. 
However, this does not seem substantial enough to impair the postprandial muscle protein 
synthetic response to protein ingestion in older individuals [52-54]. Likewise, although the 
greater insulin response following carbohydrate co-ingestion could theoretically further 
stimulate postprandial muscle protein synthesis, this does not seem to happen [52, 54]. This 
could be explained by the idea that postprandial insulin levels are merely permissive and not 
modulatory for the postprandial rise in muscle protein synthesis rates [52, 55, 56]. Multiple 
other factors in a meal such as the protein matrix [57, 58], food density [37, 59], food texture 
[60, 61], food preparation (procedure and temperature) [60, 61], mastication (chewing) [62], 
body posture [63, 64], micronutrients and other nutritional components (i.e. vitamins, 
polyphenols, n-3-polyunsaturated fatty acids (PUFA), nitrates, and fibers) [65] all have been 
suggested to influence gastric emptying, protein digestion and absorption kinetics, plasma 
amino acid availability, and/or postprandial muscle protein synthesis rates. To summarize, 
Figure 2 provides an overview of the potential factors that need to be taken into account 
when assessing the postprandial response to a meal. 
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Apart from the nutrition-related factors described above, physical activity represents another 
key anabolic stimulus required to maintain skeletal muscle mass. A single session of physical 
activity increases post-absorptive muscle protein synthesis rates for up to 24-48 h [66]. 
However, the muscle protein net balance will remain negative in the absence of food intake 
[66]. Interestingly, physical activity performed prior to food intake further increases the 
postprandial rise in muscle protein synthesis rates and allows more of the ingested protein to 
be used for de novo muscle protein synthesis [67]. Physical activity sensitizes skeletal muscle 
tissue to the anabolic properties of the provided amino acids and, as such, further enhances 
the muscle protein synthetic response to food intake (Figure 1B) [26, 67, 68]. Since the level 
of physical activity and the anabolic properties of food intake have a synergistic effect, it is 
obvious that lifestyle changes over the lifespan are key aspects influencing skeletal muscle 
mass maintenance during healthy aging and disease.  
 
Anabolic resistance  
Several studies have shown that older individuals display a reduced responsiveness to the 
anabolic properties of amino acid and protein administration [23, 69, 70]. In agreement, the 
muscle protein synthetic response to the ingestion of a single bolus of protein is lower in older 
individuals when compared with young [20, 38], a condition that is now referred to as anabolic 
resistance (Figure 1C) [17]. This anabolic resistance to food intake is suggested to represent a 
key factor responsible for the age-related muscle loss. Although the anabolic resistance to 
protein ingestion is most likely dependent on several factors such as health status, habitual 
physical activity level, and/or dietary habits, the mechanisms responsible for the blunted 
muscle protein synthetic response to protein ingestion remain unclear. Impairments in 
postprandial protein handling may reside at various levels [17, 71]; including dietary protein 
digestion [72], amino acid absorption [73], the postprandial hormonal response [74] and 
subsequent microvascular perfusion [75], amino acid uptake in muscle [76], intramuscular 
signaling [23, 77], and/or myofibrillar protein synthesis [20, 38]. For example, differences in 
protein digestion and absorption kinetics following the ingestion of a protein containing meal 
observed between young and older subjects may result in fewer amino acids becoming 
available in the circulation [25, 52, 72]. In addition, splanchnic retention of dietary protein-
derived amino acids, which includes amino acid uptake by gut and liver tissue, may modulate 
postprandial muscle protein synthesis by affecting the postprandial availability of circulation 
amino acids. Moreover, impairments in the postprandial rise in insulin-mediated muscle tissue 
perfusion has been suggested to lower the availability of nutrients and growth factors and, as 
such, the postprandial stimulation of muscle protein synthesis in older and/or insulin resistant 
individuals [56, 78]. Likely, one or more of these processes might be compromised to a certain 
extent with aging, physical inactivity, or the presence of chronic metabolic diseases, thus 
contributing to the accelerated loss of skeletal muscle mass.  
Since physical activity increases the sensitivity of skeletal muscle to the anabolic properties of 
amino acids, physical inactivity likely lowers the anabolic response to protein ingestion. 
Therefore, anabolic resistance may be secondary to a lower level of habitual physical activity. 
In agreement, periods of limb immobilization, whole-body inactivity (bed rest), and periods of 
step reduction have been shown to lower both basal and postprandial muscle protein 
synthesis rates [2, 79, 80]. As such, lifestyle changes that come along with increased age and 
chronic metabolic disease (e.g. changes in daily physical activity levels, exercise, and habitual 
food intake) collectively contribute to the development of anabolic resistance, further 
supporting their role in the loss of skeletal muscle mass (Figure 3).  
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amino acids, physical inactivity likely lowers the anabolic response to protein ingestion. 
Therefore, anabolic resistance may be secondary to a lower level of habitual physical activity. 
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food intake) collectively contribute to the development of anabolic resistance, further 
supporting their role in the loss of skeletal muscle mass (Figure 3).  
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Figure 3 | Anabolic resistance can be attributed to impairments on various levels (left) due to changes in various 
conditions and/or the development of health issues (right). 
Clinical populations  
Hospitalization is generally accompanied by a reduction in food intake and a decline in 
physical activity level [81, 82]. Low levels of food intake during hospitalization increases the 
length of hospital stay, impairs functional outcome, increases the risk for infections, and is 
associated with a higher incidence of hospital readmissions and increased mortality [82-85]. 
Even a short period of hospitalization in older individuals can have detrimental effects, 
accelerating the age-related loss of skeletal muscle mass after discharge [86]. Moreover, 
hospitalization itself likely has a negative effect on muscle tissue, as 4-7 days of bed rest or 
immobilization have been shown to result in a decrease in muscle mass and muscle strength 
in both young and older individuals [3, 4, 87-89]. This muscle disuse atrophy is most rapid 
during the first few days of inactivity and, as such, can pose a major threat on clinical outcome 
during a period of hospitalization [3]. Furthermore, older individuals generally do not regain 
all muscle tissue lost following a period of disuse [90-92]. As such, short successive periods of 
muscle disuse atrophy due to injury or disease can contribute substantially to the overall age-
related loss of muscle mass and strength [10, 12].  
Both the absolute amount of skeletal muscle mass at time of hospital admission as well as the 
amount of muscle loss during hospitalization affect clinical outcomes such as the length of 
hospital stay [14, 16, 93], the ability to perform activities of daily living [81, 94], functional 
 
mobility [81, 93], the incidence of co-morbidities [14, 93], the risk for readmissions [14, 81, 93, 
95], quality of life [96], and mortality rates [14, 81, 93, 95]. Furthermore, the loss of skeletal 
muscle mass, strength, and functional capacity following hospitalization often forms the 
tipping point for older patients to shift from a self-supporting living status to dependency [14, 
86, 97].  
Interventional strategies to attenuate muscle loss  
To support muscle mass maintenance during healthy aging and periods of disease, effective 
interventional strategies should be established aimed at attenuating accelerated muscle loss. 
Muscle tissue loss has been shown to be more rapid in individuals consuming less energy than 
required during a period of bed rest when compared with volunteers who maintain energy 
balance [8]. Therefore, first we need to avoid overall undernutrition by ensuring energy 
balance. Besides energy intake, adequate protein intake is necessary to support muscle mass 
maintenance. Protein recommendations suggest a protein intake level of 1.2-1.5 g·kg-1·day-1 
for older individuals during hospitalization and illness [98, 99]. Since daily protein consumption 
is generally sufficient in the community dwelling, older population [6, 100], habitual protein 
intake levels should be at least maintained or increased during periods of hospitalization. 
Increasing habitual protein intake can be achieved by providing a more protein-dense diet. 
For example, the use of protein-dense foods [101-103], fortification of meals [104, 105], and/or 
the use of oral nutrition supplements (ONS) [106-108] have been shown to effectively increase 
protein consumption in older individuals. Obviously, a proper choice of the ingested dietary 
protein component should be defined by the dose, amount, source, and timing as previously 
described.  
Furthermore, several other nutritional compounds have been described to have anti-catabolic 
or anabolic properties [65]. Potential compounds may include: essential amino acids, 
branched-chain amino acids, specific amino acids such as leucine, arginine or glutamine, β-
hydroxy-β-methylbutyric acid (HMB), creatine, PUFA, nitrates, vitamin D, and/or antioxidants 
[65, 109-111]. Since physical activity sensitizes - and physical inactivity desensitizes – the 
muscle to the anabolic properties of food, optimizing the level of physical activity is essential 
to maximize the anabolic response to food ingestion [2, 67, 79]. Therefore, physical activity 
should be applied in both healthy conditions as well as during periods of muscle disuse and 
disease to increase the muscle protein synthetic response to protein ingestion. For example, 
pre-surgery exercise training, physiotherapy during hospitalization, and/or post-hospital 
rehabilitation programs have been shown to improve physical function and muscle mass 
before, during, and after a period of hospitalization [112, 113]. However, physical activity is, at 
least in some conditions, not always feasible. Therefore, exercise mimetics including 
mobilization, passive training, massage, vibration training, and neuromuscular electrical 
stimulation (NMES) can be applied to further support muscle mass maintenance, strength, and 
functional capacity in patients [114, 115]. Though beyond the scope of this thesis, there is also 
considerable interest in pharmacological anabolic stimulants (such as various androgens, β2-
adrenergic agonists, statins, appetite stimulants, non-steroidal anti-inflammatory drugs, 
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myostatin inhibitors, anabolic steroids, growth hormone, and other therapeutic interventions) 
to offset muscle mass and strength loss in both health and disease [109, 111]. Collectively, 
while there is extensive evidence available on the effect of different interventional strategies 
to support muscle mass maintenance in the older population, more research is required to 
develop effective interventional strategies that can be applied in a clinical setting to attenuate 
muscle mass and strength loss and/or regain muscle mass and functional capacity in older, 
more clinically compromised, populations.  
  
 
A IM  AND THESIS  OUTL INE  
Since muscle mass maintenance is of great clinical relevance in both health and disease, the 
present thesis investigates aspects of muscle protein metabolism in healthy and more clinically 
compromised older populations. To determine the extent of muscle loss during short-term 
hospital admission, we assessed the impact of hospital admission in older patients showing 
substantial muscle atrophy in the 5 days following elective hip replacement surgery (chapter 
2). In chapter 3 we recorded food intake in hospitalized older patients and compared the 
amount of protein that was provided with the amount of protein that was actually consumed 
in these patients. Since there is an accelerated loss of muscle mass in patients with metabolic 
diseases such as obesity, cardiovascular diseases, and type 2 diabetes, we examined our 
hypothesis that older type 2 diabetes patients show impairments in either basal and/or 
postprandial muscle protein synthesis rates (chapter 4). In chapter 5, we investigated whether 
the postprandial muscle protein synthetic response to protein ingestion is reduced in obese 
compared with healthy, lean males. In chapters 6-8, we propose several nutritional strategies 
to support muscle mass maintenance in healthy and more clinically compromised older 
populations. In view of the recent interest in dietary nitrate as a nutritional compound to 
increase vasodilation and improve muscle tissue perfusion, we investigated the impact of 
ingesting a single bolus of dietary nitrate with protein on postprandial muscle protein 
synthesis rates in older type 2 diabetes patients in chapter 6. In chapter 7 we assessed the 
dose-response relationship between the overnight muscle protein synthetic response to 
different amounts of protein ingested prior to sleep. We subsequently investigated the surplus 
benefits of physical activity performed in the evening to increase the overnight muscle protein 
synthetic response to pre-sleep protein ingestion (chapter 8). Finally, in chapter 9, the 
outcome of chapters 2 through 8 are discussed in the light of the existing literature. 
Additionally, the implications of this thesis are discussed and directions for future research are 
formulated.  
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ABSTRACT 
Objectives:  Short successive periods of skeletal muscle disuse have been suggested to 
substantially contribute to the observed loss of skeletal muscle mass over 
the life span. Hospitalization of older individuals due to acute illness, injury, 
or major surgery generally results in a mean hospital stay of 5 to 7 days, 
during which the level of physical activity is strongly reduced. We 
hypothesized that hospitalization following elective total hip arthroplasty is 
accompanied by substantial leg muscle atrophy in older men and women. 
Design and participants:  
Twenty-six older patients (75±1 y) undergoing elective total hip arthroplasty 
participated in this observational study. 
Measurements:   On hospital admission and on the day of discharge, computed tomographic 
(CT) scans were performed to assess muscle cross-sectional area (CSA) of 
both legs. During surgery and on the day of hospital discharge, a skeletal 
muscle biopsy was taken from the m. vastus lateralis of the operated leg to 
assess muscle fiber type-specific CSA. 
Results:  An average of 5.6±0.3 days of hospitalization resulted in a significant decline 
in quadriceps (-3.4±1.0%) and thigh muscle CSA (-4.2±1.1%) in the non-
operated leg (P<0.05). Edema resulted in a 10.3±1.7% increase in leg CSA in 
the operated leg (P<0.05). At hospital admission, muscle fiber CSA was 
smaller in the type II vs type I fibers (3326±253 vs 4075±279 µm2, 
respectively; P<0.05). During hospitalization, type I and II muscle fiber CSA 
tended to increase, likely due to edema in the operated leg (P=0.10). 
Conclusions:  Six days of hospitalization following elective total hip arthroplasty leads to 
substantial leg muscle atrophy in older patients. Effective intervention 
strategies are warranted to prevent the loss of muscle mass induced by short 
periods of muscle disuse during hospitalization. 
 
  
 
 
IN TRODU CTION  
Aging is associated with the progressive loss of skeletal muscle mass and function, termed 
sarcopenia, which is accompanied by a decline in muscle strength and physical capacity, and 
an increased risk of developing chronic metabolic diseases [1, 2]. Various situations such as 
hospitalization or recovery from illness or injury often necessitate a period of physical inactivity 
that is accompanied by the accelerated loss of muscle mass and muscle strength [3-5]. Such 
disuse-induced muscle loss contributes to negative health outcomes, including a reduction in 
the ability to perform activities of daily living, increased incidence of complications and 
subsequent need for readmission, decreased quality of life, and an increased risk for 
permanent institutionalization [6-8]. This is likely associated with the fact that older individuals 
generally do not regain all muscle tissue that was lost during a period of disuse [9-11]. As such, 
accumulation of (short) periods of muscle disuse that occur throughout the life span may 
contribute substantially to the etiology of sarcopenia [3, 4, 12].  
Muscle disuse has been studied in healthy young and older subjects using different lab-based 
models such as limb immobilization or bed rest. Studies investigating muscle disuse atrophy 
models in humans generally apply a relatively prolonged period of limb immobilization or bed 
rest (>10 days) to ensure measurable muscle loss in a research setting [13-16]. Recently, we 
[17-19] as well as others [20-22] showed that even a few days of disuse already leads to 
significant losses in muscle mass and strength in both young and older individuals. At present, 
hospitalization in older patients ranges between 5 and 13 days, [23, 24] during which the level 
of physical activity is strongly reduced [25, 26]. As such, short-term hospitalization might be 
accompanied by a significant loss in skeletal muscle mass and strength in older patients, 
posing a major threat to fully regaining physical function after discharge. Muscle disuse 
models are often used to predict changes in muscle mass during hospitalization. However, the 
impact of surgery, associated physical and mental stress, and reduced food intake during 
hospitalization are likely to further aggravate skeletal muscle loss in clinical practice. Although 
hospital-based deconditioning is well recognized as a negative consequence of 
hospitalization, there is a paucity of data on the actual loss of muscle tissue during the 
hospitalized period [27-29]. Moreover, studies so far have largely focused on rather severe 
conditions, such as cancer cachexia and critical illness [29-35], leaving a gap in knowledge on 
the negative impact of (planned) short-term hospitalization in relatively healthy older patients. 
Elective total hip arthroplasty (THA), a surgical procedure for end-stage osteoarthritis, has 
evolved into a reliable and suitable surgical procedure to gain pain relief and improve quality 
of life and function of patients within 3 months up to 2 years after surgery [36, 37]. Despite 
the success in treating the osteoarthritic joint, THA patients suffer from muscle atrophy [38-
40], reduced muscle strength [40-42], and mobility impairment [40, 42, 43] in the longer term. 
This places a huge burden on the health care system, which will take on dramatic proportions 
given the expected doubling of the number of joint arthroplasties over the coming years [37, 
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44]. To what extent muscle disuse atrophy occurs during short-term hospitalization following 
elective total hip replacement surgery is currently unknown.  
The specific aim of the present study was to quantitatively assess the extent of muscle atrophy 
in older hospitalized patients during the first (hospital-based) days of recovery from THA, 
representing a relatively healthy group of older patients entering the hospital for planned 
surgery. Therefore, in the present study, we selected 26 male and female patients who were 
scheduled for THA and assessed skeletal muscle mass and muscle fiber characteristics at 
admission and on subsequent discharge from the hospital.   
 
 
M ETHO DS 
Subjects 
Twenty-six older patients (n = 7 males, n = 19 females, aged ≥65 years) participated in this 
observational study during an average length of hospital stay of 5.6±0.3 days. On hospital 
admission and on the day of discharge, computed tomographic (CT) scans were obtained to 
assess muscle mass (primary outcome measure); no CT scans were taken in n = 6 patients 
because of conflicting medical appointments, inability to mobilize, or pain. During surgery and 
on the day of hospital discharge, a skeletal muscle biopsy was taken from the m. vastus lateralis 
of the (to be) operated leg to assess muscle fiber characteristics (secondary outcome measure). 
In all 26 patients, skeletal muscle biopsies were taken during surgery; however, no muscle 
biopsies were taken at hospital discharge in 8 patients because of excessive edema or at the 
patient’s request. A flowchart of patients’ enrolment is shown in Figure 1.  
 
Figure 1 | Flow diagram of patients’ enrolment procedure. 
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All participants were recruited via the outpatient clinic of the Department of Orthopedic 
Surgery after scheduling an elective THA. Subjects were informed about the nature and risks 
of the experimental procedures before written consent was obtained. The study was part of a 
larger project on the impact of immobility and nutrition on skeletal muscle adaptation during 
hospitalization and approved by the Medical Ethical Committee of the Maastricht University 
Medical Centre+, the Netherlands (registered as NTR3773 at www.trialregister.nl), conformed 
to the standards for the use of human subjects in research as outlined in the latest version of 
the Declaration of Helsinki. 
Protocol 
All eligible subjects were pretested on the day before surgery directly after arrival at the 
hospital ward. Exclusion criteria included age ≤65 years, all comorbidities and use of 
medication interacting with muscle metabolism and mobility of the limbs, such as chronic 
obstructive pulmonary disease, peripheral arterial disease, severe cardiovascular impairment, 
neurological disorders, coagulation diseases, and malignant disease. Height and weight were 
measured and body composition was assessed using dual-energy x-ray absorptiometry 
(Discovery A; Hologic, Bedford, MA). Thereafter, a single-slice CT scan (Brilliance 64, Philips 
Medical Systems, Best, the Netherlands) was performed to assess upper leg muscle cross-
sectional area (CSA). The scanning characteristics were as follows: 120 kV, 300 mA, rotation 
time of 0.75 seconds, and a field of view of 500 mm. With subjects lying supine with their legs 
extended, a 3-mm-thick axial image was taken 15 cm proximal to the top of the patella for 
both legs. The exact scanning position was measured and marked for replication at the time 
of discharge from the hospital. Intramuscular adipose tissue was defined using radiation 
attenuation ranges from -190 to -30 Hounsfield units (HUs), and muscle area of the legs was 
selected between -29 and +150 HU [45], after which the quadriceps muscle was selected by 
manual tracing using ImageJ software (version 1.45d; National Institute of Health, Bethesda, 
MD) [46, 47]. Leg volume measurements were performed using anthropometric 
measurements on both legs [48].  
Information regarding quality of life, habitual physical activity, and nutritional status were 
evaluated using several questionnaires: Short Form-36 [49], Physical Activity Scale for the 
Elderly [50, 51], Mini Nutritional Assessment (MNA) [52], Malnutrition Universal Screening Tool 
[53], and Mini-Mental State Examination [54]. Maximal handgrip strength was measured using 
a JAMAR handheld dynamometer (model BK-7498, Fred Sammons Inc., Burr Ridge, IL). Grip 
strength was measured 3 times (with a 10-second interval) with each hand, and the highest 
value for both hands was reported. Measurements of handgrip strength were taken with the 
patient sitting on a chair with the elbow in 90° flexion and the forearm in the neutral position. 
On the day of surgery, a first muscle biopsy was collected from the m. vastus lateralis of the 
operated leg during the surgical procedure. A second muscle biopsy was taken from the same 
leg on the day of hospital discharge. In addition, on the day of hospital discharge, a second 
CT scan was performed, and maximal handgrip strength and leg volume were assessed. 
 
 
Muscle biopsy  
Skeletal muscle biopsy samples were obtained from the operated leg from the middle region 
of the m. vastus lateralis 15 cm above the patella and approximately 2 cm away from the fascia 
by means of the percutaneous needle biopsy technique described by Bergström et al. [55]. 
Biopsies were spaced by 1 to 2 cm, and the order of distal and proximal incision was 
randomized to minimize any potential systematic effect of the previous biopsy. Muscle 
biopsies were carefully freed from any visible fat and blood, embedded in Tissue-Tek (Sakura 
Finetek Europe B.V., Zoeterwoude, the Netherlands), and rapidly frozen in liquid nitrogen 
cooled isopentane and stored at -80 °C for subsequent histochemical analysis. 
Diet and physical activity 
Nutritional intake was ad libitum during hospitalization, except from the perioperative period 
since all patients were operated in a fasted state. Nutritional intake was monitored during 
hospitalization on a thrice-daily basis. Hospital meals were provided at 3 strict timeslots every 
day-breakfast, lunch, and dinner. In between the meals, patients were provided with hot 
and/or cold drinks 3 times a day. On the serving tray, patients received a description of their 
ordered menu, which was collected for the study. Products that were not consumed were 
recorded. Total energy [mega joules (MJ)] and protein [grams and energy % (En%)] contents 
were calculated for all consumed food based on product specifications provided by the food 
suppliers and the Dutch Food Consumption Database 2016 (NEVO; RIVM, Bilthoven, the 
Netherlands). Food intake data were available for 23 patients. Dietary intake was only reported 
when complete data for all 3 main meals was available; separate data were calculated for the 
day of surgery (n = 13) and combined for the hospitalization days following surgery (n = 23). 
During hospital stay, patients were encouraged to mobilize as soon as possible and received 
physiotherapy training twice daily for 20 minutes from the first day after surgery onward. 
Patients were allowed to also mobilize without supervision from nursing staff or physical 
therapists from day 1 onward; however, from observations made while being on the nursing 
ward, patients mainly performed sedentary behavior outside of the therapy sessions (i.e., 
sitting in and around their hospital bed, except for toilet visits and bedside transfers). 
Immunohistochemistry 
Frozen muscle biopsies were cut into 5-mm-thick cryosections using a cryostat at _20_C, and 
thaw mounted on uncoated precleaned glass slides. Samples from pre- and post surgery were 
mounted together on the same glass slide. Care was taken to properly align the samples for 
cross-sectional fiber analyses. Muscle biopsies were stained for muscle fiber type 
determination, that is, type I and type II muscle fibers. Details of the analytical procedures have 
been described previously [56]. First, antibodies were directed against laminin (polyclonal 
rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and myosin heavy 
chain-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA). Images 
were visualized and automatically captured at x 10 magnification with a fluorescent 
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strength was measured 3 times (with a 10-second interval) with each hand, and the highest 
value for both hands was reported. Measurements of handgrip strength were taken with the 
patient sitting on a chair with the elbow in 90° flexion and the forearm in the neutral position. 
On the day of surgery, a first muscle biopsy was collected from the m. vastus lateralis of the 
operated leg during the surgical procedure. A second muscle biopsy was taken from the same 
leg on the day of hospital discharge. In addition, on the day of hospital discharge, a second 
CT scan was performed, and maximal handgrip strength and leg volume were assessed. 
 
 
Muscle biopsy  
Skeletal muscle biopsy samples were obtained from the operated leg from the middle region 
of the m. vastus lateralis 15 cm above the patella and approximately 2 cm away from the fascia 
by means of the percutaneous needle biopsy technique described by Bergström et al. [55]. 
Biopsies were spaced by 1 to 2 cm, and the order of distal and proximal incision was 
randomized to minimize any potential systematic effect of the previous biopsy. Muscle 
biopsies were carefully freed from any visible fat and blood, embedded in Tissue-Tek (Sakura 
Finetek Europe B.V., Zoeterwoude, the Netherlands), and rapidly frozen in liquid nitrogen 
cooled isopentane and stored at -80 °C for subsequent histochemical analysis. 
Diet and physical activity 
Nutritional intake was ad libitum during hospitalization, except from the perioperative period 
since all patients were operated in a fasted state. Nutritional intake was monitored during 
hospitalization on a thrice-daily basis. Hospital meals were provided at 3 strict timeslots every 
day-breakfast, lunch, and dinner. In between the meals, patients were provided with hot 
and/or cold drinks 3 times a day. On the serving tray, patients received a description of their 
ordered menu, which was collected for the study. Products that were not consumed were 
recorded. Total energy [mega joules (MJ)] and protein [grams and energy % (En%)] contents 
were calculated for all consumed food based on product specifications provided by the food 
suppliers and the Dutch Food Consumption Database 2016 (NEVO; RIVM, Bilthoven, the 
Netherlands). Food intake data were available for 23 patients. Dietary intake was only reported 
when complete data for all 3 main meals was available; separate data were calculated for the 
day of surgery (n = 13) and combined for the hospitalization days following surgery (n = 23). 
During hospital stay, patients were encouraged to mobilize as soon as possible and received 
physiotherapy training twice daily for 20 minutes from the first day after surgery onward. 
Patients were allowed to also mobilize without supervision from nursing staff or physical 
therapists from day 1 onward; however, from observations made while being on the nursing 
ward, patients mainly performed sedentary behavior outside of the therapy sessions (i.e., 
sitting in and around their hospital bed, except for toilet visits and bedside transfers). 
Immunohistochemistry 
Frozen muscle biopsies were cut into 5-mm-thick cryosections using a cryostat at _20_C, and 
thaw mounted on uncoated precleaned glass slides. Samples from pre- and post surgery were 
mounted together on the same glass slide. Care was taken to properly align the samples for 
cross-sectional fiber analyses. Muscle biopsies were stained for muscle fiber type 
determination, that is, type I and type II muscle fibers. Details of the analytical procedures have 
been described previously [56]. First, antibodies were directed against laminin (polyclonal 
rabbit anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and myosin heavy 
chain-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA). Images 
were visualized and automatically captured at x 10 magnification with a fluorescent 
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microscope equipped with an automatic stage (IX81 motorized inverted microscope; Olympus, 
Hamburg, Germany). Quantitative analyses were performed using ImageJ version 1.46d 
software package (version 1.45d, National Institute of Health [47]). All image recordings and 
analyses were performed by an investigator blinded to subject coding. Muscle fiber type (fiber 
%) and fiber CSA were measured for each separate muscle fiber. As such, mean muscle fiber 
size was calculated for the type I and type II muscle fibers separately. Mean numbers of 476±72 
and 504±70 muscle fibers were analyzed in the biopsy samples collected during surgery and 
(on average) 5 days following surgery, respectively. 
Statistics 
All data are expressed as mean± standard error of the mean. A sample size of n = 16 was 
calculated assuming a decline of 2% (standard deviation 2%) in muscle CSA based on CT scans, 
using an α-level of 0.05 and 95% power, based upon previous disuse studies [17, 19, 22]. To 
err on the side of caution, we aimed to include 20 patients for our primary outcome; 26 
patients were finally needed to obtain full data sets (pre and post) for CT scans (Figure 1). 
Data were analyzed using paired samples t-tests to assess changes from pre- (hospital 
admission) to post-hospitalization (discharge). Muscle CSA and muscle fiber characteristics 
were analyzed using repeated measures analysis of variance with time (pre vs post) and leg 
(nonoperated or operated) or fiber type (type I vs II) as within-subject factors. Because of 
significant ‘time x leg’ interaction, paired samples t-tests were used to assess changes for each 
leg separately. Statistical significance was set at P<0.05. All calculations were performed using 
SPSS Statistics (version 24.0, IBM Corp., Armonk, NY). 
 
  
 
 
R ESULTS  
Patients’ characteristics and body composition  
Patients’ characteristics and body composition data are shown in Table 1. Total lean body 
mass (presented in absolute and relative numbers) averaged 47.6±1.9 kg (63.0±1.1%), 
appendicular lean mass: 19.9±1.0 kg (26.2±0.7%), and fat mass: 25.5±1.1 kg (34.0±1.2%). 
Skeletal muscle mass index (SMMI) was calculated for women (n=19) and men (n=7) 
separately and averaged 7.0±0.2 in women and 9.2±0.4 kg·m-2 in men. None of the patients 
were classified as malnourished based on the MNA (average score 26.2±0.4). However, 4 of 
the patients were classified as ‘high risk for malnutrition’ (a Malnutrition Universal Screening 
Tool score 2 based on recent weight loss) on hospital admission. Scores for the Short Form-
36, Physical Activity Scale for the Elderly, and Mine-Mental State Examination are depicted in 
Table 1. Based on the MMSE, none of the patients presented cognitive impairments at hospital 
admission. Handgrip strength before surgery averaged 26.4±1.8 kg and 25.0±1.6 kg in the 
right and left hand, respectively, and did not change during hospitalization (both P>0.05).  
Table 1 | Patients’ baseline characteristics. 
 Patients (n = 26) 
Age (y) 74.7±0.8 
Gender: male / female (n) 7/19 
Hospitalization duration (d) 5.6±0.3 
Weight (kg) 73.9±2.3 
BMI (kg·m-2) 28.0±0.8 
Lean body mass (kg and %)  47.6±1.9 (63.0±1.1%) 
Fat mass (%) 34.0±1.2 
SMMI (kg·m-2) 7.6±0.3 
Anesthesia: epidural / general anesthesia (n) 12/14 
MNA score  26.2±0.4 
SF-36 score:  physical component summary 
                      mental component summary 
45.8±3.4 
54.8±4.3 
MMSE score  28.4±0.4 
PASE  101.7±14.9 
BMI: body mass index; MMSE: Mini Mental State Examination; MNA: Mini Nutritional Assessment, PASE: Physical 
Activity Scale for the Elderly; SF-36: Short Form-36; SMMI: skeletal muscle mass index. Values are expressed as 
mean ± standard error of the mean. 
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microscope equipped with an automatic stage (IX81 motorized inverted microscope; Olympus, 
Hamburg, Germany). Quantitative analyses were performed using ImageJ version 1.46d 
software package (version 1.45d, National Institute of Health [47]). All image recordings and 
analyses were performed by an investigator blinded to subject coding. Muscle fiber type (fiber 
%) and fiber CSA were measured for each separate muscle fiber. As such, mean muscle fiber 
size was calculated for the type I and type II muscle fibers separately. Mean numbers of 476±72 
and 504±70 muscle fibers were analyzed in the biopsy samples collected during surgery and 
(on average) 5 days following surgery, respectively. 
Statistics 
All data are expressed as mean± standard error of the mean. A sample size of n = 16 was 
calculated assuming a decline of 2% (standard deviation 2%) in muscle CSA based on CT scans, 
using an α-level of 0.05 and 95% power, based upon previous disuse studies [17, 19, 22]. To 
err on the side of caution, we aimed to include 20 patients for our primary outcome; 26 
patients were finally needed to obtain full data sets (pre and post) for CT scans (Figure 1). 
Data were analyzed using paired samples t-tests to assess changes from pre- (hospital 
admission) to post-hospitalization (discharge). Muscle CSA and muscle fiber characteristics 
were analyzed using repeated measures analysis of variance with time (pre vs post) and leg 
(nonoperated or operated) or fiber type (type I vs II) as within-subject factors. Because of 
significant ‘time x leg’ interaction, paired samples t-tests were used to assess changes for each 
leg separately. Statistical significance was set at P<0.05. All calculations were performed using 
SPSS Statistics (version 24.0, IBM Corp., Armonk, NY). 
 
  
 
 
R ESULTS  
Patients’ characteristics and body composition  
Patients’ characteristics and body composition data are shown in Table 1. Total lean body 
mass (presented in absolute and relative numbers) averaged 47.6±1.9 kg (63.0±1.1%), 
appendicular lean mass: 19.9±1.0 kg (26.2±0.7%), and fat mass: 25.5±1.1 kg (34.0±1.2%). 
Skeletal muscle mass index (SMMI) was calculated for women (n=19) and men (n=7) 
separately and averaged 7.0±0.2 in women and 9.2±0.4 kg·m-2 in men. None of the patients 
were classified as malnourished based on the MNA (average score 26.2±0.4). However, 4 of 
the patients were classified as ‘high risk for malnutrition’ (a Malnutrition Universal Screening 
Tool score 2 based on recent weight loss) on hospital admission. Scores for the Short Form-
36, Physical Activity Scale for the Elderly, and Mine-Mental State Examination are depicted in 
Table 1. Based on the MMSE, none of the patients presented cognitive impairments at hospital 
admission. Handgrip strength before surgery averaged 26.4±1.8 kg and 25.0±1.6 kg in the 
right and left hand, respectively, and did not change during hospitalization (both P>0.05).  
Table 1 | Patients’ baseline characteristics. 
 Patients (n = 26) 
Age (y) 74.7±0.8 
Gender: male / female (n) 7/19 
Hospitalization duration (d) 5.6±0.3 
Weight (kg) 73.9±2.3 
BMI (kg·m-2) 28.0±0.8 
Lean body mass (kg and %)  47.6±1.9 (63.0±1.1%) 
Fat mass (%) 34.0±1.2 
SMMI (kg·m-2) 7.6±0.3 
Anesthesia: epidural / general anesthesia (n) 12/14 
MNA score  26.2±0.4 
SF-36 score:  physical component summary 
                      mental component summary 
45.8±3.4 
54.8±4.3 
MMSE score  28.4±0.4 
PASE  101.7±14.9 
BMI: body mass index; MMSE: Mini Mental State Examination; MNA: Mini Nutritional Assessment, PASE: Physical 
Activity Scale for the Elderly; SF-36: Short Form-36; SMMI: skeletal muscle mass index. Values are expressed as 
mean ± standard error of the mean. 
 40
 
 
Leg muscle mass 
In the nonoperated leg, CSA of the thigh muscles declined by 4.2±1.1% (from 11,071±577 to 
10,565±528 mm2) during hospitalization (P=0.001; Figure 2). In accordance, quadriceps 
femoris CSA in the nonoperated leg declined by 3.4±1.0% from hospital admission to hospital 
discharge (from 5285±320 to 5095±303 mm2, respectively, P=0.004; Figure 2). Total thigh 
volume assessed by CT scans decreased by 2.8±1.2% during hospitalization in the 
nonoperated leg (from 20,477±909 to 19,841±876 mm2, respectively, P=0.03). 
Anthropometric whole leg volume in the nonoperated leg did not change from hospital 
admission to hospital discharge (7436±386 and 7646±335 cm3, respectively, P=0.54). Average 
muscle radiation attenuation values in the nonoperated leg decreased by 6.4±1.0% in the 
thigh muscles and 6.4±1.1% in the quadriceps femoris (from 39.5±1.4 to 37.0±1.5 HU and 
from 45.0±1.2 to 42.2±1.4 HU, respectively, both P<0.001). 
At hospital admission, both thigh and quadriceps muscles CSA were lower in the operated leg 
(10,359±599 and 4740±332 mm2) when compared with the nonoperated leg (11,071±577 and 
5285±320 mm2; both P<0.05). In the operated leg, thigh muscle CSA increased by 8.0±1.7% 
during hospitalization (from 10,359±599 to 11,095±584 mm2, P<0.001) and quadriceps CSA 
increased by 12.2±2.9% when compared with baseline values (from 4740±332 to 5209±308 
mm2, P<0.001). In accordance, total thigh CSA of the operated leg assessed by CT scans 
increased during hospital stay with 10.3±1.7% (from 20,185±867 mm2 at hospital admission 
to 22,154±897 mm2 at hospital discharge, respectively, P<0.001). Anthropometric whole leg 
volume increased by 16.2±4.6% during hospitalization (from 7606±387 to 8715±420 cm3, 
respectively, P<0.001). Average muscle radiation attenuation in the operated leg decreased by 
14.1±1.7% in the thigh muscles and 14.5±1.8% in quadriceps femoris CSA (from 37.4±1.5 to 
32.3±1.6 HU and from 42.9±1.4 to 37.0±1.7 HU, respectively; both P<0.001).  
Total thigh CSA and anthropometric whole leg volume did not differ between legs at hospital 
admission (both P>0.05), but were significantly lower in the nonoperated leg when compared 
with the operated leg at hospital discharge (both P<0.001). Moreover, the change in leg 
volume (both CT and anthropometric measurements) differed between legs (time x leg 
interaction effect, P<0.001). This was likely due to swelling of the operated leg following the 
surgery; therefore, muscle mass changes were only presented graphically for the nonoperated 
leg (Figure 2). Moreover, a significant time x leg interaction effect was observed for muscle 
radiation attenuation in thigh muscles and quadriceps CSA (both P<0.05). HU values in thigh 
muscles and quadriceps femoris were lower in the operated leg when compared with the 
nonoperated leg both at hospital admission and hospital discharge (both P<0.05). 
 
 
 
 
Figure 2 | Muscle cross-sectional area (CSA in millimeters squared) of the quadriceps and thigh musc les of the 
nonoperated leg in older patients (n = 20) undergoing elective total hip arthroplasty, assessed by single-slice CT 
scans taken on the day of hospital admission and on the day of discharge. (A) mean standard error of the mean; 
(B) individual data; (C) mean standard error of the mean of relative decline CSA (in percentage). *Significantly 
different from hospital admission.  
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Leg muscle mass 
In the nonoperated leg, CSA of the thigh muscles declined by 4.2±1.1% (from 11,071±577 to 
10,565±528 mm2) during hospitalization (P=0.001; Figure 2). In accordance, quadriceps 
femoris CSA in the nonoperated leg declined by 3.4±1.0% from hospital admission to hospital 
discharge (from 5285±320 to 5095±303 mm2, respectively, P=0.004; Figure 2). Total thigh 
volume assessed by CT scans decreased by 2.8±1.2% during hospitalization in the 
nonoperated leg (from 20,477±909 to 19,841±876 mm2, respectively, P=0.03). 
Anthropometric whole leg volume in the nonoperated leg did not change from hospital 
admission to hospital discharge (7436±386 and 7646±335 cm3, respectively, P=0.54). Average 
muscle radiation attenuation values in the nonoperated leg decreased by 6.4±1.0% in the 
thigh muscles and 6.4±1.1% in the quadriceps femoris (from 39.5±1.4 to 37.0±1.5 HU and 
from 45.0±1.2 to 42.2±1.4 HU, respectively, both P<0.001). 
At hospital admission, both thigh and quadriceps muscles CSA were lower in the operated leg 
(10,359±599 and 4740±332 mm2) when compared with the nonoperated leg (11,071±577 and 
5285±320 mm2; both P<0.05). In the operated leg, thigh muscle CSA increased by 8.0±1.7% 
during hospitalization (from 10,359±599 to 11,095±584 mm2, P<0.001) and quadriceps CSA 
increased by 12.2±2.9% when compared with baseline values (from 4740±332 to 5209±308 
mm2, P<0.001). In accordance, total thigh CSA of the operated leg assessed by CT scans 
increased during hospital stay with 10.3±1.7% (from 20,185±867 mm2 at hospital admission 
to 22,154±897 mm2 at hospital discharge, respectively, P<0.001). Anthropometric whole leg 
volume increased by 16.2±4.6% during hospitalization (from 7606±387 to 8715±420 cm3, 
respectively, P<0.001). Average muscle radiation attenuation in the operated leg decreased by 
14.1±1.7% in the thigh muscles and 14.5±1.8% in quadriceps femoris CSA (from 37.4±1.5 to 
32.3±1.6 HU and from 42.9±1.4 to 37.0±1.7 HU, respectively; both P<0.001).  
Total thigh CSA and anthropometric whole leg volume did not differ between legs at hospital 
admission (both P>0.05), but were significantly lower in the nonoperated leg when compared 
with the operated leg at hospital discharge (both P<0.001). Moreover, the change in leg 
volume (both CT and anthropometric measurements) differed between legs (time x leg 
interaction effect, P<0.001). This was likely due to swelling of the operated leg following the 
surgery; therefore, muscle mass changes were only presented graphically for the nonoperated 
leg (Figure 2). Moreover, a significant time x leg interaction effect was observed for muscle 
radiation attenuation in thigh muscles and quadriceps CSA (both P<0.05). HU values in thigh 
muscles and quadriceps femoris were lower in the operated leg when compared with the 
nonoperated leg both at hospital admission and hospital discharge (both P<0.05). 
 
 
 
 
Figure 2 | Muscle cross-sectional area (CSA in millimeters squared) of the quadriceps and thigh musc les of the 
nonoperated leg in older patients (n = 20) undergoing elective total hip arthroplasty, assessed by single-slice CT 
scans taken on the day of hospital admission and on the day of discharge. (A) mean standard error of the mean; 
(B) individual data; (C) mean standard error of the mean of relative decline CSA (in percentage). *Significantly 
different from hospital admission.  
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Muscle fiber characteristics  
Muscle fiber characteristics of skeletal muscle biopsies collected from the operated leg during 
surgery and on the day of hospital discharge are displayed in Table 2. At hospital admission 
and discharge, type II muscle fibers were smaller when compared with type I muscle fibers 
(3325±253 vs 4075±279 µm2, respectively, P=0.001). No significant time x fiber type 
interaction was observed for muscle fiber size (P=0.37). Six days of hospitalization tended to 
increase both type I and II muscle fiber size by 21.9±11.0% and 17.8±9.2%, respectively (main 
time effect, P=0.10). Subtle changes in fiber type distribution were observed during 
hospitalization (Table 2). 
Table 2 | Muscle fiber characteristics. 
   Hospital admission Hospital discharge 
  Type I Type II Type I Type II 
No. of fibers  198±32 278±45 175±28 329±48 
Muscle fiber CSA (µm2)  4075±279 3326±253* 4881±548 3953±471* 
% fiber  42.3±3.4 57.7±3.4 34.7±2.5† 65.3±2.5 
% fiber area  47.2±4.1 52.8±4.1 40.1±3.1† 59.9±3.1 
Values are expressed as mean standard error of the mean.  No time x fiber type interaction was observed for any 
of the outcomes (P>0.05). * Main fiber type effect: significantly different from type I,† Main time effect: significantly 
different from hospital admission, P=0.01.  
Nutritional intake  
On the day of surgery, energy intake averaged 1.32±0.62 MJ, whereas energy intake increased 
to 4.21±0.38 MJ (P<0.001) on the hospitalization days following surgery. Protein intake 
averaged 0.08±0.03 g/kg bodyweight/day on the day of surgery, after which protein intake 
increased to 0.58±0.04 g/kg bodyweight/day during the following days of hospitalization 
(P<0.001).   
 
 
D ISCUSSION  
Six days of hospitalization leads to a substantial decrease in thigh and quadriceps femoris 
muscle CSA in the nonoperated leg following elective hip arthroplasty. This reduction in 
muscle CSA is not observed in the operated leg, showing a ~10% increase in thigh CSA and 
~16% increase in whole leg volume due to postsurgery edema.  
Muscle disuse is associated with a decline in skeletal muscle mass and strength [4]. 
Experimental models studying muscle disuse have shown a ~2 to 6% decrease in leg muscle 
mass and an ~8 to 22% decrease in leg strength following as little as 4 to 7 days of limb 
immobilization in both young [17, 19, 57] and older [18, 20] subjects. Moreover, up to 14 days 
of bed rest typically results in a similar decline in whole-body and appendicular lean body 
mass in young and older individuals [11, 21, 58-62]. As the average hospital length of stay in 
older patients is 5 to 13 days [23, 24], a short period of hospitalization may already induce a 
substantial decline in skeletal muscle mass and strength. Studies applying muscle disuse 
models are often used to predict changes in muscle mass during hospitalization; however, 
only few data are available on actual muscle loss in a clinical setting. Such a period of 
hospitalization is generally accompanied by general anesthesia, surgery, associated physical 
and mental stress, a reduced level of physical activity, enforced bedrest, and/or changes in 
habitual food intake. Therefore, we hypothesized that even a short period of hospitalization is 
associated with substantial muscle loss.  
With the increasing aging population, elective joint replacement surgeries such as THA have 
increased exponentially over the last decades with more than 60% of the patients being 65 
years and older [37, 44, 63]. Elective hip replacement surgeries are effective for pain relief and 
improving quality of life and function in patients with end stage osteoarthritis [36, 37]; 
however, elective THA in older patients is typically followed by a short hospitalization period 
of 3 to 4 days [63]. In the present study, we assessed the impact of such a short-term 
hospitalization period on skeletal muscle mass following elective THA. We performed single-
slice CT scans of the upper leg on the day of hospital admission and on the day of discharge 
to assess muscle CSA of both legs. We show for the first time that 5 days of hospitalization 
following elective THA is accompanied by a substantial loss of muscle CSA. Thigh muscle CSA 
significantly declined by 4.2±1.1% and quadriceps femoris CSA by 3.4±1.0% during 
hospitalization in the nonoperated leg when compared with baseline values (both P<0.001). 
In contrast, in the operated leg, we observed a ~10% increase in total thigh CSA and a ~16% 
increase in anthropometrically determined leg volume, probably because of swelling following 
surgery. In support, muscle radiation attenuation values in the thigh and quadriceps femoris 
muscle area were substantially decreased in the operated leg when compared with the 
nonoperated leg (P<0.001). The pronounced decrease in muscle attenuation in the operated 
leg may be attributed to edema, fluid retention in the interstitial spaces, and/or fat deposition 
[45]. For example, reduced muscle attenuation values have been associated with conditions 
such as obesity, diabetes, physical inactivity, and muscle deconditioning [38, 45, 64]. Because 
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Muscle fiber characteristics  
Muscle fiber characteristics of skeletal muscle biopsies collected from the operated leg during 
surgery and on the day of hospital discharge are displayed in Table 2. At hospital admission 
and discharge, type II muscle fibers were smaller when compared with type I muscle fibers 
(3325±253 vs 4075±279 µm2, respectively, P=0.001). No significant time x fiber type 
interaction was observed for muscle fiber size (P=0.37). Six days of hospitalization tended to 
increase both type I and II muscle fiber size by 21.9±11.0% and 17.8±9.2%, respectively (main 
time effect, P=0.10). Subtle changes in fiber type distribution were observed during 
hospitalization (Table 2). 
Table 2 | Muscle fiber characteristics. 
   Hospital admission Hospital discharge 
  Type I Type II Type I Type II 
No. of fibers  198±32 278±45 175±28 329±48 
Muscle fiber CSA (µm2)  4075±279 3326±253* 4881±548 3953±471* 
% fiber  42.3±3.4 57.7±3.4 34.7±2.5† 65.3±2.5 
% fiber area  47.2±4.1 52.8±4.1 40.1±3.1† 59.9±3.1 
Values are expressed as mean standard error of the mean.  No time x fiber type interaction was observed for any 
of the outcomes (P>0.05). * Main fiber type effect: significantly different from type I,† Main time effect: significantly 
different from hospital admission, P=0.01.  
Nutritional intake  
On the day of surgery, energy intake averaged 1.32±0.62 MJ, whereas energy intake increased 
to 4.21±0.38 MJ (P<0.001) on the hospitalization days following surgery. Protein intake 
averaged 0.08±0.03 g/kg bodyweight/day on the day of surgery, after which protein intake 
increased to 0.58±0.04 g/kg bodyweight/day during the following days of hospitalization 
(P<0.001).   
 
 
D ISCUSSION  
Six days of hospitalization leads to a substantial decrease in thigh and quadriceps femoris 
muscle CSA in the nonoperated leg following elective hip arthroplasty. This reduction in 
muscle CSA is not observed in the operated leg, showing a ~10% increase in thigh CSA and 
~16% increase in whole leg volume due to postsurgery edema.  
Muscle disuse is associated with a decline in skeletal muscle mass and strength [4]. 
Experimental models studying muscle disuse have shown a ~2 to 6% decrease in leg muscle 
mass and an ~8 to 22% decrease in leg strength following as little as 4 to 7 days of limb 
immobilization in both young [17, 19, 57] and older [18, 20] subjects. Moreover, up to 14 days 
of bed rest typically results in a similar decline in whole-body and appendicular lean body 
mass in young and older individuals [11, 21, 58-62]. As the average hospital length of stay in 
older patients is 5 to 13 days [23, 24], a short period of hospitalization may already induce a 
substantial decline in skeletal muscle mass and strength. Studies applying muscle disuse 
models are often used to predict changes in muscle mass during hospitalization; however, 
only few data are available on actual muscle loss in a clinical setting. Such a period of 
hospitalization is generally accompanied by general anesthesia, surgery, associated physical 
and mental stress, a reduced level of physical activity, enforced bedrest, and/or changes in 
habitual food intake. Therefore, we hypothesized that even a short period of hospitalization is 
associated with substantial muscle loss.  
With the increasing aging population, elective joint replacement surgeries such as THA have 
increased exponentially over the last decades with more than 60% of the patients being 65 
years and older [37, 44, 63]. Elective hip replacement surgeries are effective for pain relief and 
improving quality of life and function in patients with end stage osteoarthritis [36, 37]; 
however, elective THA in older patients is typically followed by a short hospitalization period 
of 3 to 4 days [63]. In the present study, we assessed the impact of such a short-term 
hospitalization period on skeletal muscle mass following elective THA. We performed single-
slice CT scans of the upper leg on the day of hospital admission and on the day of discharge 
to assess muscle CSA of both legs. We show for the first time that 5 days of hospitalization 
following elective THA is accompanied by a substantial loss of muscle CSA. Thigh muscle CSA 
significantly declined by 4.2±1.1% and quadriceps femoris CSA by 3.4±1.0% during 
hospitalization in the nonoperated leg when compared with baseline values (both P<0.001). 
In contrast, in the operated leg, we observed a ~10% increase in total thigh CSA and a ~16% 
increase in anthropometrically determined leg volume, probably because of swelling following 
surgery. In support, muscle radiation attenuation values in the thigh and quadriceps femoris 
muscle area were substantially decreased in the operated leg when compared with the 
nonoperated leg (P<0.001). The pronounced decrease in muscle attenuation in the operated 
leg may be attributed to edema, fluid retention in the interstitial spaces, and/or fat deposition 
[45]. For example, reduced muscle attenuation values have been associated with conditions 
such as obesity, diabetes, physical inactivity, and muscle deconditioning [38, 45, 64]. Because 
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of the observed swelling and extensive increase in leg volume in the operated leg, we were 
not able to reliably assess changes in muscle mass in the operated leg. However, the 
substantial declines in leg muscle mass observed in the nonoperated leg within as little as 5 
days of hospital stay clearly indicate the detrimental impact of hospitalization on muscle mass 
maintenance in older patients. In a recent meta-analysis, it was reported that muscle mass is 
lost in electively admitted older patients (in line with our findings), whereas generally no 
decline was observed when patients were admitted acutely [29]. Importantly though, changes 
in hydration status may strongly influence the assessment of muscle mass, and the 
methodology used to determine muscle loss likely explains part of the inconsistent findings in 
literature [29, 35]. As such, the CT scans performed on the nonoperated leg in the present 
study provide a very accurate and sensitive measure, clearly showing substantial reductions in 
muscle mass during hospitalization.  
In addition to performing CT scans, we obtained skeletal muscle biopsies from the vastus 
lateralis muscle of the operated leg during the surgical procedure and on the day of hospital 
discharge to assess muscle atrophy-related changes in muscle fiber characteristics. At baseline, 
type II muscle fibers were smaller than type I muscle fibers (P<0.05), which is in line with 
previous research showing substantial type II muscle fiber atrophy with aging [65, 66], type 2 
diabetes [67], and hip fracture patients [68]. Six days of hospitalization tended to increase both 
type I and II muscle fiber size by ~20% (P=0.10). The observed swelling and substantial 
increase in leg volume observed in the operated as opposed to the nonoperated leg was likely 
not only associated with extracellular edema, but also caused a fluid shift into the muscle cells 
and, as such, intracellular edema, thereby increasing muscle fiber CSA. Therefore, we were 
unable to adequately assess muscle fiber size and characteristics following surgery in these 
hospitalized patients. We hypothesized that short-term hospitalization would be characterized 
by a decline in muscle fiber size in the operated leg, which could explain the observed muscle 
atrophy in such a clinical setting. For example, substantial decreases in muscle fiber size have 
been observed during critical illness [69] and bed rest [62]. However, because of the presence 
of postoperative (intracellular) edema, we could not reliably assess muscle fiber changes in 
the operated leg. Therefore, future studies should be aware that muscle fiber size loss during 
hospitalization after orthopedic surgery should not be assessed in the limb in which surgery 
has been performed.  
Short, successive ‘catabolic crises’ have been proposed to contribute to the persistent age-
related loss of skeletal muscle mass and strength [3, 12]. Assuming the usual age-related 
decline in muscle mass of 1 to 2% per year above the age of 65 [1, 3], the 3 to 4% muscle loss 
observed during only a few days of hospitalization likely has a dramatic impact on the 
development of sarcopenia. Moreover, older individuals generally do not regain all muscle 
tissue that was lost during a period of disuse [9-11]. Therefore, cumulative periods of disuse 
episodes do not only impact muscle loss during hospitalization but likely also contribute to 
impaired recovery and physical functioning after hospital discharge. Indeed, it has been well 
established that hospital-associated deconditioning in the older population contributes to an 
overall functional decline during and following a period of hospitalization, impacting long-
 
 
term clinical outcomes after hospitalization [12, 27, 28]. Although such deconditioning is 
known to occur in various clinical situations, the actual loss of muscle mass during 
hospitalization is rarely assessed. Moreover, much of this work so far has focused on severe 
medical conditions (e.g., ICU-acquired weakness, organ failure, and cancer cachexia [29-35], 
which may be different from the large group of relatively healthy individuals entering the 
hospital for planned surgery. In the present study, we quantitatively assessed the extent of 
skeletal muscle atrophy during short-term hospitalization in older patients who were electively 
admitted for THA. We observed substantial muscle loss during only several days of 
hospitalization, although patients were encouraged to mobilize as soon as possible and were 
provided with daily physical therapy and standard nutritional care. This loss in skeletal muscle 
mass seems greater when compared to muscle disuse observed in experimental models, which 
generally report ~0.5% loss of appendicular muscle mass per day during limb immobilization 
or bedrest [4, 5]. In line with the literature on deconditioning, probably the combination of 
multiple factors such as the impact of surgery, the associated physical and mental stress, 
reduced food intake during hospitalization, inflammation, medication, type of anesthesia, and 
medical history could further impact skeletal muscle loss in clinical practice [27, 28]. With the 
relative low number of patients included here (n = 26) we are unable to further study the 
relative contribution of these factors to the observed muscle loss. Furthermore, although we 
would expect the substantial loss of muscle mass during hospitalization to also occur in other 
older patient populations, it is clear that the reason for admission (i.e., underlying pathology) 
and the type of admission (i.e., acute vs elective [29]) can affect the extent of muscle loss. Thus, 
future work is needed to further establish the various factors that affect the extent of muscle 
atrophy in clinical conditions, and to what extent hospital-associated muscle loss differs 
between various patient populations. 
Apart from the above-mentioned patient-related factors that may affect muscle maintenance, 
the 2 key anabolic stimuli for skeletal muscle tissue are muscle contraction and food intake 
[2]. In the present study, daily protein intake was very low on the day of surgery (only ~6 g in 
total), as well as on the following days of hospitalization (~0.6 g/kg bodyweight/day). As such, 
daily protein intake remained well below the recommended protein intake guidelines of 1.2 
to 1.5 g/kg bodyweight/day for older adults [70]. A protein intake of less than 1.2 g/kg 
bodyweight/day will likely be insufficient to maintain or regain skeletal muscle mass during 
postsurgery hospitalization in these patients. Increasing protein intake has been proposed as 
a nutritional strategy to attenuate the loss of muscle mass during hospitalization. Protein 
supplementation has been shown to increase muscle mass and function in older adults [71, 
72]. Moreover, amino acid supplementation (i.e., leucine and β-hydroxy β-methylbutyric acid) 
have been shown to attenuate the loss of muscle mass during a period of bed rest [14, 60, 61]. 
However, additional protein supplementation during limb immobilization does not seem to 
preserve the loss of skeletal muscle mass in healthy older subjects [18, 73]. Though it has not 
been proven whether increasing habitual protein intake during short-term hospitalization can 
attenuate muscle loss, it has been well established that a decline in protein intake below 
habitual intake levels aggravates muscle loss during a period of bedrest or immobilization [3, 
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of the observed swelling and extensive increase in leg volume in the operated leg, we were 
not able to reliably assess changes in muscle mass in the operated leg. However, the 
substantial declines in leg muscle mass observed in the nonoperated leg within as little as 5 
days of hospital stay clearly indicate the detrimental impact of hospitalization on muscle mass 
maintenance in older patients. In a recent meta-analysis, it was reported that muscle mass is 
lost in electively admitted older patients (in line with our findings), whereas generally no 
decline was observed when patients were admitted acutely [29]. Importantly though, changes 
in hydration status may strongly influence the assessment of muscle mass, and the 
methodology used to determine muscle loss likely explains part of the inconsistent findings in 
literature [29, 35]. As such, the CT scans performed on the nonoperated leg in the present 
study provide a very accurate and sensitive measure, clearly showing substantial reductions in 
muscle mass during hospitalization.  
In addition to performing CT scans, we obtained skeletal muscle biopsies from the vastus 
lateralis muscle of the operated leg during the surgical procedure and on the day of hospital 
discharge to assess muscle atrophy-related changes in muscle fiber characteristics. At baseline, 
type II muscle fibers were smaller than type I muscle fibers (P<0.05), which is in line with 
previous research showing substantial type II muscle fiber atrophy with aging [65, 66], type 2 
diabetes [67], and hip fracture patients [68]. Six days of hospitalization tended to increase both 
type I and II muscle fiber size by ~20% (P=0.10). The observed swelling and substantial 
increase in leg volume observed in the operated as opposed to the nonoperated leg was likely 
not only associated with extracellular edema, but also caused a fluid shift into the muscle cells 
and, as such, intracellular edema, thereby increasing muscle fiber CSA. Therefore, we were 
unable to adequately assess muscle fiber size and characteristics following surgery in these 
hospitalized patients. We hypothesized that short-term hospitalization would be characterized 
by a decline in muscle fiber size in the operated leg, which could explain the observed muscle 
atrophy in such a clinical setting. For example, substantial decreases in muscle fiber size have 
been observed during critical illness [69] and bed rest [62]. However, because of the presence 
of postoperative (intracellular) edema, we could not reliably assess muscle fiber changes in 
the operated leg. Therefore, future studies should be aware that muscle fiber size loss during 
hospitalization after orthopedic surgery should not be assessed in the limb in which surgery 
has been performed.  
Short, successive ‘catabolic crises’ have been proposed to contribute to the persistent age-
related loss of skeletal muscle mass and strength [3, 12]. Assuming the usual age-related 
decline in muscle mass of 1 to 2% per year above the age of 65 [1, 3], the 3 to 4% muscle loss 
observed during only a few days of hospitalization likely has a dramatic impact on the 
development of sarcopenia. Moreover, older individuals generally do not regain all muscle 
tissue that was lost during a period of disuse [9-11]. Therefore, cumulative periods of disuse 
episodes do not only impact muscle loss during hospitalization but likely also contribute to 
impaired recovery and physical functioning after hospital discharge. Indeed, it has been well 
established that hospital-associated deconditioning in the older population contributes to an 
overall functional decline during and following a period of hospitalization, impacting long-
 
 
term clinical outcomes after hospitalization [12, 27, 28]. Although such deconditioning is 
known to occur in various clinical situations, the actual loss of muscle mass during 
hospitalization is rarely assessed. Moreover, much of this work so far has focused on severe 
medical conditions (e.g., ICU-acquired weakness, organ failure, and cancer cachexia [29-35], 
which may be different from the large group of relatively healthy individuals entering the 
hospital for planned surgery. In the present study, we quantitatively assessed the extent of 
skeletal muscle atrophy during short-term hospitalization in older patients who were electively 
admitted for THA. We observed substantial muscle loss during only several days of 
hospitalization, although patients were encouraged to mobilize as soon as possible and were 
provided with daily physical therapy and standard nutritional care. This loss in skeletal muscle 
mass seems greater when compared to muscle disuse observed in experimental models, which 
generally report ~0.5% loss of appendicular muscle mass per day during limb immobilization 
or bedrest [4, 5]. In line with the literature on deconditioning, probably the combination of 
multiple factors such as the impact of surgery, the associated physical and mental stress, 
reduced food intake during hospitalization, inflammation, medication, type of anesthesia, and 
medical history could further impact skeletal muscle loss in clinical practice [27, 28]. With the 
relative low number of patients included here (n = 26) we are unable to further study the 
relative contribution of these factors to the observed muscle loss. Furthermore, although we 
would expect the substantial loss of muscle mass during hospitalization to also occur in other 
older patient populations, it is clear that the reason for admission (i.e., underlying pathology) 
and the type of admission (i.e., acute vs elective [29]) can affect the extent of muscle loss. Thus, 
future work is needed to further establish the various factors that affect the extent of muscle 
atrophy in clinical conditions, and to what extent hospital-associated muscle loss differs 
between various patient populations. 
Apart from the above-mentioned patient-related factors that may affect muscle maintenance, 
the 2 key anabolic stimuli for skeletal muscle tissue are muscle contraction and food intake 
[2]. In the present study, daily protein intake was very low on the day of surgery (only ~6 g in 
total), as well as on the following days of hospitalization (~0.6 g/kg bodyweight/day). As such, 
daily protein intake remained well below the recommended protein intake guidelines of 1.2 
to 1.5 g/kg bodyweight/day for older adults [70]. A protein intake of less than 1.2 g/kg 
bodyweight/day will likely be insufficient to maintain or regain skeletal muscle mass during 
postsurgery hospitalization in these patients. Increasing protein intake has been proposed as 
a nutritional strategy to attenuate the loss of muscle mass during hospitalization. Protein 
supplementation has been shown to increase muscle mass and function in older adults [71, 
72]. Moreover, amino acid supplementation (i.e., leucine and β-hydroxy β-methylbutyric acid) 
have been shown to attenuate the loss of muscle mass during a period of bed rest [14, 60, 61]. 
However, additional protein supplementation during limb immobilization does not seem to 
preserve the loss of skeletal muscle mass in healthy older subjects [18, 73]. Though it has not 
been proven whether increasing habitual protein intake during short-term hospitalization can 
attenuate muscle loss, it has been well established that a decline in protein intake below 
habitual intake levels aggravates muscle loss during a period of bedrest or immobilization [3, 
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14, 74, 75]. Therefore, nutritional interventions should focus on maintaining habitual protein 
intake levels in both the perioperative phase as well as during hospital stay.  
Hospitalization is typically a period during which physical activity levels are reduced, and it has 
been shown that older patients spend >80% of their hospital stay in bed [25, 26]. Because 
muscle contraction directly stimulates muscle protein synthesis [2], increasing physical activity 
and/or introducing physical activity mimetics during hospitalization forms an important 
strategy to reduce muscle loss. In addition, as protein ingestion and exercise have a synergistic 
effect [2], physical activity (mimetics) should be combined with nutritional support in clinical 
practice to minimize muscle and strength loss in older and more clinically compromised 
patient groups.  
Conclusion 
We conclude that short-term hospitalization following elective THA leads to substantial 
muscle loss in older patients. Effective intervention strategies are warranted to prevent the 
loss of muscle mass induced by short periods of muscle disuse during hospitalization.  
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14, 74, 75]. Therefore, nutritional interventions should focus on maintaining habitual protein 
intake levels in both the perioperative phase as well as during hospital stay.  
Hospitalization is typically a period during which physical activity levels are reduced, and it has 
been shown that older patients spend >80% of their hospital stay in bed [25, 26]. Because 
muscle contraction directly stimulates muscle protein synthesis [2], increasing physical activity 
and/or introducing physical activity mimetics during hospitalization forms an important 
strategy to reduce muscle loss. In addition, as protein ingestion and exercise have a synergistic 
effect [2], physical activity (mimetics) should be combined with nutritional support in clinical 
practice to minimize muscle and strength loss in older and more clinically compromised 
patient groups.  
Conclusion 
We conclude that short-term hospitalization following elective THA leads to substantial 
muscle loss in older patients. Effective intervention strategies are warranted to prevent the 
loss of muscle mass induced by short periods of muscle disuse during hospitalization.  
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ABST RACT  
Background: Hospitalization is generally accompanied by changes in food intake. Patients 
typically receive hospital meals upon personal preference within the 
framework of the food administration services of the hospital.  
Aim:  In the present study, we assessed food provision and actual food and snack 
consumption in older patients admitted for elective hip or knee arthroplasty. 
Methods:  In the present study n = 101 patients (age: 67±10 y; hospital stay: 6.1±1.8 d) 
were monitored during hospitalization following elective hip or knee 
arthroplasty. Food provided by self-selected hospital meals and snacks, and 
actual food consumed by patients was weighed and recorded throughout 
1-6 days. Nutritional values of food products were calculated using product 
specifications.  
Results:  Self-selected meals provided 6.5±1.5 MJ·d-1, with 16, 48, and 34 En% 
provided as protein, carbohydrate, and fat, respectively. Self-selected 
hospital meals provided 0.75±0.16 and 0.79±0.21 g·kg-1·d-1 protein in males 
and females, respectively. Actual protein consumption averaged merely 
0.59±0.18 and 0.50±0.21 g·kg-1·d-1, respectively. Protein consumption at 
breakfast, lunch, and dinner averaged 16±8, 18±9, and 20±6 g per meal, 
respectively. 
Conclusions:  Though self-selected hospital meals provide patients with ~0.8 g·kg-1·d-1 
protein during short-term hospitalization, actual protein consumption falls 
well below 0.6 g·kg-1·d-1 with a large proportion (~32%) of the provided food 
being discarded. Alternative strategies are required to ensure maintenance 
of habitual protein intake in older patients admitted for elective orthopedic 
surgery. 
  
 
 
 
IN TRODU CTION  
Hospitalization in older adults is accompanied by substantial changes in food intake. At 
present, the hospitalization duration in older patients is 5 days or longer [1, 2]. During such a 
short period of hospitalization, food intake is generally reduced due to periods of fasting, 
adverse effects of medication, strict timing of food provision, reduced appetite, and/or pain 
and discomfort [3-5]. Such a reduced food intake throughout the hospitalization period often 
results in a negative energy and/or protein balance. Low levels of energy and protein intake, 
also referred to as protein-energy malnutrition, result in accelerated loss of lean body mass, 
muscle strength, and impairments in functional capacity [6-8]. Moreover, malnutrition during 
hospitalization has been shown to increase the length of hospital stay, the risk for infections, 
the incidence of hospital readmissions, and mortality rates [9-12].  
The negative health consequences of malnutrition are at least partly attributed to the 
concomitant loss of skeletal muscle mass and strength. Several studies from our group, as well 
as others, have shown significant declines in muscle mass and strength during short periods 
of immobilization [13-18] and hospitalization [19]. It has been well-established that the loss of 
muscle tissue is accelerated when energy balance remains negative [20]. Apart from the 
negative effects of physical inactivity, the loss of muscle mass observed during hospitalization 
may be particularly attributed to an insufficient protein intake as a direct consequence of the 
lower energy intake. The current recommended dietary intake for protein has been set at 0.8 
g·kg-1·d-1 for healthy adults of all ages. In the general population, older community-dwelling 
individuals consume well above (~1.0 g·kg-1·d-1) these recommended protein intake levels [6, 
21-23]. Recently updated guidelines suggest a protein intake of 1.2-1.5 g·kg-1·d-1 for older 
individuals suffering from acute or chronic diseases in order to maintain muscle mass during 
hospitalization [24, 25]. Minimal requirements during hospitalization should be aimed at 
achieving energy balance and maintaining habitual protein intake. Currently, patients typically 
receive hospital meals upon personal request within the framework of the food administration 
services of the hospital. However, it is unknown whether these self-selected hospital meals 
provide sufficient energy and/or protein. 
Whereas several studies have assessed energy and/or protein provision in patients during 
hospitalization [3, 9, 26-32], only few studies have measured the actual amount of energy and 
protein consumed by patients [4, 33-37]. In addition, snack consumption between meals is 
generally not reported. Recent studies show that less than 30% of the older hospitalized 
patients reach a protein intake of 1.2 g·kg-1·d-1 [35, 38]. Moreover, protein intake has been 
shown to be well below these increased recommendation levels for at least one day in older 
patients during hospitalization [35, 37]. There is no data available on actual energy and protein 
intake during the entire hospitalization period in older patients. In addition, a clear 
quantification on the protein consumption pattern in hospitalized patients such as the protein 
amount per meal, protein distribution, and protein sources has not been reported. We 
   
   
  C
HA
PT
ER
 T
HR
EE
  
 
55
        Protein intake during hospitalization   
 
 
ABST RACT  
Background: Hospitalization is generally accompanied by changes in food intake. Patients 
typically receive hospital meals upon personal preference within the 
framework of the food administration services of the hospital.  
Aim:  In the present study, we assessed food provision and actual food and snack 
consumption in older patients admitted for elective hip or knee arthroplasty. 
Methods:  In the present study n = 101 patients (age: 67±10 y; hospital stay: 6.1±1.8 d) 
were monitored during hospitalization following elective hip or knee 
arthroplasty. Food provided by self-selected hospital meals and snacks, and 
actual food consumed by patients was weighed and recorded throughout 
1-6 days. Nutritional values of food products were calculated using product 
specifications.  
Results:  Self-selected meals provided 6.5±1.5 MJ·d-1, with 16, 48, and 34 En% 
provided as protein, carbohydrate, and fat, respectively. Self-selected 
hospital meals provided 0.75±0.16 and 0.79±0.21 g·kg-1·d-1 protein in males 
and females, respectively. Actual protein consumption averaged merely 
0.59±0.18 and 0.50±0.21 g·kg-1·d-1, respectively. Protein consumption at 
breakfast, lunch, and dinner averaged 16±8, 18±9, and 20±6 g per meal, 
respectively. 
Conclusions:  Though self-selected hospital meals provide patients with ~0.8 g·kg-1·d-1 
protein during short-term hospitalization, actual protein consumption falls 
well below 0.6 g·kg-1·d-1 with a large proportion (~32%) of the provided food 
being discarded. Alternative strategies are required to ensure maintenance 
of habitual protein intake in older patients admitted for elective orthopedic 
surgery. 
  
 
 
 
IN TRODU CTION  
Hospitalization in older adults is accompanied by substantial changes in food intake. At 
present, the hospitalization duration in older patients is 5 days or longer [1, 2]. During such a 
short period of hospitalization, food intake is generally reduced due to periods of fasting, 
adverse effects of medication, strict timing of food provision, reduced appetite, and/or pain 
and discomfort [3-5]. Such a reduced food intake throughout the hospitalization period often 
results in a negative energy and/or protein balance. Low levels of energy and protein intake, 
also referred to as protein-energy malnutrition, result in accelerated loss of lean body mass, 
muscle strength, and impairments in functional capacity [6-8]. Moreover, malnutrition during 
hospitalization has been shown to increase the length of hospital stay, the risk for infections, 
the incidence of hospital readmissions, and mortality rates [9-12].  
The negative health consequences of malnutrition are at least partly attributed to the 
concomitant loss of skeletal muscle mass and strength. Several studies from our group, as well 
as others, have shown significant declines in muscle mass and strength during short periods 
of immobilization [13-18] and hospitalization [19]. It has been well-established that the loss of 
muscle tissue is accelerated when energy balance remains negative [20]. Apart from the 
negative effects of physical inactivity, the loss of muscle mass observed during hospitalization 
may be particularly attributed to an insufficient protein intake as a direct consequence of the 
lower energy intake. The current recommended dietary intake for protein has been set at 0.8 
g·kg-1·d-1 for healthy adults of all ages. In the general population, older community-dwelling 
individuals consume well above (~1.0 g·kg-1·d-1) these recommended protein intake levels [6, 
21-23]. Recently updated guidelines suggest a protein intake of 1.2-1.5 g·kg-1·d-1 for older 
individuals suffering from acute or chronic diseases in order to maintain muscle mass during 
hospitalization [24, 25]. Minimal requirements during hospitalization should be aimed at 
achieving energy balance and maintaining habitual protein intake. Currently, patients typically 
receive hospital meals upon personal request within the framework of the food administration 
services of the hospital. However, it is unknown whether these self-selected hospital meals 
provide sufficient energy and/or protein. 
Whereas several studies have assessed energy and/or protein provision in patients during 
hospitalization [3, 9, 26-32], only few studies have measured the actual amount of energy and 
protein consumed by patients [4, 33-37]. In addition, snack consumption between meals is 
generally not reported. Recent studies show that less than 30% of the older hospitalized 
patients reach a protein intake of 1.2 g·kg-1·d-1 [35, 38]. Moreover, protein intake has been 
shown to be well below these increased recommendation levels for at least one day in older 
patients during hospitalization [35, 37]. There is no data available on actual energy and protein 
intake during the entire hospitalization period in older patients. In addition, a clear 
quantification on the protein consumption pattern in hospitalized patients such as the protein 
amount per meal, protein distribution, and protein sources has not been reported. We 
 56
 
 
hypothesized that older patients during several days of hospitalization consume well below 
the recommended protein intake level of 1.2-1.5 g·kg-1·d-1.  
In the present study we assessed food provision as well as actual food and snack consumption 
in older patients (n = 101) during short-term hospitalization following elective total hip or 
knee arthroplasty. We quantified the amount, distribution, and source of protein in self-
selected hospital meals consumed at breakfast, lunch, dinner, and snacks during several days 
of hospitalization.  
  
 
 
 
M ETHO DS 
Study design 
This observational study assessed the nutritional content of self-selected hospital meals, and 
measured actual food and snack consumption in all patients undergoing elective hip or knee 
arthroplasty between April 2016 and August 2016. Patients were screened for malnutrition 
using the Malnutrition Universal Screening Tool (MUST) [39] upon arrival on the nursing ward 
as part of standard admission procedures (all included patients had a MUST = 0 score upon 
hospital admission). Information concerning the project was given orally and patients gave 
consent to collect their food trays after meal consumption. Age, BMI, type of anesthesia used 
during surgery, and length of stay (LOS) were recorded. There was no extra burden on the 
patient during hospitalization. There were no exclusion criteria. The study was registered as 
NTR5942 (www.trialregister.nl). 
Provision of hospital meals 
Hospital meals were provided at three strict timeslots every day; at breakfast, lunch, and 
dinner. In between the main meals, patients were provided with hot and/or cold drinks 3 times 
a day. There was mealtime assistance during the provision of all meals. Patients selected their 
meals upon request the day before and could indicate different portion sizes of 0.5, 1, or 2 
portion(s). During the first day after surgery, when patients were not able to select their meals 
due to the time spent at the surgery room, they received standard hospital meals.  
Consumption of hospital meals 
On the serving tray, patients received a description of their ordered menu, which was collected 
for the study. When patients were finished eating, the serving tray was taken and all leftovers 
were weighed using a scale (Exacta Pure, Soehnle) and reported. This was done for breakfast, 
lunch, and dinner. To assess snack consumption, patients were asked to fill in a daily snack list 
during hospitalization that was collected daily. If patients were not able to complete the snack 
list, the researcher recalled their snack consumption in between meals and reported this. 
During the entire assessment period the researcher was present at the ward. 
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Nutritional content of hospital meals 
Total energy (MJ), protein (g and En%), carbohydrate (g and En%), and fat (g and En%) were 
calculated for all provided and consumed food based upon product specifications provided 
by the food suppliers and the Dutch Food Consumption Database 2016 (NEVO; RIVM, 
Bilthoven, the Netherlands) [40]. The contribution of animal- and plant-based sources to 
dietary protein intake was determined and expressed as a percentage of total protein intake 
for all meals. In addition, food products were divided in five categories: “meat and fish”, “dairy 
products and eggs”, “bread, cereal, and potatoes”, “fruits, vegetables, and legumes”, and 
“other plant sources”. Food intake was recorded from the day of hospital admission (day 0) 
until the day of hospital discharge (day 2-6). Data on food intake on the day of hospital 
admission and discharge was not included, since these days did not include all main meals. 
The reported intake was calculated in n = 101 patients from the day of surgery (day 1) until 
day 2, in n = 98 until day 3, in n = 52 until day 4, and in n = 17 until day 5. To determine 
patients’ nutritional needs, energy requirements were calculated based upon resting energy 
expenditure using the Harris and Benedict equation [41]. A Physical Activity Level (PAL) of 1.3 
for patients “not restricted to bed” and an Injury Factor (IF) of 1.2 for “minor operation” was 
used, resulting in a correction factor of 1.56 to estimate (minimal) energy requirements [42]. 
During hospital stay patients were encouraged to mobilize as soon as possible and received 
physiotherapy training for 30 min daily, from day 2 onwards.  
Statistical analysis  
All data was checked for normality and was normal distributed, except for energy and protein 
consumption on day of surgery (day 1). Data are expressed as mean±SD (for consistency; both 
normal and non-normal distributed data). Differences between provided and consumed food 
intake were analyzed using a paired Students t-test. Energy and protein intake during 
hospitalization and between main meals were analyzed using repeated measures ANOVA with 
time as within-group factor (either days or meals) and gender as between-group factor. 
Analyses for energy and protein intake were performed for patients hospitalized until day 3 
(Figure 1 and 2) and analyses for protein intake distribution were performed excluding snack 
consumption (Figure 3). In case of a significant interaction between time and gender, separate 
analyses were performed to determine time-effects for males and females (one-factor 
repeated measures ANOVA) with a Bonferroni post-hoc test to locate these differences and 
between-group effects for each time-point (Students t-test). Statistical significance was set at 
P<0.05. All calculations were performed using the statistical software program SPSS (version 
24.0, IBM Corp., Armonk, USA).  
  
 
 
 
R ESULTS  
Patients’ characteristics  
In total, 101 older patients were monitored (males/females: 37/64; age: 67±10 y; hospital stay: 
6.1±1.8 d) during hospitalization following elective hip or knee arthroplasty. Patients’ 
characteristics are presented in Table 1. Estimated resting metabolic rate averaged 7.15±0.74 
MJ·d-1 in males and 5.81±0.87 MJ·d-1 in females. The estimated (minimal) energy requirements 
were calculated using a correction factor of 1.56 and averaged 11.15±1.16 MJ·d-1 in males and 
9.06±1.35 MJ·d-1 in females.  
Table 1 | Patients’ characteristics. 
 All patients (n = 101) 
Males 
(n = 37) 
Females 
(n = 64) 
Age (y) 67±10 66±8 68±10 
Body weight (kg) 81.1±16.9 86.3±11.0 78.1±18.9* 
Height (m) 1.69±0.09 1.75±0.07 1.65±0.08* 
BMI (kg·m-2) 28.4±5.0 28.3±3.6 28.5±5.7 
Length of stay (d) 6.1±1.8 6.1±1.8 6.1±1.9 
Resting metabolic rate (MJ·d-1) 6.30±1.04 7.15±0.74 5.81±0.87* 
General anesthesia (n) 68 (67%) 25 (68%) 43 (67%) 
Spinal anesthesia (n) 33 (33%) 12 (32%) 21 (33%) 
THA (n and %) 57 (56%) 19 (51%) 25 (39%) 
TKA (n and %) 44 (44%) 18 (49%) 39 (61%) 
Values are mean±SD. BMI: body mass index, THA: total hip arthroplasty, TKA: total knee arthroplasty. Resting 
metabolic rate was calculated based upon gender, body weight, height and age, using the adjusted Harris and 
Benedict equation. Data were analyzed by a Students t-test. * Indicates a significant difference between males 
and females, P<0.05. 
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Benedict equation. Data were analyzed by a Students t-test. * Indicates a significant difference between males 
and females, P<0.05. 
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Energy provision and consumption 
Energy provision and consumption (MJ·d-1) from self-selected hospital meals during 
hospitalization are presented in Figure 1. Hospital meals provided 6.90±1.78 MJ·d-1 in males 
(Figure 1A) and 6.25±1.34 MJ·d-1 in females (Figure 1B) during the entire hospitalization 
period, while energy consumption averaged 5.29±1.77 and 3.96±1.39 MJ·d-1, respectively. On 
average, 32±17% of the provided food (i.e. energy content) was not consumed (P<0.001). For 
energy intake, a significant time x gender interaction was observed (P<0.001). For both males 
and females, energy intake increased from day 1 (1.58±1.87 and 1.02 ±1.38 MJ·d-1) to day 2 
(6.45±2.66 and 4.60±2.00 MJ·d-1; P<0.001), with a further increase observed to day 3 
(6.92±2.77 and 5.24±1.73 MJ·d-1) although this only reached significance for females 
(P=0.001). Energy consumption was lower in females when compared with males on day 2 and 
3 of hospitalization (both P<0.001) and tended to be lower in females on day 1 (P=0.084). 
Total macronutrient consumption (g and En%) in males and females are presented in Table 2.  
 
Figure 1 | Mean(±SD) energy provision and consumption (MJ·d-1) during short-term hospitalization in older, 
hospitalized males (A) and females (B). Food intake was calculated in n = 101 (M/F: 37/64) patients until day 2, in 
n = 98 (M/F 36/62) until day 3, in n = 52 (M/F: 17/35) until day 4, and in n = 17 (M/F: 6/11) until day 5. * Indicates 
a significant difference when compared with provided food, P<0.001.  
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Protein provision and consumption 
Protein provision and consumption (g·kg-1·d-1) from self-selected hospital meals during 
hospitalization are presented in Figure 2. Self-selected hospital meals provided 0.75±0.16 
g·kg-1·d-1 in males (Figure 2A) and 0.79±0.21 g·kg-1·d-1 in females (Figure 2B) during 
hospitalization, while actual protein consumption averaged merely 0.59±0.18 and 0.50±0.21 
g·kg-1·d-1, respectively. The consumed amount of protein was 32±19% lower than the provided 
amount of protein at all days of hospitalization (P<0.001). Protein intake levels increased 
during hospitalization to a similar extent in males and females (time x gender interaction 
effect, P=0.306, main time effect, P<0.001), with lower protein intakes on the day of surgery 
(day 1) when compared with day 2 and day 3 (P<0.001), and on day 2 when compared with 
day 3 (P=0.007). Protein intake during hospitalization was overall lower in females when 
compared with males (main gender effect, P=0.028).  
 
Figure 2 | Mean(±SD) protein provision and consumption (g·kg-1·d-1) during short-term hospitalization in older, 
hospitalized males (A) and females (B). Food intake was calculated in n = 101 (M/F: 37/64) patients until day 2, in 
n = 98 (M/F 36/62) until day 3, in n = 52 (M/F: 17/35) until day 4, and in n = 17 (M/F: 6/11) until day 5. The dotted 
lines represent the recommended dietary intake of 0.8 g·kg-1·d-1 and the recommended protein intake of 1.2 g· 
kg-1·d-1 suggested for older, hospitalized individuals. * Indicates a significant difference when compared with 
provided food, P<0.001. 
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Energy provision and consumption 
Energy provision and consumption (MJ·d-1) from self-selected hospital meals during 
hospitalization are presented in Figure 1. Hospital meals provided 6.90±1.78 MJ·d-1 in males 
(Figure 1A) and 6.25±1.34 MJ·d-1 in females (Figure 1B) during the entire hospitalization 
period, while energy consumption averaged 5.29±1.77 and 3.96±1.39 MJ·d-1, respectively. On 
average, 32±17% of the provided food (i.e. energy content) was not consumed (P<0.001). For 
energy intake, a significant time x gender interaction was observed (P<0.001). For both males 
and females, energy intake increased from day 1 (1.58±1.87 and 1.02 ±1.38 MJ·d-1) to day 2 
(6.45±2.66 and 4.60±2.00 MJ·d-1; P<0.001), with a further increase observed to day 3 
(6.92±2.77 and 5.24±1.73 MJ·d-1) although this only reached significance for females 
(P=0.001). Energy consumption was lower in females when compared with males on day 2 and 
3 of hospitalization (both P<0.001) and tended to be lower in females on day 1 (P=0.084). 
Total macronutrient consumption (g and En%) in males and females are presented in Table 2.  
 
Figure 1 | Mean(±SD) energy provision and consumption (MJ·d-1) during short-term hospitalization in older, 
hospitalized males (A) and females (B). Food intake was calculated in n = 101 (M/F: 37/64) patients until day 2, in 
n = 98 (M/F 36/62) until day 3, in n = 52 (M/F: 17/35) until day 4, and in n = 17 (M/F: 6/11) until day 5. * Indicates 
a significant difference when compared with provided food, P<0.001.  
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Protein provision and consumption 
Protein provision and consumption (g·kg-1·d-1) from self-selected hospital meals during 
hospitalization are presented in Figure 2. Self-selected hospital meals provided 0.75±0.16 
g·kg-1·d-1 in males (Figure 2A) and 0.79±0.21 g·kg-1·d-1 in females (Figure 2B) during 
hospitalization, while actual protein consumption averaged merely 0.59±0.18 and 0.50±0.21 
g·kg-1·d-1, respectively. The consumed amount of protein was 32±19% lower than the provided 
amount of protein at all days of hospitalization (P<0.001). Protein intake levels increased 
during hospitalization to a similar extent in males and females (time x gender interaction 
effect, P=0.306, main time effect, P<0.001), with lower protein intakes on the day of surgery 
(day 1) when compared with day 2 and day 3 (P<0.001), and on day 2 when compared with 
day 3 (P=0.007). Protein intake during hospitalization was overall lower in females when 
compared with males (main gender effect, P=0.028).  
 
Figure 2 | Mean(±SD) protein provision and consumption (g·kg-1·d-1) during short-term hospitalization in older, 
hospitalized males (A) and females (B). Food intake was calculated in n = 101 (M/F: 37/64) patients until day 2, in 
n = 98 (M/F 36/62) until day 3, in n = 52 (M/F: 17/35) until day 4, and in n = 17 (M/F: 6/11) until day 5. The dotted 
lines represent the recommended dietary intake of 0.8 g·kg-1·d-1 and the recommended protein intake of 1.2 g· 
kg-1·d-1 suggested for older, hospitalized individuals. * Indicates a significant difference when compared with 
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Protein intake per meal  
Distribution of protein provision and consumption (g) across main meals is presented in 
Figure 3. Absolute protein intake across main meals is shown in Table 2. Self-selected hospital 
meals provided 26±8, 28±10, and 23±4 g protein in males, and 23±7, 23±6, and 24±4 g 
protein in females at breakfast, lunch, and dinner, respectively. Protein consumption was 
32±23% lower than protein provision at breakfast (P<0.001), 27±23% at lunch (P<0.001), and 
17±18% at dinner (P<0.001). A significant time x gender interaction effect was observed for 
protein intake distribution during hospitalization (P<0.001). Protein intake in males averaged 
20±7, 22±11, and 21±6 g at breakfast, lunch, and dinner, respectively, with no differences 
between main meals (P=0.157). Protein intake in females differed between main meals and 
averaged 14±7, 16±7, and 19±6 g, respectively (P<0.001). Post-hoc analyses in females 
showed that protein consumption was lower at breakfast and lunch when compared with 
dinner (both P<0.001), and lower at breakfast when compared with lunch (P=0.042). Protein 
consumption during hospital admission was lower in females when compared with males at 
breakfast and lunch (both P<0.001), but did not differ at dinner between genders (P=0.120). 
Snack consumption provided merely 3±5 g protein per day in males and 2±2 g in females, 
with no differences between genders (Figure 3A and B; P=0.141). Protein distribution per 
main meal as % of the total consumed amount of protein is presented in Figure 4. Breakfast, 
lunch, and dinner provided 30±7, 33±8, and 33±7% protein in males (Figure 4A) and 27±8, 
30±7, 39±9% protein in females (Figure 4B). Snacks contributed for the remaining 4±5% 
protein in males and 4±3% in females. 
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Protein intake per meal  
Distribution of protein provision and consumption (g) across main meals is presented in 
Figure 3. Absolute protein intake across main meals is shown in Table 2. Self-selected hospital 
meals provided 26±8, 28±10, and 23±4 g protein in males, and 23±7, 23±6, and 24±4 g 
protein in females at breakfast, lunch, and dinner, respectively. Protein consumption was 
32±23% lower than protein provision at breakfast (P<0.001), 27±23% at lunch (P<0.001), and 
17±18% at dinner (P<0.001). A significant time x gender interaction effect was observed for 
protein intake distribution during hospitalization (P<0.001). Protein intake in males averaged 
20±7, 22±11, and 21±6 g at breakfast, lunch, and dinner, respectively, with no differences 
between main meals (P=0.157). Protein intake in females differed between main meals and 
averaged 14±7, 16±7, and 19±6 g, respectively (P<0.001). Post-hoc analyses in females 
showed that protein consumption was lower at breakfast and lunch when compared with 
dinner (both P<0.001), and lower at breakfast when compared with lunch (P=0.042). Protein 
consumption during hospital admission was lower in females when compared with males at 
breakfast and lunch (both P<0.001), but did not differ at dinner between genders (P=0.120). 
Snack consumption provided merely 3±5 g protein per day in males and 2±2 g in females, 
with no differences between genders (Figure 3A and B; P=0.141). Protein distribution per 
main meal as % of the total consumed amount of protein is presented in Figure 4. Breakfast, 
lunch, and dinner provided 30±7, 33±8, and 33±7% protein in males (Figure 4A) and 27±8, 
30±7, 39±9% protein in females (Figure 4B). Snacks contributed for the remaining 4±5% 
protein in males and 4±3% in females. 
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Figure 3 | Mean(±SD) dietary protein provision and consumption (g) across main meals in older, hospitalized 
males (A; n = 37) and females (B; n = 64). * Indicates a significant difference when compared with provided, 
P<0.001; † Indicates a significant difference when compared with dinner,  P<0.001; ‡ Indicates a significant 
difference when compared with lunch, P<0.05. 
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Figure 4 | Distribution of protein intake across main meals and snacks (in % of the total amount of protein 
consumed) during short-term hospitalization in older, hospitalized males (A; n = 37) and females (B; n = 64). 
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males (A; n = 37) and females (B; n = 64). * Indicates a significant difference when compared with provided, 
P<0.001; † Indicates a significant difference when compared with dinner,  P<0.001; ‡ Indicates a significant 
difference when compared with lunch, P<0.05. 
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Figure 4 | Distribution of protein intake across main meals and snacks (in % of the total amount of protein 
consumed) during short-term hospitalization in older, hospitalized males (A; n = 37) and females (B; n = 64). 
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Protein sources  
The contribution of animal- and plant-based sources to total protein intake (%) is shown in 
Figure 5. In total, protein intake from self-selected hospital meals contained a higher amount 
animal-based protein sources when compared with plant-based protein sources (66±7% and 
34±7%, respectively, P<0.001). Dairy products and eggs provided the largest amount of 
animal-based proteins (35±12%), followed by meat and fish (30±11%). For plant-based 
protein sources, bread, cereals, and potatoes provided the largest amount of protein (26±7%). 
Fruit, vegetables, and legumes provided only 4±2% of plant-based protein to the total diet, 
and 4±3% did not fit in any of these categories.  
 
 
Figure 5 | Contribution of animal- and plant-based sources to total dietary protein intake (expressed as a 
percentage of total protein intake) in older, hospitalized patients (n = 101).  
 
 
 
D ISCUSSION  
Self-selected hospital meals provided patients with ~0.8 g·kg-1·d-1 protein during short-term 
hospitalization, while actual protein intake was below 0.6 g·kg-1·d-1 with more than 30% of the 
provided food being discarded. Absolute protein intake per main meal ranged from 14 to 22 
g in all patients, with protein intake being particularly low at breakfast in females. A total of 
34% of daily protein intake was derived from plant-based protein sources. 
In the present study, we assessed actual energy and protein consumption patterns during 
short-term hospitalization in older patients admitted for elective hip and knee arthroplasty. 
Daily energy consumption averaged 5.29±1.77 and 3.96±1.39 MJ·d-1 in males and females, 
respectively, which is merely ~50% of the estimated energy requirements. Consequently, all 
patients remained in a negative energy balance throughout their hospitalization. At present, 
up to 30% of the older patients in Western-European hospitals have been identified as being 
malnourished during hospitalization [9-11, 43, 44]. Poor nutritional status in older hospitalized 
patients has been associated with accelerated weight loss, slower wound healing, an increase 
in length of hospital stay, higher mortality rates, and more frequent hospital readmission [9-
11, 44, 45]. An energy deficit during hospitalization and bedrest accelerates the loss of skeletal 
muscle mass [20]. The muscle atrophy typically observed during hospitalization [19, 46] may 
be largely attributed to the lack of sufficient protein consumed as a result of low(er) energy 
intake levels. We assessed dietary protein consumption in older patients during short-term 
hospitalization after total hip or knee arthroplasty. Self-selected hospital meals provided 
patients with merely ~0.8 g·kg-1·d-1 protein, which is well below recommended daily intake 
levels of 1.2 g·kg-1·d-1. Since 30% of food provided was discarded, actual protein consumption 
was much lower and averaged 0.6 g·kg-1·d-1. Protein intake was particularly low on the day of 
surgery when compared with subsequent hospitalization days (Figure 2). Though protein 
consumption increased on the following days of recovery on the orthopedic ward, protein 
consumption still remained far below recommended daily intake levels (1.2 g·kg-1·d-1) 
throughout the entire hospitalization period. This seems to support previous work showing 
that protein consumption is insufficient in older patients during short-term hospitalization [35, 
38]. Consequently, interventional strategies should be employed to effectively increase energy 
intake to match energy requirements and, as such, avoid energy malnutrition. Furthermore, 
protein intake should be maintained at habitual intake levels, which in the light of a reduced 
daily energy intake, requires the instalment of a more protein-dense diet. 
The ingestion of dietary protein, and more specifically the postprandial rise in plasma amino 
acid concentrations, stimulates muscle protein synthesis and inhibits muscle protein 
breakdown, thereby stimulating muscle protein accretion [47]. The postprandial increase in 
muscle protein synthesis rates forms an important factor in muscle mass maintenance. 
Ingestion of 20 g of a high quality protein has been shown to increase postprandial muscle 
protein synthesis rates in young adults [48, 49]. Due to anabolic resistance with aging, greater 
amounts of protein (>20 g per meal) are required to significantly stimulate muscle protein 
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Daily energy consumption averaged 5.29±1.77 and 3.96±1.39 MJ·d-1 in males and females, 
respectively, which is merely ~50% of the estimated energy requirements. Consequently, all 
patients remained in a negative energy balance throughout their hospitalization. At present, 
up to 30% of the older patients in Western-European hospitals have been identified as being 
malnourished during hospitalization [9-11, 43, 44]. Poor nutritional status in older hospitalized 
patients has been associated with accelerated weight loss, slower wound healing, an increase 
in length of hospital stay, higher mortality rates, and more frequent hospital readmission [9-
11, 44, 45]. An energy deficit during hospitalization and bedrest accelerates the loss of skeletal 
muscle mass [20]. The muscle atrophy typically observed during hospitalization [19, 46] may 
be largely attributed to the lack of sufficient protein consumed as a result of low(er) energy 
intake levels. We assessed dietary protein consumption in older patients during short-term 
hospitalization after total hip or knee arthroplasty. Self-selected hospital meals provided 
patients with merely ~0.8 g·kg-1·d-1 protein, which is well below recommended daily intake 
levels of 1.2 g·kg-1·d-1. Since 30% of food provided was discarded, actual protein consumption 
was much lower and averaged 0.6 g·kg-1·d-1. Protein intake was particularly low on the day of 
surgery when compared with subsequent hospitalization days (Figure 2). Though protein 
consumption increased on the following days of recovery on the orthopedic ward, protein 
consumption still remained far below recommended daily intake levels (1.2 g·kg-1·d-1) 
throughout the entire hospitalization period. This seems to support previous work showing 
that protein consumption is insufficient in older patients during short-term hospitalization [35, 
38]. Consequently, interventional strategies should be employed to effectively increase energy 
intake to match energy requirements and, as such, avoid energy malnutrition. Furthermore, 
protein intake should be maintained at habitual intake levels, which in the light of a reduced 
daily energy intake, requires the instalment of a more protein-dense diet. 
The ingestion of dietary protein, and more specifically the postprandial rise in plasma amino 
acid concentrations, stimulates muscle protein synthesis and inhibits muscle protein 
breakdown, thereby stimulating muscle protein accretion [47]. The postprandial increase in 
muscle protein synthesis rates forms an important factor in muscle mass maintenance. 
Ingestion of 20 g of a high quality protein has been shown to increase postprandial muscle 
protein synthesis rates in young adults [48, 49]. Due to anabolic resistance with aging, greater 
amounts of protein (>20 g per meal) are required to significantly stimulate muscle protein 
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synthesis in older individuals [50-52]. In the present study, the amount of protein consumed 
at breakfast, lunch, and dinner varied between 14 and 22 g in both the male and female 
patients (Table 2). While protein intake per meal was likely sufficient to induce an anabolic 
response in the male patients, protein intake remained well below 20 g for most meals in 
females. Particularly at breakfast, protein intake averaged only 14±7 g in the female patients. 
This seems to agree with previous findings showing that protein consumption is particularly 
low at breakfast in older individuals [21, 23, 53]. Given the suboptimal anabolic response with 
every main meal and the presence of anabolic resistance to protein ingestion in older 
individuals [52], the protein content of each main meal should be increased to allow ingestion 
of at least 20 g protein per main meal.  
As animal-based proteins are generally regarded as being more anabolic than plant-based 
proteins [54, 55], we also assessed the contribution of animal- and plant-based protein sources 
to total dietary protein intake (Figure 5). Self-selected hospital meals contained a relative large 
amount of animal-based protein sources (66±1%) when compared with plant-based protein 
sources (34±1%). This is in line with the general Western diet in community-dwelling older 
adults [56]. As shown in Figure 5, protein intake in older patients was mainly derived from 
meat, fish, dairy products and eggs, which are the main protein sources consumed in the aging 
population [6, 57, 58]. The relative contribution of animal versus plant-based protein sources 
in the hospital diet does not seem to require any modification. 
Our data clearly show that even healthy patients admitted for elective hip or knee arthroplasty 
consume far less energy and protein than the estimated daily requirements. Since more than 
30% of the provided food is not consumed, it is obvious that simply increasing food provision 
will not be effective to prevent energy and protein malnutrition during hospitalization. As the 
maintenance of habitual protein intake levels is key to attenuate muscle mass loss, a more 
protein-dense diet should be consumed as total energy intake is typically reduced during 
hospitalization. Various strategies can be applied to increase the relative protein intake in the 
diet, including the consumption of more protein-rich foods, supplementation with oral 
nutritional supplements (ONS), fortification of meals with protein isolates, and/or the provision 
of well-timed protein-rich snacks [35, 37, 59, 60]. To increase absolute protein intake in the 
diet, a first target for intervention should be breakfast. As protein consumption is typically low 
at breakfast (Figure 3), increasing protein intake at breakfast should be of greater benefit. In 
support, additional protein supplementation at breakfast has been shown to increase skeletal 
muscle mass and function in older, frail individuals [61, 62]. Another target would be increasing 
food consumption on the day of surgery. As energy and protein intake were hardly existing 
on the day of surgery, food provision during the pre- and post-surgery period could be 
installed within the restraints set by the surgical procedures. The provision of ONS may help 
to cover the energy and protein deficits during the first 1-2 days following surgery. However, 
as time progresses food fortification, provision of more protein-dense foods, and/or an adding 
an extra protein meal will likely be more appropriate. In line, provision of protein-enriched 
foods (such as bread, yoghurt, cake, fruit juice, and soup) or the use of more protein-dense 
foods throughout the day have been shown effective in improving protein intake during 
 
 
 
hospitalization [35, 37, 59]. In addition, the timing of protein-rich products serves as alternative 
strategy to increase protein intake levels during hospitalization. We have recently shown that 
protein ingestion prior to sleep increases overnight muscle protein synthesis rates in healthy, 
older men [63, 64], and supports muscle mass and strength gains during prolonged exercise 
training in young adults [65]. However, whether prolonged pre-sleep protein supplementation 
can attenuate muscle mass and/or strength loss in older patients during hospitalization 
remains to be assessed. Nutritional intervention strategies need to be assessed for their 
efficacy to increase energy and protein intake and, as such, to help preserve muscle mass and 
strength in older patients during hospitalization. 
In conclusion, energy and protein intake levels remain well below requirements during 
hospitalization in older patients admitted for elective hip or knee arthroplasty. While patients 
are provided with 0.8 g protein·kg-1·d-1, actual protein consumption does not even reach 0.6 
g·kg-1·d-1 with 30% of the provided food being discarded. Strategic interventions are required 
to increase energy intake and ensure maintenance of habitual protein intake levels in older 
patients admitted for elective orthopedic surgery.  
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ABST RACT  
Context:  The progressive loss of muscle mass with aging is accelerated in type 2 
diabetes patients. It has been suggested that this is attributed to a blunted 
muscle protein synthetic response to food intake.  
Objective:  To test the hypothesis that the muscle protein synthetic response to protein 
ingestion is impaired in older type 2 diabetes patients when compared with 
healthy, normoglycemic controls.  
Design:  We conducted a parallel-group design, clinical intervention study between 
August 2011 and July 2012. 
Setting:  The study was conducted at our research unit of Maastricht University, the 
Netherlands. 
Intervention:  Eleven older type 2 diabetes males (Diabetes; age: 71±1 y, BMI: 26.2±0.5 
kg∙m-2) and twelve age-, and BMI-matched normoglycemic controls 
(Control; age: 74±1 y, BMI: 24.8±1.1 kg∙m-2) participated in an experiment in 
which they ingested 20 g intrinsically L-[1-13C]-phenylalanine labelled 
protein. Continuous intravenous L-[ring-2H5]-phenylalanine infusion was 
applied and blood and muscle samples were obtained to assess amino acid 
kinetics and muscle protein synthesis rates in the postabsorptive and 
postprandial state. 
Results:  Plasma insulin concentrations increased following protein ingestion in both 
groups, with a greater rise in the Diabetes group. Postabsorptive and 
postprandial muscle protein synthesis rates did not differ between groups 
and averaged 0.029±0.003 vs 0.029±0.003 %·h-1 and 0.031±0.002 vs 
0.033±0.002 %·h-1 in the Diabetes and Control group, respectively. 
Postprandial L-[1-13C]-phenylalanine incorporation in muscle protein did 
not differ between groups (0.018±0.001 vs 0.019±0.002 MPE, respectively).  
Conclusions:  Postabsorptive muscle protein synthesis and postprandial protein handling 
is not impaired in older individuals with type 2 diabetes when compared 
with age-matched, normoglycemic controls.  
  
 
 
IN TRODU CTION  
The progressive loss of muscle mass and strength with aging, termed sarcopenia, leads to a 
decline in functional capacity and an increased risk for developing chronic metabolic diseases, 
such as obesity and type 2 diabetes. Our laboratory [1, 2] as well as others [3, 4] have 
demonstrated that sarcopenia is more pronounced in older individuals with type 2 diabetes 
when compared with age-matched, normoglycemic controls. Combined with the fact that 
skeletal muscle tissue is responsible for most of the glucose taken up from the circulation, it 
is evident that age-related muscle loss can be regarded both a cause as well as a consequence 
of type 2 diabetes. 
Skeletal muscle mass maintenance is regulated by the dynamic balance between muscle 
protein synthesis and breakdown. A substantial loss of skeletal muscle mass must be attributed 
to a chronic increase in muscle protein breakdown rate and/or a decrease in the rate of muscle 
protein synthesis [5, 6]. Because basal (postabsorptive) muscle protein synthesis [7-10] and 
breakdown [9, 10] rates do not seem to be affected by age, recent work has been focusing on 
the anabolic response to food intake. It has been well established that dietary protein ingestion 
directly stimulates muscle protein synthesis [6, 11-13]. More recent work shows that older 
individuals display a reduced responsiveness to the anabolic properties of amino acid or 
protein administration [7, 9, 11, 14]. This anabolic resistance to protein feeding is now believed 
to represent a key factor responsible for the age-related muscle loss [5, 6, 15]. It has been 
suggested that skeletal muscle insulin resistance may play a key role in the development of 
this age-related anabolic resistance [10, 16, 17]. A reduced capacity of the postprandial rise in 
circulating insulin levels to stimulate muscle perfusion has previously been demonstrated to 
restrict amino acid delivery to the muscle and, as such, may attenuate the postprandial 
stimulation of muscle protein synthesis rates [9, 10]. 
We hypothesize that the muscle protein synthetic response to protein ingestion is more 
impaired in older individuals with type 2 diabetes when compared with age-matched, 
normoglycemic controls. Few studies have addressed the possible impairments in muscle 
protein metabolism in the type 2 diabetic state [18-22]. Although several studies have 
compared basal whole-body [18, 20-27] or muscle protein synthesis rates [19, 21, 22, 28], no 
studies have been carried out comparing postprandial muscle protein synthesis rates between 
type 2 diabetes patients and age-matched, normoglycemic controls. 
In the present study, we assess both basal muscle protein synthesis rates and muscle protein 
synthesis rates after the ingestion of a single meal-like bolus (20 g) of dietary protein in older 
individuals with and without controlled type 2 diabetes. We combined contemporary stable 
isotope methodology with the ingestion of intrinsically labeled protein [29, 30] which allows 
us to assess both postabsorptive and postprandial muscle protein synthesis rates as well as 
the incorporation of dietary-protein derived amino acids into skeletal muscle proteins.   
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ABST RACT  
Context:  The progressive loss of muscle mass with aging is accelerated in type 2 
diabetes patients. It has been suggested that this is attributed to a blunted 
muscle protein synthetic response to food intake.  
Objective:  To test the hypothesis that the muscle protein synthetic response to protein 
ingestion is impaired in older type 2 diabetes patients when compared with 
healthy, normoglycemic controls.  
Design:  We conducted a parallel-group design, clinical intervention study between 
August 2011 and July 2012. 
Setting:  The study was conducted at our research unit of Maastricht University, the 
Netherlands. 
Intervention:  Eleven older type 2 diabetes males (Diabetes; age: 71±1 y, BMI: 26.2±0.5 
kg∙m-2) and twelve age-, and BMI-matched normoglycemic controls 
(Control; age: 74±1 y, BMI: 24.8±1.1 kg∙m-2) participated in an experiment in 
which they ingested 20 g intrinsically L-[1-13C]-phenylalanine labelled 
protein. Continuous intravenous L-[ring-2H5]-phenylalanine infusion was 
applied and blood and muscle samples were obtained to assess amino acid 
kinetics and muscle protein synthesis rates in the postabsorptive and 
postprandial state. 
Results:  Plasma insulin concentrations increased following protein ingestion in both 
groups, with a greater rise in the Diabetes group. Postabsorptive and 
postprandial muscle protein synthesis rates did not differ between groups 
and averaged 0.029±0.003 vs 0.029±0.003 %·h-1 and 0.031±0.002 vs 
0.033±0.002 %·h-1 in the Diabetes and Control group, respectively. 
Postprandial L-[1-13C]-phenylalanine incorporation in muscle protein did 
not differ between groups (0.018±0.001 vs 0.019±0.002 MPE, respectively).  
Conclusions:  Postabsorptive muscle protein synthesis and postprandial protein handling 
is not impaired in older individuals with type 2 diabetes when compared 
with age-matched, normoglycemic controls.  
  
 
 
IN TRODU CTION  
The progressive loss of muscle mass and strength with aging, termed sarcopenia, leads to a 
decline in functional capacity and an increased risk for developing chronic metabolic diseases, 
such as obesity and type 2 diabetes. Our laboratory [1, 2] as well as others [3, 4] have 
demonstrated that sarcopenia is more pronounced in older individuals with type 2 diabetes 
when compared with age-matched, normoglycemic controls. Combined with the fact that 
skeletal muscle tissue is responsible for most of the glucose taken up from the circulation, it 
is evident that age-related muscle loss can be regarded both a cause as well as a consequence 
of type 2 diabetes. 
Skeletal muscle mass maintenance is regulated by the dynamic balance between muscle 
protein synthesis and breakdown. A substantial loss of skeletal muscle mass must be attributed 
to a chronic increase in muscle protein breakdown rate and/or a decrease in the rate of muscle 
protein synthesis [5, 6]. Because basal (postabsorptive) muscle protein synthesis [7-10] and 
breakdown [9, 10] rates do not seem to be affected by age, recent work has been focusing on 
the anabolic response to food intake. It has been well established that dietary protein ingestion 
directly stimulates muscle protein synthesis [6, 11-13]. More recent work shows that older 
individuals display a reduced responsiveness to the anabolic properties of amino acid or 
protein administration [7, 9, 11, 14]. This anabolic resistance to protein feeding is now believed 
to represent a key factor responsible for the age-related muscle loss [5, 6, 15]. It has been 
suggested that skeletal muscle insulin resistance may play a key role in the development of 
this age-related anabolic resistance [10, 16, 17]. A reduced capacity of the postprandial rise in 
circulating insulin levels to stimulate muscle perfusion has previously been demonstrated to 
restrict amino acid delivery to the muscle and, as such, may attenuate the postprandial 
stimulation of muscle protein synthesis rates [9, 10]. 
We hypothesize that the muscle protein synthetic response to protein ingestion is more 
impaired in older individuals with type 2 diabetes when compared with age-matched, 
normoglycemic controls. Few studies have addressed the possible impairments in muscle 
protein metabolism in the type 2 diabetic state [18-22]. Although several studies have 
compared basal whole-body [18, 20-27] or muscle protein synthesis rates [19, 21, 22, 28], no 
studies have been carried out comparing postprandial muscle protein synthesis rates between 
type 2 diabetes patients and age-matched, normoglycemic controls. 
In the present study, we assess both basal muscle protein synthesis rates and muscle protein 
synthesis rates after the ingestion of a single meal-like bolus (20 g) of dietary protein in older 
individuals with and without controlled type 2 diabetes. We combined contemporary stable 
isotope methodology with the ingestion of intrinsically labeled protein [29, 30] which allows 
us to assess both postabsorptive and postprandial muscle protein synthesis rates as well as 
the incorporation of dietary-protein derived amino acids into skeletal muscle proteins.   
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Subjects 
Eleven older, type 2 diabetes mellitus patients [Diabetes; age: 71±1 y, body weight: 80±2 kg, 
body mass index: (BMI) 26.2±0.5 kg·m-2, lean body mass: 61±1 kg] and 12 age- and BMI-
matched, normoglycemic controls (Control; age: 74±1 y, body weight: 75±4 kg, BMI: 24.8±1.1 
kg·m-2, lean body mass: 57±3 kg) were examined in the current study. Subjects' characteristics 
are presented in Table 1. Diabetes patients were using oral blood glucose-lowering 
medication [buguanides (n = 4); sulfonylurea derivatives (n = 2); buguanides in combination 
with sulfonylurea derivatives (n = 1); buguanides in combination with dipeptidyl peptidase IV 
inhibitor (n = 1); buguanides in combination with sulfonylurea derivatives and dipeptidyl 
peptidase IV inhibitor (n = 1)] or were undergoing lifestyle intervention (n = 2). Habitual 
medication use was continued prior to and on the day of the experimental trial to be able to 
maintain their daily living setting of the patients and not disturb their glucose control. Diabetes 
patients had been diagnosed with type 2 diabetes between 2 and 18 years prior to screening. 
The subjects were part of two larger projects on muscle protein metabolism in older subjects. 
The trial was conducted between August 2011 and July 2012 at Maastricht University, The 
Netherlands. One subject in the diabetes group was unable to complete the trial and was 
withdrawn from analysis. Subjects were informed of the nature and possible risks of the 
experimental procedures prior to obtaining written informed consent. This study was 
approved by the Medical Ethical Committee of the Maastricht University Medical Centre, The 
Netherlands, conformed to standards for the use of human subjects in research as outlined in 
the sixth Declaration of Helsinki. 
Pretesting 
All subjects participated in a screening session to assess glycated hemoglobin (HbA1C), glucose 
tolerance (by a 2-hour oral glucose tolerance test (OGTT) [31], blood pressure, and body 
composition (by dual-energy X-ray absorptiometry; Discovery A; Hologic). The diabetes 
patients refrained from consuming their oral blood glucose-lowering medication for 48 hours 
prior to the screening session. The participants were deemed healthy (except for type 2 
diabetes in the diabetes patients) based on their responses to a medical questionnaire and 
screening results. All participants refrained from strenuous physical activity and maintained 
their diet as constant as possible for 2 days prior to the experiment. On the evening before 
the trial, a standardized meal was consumed (570 kcal; 31.7±1.1 kJ·kg-1 body weight) 
composed of 16 energy (En)% protein, 32 En% carbohydrate, and 49 En% fat.  
  
 
 
Table 1 | Subjects’ characteristics 
 Control (n = 12) Diabetes (n = 11) 
Age (y) 74±1 71±1 
Weight (kg) 75.0±4.2 80.4±1.6 
BMI (kg·m2) 24.8±1.1 26.2±0.5 
Fat (%) 20.2±1.3 21.5±0.8 
Lean body mass (kg) 57.3±2.6 60.6±1.0 
Appendicular lean mass (kg and %) 24.5±1.1 (33±1%) 26.1±0.5 (33±1%) 
Skeletal muscle mass index (kg·m-2) 8.1±0.3 8.5±0.1 
Basal plasma leucine (μmol·L-1)  124 ± 5 144 ± 5* 
Basal plasma glucose (mmol·L-1) 5.7±0.1 9.6±0.8* 
Plasma glucose OGTT t=120 min (mmol·L-1) 5.5±0.4 16.3±0.9* 
Basal plasma insulin (mU·L-1) 5.2±0.7 16.8±2.3* 
Plasma insulin OGTT t=120 min (mU·L-1) 30.9±5.2 45.6±7.7 
HbA1C (% and mmol·mol-1) 5.6±0.1 (38.2±1.2) 7.2±0.3 (54.6±2.8)* 
OGIS (mL·min-1·m-2) 391±15 286±11* 
HOMA-IR 0.7±0.1 2.5±0.3* 
Values are mean ± SEM. HbA1C: glycated hemoglobin; OGTT: oral glucose tolerance test; OGIS: oral glucose insulin 
sensitivity, HOMA: homeostasis model assessment. Data were analyzed by unpaired Student’s t-tests. * Statistically 
significant difference with P<0.001. 
Experimental protocol 
At 8:00 AM, after an overnight fast, participants arrived at the laboratory by car or public 
transport. A Teflon catheter was inserted into an antecubital vein for infusion and a second 
cannula into the dorsal hand vein of the contralateral arm and was placed in a hot box (60°C) 
for arterialized blood sampling [32]. After baseline blood collection (t = −210 min), the plasma 
phenylalanine and tyrosine pools were primed with a single iv dose of L-[ring-2H5]-
phenylalanine (2 μmol·kg-1) and L-[ring-3,5-2H2]-tyrosine (0.615 μmol·kg-1), after which a 
continuous 8.5-hour L-[ring-2H5]-phenylalanine and L-[ring-3,5-2H2]-tyrosine infusion was 
initiated (0.05 and 0.15 μmol·kg-1·min1, respectively). Multiple blood samples were collected 
during the infusion at t = −210, −120, −90, −60, −30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 
240, 270, and 300 minutes. Blood samples were collected in EDTA-containing tubes and 
centrifuged at 1000 × g at 4°C for 10 minutes. Aliquots of plasma were frozen in liquid 
nitrogen and stored at −80°C. Muscle biopsies were collected for the determination of 
postabsorptive muscle protein synthesis rates (t = −120 and 0 min). Immediately after the 
second biopsy, subjects ingested a single bolus of 20 g intrinsically L-[1-13C]-phenylalanine-
labeled casein protein dissolved in 350 mL water, which was flavored with 1.5 mL vanilla (IMCD 
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Subjects 
Eleven older, type 2 diabetes mellitus patients [Diabetes; age: 71±1 y, body weight: 80±2 kg, 
body mass index: (BMI) 26.2±0.5 kg·m-2, lean body mass: 61±1 kg] and 12 age- and BMI-
matched, normoglycemic controls (Control; age: 74±1 y, body weight: 75±4 kg, BMI: 24.8±1.1 
kg·m-2, lean body mass: 57±3 kg) were examined in the current study. Subjects' characteristics 
are presented in Table 1. Diabetes patients were using oral blood glucose-lowering 
medication [buguanides (n = 4); sulfonylurea derivatives (n = 2); buguanides in combination 
with sulfonylurea derivatives (n = 1); buguanides in combination with dipeptidyl peptidase IV 
inhibitor (n = 1); buguanides in combination with sulfonylurea derivatives and dipeptidyl 
peptidase IV inhibitor (n = 1)] or were undergoing lifestyle intervention (n = 2). Habitual 
medication use was continued prior to and on the day of the experimental trial to be able to 
maintain their daily living setting of the patients and not disturb their glucose control. Diabetes 
patients had been diagnosed with type 2 diabetes between 2 and 18 years prior to screening. 
The subjects were part of two larger projects on muscle protein metabolism in older subjects. 
The trial was conducted between August 2011 and July 2012 at Maastricht University, The 
Netherlands. One subject in the diabetes group was unable to complete the trial and was 
withdrawn from analysis. Subjects were informed of the nature and possible risks of the 
experimental procedures prior to obtaining written informed consent. This study was 
approved by the Medical Ethical Committee of the Maastricht University Medical Centre, The 
Netherlands, conformed to standards for the use of human subjects in research as outlined in 
the sixth Declaration of Helsinki. 
Pretesting 
All subjects participated in a screening session to assess glycated hemoglobin (HbA1C), glucose 
tolerance (by a 2-hour oral glucose tolerance test (OGTT) [31], blood pressure, and body 
composition (by dual-energy X-ray absorptiometry; Discovery A; Hologic). The diabetes 
patients refrained from consuming their oral blood glucose-lowering medication for 48 hours 
prior to the screening session. The participants were deemed healthy (except for type 2 
diabetes in the diabetes patients) based on their responses to a medical questionnaire and 
screening results. All participants refrained from strenuous physical activity and maintained 
their diet as constant as possible for 2 days prior to the experiment. On the evening before 
the trial, a standardized meal was consumed (570 kcal; 31.7±1.1 kJ·kg-1 body weight) 
composed of 16 energy (En)% protein, 32 En% carbohydrate, and 49 En% fat.  
  
 
 
Table 1 | Subjects’ characteristics 
 Control (n = 12) Diabetes (n = 11) 
Age (y) 74±1 71±1 
Weight (kg) 75.0±4.2 80.4±1.6 
BMI (kg·m2) 24.8±1.1 26.2±0.5 
Fat (%) 20.2±1.3 21.5±0.8 
Lean body mass (kg) 57.3±2.6 60.6±1.0 
Appendicular lean mass (kg and %) 24.5±1.1 (33±1%) 26.1±0.5 (33±1%) 
Skeletal muscle mass index (kg·m-2) 8.1±0.3 8.5±0.1 
Basal plasma leucine (μmol·L-1)  124 ± 5 144 ± 5* 
Basal plasma glucose (mmol·L-1) 5.7±0.1 9.6±0.8* 
Plasma glucose OGTT t=120 min (mmol·L-1) 5.5±0.4 16.3±0.9* 
Basal plasma insulin (mU·L-1) 5.2±0.7 16.8±2.3* 
Plasma insulin OGTT t=120 min (mU·L-1) 30.9±5.2 45.6±7.7 
HbA1C (% and mmol·mol-1) 5.6±0.1 (38.2±1.2) 7.2±0.3 (54.6±2.8)* 
OGIS (mL·min-1·m-2) 391±15 286±11* 
HOMA-IR 0.7±0.1 2.5±0.3* 
Values are mean ± SEM. HbA1C: glycated hemoglobin; OGTT: oral glucose tolerance test; OGIS: oral glucose insulin 
sensitivity, HOMA: homeostasis model assessment. Data were analyzed by unpaired Student’s t-tests. * Statistically 
significant difference with P<0.001. 
Experimental protocol 
At 8:00 AM, after an overnight fast, participants arrived at the laboratory by car or public 
transport. A Teflon catheter was inserted into an antecubital vein for infusion and a second 
cannula into the dorsal hand vein of the contralateral arm and was placed in a hot box (60°C) 
for arterialized blood sampling [32]. After baseline blood collection (t = −210 min), the plasma 
phenylalanine and tyrosine pools were primed with a single iv dose of L-[ring-2H5]-
phenylalanine (2 μmol·kg-1) and L-[ring-3,5-2H2]-tyrosine (0.615 μmol·kg-1), after which a 
continuous 8.5-hour L-[ring-2H5]-phenylalanine and L-[ring-3,5-2H2]-tyrosine infusion was 
initiated (0.05 and 0.15 μmol·kg-1·min1, respectively). Multiple blood samples were collected 
during the infusion at t = −210, −120, −90, −60, −30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 
240, 270, and 300 minutes. Blood samples were collected in EDTA-containing tubes and 
centrifuged at 1000 × g at 4°C for 10 minutes. Aliquots of plasma were frozen in liquid 
nitrogen and stored at −80°C. Muscle biopsies were collected for the determination of 
postabsorptive muscle protein synthesis rates (t = −120 and 0 min). Immediately after the 
second biopsy, subjects ingested a single bolus of 20 g intrinsically L-[1-13C]-phenylalanine-
labeled casein protein dissolved in 350 mL water, which was flavored with 1.5 mL vanilla (IMCD 
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Benelux N.V.). Additional biopsies were collected at t = 120 and 300 minutes (from the 
contralateral leg) for the determination of postprandial muscle protein synthesis rates. Muscle 
biopsies were collected from the middle region of the vastus lateralis (15 cm above the patella) 
using the Bergström needle technique [33]. All biopsy samples were freed from any visible 
adipose tissue and blood, immediately frozen in liquid nitrogen, and stored at −80°C until 
subsequent analysis.  
Production of intrinsically labeled protein 
Intrinsically L-[1-13C]-phenylalanine labeled casein was produced by infusing L-[1-13C]-
phenylalanine into a lactating Holstein cow, collecting milk, and purifying the casein fraction 
as described previously [29]. The L-[1-13C]-phenylalanine enrichment in casein protein was 
measured by gas chromatography mass spectrometry (GC-MS; Agilent 7890A GC/5975C; 
MSD) and averaged 39 mole percent excess (MPE). The dietary protein met all chemical and 
bacteriologic specifications for human consumption. 
Plasma analyses  
Plasma glucose and insulin concentrations were analyzed using commercially available kits 
(GLUC3; Roche; reference 05168791 190; and Immunologic; Roche; reference 12017547 122, 
respectively). Plasma amino acid concentrations and enrichments were determined by GC-MS. 
Specifically, internal standards of [U-13C6]-leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-
tyrosine were added to the samples. The plasma was deproteinized on ice with 5-sulfosalicylic 
acid. Free amino acids were purified using cation exchange chromatography (AG 50W-X8 
resin, 100–200 µm dry mesh size; Bio-Rad Laboratories, Hercules, CA). The free amino acids 
were converted to their tert-butyl dimethylsilyl (TBDMS) derivative with MTBSTFA before 
analysis by GC-MS. The AA concentrations were determined using electron impact ionization 
by monitoring ions at mass/charge (m/z) 302 and 308 for unlabeled and [U-13C6]-leucine 
respectively, 336 and 346 for unlabeled and [U-13C915N]-phenylalanine respectively, and 466 
and 476 for unlabeled and [U-13C915N]-tyrosine respectively. The plasma phenylalanine and 
tyrosine 13C and 2H enrichments were determined using selective ion monitoring at m/z 336, 
337, and 341 for unlabeled and labeled (1-13C and ring-2H5)-phenylalanine respectively, and 
m/z 466, 467, 468, and 470 for unlabeled and labeled (1-13C, ring-3,5-2H2, and ring-2H4)-
tyrosine respectively. Standard regression curves were applied from a series of known standard 
enrichment values against the measured values to assess the linearity of the mass 
spectrometer and to account for any isotope fractionation which may have occurred during 
the analysis. Phenylalanine and tyrosine enrichments were corrected for the presence of both 
the 13C and 2H isotopes.  
  
 
 
Muscle analyses  
Muscle-tissue free (intracellular) L-[ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine 
enrichments were determined using GC-MS analysis. Mixed muscle protein-bound L-[ring-
2H5]-phenylalanine enrichment was determined by GC-MS, and mixed muscle protein-bound 
L-[1-13C]-phenylalanine enrichment were measured by GC-C-isotope ratio mass (Finnigan 
MAT 253; Bremen) using an HP Ultra I GC-column (number 19091A-112; Hewlett-Packard).  
A piece of wet muscle (~50 mg) was freeze-dried, and collagen, blood, and other non-muscle 
tissue were removed under a dissecting microscope. The freeze-dried muscle was weighed 
(~8 mg) and homogenized in 35 volumes of ice-cold 2% perchloric acid (PCA). Samples were 
incubated on ice for 10 min. After centrifugation, the supernatant was collected for 
determination of L-[ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine enrichments in the 
muscle-free AA pool using GC-MS analysis. The mixed muscle protein pellet was washed three 
times with 1 mL of ice-cold 2% PCA and hydrolyzed in 3 mL of 6 M HCl overnight at 120 °C. 
The free AA were then dissolved in 50% acetic acid solution and passed over cation exchange 
AG 50W-X8 resin columns (mesh size: 100-200 µm, ionic form: hydrogen (Bio-Rad 
Laboratories, Hercules, CA)). AA were eluted with 2M NH4OH and divided over 2 vials for 
separate measurements of L-[1-13C]-phenylalanine and L-[ring-2H5]-phenylalanine 
enrichments in mixed muscle protein. To determine the L-[ring-2H5]-phenylalanine enrichment 
of mixed muscle protein, the purified AA were derivatized into their TBDMS derivatives with 
MTBSTFA before the ratios of labeled to unlabeled derivatives were determined by GC-MS. To 
determine the L-[1-13C]-phenylalanine enrichment of mixed muscle protein, the purified AA 
were derivatized into their N(O,S)-ethoxycarbonyl ethyl ester derivatives with ethyl 
chloroformate. The derivatives were then measured by GC-C-IRMS (Finnigan MAT 253, 
Bremen, Germany) using an HP Ultra I GC-column (no. 19091A-112; Hewlett-Packard, Palo 
Alto, CA) and monitoring of ion masses 44 and 45. By establishing the relation between the 
enrichment of a series of L-[1-13C]-phenylalanine standards of variable enrichments and the 
enrichments of the N(O,S)-ethoxycarbonyl ethyl esters of these standards, the mixed muscle 
protein-bound enrichment of phenylalanine was determined. Standard regression curves were 
applied to assess the linearity of the mass spectrometer and to control for the loss of tracer. 
Calculations 
Whole-body amino acid kinetics (expressed in micromoles of phenylalanine per kilogram body 
weight-1 per hour1) in nonsteady-state conditions were calculated from the ingestion of L-[1-
13C]-phenylalanine-labeled protein, iv infusion of L-[ring-2H5]-phenylalanine, and L-[ring-3,5-
2H2]-tyrosine and arterialized blood sampling. Total, exogenous, and endogenous 
phenylalanine rates of appearance (Ra) as well as plasma phenylalanine availability (i.e., the 
fraction of dietary protein derived phenylalanine that appeared in the systemic circulation) 
were calculated using modified Steele's equations [34, 35].  
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Benelux N.V.). Additional biopsies were collected at t = 120 and 300 minutes (from the 
contralateral leg) for the determination of postprandial muscle protein synthesis rates. Muscle 
biopsies were collected from the middle region of the vastus lateralis (15 cm above the patella) 
using the Bergström needle technique [33]. All biopsy samples were freed from any visible 
adipose tissue and blood, immediately frozen in liquid nitrogen, and stored at −80°C until 
subsequent analysis.  
Production of intrinsically labeled protein 
Intrinsically L-[1-13C]-phenylalanine labeled casein was produced by infusing L-[1-13C]-
phenylalanine into a lactating Holstein cow, collecting milk, and purifying the casein fraction 
as described previously [29]. The L-[1-13C]-phenylalanine enrichment in casein protein was 
measured by gas chromatography mass spectrometry (GC-MS; Agilent 7890A GC/5975C; 
MSD) and averaged 39 mole percent excess (MPE). The dietary protein met all chemical and 
bacteriologic specifications for human consumption. 
Plasma analyses  
Plasma glucose and insulin concentrations were analyzed using commercially available kits 
(GLUC3; Roche; reference 05168791 190; and Immunologic; Roche; reference 12017547 122, 
respectively). Plasma amino acid concentrations and enrichments were determined by GC-MS. 
Specifically, internal standards of [U-13C6]-leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-
tyrosine were added to the samples. The plasma was deproteinized on ice with 5-sulfosalicylic 
acid. Free amino acids were purified using cation exchange chromatography (AG 50W-X8 
resin, 100–200 µm dry mesh size; Bio-Rad Laboratories, Hercules, CA). The free amino acids 
were converted to their tert-butyl dimethylsilyl (TBDMS) derivative with MTBSTFA before 
analysis by GC-MS. The AA concentrations were determined using electron impact ionization 
by monitoring ions at mass/charge (m/z) 302 and 308 for unlabeled and [U-13C6]-leucine 
respectively, 336 and 346 for unlabeled and [U-13C915N]-phenylalanine respectively, and 466 
and 476 for unlabeled and [U-13C915N]-tyrosine respectively. The plasma phenylalanine and 
tyrosine 13C and 2H enrichments were determined using selective ion monitoring at m/z 336, 
337, and 341 for unlabeled and labeled (1-13C and ring-2H5)-phenylalanine respectively, and 
m/z 466, 467, 468, and 470 for unlabeled and labeled (1-13C, ring-3,5-2H2, and ring-2H4)-
tyrosine respectively. Standard regression curves were applied from a series of known standard 
enrichment values against the measured values to assess the linearity of the mass 
spectrometer and to account for any isotope fractionation which may have occurred during 
the analysis. Phenylalanine and tyrosine enrichments were corrected for the presence of both 
the 13C and 2H isotopes.  
  
 
 
Muscle analyses  
Muscle-tissue free (intracellular) L-[ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine 
enrichments were determined using GC-MS analysis. Mixed muscle protein-bound L-[ring-
2H5]-phenylalanine enrichment was determined by GC-MS, and mixed muscle protein-bound 
L-[1-13C]-phenylalanine enrichment were measured by GC-C-isotope ratio mass (Finnigan 
MAT 253; Bremen) using an HP Ultra I GC-column (number 19091A-112; Hewlett-Packard).  
A piece of wet muscle (~50 mg) was freeze-dried, and collagen, blood, and other non-muscle 
tissue were removed under a dissecting microscope. The freeze-dried muscle was weighed 
(~8 mg) and homogenized in 35 volumes of ice-cold 2% perchloric acid (PCA). Samples were 
incubated on ice for 10 min. After centrifugation, the supernatant was collected for 
determination of L-[ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine enrichments in the 
muscle-free AA pool using GC-MS analysis. The mixed muscle protein pellet was washed three 
times with 1 mL of ice-cold 2% PCA and hydrolyzed in 3 mL of 6 M HCl overnight at 120 °C. 
The free AA were then dissolved in 50% acetic acid solution and passed over cation exchange 
AG 50W-X8 resin columns (mesh size: 100-200 µm, ionic form: hydrogen (Bio-Rad 
Laboratories, Hercules, CA)). AA were eluted with 2M NH4OH and divided over 2 vials for 
separate measurements of L-[1-13C]-phenylalanine and L-[ring-2H5]-phenylalanine 
enrichments in mixed muscle protein. To determine the L-[ring-2H5]-phenylalanine enrichment 
of mixed muscle protein, the purified AA were derivatized into their TBDMS derivatives with 
MTBSTFA before the ratios of labeled to unlabeled derivatives were determined by GC-MS. To 
determine the L-[1-13C]-phenylalanine enrichment of mixed muscle protein, the purified AA 
were derivatized into their N(O,S)-ethoxycarbonyl ethyl ester derivatives with ethyl 
chloroformate. The derivatives were then measured by GC-C-IRMS (Finnigan MAT 253, 
Bremen, Germany) using an HP Ultra I GC-column (no. 19091A-112; Hewlett-Packard, Palo 
Alto, CA) and monitoring of ion masses 44 and 45. By establishing the relation between the 
enrichment of a series of L-[1-13C]-phenylalanine standards of variable enrichments and the 
enrichments of the N(O,S)-ethoxycarbonyl ethyl esters of these standards, the mixed muscle 
protein-bound enrichment of phenylalanine was determined. Standard regression curves were 
applied to assess the linearity of the mass spectrometer and to control for the loss of tracer. 
Calculations 
Whole-body amino acid kinetics (expressed in micromoles of phenylalanine per kilogram body 
weight-1 per hour1) in nonsteady-state conditions were calculated from the ingestion of L-[1-
13C]-phenylalanine-labeled protein, iv infusion of L-[ring-2H5]-phenylalanine, and L-[ring-3,5-
2H2]-tyrosine and arterialized blood sampling. Total, exogenous, and endogenous 
phenylalanine rates of appearance (Ra) as well as plasma phenylalanine availability (i.e., the 
fraction of dietary protein derived phenylalanine that appeared in the systemic circulation) 
were calculated using modified Steele's equations [34, 35].  
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 Total Ra =   𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
     (1)    
Total phenylalanine Ra was calculated using equation 1, where Fiv is the intravenous tracer 
infusion rate (mol·kg-1·min-1) and pV is the distribution volume for phenylalanine (0.125       
L·kg-1) [35]. C(t) is the mean plasma phenylalanine concentration between two consecutive 
time points, dEiv/dt represents the time-dependent change in plasma phenylalanine 
enrichment derived from the intravenous tracer, and Eiv(t) is the mean plasma phenylalanine 
enrichment from the intravenous tracer between two consecutive time points.  
 Exogenous Ra =   𝑇𝑇𝑇𝑇𝑡𝑡𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎∙𝐸𝐸𝑝𝑝𝑝𝑝 (𝑡𝑡)+[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑝𝑝𝑝𝑝
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
   (2) 
Exogenous phenylalanine rate of appearance (Exo Ra) represents the plasma entry rate of 
dietary protein-derived phenylalanine. Epo(t) is the mean plasma phenylalanine enrichment of 
the oral tracer, dEpo/dt represents the time-dependent change in plasma phenylalanine 
enrichment derived from the oral tracer, and Eprot is the enrichment of L-[1-13C]-
phenylalanine in the dietary protein. 
 Endogenous Ra =  Total𝑅𝑅𝑇𝑇 –  Exo𝑅𝑅𝑇𝑇 – 𝐹𝐹𝑖𝑖𝑖𝑖    (3) 
Endogenous phenylalanine Ra (Endo Ra) represents the plasma entry rate of phenylalanine 
derived from whole-body protein breakdown.  
 Pheplasma = [ 𝐴𝐴𝐴𝐴𝐶𝐶𝐸𝐸𝐸𝐸𝑝𝑝𝐸𝐸𝑎𝑎
𝑃𝑃ℎ𝑒𝑒𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
] ∙ BW ∙ 100%   (4)  
The fraction of dietary protein-derived phenylalanine appearing in the systemic circulation 
(Pheplasma) was calculated using equation 4. AUCExoRa is the area under the curve (AUC) of 
Exo Ra; BW is the body weight of the subject in kg; Pheprot is the amount of dietary 
phenylalanine that is ingested.  
Total phenylalanine rate of disappearance (Rd, µmol Phe·kg-1·min-1) equals the rate of 
phenylalanine hydroxylation (first step in the conversion of phenylalanine to tyrosine) to the 
rate of phenylalanine utilization for protein synthesis. These parameters are calculated as 
follows: 
 Total Rd = 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑇𝑇 −  𝑝𝑝𝑝𝑝 ∙ 𝑑𝑑𝐶𝐶𝑑𝑑𝑡𝑡     (5)  
 Phe hydroxylation = 𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑇𝑇 ∙ 𝐸𝐸𝑑𝑑𝑡𝑡𝑝𝑝(𝑡𝑡)𝐸𝐸𝑝𝑝ℎ𝑒𝑒(𝑡𝑡)  ∙
𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑
(𝐹𝐹𝑃𝑃ℎ𝑒𝑒+𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑 )
   (6)  
 Protein synthesis = Total Rd – Phe hydroxylation  (7)  
 Phe net balance = Protein synthesis – Endo Ra  (8)  
TyrRa is the total rate of tyrosine appearance based on the L-[ring-3,5-2H2]-tyrosine infusion 
and plasma enrichment. Etyr(t) and EPhe(t) represent the mean plasma L-[ring-2H4]-tyrosine 
and L-[ring-2H5]-phenylalanine enrichment between 2 consecutive time points, respectively. 
Phe is the intravenous infusion rate of L-[ring-2H5]-phenylalanine (µmol∙kg-1∙min-1).  
 
 
Whole-body net protein balance was calculated by subtracting protein synthesis from 
endogenousRa and presented as the weighted mean over the 5-hour (t = 0 and t = 300 min) 
postprandial phase. 
Mixed muscle protein fractional synthesis rates (FSR) were calculated using the standard 
precursor-product equation. For basal muscle protein FSR, muscle biopsies at t = −120 and t = 
0 min were used, and for postprandial muscle protein FSR biopsies at t = 0, 120, and 300 
minutes were used to calculate the early (0–2 hours), late (2–5 hours), and aggregate response 
(0–5 hours).  
 𝐹𝐹𝐹𝐹𝐹𝐹 = 𝛥𝛥𝛥𝛥𝛥𝛥
𝛥𝛥𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 ∙ 𝑡𝑡
 ∙ 100%    (9)    
ΔEp is the increment in mixed muscle protein-bound L-[ring-2H5]-phenylalanine (MPE) after 
an incorporation period. Eprecursor is the average plasma L-[ring-2H5]-phenylalanine 
enrichment (MPE) during that incorporation period, and t is the incorporation period (h).  
Statistics 
All data are expressed as mean±SEM. Differences in baseline values were determined using 
an unpaired, two-tailed Student's t test. Area under curve (AUC), peak value, and time to peak 
were calculated for all plasma time curves, and differences were determined using an unpaired, 
two-tailed Student's t test. A two-way ANOVA with time as within-group factor and condition 
as between-group factor was used to compare differences over time in plasma glucose, insulin, 
and amino acid concentrations, plasma L-[1-13C]-phenylalanine enrichments, and whole-body 
amino acid kinetics appearance rates. Differences between groups in muscle free and protein-
bound L-[1-13C]-phenylalanine enrichments and mixed-muscle FSR were analyzed with an 
unpaired, two-tailed Student's t test. For all analyses, statistical significance was set at P<0.05. 
All calculations were performed using IBM SPSS Statistics (version 21).  
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enrichment from the intravenous tracer between two consecutive time points.  
 Exogenous Ra =   𝑇𝑇𝑇𝑇𝑡𝑡𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎∙𝐸𝐸𝑝𝑝𝑝𝑝 (𝑡𝑡)+[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑝𝑝𝑝𝑝
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
   (2) 
Exogenous phenylalanine rate of appearance (Exo Ra) represents the plasma entry rate of 
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enrichment derived from the oral tracer, and Eprot is the enrichment of L-[1-13C]-
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The fraction of dietary protein-derived phenylalanine appearing in the systemic circulation 
(Pheplasma) was calculated using equation 4. AUCExoRa is the area under the curve (AUC) of 
Exo Ra; BW is the body weight of the subject in kg; Pheprot is the amount of dietary 
phenylalanine that is ingested.  
Total phenylalanine rate of disappearance (Rd, µmol Phe·kg-1·min-1) equals the rate of 
phenylalanine hydroxylation (first step in the conversion of phenylalanine to tyrosine) to the 
rate of phenylalanine utilization for protein synthesis. These parameters are calculated as 
follows: 
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   (6)  
 Protein synthesis = Total Rd – Phe hydroxylation  (7)  
 Phe net balance = Protein synthesis – Endo Ra  (8)  
TyrRa is the total rate of tyrosine appearance based on the L-[ring-3,5-2H2]-tyrosine infusion 
and plasma enrichment. Etyr(t) and EPhe(t) represent the mean plasma L-[ring-2H4]-tyrosine 
and L-[ring-2H5]-phenylalanine enrichment between 2 consecutive time points, respectively. 
Phe is the intravenous infusion rate of L-[ring-2H5]-phenylalanine (µmol∙kg-1∙min-1).  
 
 
Whole-body net protein balance was calculated by subtracting protein synthesis from 
endogenousRa and presented as the weighted mean over the 5-hour (t = 0 and t = 300 min) 
postprandial phase. 
Mixed muscle protein fractional synthesis rates (FSR) were calculated using the standard 
precursor-product equation. For basal muscle protein FSR, muscle biopsies at t = −120 and t = 
0 min were used, and for postprandial muscle protein FSR biopsies at t = 0, 120, and 300 
minutes were used to calculate the early (0–2 hours), late (2–5 hours), and aggregate response 
(0–5 hours).  
 𝐹𝐹𝐹𝐹𝐹𝐹 = 𝛥𝛥𝛥𝛥𝛥𝛥
𝛥𝛥𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 ∙ 𝑡𝑡
 ∙ 100%    (9)    
ΔEp is the increment in mixed muscle protein-bound L-[ring-2H5]-phenylalanine (MPE) after 
an incorporation period. Eprecursor is the average plasma L-[ring-2H5]-phenylalanine 
enrichment (MPE) during that incorporation period, and t is the incorporation period (h).  
Statistics 
All data are expressed as mean±SEM. Differences in baseline values were determined using 
an unpaired, two-tailed Student's t test. Area under curve (AUC), peak value, and time to peak 
were calculated for all plasma time curves, and differences were determined using an unpaired, 
two-tailed Student's t test. A two-way ANOVA with time as within-group factor and condition 
as between-group factor was used to compare differences over time in plasma glucose, insulin, 
and amino acid concentrations, plasma L-[1-13C]-phenylalanine enrichments, and whole-body 
amino acid kinetics appearance rates. Differences between groups in muscle free and protein-
bound L-[1-13C]-phenylalanine enrichments and mixed-muscle FSR were analyzed with an 
unpaired, two-tailed Student's t test. For all analyses, statistical significance was set at P<0.05. 
All calculations were performed using IBM SPSS Statistics (version 21).  
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R ESULTS  
Plasma analyses 
Plasma glucose and insulin concentrations are presented in Figure 1. Fasting plasma glucose 
concentrations were significantly different between groups (8.2±0.6 and 5.6±0.1 mmol·L-1 in 
the diabetes and control groups, respectively, P<0.001; Figure 1A). Postprandial glucose 
levels were higher in the diabetes group (P<0.05) and decreased over time, whereas plasma 
glucose levels remained at baseline values in the controls (group × time interaction P<0.001). 
Basal plasma insulin concentrations were significantly higher in the diabetes group when 
compared with the control group (9.6±1.1 and 5.7±0.6 mU·L-1, respectively, P<0.001; Figure 
1B). Plasma insulin concentrations increased after the protein ingestion (P<0.001) to a greater 
extent in the diabetes group when compared with the controls (group × time 
interaction P<0.05) reaching peak values of 23.3±2.6 and 11.9±2.1 mU·L-1 in the diabetes and 
control groups (P<0.01), respectively. The AUC of the postprandial period was significantly 
higher in the diabetes group when compared with the healthy controls (P<0.001; Figure 1B, 
inset). 
Plasma amino acid concentrations are presented in Figure 2. Phenylalanine and tyrosine 
concentrations increased after the protein ingestion (P<0.001), with no differences between 
groups (Figure 2A and B). Fasting plasma leucine concentrations (Figure 2C) were 
significantly higher in the diabetes group compared with the controls (144±5 and 124±6 mU·  
L-1, respectively; P<0.001). Plasma leucine concentrations increased after the protein ingestion 
in both groups (time effect P<0.05) and remained higher in the diabetes group (group effect 
P<0.01; AUC: P<0.01). Peak levels were higher in diabetes patients (P<0.05; 314±19 and 
254±13 mU·L-1 in the diabetes and control group, respectively). 
  
 
 
 
Figure 1 | Mean(±SEM) plasma glucose (A) and insulin (B) concentrations (mmol·L-1 and mU·L-1, respectively) in 
healthy (n = 12) and type 2 diabetes (n = 11) older subjects after the ingestion of 20 g casein. The dotted line 
indicates the ingestion of the protein beverage. Data were analyzed by unpaired Student’s t -test (between groups) 
and repeated-measures (time x group) ANOVA. * Significantly different from control (P<0.001). Postprandial 
plasma glucose: time effect P<0.001; group effect P<0.05, interaction of time x group P<0.001; AUC between 
groups: P=0.09. Postprandial plasma insulin: time effect P<0.001; group effect P<0.001; interaction of time x 
group, P<0.05; AUC between groups: P<0.001. 
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higher in the diabetes group when compared with the healthy controls (P<0.001; Figure 1B, 
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concentrations increased after the protein ingestion (P<0.001), with no differences between 
groups (Figure 2A and B). Fasting plasma leucine concentrations (Figure 2C) were 
significantly higher in the diabetes group compared with the controls (144±5 and 124±6 mU·  
L-1, respectively; P<0.001). Plasma leucine concentrations increased after the protein ingestion 
in both groups (time effect P<0.05) and remained higher in the diabetes group (group effect 
P<0.01; AUC: P<0.01). Peak levels were higher in diabetes patients (P<0.05; 314±19 and 
254±13 mU·L-1 in the diabetes and control group, respectively). 
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Figure 2 | Mean(±SEM) plasma phenylalanine (A), tyrosine (B), and leucine (C) concentrations (μmol·L-1) in healthy 
(n = 12) and type 2 diabetes (n = 11) older subjects after the ingestion of 20 g casein. Inset shows the AUC 
calculated over the 5-hour postprandial period. The dotted line indicates the ingestion of the protein beverage. 
Data were analyzed with repeated-measures (time × group) ANOVA. * Significantly different from control 
(P<0.001). Postprandial plasma phenylalanine: time effect P<0.001. Postprandial plasma tyrosine: time effect 
P<0.001. Basal plasma leucine: time effect P<0.01; group effect P<0.001; interaction of time x group P<0.01. 
Postprandial plasma leucine: time effect P<0.001; group effect P<0.01; AUC between groups: P<0.01. 
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Plasma L-[ring-2H5]-phenylalanine, L-[ring-2H4]-phenylalanine, and L-[3,5-2H2]-phenylalanine 
enrichments (from the infused tracer), and L-[1-13C]-phenylalanine and L-[1-13C]-tyrosine 
enrichments (from the ingested tracer) are presented in Figure 3 and 4. Plasma L-[ring-2H5]-
phenylalanine enrichments (Figure 3A) did not differ between groups in the postabsorptive 
period and transiently declined after the protein ingestion, with no differences between 
groups. Plasma L-[1-13C]-phenylalanine enrichments (Figure 3B) rapidly increased after 
ingestion of protein in both groups (P<0.001), reaching peak levels of 12.3±0.7 MPE at 72±12 
minutes and 11.5±0.9 MPE at 76±16 minutes in the diabetes and control groups, respectively, 
with no differences between groups (AUC, peak values, and time to peak). 
 
Figure 3 | Mean(±SEM) plasma L-[ring-2H5]-phenylalanine (A) and L-[1-13C]-phenylalanine (B) enrichments (mole 
percent excess, MPE) enrichments (MPE) in healthy (n = 12) and type 2 diabetes (n = 11) older subjects after the 
ingestion of 20 g casein. The dotted line indicates the ingestion of the protein beverage. Data were analyzed with 
repeated-measures (time × group) ANOVA. Postprandial plasma L-[ring-2H5]-phenylalanine enrichments: time 
effect P<0.001. Plasma L-[1-13C]-phenylalanine enrichments: time effect P<0.001.   
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Figure 2 | Mean(±SEM) plasma phenylalanine (A), tyrosine (B), and leucine (C) concentrations (μmol·L-1) in healthy 
(n = 12) and type 2 diabetes (n = 11) older subjects after the ingestion of 20 g casein. Inset shows the AUC 
calculated over the 5-hour postprandial period. The dotted line indicates the ingestion of the protein beverage. 
Data were analyzed with repeated-measures (time × group) ANOVA. * Significantly different from control 
(P<0.001). Postprandial plasma phenylalanine: time effect P<0.001. Postprandial plasma tyrosine: time effect 
P<0.001. Basal plasma leucine: time effect P<0.01; group effect P<0.001; interaction of time x group P<0.01. 
Postprandial plasma leucine: time effect P<0.001; group effect P<0.01; AUC between groups: P<0.01. 
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enrichments (from the infused tracer), and L-[1-13C]-phenylalanine and L-[1-13C]-tyrosine 
enrichments (from the ingested tracer) are presented in Figure 3 and 4. Plasma L-[ring-2H5]-
phenylalanine enrichments (Figure 3A) did not differ between groups in the postabsorptive 
period and transiently declined after the protein ingestion, with no differences between 
groups. Plasma L-[1-13C]-phenylalanine enrichments (Figure 3B) rapidly increased after 
ingestion of protein in both groups (P<0.001), reaching peak levels of 12.3±0.7 MPE at 72±12 
minutes and 11.5±0.9 MPE at 76±16 minutes in the diabetes and control groups, respectively, 
with no differences between groups (AUC, peak values, and time to peak). 
 
Figure 3 | Mean(±SEM) plasma L-[ring-2H5]-phenylalanine (A) and L-[1-13C]-phenylalanine (B) enrichments (mole 
percent excess, MPE) enrichments (MPE) in healthy (n = 12) and type 2 diabetes (n = 11) older subjects after the 
ingestion of 20 g casein. The dotted line indicates the ingestion of the protein beverage. Data were analyzed with 
repeated-measures (time × group) ANOVA. Postprandial plasma L-[ring-2H5]-phenylalanine enrichments: time 
effect P<0.001. Plasma L-[1-13C]-phenylalanine enrichments: time effect P<0.001.   
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Figure 4 | Mean (±SEM) plasma L-[ring-2H4]-tyrosine (A), L-[ring-3,5-2H2]-tyrosine (B), and L-[1-13C]-tyrosine (C) 
enrichments (mole percent excess, MPE) in healthy (n = 12) and type 2 diabetes (n = 11) older subjects following 
ingestion of 20 g casein. The dotted line indicates the ingestion of the protein beverage. Data were analyzed with 
repeated measures (time x group) ANOVA.Basal L-[ring-2H4]-tyrosine enrichments: time P<0.001, group P<0.05, 
group x time interaction P=0.7, postprandial L-[ring-2H4]-tyrosine enrichments: time P<0.001, group P =0.1, group 
x time interaction P=0.1. Basal L-[ring-3,5-2H2]-tyrosine enrichments: time P<0.001, group P=0.2, group x time 
interaction P=0.3, postprandial L-[ring-3,5-2H2]-tyrosine enrichments: time P<0.001, group P=0.4, group x time 
interaction P=0.09. Postprandial L-[1-13C]-tyrosine enrichments: time P<0.001, group P=0.2, group x time 
interaction P=0.4. 
Plasma L-[13C]-Tyrosine
-120 -60 0 60 120 180 240 300
0
2
4
6
8
10
12
Time (min)
Pla
sm
a e
nr
ich
m
en
t (
M
PE
)
Plasma L-[2H4]-Tyrosine
-120 -60 0 60 120 180 240 300
0.0
0.2
0.4
0.6
0.8
1.0
Control
Diabetes
Time (min)
Pla
sm
a e
nr
ich
m
en
t (
M
PE
)
Plasma L-[2H2]-Tyrosine
-120 -60 0 60 120 180 240 300
0
1
2
3
4
Time (min)
Pla
sm
a e
nr
ich
m
en
t (
M
PE
)
A
B
C
 
 
Whole-body amino acid kinetics 
Whole-body phenylalanine kinetics are presented in Figure 5. Exogenous phenylalanine rates 
of appearance (Figure 5A) (i.e., the rate at which dietary protein derived phenylalanine enters 
the circulation) increased after the protein ingestion (P<0.001) and did not differ between 
groups. The fraction of dietary protein-derived phenylalanine that appeared in the plasma 
over the 5-hour postprandial period was 55±3% and 62±4% in the diabetes and control 
groups, respectively (P=0.2). Endogenous phenylalanine rates of appearance (Figure 5B) (i.e., 
the rate at which phenylalanine derived from whole body protein breakdown enters the 
circulation) decreased after the protein ingestion (P<0.001), with no significant differences 
between groups. Total phenylalanine rates of disappearance (Figure 5C) increased after the 
protein ingestion (P<0.001), with no significant differences between groups. 
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Figure 4 | Mean (±SEM) plasma L-[ring-2H4]-tyrosine (A), L-[ring-3,5-2H2]-tyrosine (B), and L-[1-13C]-tyrosine (C) 
enrichments (mole percent excess, MPE) in healthy (n = 12) and type 2 diabetes (n = 11) older subjects following 
ingestion of 20 g casein. The dotted line indicates the ingestion of the protein beverage. Data were analyzed with 
repeated measures (time x group) ANOVA.Basal L-[ring-2H4]-tyrosine enrichments: time P<0.001, group P<0.05, 
group x time interaction P=0.7, postprandial L-[ring-2H4]-tyrosine enrichments: time P<0.001, group P =0.1, group 
x time interaction P=0.1. Basal L-[ring-3,5-2H2]-tyrosine enrichments: time P<0.001, group P=0.2, group x time 
interaction P=0.3, postprandial L-[ring-3,5-2H2]-tyrosine enrichments: time P<0.001, group P=0.4, group x time 
interaction P=0.09. Postprandial L-[1-13C]-tyrosine enrichments: time P<0.001, group P=0.2, group x time 
interaction P=0.4. 
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Whole-body amino acid kinetics 
Whole-body phenylalanine kinetics are presented in Figure 5. Exogenous phenylalanine rates 
of appearance (Figure 5A) (i.e., the rate at which dietary protein derived phenylalanine enters 
the circulation) increased after the protein ingestion (P<0.001) and did not differ between 
groups. The fraction of dietary protein-derived phenylalanine that appeared in the plasma 
over the 5-hour postprandial period was 55±3% and 62±4% in the diabetes and control 
groups, respectively (P=0.2). Endogenous phenylalanine rates of appearance (Figure 5B) (i.e., 
the rate at which phenylalanine derived from whole body protein breakdown enters the 
circulation) decreased after the protein ingestion (P<0.001), with no significant differences 
between groups. Total phenylalanine rates of disappearance (Figure 5C) increased after the 
protein ingestion (P<0.001), with no significant differences between groups. 
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Figure 5 | Whole-body phenylalanine kinetics. Mean(±SEM) exogenous rate of appearance (Ra, A), endogenous 
Ra (B), and total rate of disappearance (Rd, C) (μmol phenylalanine·kg-1·min-1) in healthy (n = 12) and type 2 
diabetes (n = 11) elderly subjects following ingestion of 20 g casein. The dotted line indicates the ingestion of 
the protein beverage. Data were analysed with repeated measures (time x group) ANOVA. Exogenous 
phenylalanine rates of appearance: time effect P<0.001. Endogenous phenylalanine rates of appearance: time 
effect P<0.001. Total phenylalanine rates of disappearance: time effect P<0.001. 
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Postabsorptive and postprandial whole-body protein breakdown, synthesis, oxidation, and net 
balance are presented in Figure 6. No differences were observed in postabsorptive whole-
body protein breakdown, synthesis, and oxidation rates between groups. Whole-body net 
protein balance did not differ between groups and averaged 0.7±0.1 vs 0.2±0.2 μmol·h-1·       
kg-1 phenylalanine in the diabetes and control groups, respectively. During the 5-hour 
postprandial period, whole-body protein breakdown decreased, and protein synthesis and 
oxidation rates significantly increased (P<0.001), with no differences being observed between 
groups. Whole-body net protein balance increased in the postprandial state to 7.1±0.3 and 
7.8±0.6 μmol·h-1·kg-1 phenylalanine in the diabetes and control groups, respectively (P<0.001) 
and did not differ between groups. 
 
Figure 6 | Whole-body protein metabolism during the postabsorptive (A) and postprandial (B) state in healthy   
(n = 12) and type 2 diabetes (n = 11) older subjects following ingestion of 20 g casein. Values represent 
mean±SEM. Data were analyzed with unpaired Student’s t-test (between groups) and repeated measures (time x 
group) ANOVA. Whole-body protein synthesis rates: time effect P<0.001; whole-body protein breakdown rates: 
time effect P<0.001; interaction of time x group P<0.01; whole-body protein oxidation rates: time effect P<0.001; 
whole-body protein net balance: time effect P<0.001; * Significantly different from control, P<0.05.  
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Figure 5 | Whole-body phenylalanine kinetics. Mean(±SEM) exogenous rate of appearance (Ra, A), endogenous 
Ra (B), and total rate of disappearance (Rd, C) (μmol phenylalanine·kg-1·min-1) in healthy (n = 12) and type 2 
diabetes (n = 11) elderly subjects following ingestion of 20 g casein. The dotted line indicates the ingestion of 
the protein beverage. Data were analysed with repeated measures (time x group) ANOVA. Exogenous 
phenylalanine rates of appearance: time effect P<0.001. Endogenous phenylalanine rates of appearance: time 
effect P<0.001. Total phenylalanine rates of disappearance: time effect P<0.001. 
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Postabsorptive and postprandial whole-body protein breakdown, synthesis, oxidation, and net 
balance are presented in Figure 6. No differences were observed in postabsorptive whole-
body protein breakdown, synthesis, and oxidation rates between groups. Whole-body net 
protein balance did not differ between groups and averaged 0.7±0.1 vs 0.2±0.2 μmol·h-1·       
kg-1 phenylalanine in the diabetes and control groups, respectively. During the 5-hour 
postprandial period, whole-body protein breakdown decreased, and protein synthesis and 
oxidation rates significantly increased (P<0.001), with no differences being observed between 
groups. Whole-body net protein balance increased in the postprandial state to 7.1±0.3 and 
7.8±0.6 μmol·h-1·kg-1 phenylalanine in the diabetes and control groups, respectively (P<0.001) 
and did not differ between groups. 
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Muscle protein synthesis  
Muscle tissue-free L-[ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine enrichments are 
presented in Table 2. Muscle intracellular-free L-[ring-2H5]-phenylalanine enrichments 
increased in both the entire postabsorptive and postprandial states (P<0.001) and decreased 
in the first 2 hours after the protein ingestion when compared with the basal values (P<0.05), 
with no differences between groups. The muscle-intracellular free L-[1-13Cphenylalanine 
enrichments were higher at 2 hours when compared with 5 hours (P<0.001) and did not differ 
between groups. 
Table 2 | Muscle tissue-free enrichments 
  -2h 0h 2h 5h 
L-[ring-2H5]-
phenylalanine 
(MPE) 
Control (n = 12) 4.08±0.20 5.57±0.25 4.88±0.20 5.85±0.25 
Diabetes (n = 11) 4.37±0.41 5.50±0.39 5.00±0.25 5.91±0.18 
L-[1-13C]-
phenylalanine 
(MPE) 
Control (n = 12) N/A N/A 5.64±0.61 3.67±0.30 
Diabetes (n = 11) N/A N/A 5.44±0.68 3.10±0.33 
Values are mean±SEM. MPE: mole percent excess. Data were analyzed by repeated measures (time x group) 
ANOVA. L-[ring-2H5]-phenylalanine: time effect P<0.001. L-[1-13C]-phenylalanine: time effect P<0.001. There were 
no differences between groups. 
Mixed-muscle protein synthesis rates, expressed as FSR, are presented in Figure 7A. Basal 
mixed-muscle protein FSR, using the plasma L-[ring-2H5]-phenylalanine enrichments as 
precursor, averaged 0.029±0.003 and 0.029±0.003 %·h-1 in the diabetes and control groups, 
respectively, with no significant differences between groups. After the protein ingestion, FSR 
values did not increase during the early stages of the postprandial period and averaged 
0.027±0.005 and 0.028±0.004 %·h-1 during the first 2 hours of the postprandial phase (0–2 
hours) in the diabetes and control groups, respectively (P=0.7). Muscle protein synthesis rates 
were significantly higher in the later stage of the postprandial period (2-5 hours) when 
compared with the basal, postabsorptive values (0.036±0.002 and 0.037±0.003 %·h-1, 
respectively, P<0.001). The postprandial increase in muscle protein synthesis rates was 
observed in the 2–5-hour period after protein ingestion in both groups (time effect P=0.04, 
group × time interaction P=0.9), with no differences between groups (P=0.8, Figure 7A). Over 
the entire 5-hour postprandial period, FSR tended to be higher when compared with 
postabsorptive protein synthesis rates (P=0.12), with values averaging 0.031±0.002 and 
0.033±0.002 %·h-1 in the diabetes and control groups, respectively. Similar observations were 
obtained when mixed-muscle protein synthesis rates were calculated based on muscle-free 
phenylalanine enrichments as precursor pool (data not shown). Muscle protein-bound L-[1-
13C]-phenylalanine enrichments (Figure 7B) increased after the protein ingestion (0.018±0.001 
and 0.019±0.002 MPE in the diabetes and control groups, respectively, P<0.001), with no 
differences between groups.  
 
 
 
Figure 7 | Mean(±SEM) mixed-muscle protein FSR using iv L-[ring-2H5]-phenylalanine infusion (A; in (%·h-1) and 
dietary protein-derived muscle protein-bound L-[1-13C]-phenylalanine enrichments (B; in MPE) in healthy (n = 12) 
and type 2 diabetes (n = 11) older subjects after the ingestion of 20 g casein. Data were analyzed with an unpaired 
Student's t test (between groups) and a repeated-measures (time × group) ANOVA. *, Significantly different from 
basal values (P<0.001). Mixed-muscle L-[ring-2H5]-phenylalanine FSR comprised time effect P=0.04, 0-2 hours 
compared with basal P=0.7, 2–5 hours compared with basal P<0.001; muscle protein-bound L-[1-13C]-
phenylalanine enrichments comprised time effect P<0.001.  
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Muscle protein synthesis  
Muscle tissue-free L-[ring-2H5]-phenylalanine and L-[1-13C]-phenylalanine enrichments are 
presented in Table 2. Muscle intracellular-free L-[ring-2H5]-phenylalanine enrichments 
increased in both the entire postabsorptive and postprandial states (P<0.001) and decreased 
in the first 2 hours after the protein ingestion when compared with the basal values (P<0.05), 
with no differences between groups. The muscle-intracellular free L-[1-13Cphenylalanine 
enrichments were higher at 2 hours when compared with 5 hours (P<0.001) and did not differ 
between groups. 
Table 2 | Muscle tissue-free enrichments 
  -2h 0h 2h 5h 
L-[ring-2H5]-
phenylalanine 
(MPE) 
Control (n = 12) 4.08±0.20 5.57±0.25 4.88±0.20 5.85±0.25 
Diabetes (n = 11) 4.37±0.41 5.50±0.39 5.00±0.25 5.91±0.18 
L-[1-13C]-
phenylalanine 
(MPE) 
Control (n = 12) N/A N/A 5.64±0.61 3.67±0.30 
Diabetes (n = 11) N/A N/A 5.44±0.68 3.10±0.33 
Values are mean±SEM. MPE: mole percent excess. Data were analyzed by repeated measures (time x group) 
ANOVA. L-[ring-2H5]-phenylalanine: time effect P<0.001. L-[1-13C]-phenylalanine: time effect P<0.001. There were 
no differences between groups. 
Mixed-muscle protein synthesis rates, expressed as FSR, are presented in Figure 7A. Basal 
mixed-muscle protein FSR, using the plasma L-[ring-2H5]-phenylalanine enrichments as 
precursor, averaged 0.029±0.003 and 0.029±0.003 %·h-1 in the diabetes and control groups, 
respectively, with no significant differences between groups. After the protein ingestion, FSR 
values did not increase during the early stages of the postprandial period and averaged 
0.027±0.005 and 0.028±0.004 %·h-1 during the first 2 hours of the postprandial phase (0–2 
hours) in the diabetes and control groups, respectively (P=0.7). Muscle protein synthesis rates 
were significantly higher in the later stage of the postprandial period (2-5 hours) when 
compared with the basal, postabsorptive values (0.036±0.002 and 0.037±0.003 %·h-1, 
respectively, P<0.001). The postprandial increase in muscle protein synthesis rates was 
observed in the 2–5-hour period after protein ingestion in both groups (time effect P=0.04, 
group × time interaction P=0.9), with no differences between groups (P=0.8, Figure 7A). Over 
the entire 5-hour postprandial period, FSR tended to be higher when compared with 
postabsorptive protein synthesis rates (P=0.12), with values averaging 0.031±0.002 and 
0.033±0.002 %·h-1 in the diabetes and control groups, respectively. Similar observations were 
obtained when mixed-muscle protein synthesis rates were calculated based on muscle-free 
phenylalanine enrichments as precursor pool (data not shown). Muscle protein-bound L-[1-
13C]-phenylalanine enrichments (Figure 7B) increased after the protein ingestion (0.018±0.001 
and 0.019±0.002 MPE in the diabetes and control groups, respectively, P<0.001), with no 
differences between groups.  
 
 
 
Figure 7 | Mean(±SEM) mixed-muscle protein FSR using iv L-[ring-2H5]-phenylalanine infusion (A; in (%·h-1) and 
dietary protein-derived muscle protein-bound L-[1-13C]-phenylalanine enrichments (B; in MPE) in healthy (n = 12) 
and type 2 diabetes (n = 11) older subjects after the ingestion of 20 g casein. Data were analyzed with an unpaired 
Student's t test (between groups) and a repeated-measures (time × group) ANOVA. *, Significantly different from 
basal values (P<0.001). Mixed-muscle L-[ring-2H5]-phenylalanine FSR comprised time effect P=0.04, 0-2 hours 
compared with basal P=0.7, 2–5 hours compared with basal P<0.001; muscle protein-bound L-[1-13C]-
phenylalanine enrichments comprised time effect P<0.001.  
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D ISCUSSION  
In the present study, we show that basal muscle protein synthesis rates do not differ between 
older type 2 diabetes patients and age-matched, normoglycemic controls. Protein digestion 
and absorption kinetics did not differ between type 2 diabetes subjects and healthy controls. 
The postprandial rise in circulating insulin levels was greater in the type 2 diabetes patients 
when compared with healthy controls. Postprandial muscle protein synthesis rates and the use 
of dietary protein-derived amino acids for de novo muscle protein accretion did not differ 
between type 2 diabetes patients and normoglycemic controls. 
We [1, 2] as well as others [3, 4] have previously shown that muscle mass loss with aging seems 
to be more pronounced in the type 2 diabetic state. Therefore, we compared basal protein 
metabolism between older diabetes patients and aged-matched healthy controls. On a whole-
body level, we did not observe any significant differences in protein synthesis, breakdown, 
oxidation rates, and net protein balance between groups. In agreement, on a muscle tissue 
level, we did not detect differences in basal muscle protein synthesis rates between groups 
(0.029±0.003 and 0.029±0.003 %·h-1 in the diabetes and control groups, respectively. These 
data extend on previous findings in type 2 diabetes patients [18-21, 23-25, 28] and show that 
basal muscle protein synthesis rates do not differ between older type 2 diabetes patients and 
age-matched, normoglycemic controls. 
The combined application of iv amino acid tracer infusions with the ingestion of intrinsically 
labeled protein allows us to assess protein digestion and amino acid absorption kinetics. Upon 
ingestion of 20 g casein, we observed a rapid release of protein-derived phenylalanine into 
the circulation in both groups with 55±3% and 62±4% of the ingested protein-derived 
phenylalanine becoming available in the circulation in diabetes and controls, respectively. 
Consequently, protein ingestion resulted in a rapid rise in circulating plasma amino acid 
concentrations and a concomitant increase in endogenous insulin release. The postprandial 
insulin response was greater in the diabetes group compared with the control group (peak 
values: 23.3±2.6 vs 11.9±2.1 mU·L-1, respectively). This is not surprising because compensatory 
postprandial hyperinsulinemia is generally apparent in these patients, and amino acid-induced 
insulin secretion has previously been shown to be uncompromised, even in long-standing type 
2 diabetes patients [36, 37]. 
During the early stages of the postprandial phase (0-2 hours) we did not observe a significant 
increase in muscle protein synthesis rates above basal, fasting values. However, muscle protein 
synthesis rates were significantly higher during the later stages of the postprandial phase (2-
5 hours) when compared with the basal, postabsorptive values. A delay in the postprandial 
rise in muscle protein synthesis has been reported previously in the older population [22]. No 
differences were observed in the postprandial increase in muscle protein synthesis rates 
between the type 2 diabetes patients and their age-matched, normoglycemic controls. 
Because we applied intrinsically L-[1-13C]-phenylalanine-labeled casein [29, 30] , we were also 
able to assess the metabolic fate of the dietary protein-derived phenylalanine toward de novo 
 
 
skeletal muscle protein accretion. We did not observe differences in L-[1-13C]-phenylalanine 
incorporation in mixed-muscle protein after the protein ingestion between groups at 2 and 5 
hours after protein ingestion. To our knowledge, this is the first study measuring basal as well 
as postprandial muscle protein synthesis rates after the ingestion of a meal-like amount of 
protein [38] in older type 2 diabetes patients and age-matched, normoglycemic controls. Here 
we show that the use of dietary protein-derived amino acids for de novo muscle protein 
accretion does not differ between type 2 diabetes subjects and healthy controls when a meal-
like amount of dietary protein is consumed. 
We hypothesized that the greater loss of skeletal muscle mass with aging in the type 2 diabetic 
state [1] is attributed to lower postprandial muscle protein synthesis rates. Previous work did 
not observe lower basal muscle protein synthesis rates in obese and insulin resistant subjects 
[20, 25, 28, 39]. The present study shows no difference in the postprandial muscle protein 
synthetic response to the ingestion of a meal-like amount of protein between older type 2 
diabetes patients and normoglycemic controls. The level of insulin resistance does not seem 
to modulate basal protein synthesis rates or postprandial protein handling in older type 2 
diabetes patients when compared with age-matched, normoglycemic controls. However, it 
should be noted that basal and postprandial plasma insulin and leucine concentrations were 
elevated in the type 2 diabetic state. Therefore, it could be speculated that the prevalence of 
compensatory postprandial hyperinsulinemia (and/or leucinemia) in the type 2 diabetes 
patients may have compensated for the level of insulin resistance (and possibly leucine 
resistance) in the muscle protein synthetic response to feeding. 
Based on our findings, we can only conclude that the proposed greater decline in skeletal 
muscle mass with aging in the type 2 diabetic state is not attributed to a decline in basal, 
postabsorptive protein synthesis rates, impairments in dietary protein digestion and 
absorption, or the reduced postprandial muscle protein synthetic response. It could be 
speculated that higher basal muscle protein breakdown rates and/or reduced postprandial 
inhibition of proteolysis may be prevalent in an insulin-resistant state. Some studies suggest 
higher basal muscle or whole-body protein breakdown rates in an insulin resistant state [23, 
25, 26, 28, 39-42]. However, others have failed to confirm these findings [21, 22, 43, 44]. The 
few studies that assessed postprandial muscle protein breakdown rates in vivo in man [9, 45-
47] find little evidence to suggest that the postprandial inhibition of proteolysis is blunted in 
the type 2 diabetic state [21, 22]. In the present study, we observed no differences in basal or 
postprandial whole-body protein breakdown rates between diabetes patients and their 
normoglycemic controls. However, because whole-body protein breakdown rates do not 
necessarily reflect skeletal muscle tissue per se, we can only speculate on the contribution of 
greater postabsorptive muscle protein breakdown rates or a blunted muscle proteolytic 
response to feeding in the type 2 diabetic state. Moreover, multiple other factors such as 
medication use, systemic inflammation, neurological deficits associated with type 2 diabetes, 
and/or differences in lifestyle and daily living activities [1, 2, 48] may be responsible for the 
accelerated loss of muscle mass and strength in type 2 diabetes patients. 
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D ISCUSSION  
In the present study, we show that basal muscle protein synthesis rates do not differ between 
older type 2 diabetes patients and age-matched, normoglycemic controls. Protein digestion 
and absorption kinetics did not differ between type 2 diabetes subjects and healthy controls. 
The postprandial rise in circulating insulin levels was greater in the type 2 diabetes patients 
when compared with healthy controls. Postprandial muscle protein synthesis rates and the use 
of dietary protein-derived amino acids for de novo muscle protein accretion did not differ 
between type 2 diabetes patients and normoglycemic controls. 
We [1, 2] as well as others [3, 4] have previously shown that muscle mass loss with aging seems 
to be more pronounced in the type 2 diabetic state. Therefore, we compared basal protein 
metabolism between older diabetes patients and aged-matched healthy controls. On a whole-
body level, we did not observe any significant differences in protein synthesis, breakdown, 
oxidation rates, and net protein balance between groups. In agreement, on a muscle tissue 
level, we did not detect differences in basal muscle protein synthesis rates between groups 
(0.029±0.003 and 0.029±0.003 %·h-1 in the diabetes and control groups, respectively. These 
data extend on previous findings in type 2 diabetes patients [18-21, 23-25, 28] and show that 
basal muscle protein synthesis rates do not differ between older type 2 diabetes patients and 
age-matched, normoglycemic controls. 
The combined application of iv amino acid tracer infusions with the ingestion of intrinsically 
labeled protein allows us to assess protein digestion and amino acid absorption kinetics. Upon 
ingestion of 20 g casein, we observed a rapid release of protein-derived phenylalanine into 
the circulation in both groups with 55±3% and 62±4% of the ingested protein-derived 
phenylalanine becoming available in the circulation in diabetes and controls, respectively. 
Consequently, protein ingestion resulted in a rapid rise in circulating plasma amino acid 
concentrations and a concomitant increase in endogenous insulin release. The postprandial 
insulin response was greater in the diabetes group compared with the control group (peak 
values: 23.3±2.6 vs 11.9±2.1 mU·L-1, respectively). This is not surprising because compensatory 
postprandial hyperinsulinemia is generally apparent in these patients, and amino acid-induced 
insulin secretion has previously been shown to be uncompromised, even in long-standing type 
2 diabetes patients [36, 37]. 
During the early stages of the postprandial phase (0-2 hours) we did not observe a significant 
increase in muscle protein synthesis rates above basal, fasting values. However, muscle protein 
synthesis rates were significantly higher during the later stages of the postprandial phase (2-
5 hours) when compared with the basal, postabsorptive values. A delay in the postprandial 
rise in muscle protein synthesis has been reported previously in the older population [22]. No 
differences were observed in the postprandial increase in muscle protein synthesis rates 
between the type 2 diabetes patients and their age-matched, normoglycemic controls. 
Because we applied intrinsically L-[1-13C]-phenylalanine-labeled casein [29, 30] , we were also 
able to assess the metabolic fate of the dietary protein-derived phenylalanine toward de novo 
 
 
skeletal muscle protein accretion. We did not observe differences in L-[1-13C]-phenylalanine 
incorporation in mixed-muscle protein after the protein ingestion between groups at 2 and 5 
hours after protein ingestion. To our knowledge, this is the first study measuring basal as well 
as postprandial muscle protein synthesis rates after the ingestion of a meal-like amount of 
protein [38] in older type 2 diabetes patients and age-matched, normoglycemic controls. Here 
we show that the use of dietary protein-derived amino acids for de novo muscle protein 
accretion does not differ between type 2 diabetes subjects and healthy controls when a meal-
like amount of dietary protein is consumed. 
We hypothesized that the greater loss of skeletal muscle mass with aging in the type 2 diabetic 
state [1] is attributed to lower postprandial muscle protein synthesis rates. Previous work did 
not observe lower basal muscle protein synthesis rates in obese and insulin resistant subjects 
[20, 25, 28, 39]. The present study shows no difference in the postprandial muscle protein 
synthetic response to the ingestion of a meal-like amount of protein between older type 2 
diabetes patients and normoglycemic controls. The level of insulin resistance does not seem 
to modulate basal protein synthesis rates or postprandial protein handling in older type 2 
diabetes patients when compared with age-matched, normoglycemic controls. However, it 
should be noted that basal and postprandial plasma insulin and leucine concentrations were 
elevated in the type 2 diabetic state. Therefore, it could be speculated that the prevalence of 
compensatory postprandial hyperinsulinemia (and/or leucinemia) in the type 2 diabetes 
patients may have compensated for the level of insulin resistance (and possibly leucine 
resistance) in the muscle protein synthetic response to feeding. 
Based on our findings, we can only conclude that the proposed greater decline in skeletal 
muscle mass with aging in the type 2 diabetic state is not attributed to a decline in basal, 
postabsorptive protein synthesis rates, impairments in dietary protein digestion and 
absorption, or the reduced postprandial muscle protein synthetic response. It could be 
speculated that higher basal muscle protein breakdown rates and/or reduced postprandial 
inhibition of proteolysis may be prevalent in an insulin-resistant state. Some studies suggest 
higher basal muscle or whole-body protein breakdown rates in an insulin resistant state [23, 
25, 26, 28, 39-42]. However, others have failed to confirm these findings [21, 22, 43, 44]. The 
few studies that assessed postprandial muscle protein breakdown rates in vivo in man [9, 45-
47] find little evidence to suggest that the postprandial inhibition of proteolysis is blunted in 
the type 2 diabetic state [21, 22]. In the present study, we observed no differences in basal or 
postprandial whole-body protein breakdown rates between diabetes patients and their 
normoglycemic controls. However, because whole-body protein breakdown rates do not 
necessarily reflect skeletal muscle tissue per se, we can only speculate on the contribution of 
greater postabsorptive muscle protein breakdown rates or a blunted muscle proteolytic 
response to feeding in the type 2 diabetic state. Moreover, multiple other factors such as 
medication use, systemic inflammation, neurological deficits associated with type 2 diabetes, 
and/or differences in lifestyle and daily living activities [1, 2, 48] may be responsible for the 
accelerated loss of muscle mass and strength in type 2 diabetes patients. 
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In conclusion, postabsorptive and postprandial muscle protein synthesis rates are not reduced 
in older type 2 diabetes patients when compared with age-matched, normoglycemic controls. 
The more pronounced loss of skeletal muscle mass and strength in older type 2 diabetes 
patients does not seem to be attributed to a greater level of anabolic resistance. 
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In conclusion, postabsorptive and postprandial muscle protein synthesis rates are not reduced 
in older type 2 diabetes patients when compared with age-matched, normoglycemic controls. 
The more pronounced loss of skeletal muscle mass and strength in older type 2 diabetes 
patients does not seem to be attributed to a greater level of anabolic resistance. 
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ABST RACT  
Introduction:  The age-related anabolic resistance to protein ingestion is suggested to be 
associated with impairments in insulin-mediated capillary recruitment and 
postprandial muscle tissue perfusion. The present study investigated 
whether dietary nitrate co-ingestion with protein improves muscle protein 
synthesis in older, type 2 diabetes patients.  
Methods:  Twenty-four males with type 2 diabetes (72±1 y, 26.7±1.4 m·kg-2 body mass 
index; 7.3±0.4% HbA1C) received a primed continuous infusion of L-[ring-
2H5]-phenylalanine and L-[1-13C]-leucine and ingested 20 g intrinsically L-
[1-13C]-phenylalanine and L-[1-13C]-leucine-labeled protein with (PRONO3) 
or without (PRO) sodium nitrate (NaNO3-; 0.15 mmol·kg-1). Blood and muscle 
samples were collected to assess protein digestion and absorption kinetics 
and postprandial muscle protein synthesis rates.  
Results:  Upon protein ingestion, exogenous phenylalanine appearance rates 
increased in both groups (P<0.001) resulting in 55±2% and 53±2% of 
dietary protein-derived amino acids becoming available in the circulation 
over the 5h postprandial period in the PRO and PRONO3 group, 
respectively. Postprandial myofibrillar protein synthesis rates based on L-
[ring-2H5]-phenylalanine did not differ between groups (0.025±0.004 and 
0.021±0.007 %.h-1 over 0-2h and 0.032±0.004 and 0.030±0.003 %.h-1 over 2-
5h in PRO and PRONO3, respectively; P=0.7). No differences in the 
incorporation of dietary protein-derived L-[1-13C]-phenylalanine into de 
novo myofibrillar protein were observed at 5h (0.016±0.002 and 0.014±0.002 
MPE, in PRO and PRONO3, respectively; P=0.8).  
Conclusion:  Dietary nitrate co-ingestion with protein does not modulate protein 
digestion and absorption kinetics, nor does it further increase postprandial 
muscle protein synthesis rates or the incorporation of dietary protein-
derived amino acids into de novo myofibrillar protein in older, type 2 
diabetes patients.  
  
 
 
IN TRODU CTION  
Aging is associated with loss of skeletal muscle mass and strength, termed sarcopenia, and 
results in loss of functional capacity, a higher risk for hospitalization, and development of 
chronic metabolic diseases [1]. Recently we [2, 3], as well as others [4, 5], showed that 
sarcopenia is more pronounced in older individuals with type 2 diabetes than in age-matched, 
normoglycemic controls. Since skeletal muscle tissue is a large site of postprandial glucose 
disposal, it is evident that the age-related loss of skeletal muscle mass is often accompanied 
by an insulin-resistant state [2-4].  
Maintenance of skeletal muscle mass is regulated by muscle protein synthesis and muscle 
protein breakdown rates. A chronic imbalance between muscle protein synthesis and muscle 
protein breakdown rates contributes to the accelerated loss of skeletal muscle mass with 
aging. It has been well established that protein ingestion and the associated increase in 
postprandial plasma amino acids in the circulation directly increase muscle protein synthesis 
rates [6-9]. However, the postprandial stimulation of muscle protein synthesis following 
protein intake is impaired with aging, a phenomenon commonly referred to as anabolic 
resistance [9]. This anabolic resistance to protein intake is considered to be a key factor in the 
progressive loss of skeletal muscle mass with aging. Although the factor(s) underpinning 
anabolic resistance remains unclear, age-related impairments in endothelium-dependent 
vasodilation and blood flow in response to nutrient [10] and exercise [11] stimuli are suggested 
to play a key role. 
The postprandial muscle protein synthetic response to protein feeding is regulated by 
numerous factors, such as protein digestion and amino acid absorption, amino acid availability 
in the circulation, delivery to skeletal muscle tissue, and uptake in the muscle [12]. The 
postprandial increase in muscle microvascular perfusion facilitates the delivery of amino acids, 
nutrients, and growth factors to the muscle, thereby allowing muscle protein synthesis rates 
to increase after protein ingestion [13, 14]. However, aging and insulin resistance are 
associated with reduced skeletal muscle capillary density, impaired endothelial function, and 
reduced nitric oxide (NO) availability [3, 10, 15-17]. As such, age-related impairments in 
vascular function due to an impaired NO-mediated vasodilatory response and decreased 
muscle tissue perfusion may diminish feeding-mediated increases in muscle protein synthesis 
and, thus, contribute to the anabolic resistance of aging [18, 19]. 
It has been reported that dietary nitrate (NO3−) supplementation, via sequential reduction of 
NO3− to nitrite (NO2−) and NO, can stimulate NO synthesis and increase NO bioavailability 
[20]. Moreover, it has been suggested that NO has a role in promoting insulin delivery to 
skeletal muscle tissue and increasing insulin-stimulated muscle perfusion and capillary action 
[21, 22]. As such, ingestion of a single dose of dietary NO3− might increase endothelial NO 
availability, thereby increasing blood flow and tissue perfusion and the subsequent muscle 
anabolic response to food intake. Recently, the acute ingestion of NO3−-rich dietary sources 
has been shown to improve vascular function [23-26] and macro- and microvascular blood 
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flow [24, 27] in healthy subjects, as well as in overweight individuals and diabetes patients. In 
support of these findings, pharmacological increases in blood flow and tissue perfusion 
following administration of a NO-donating vasodilator, sodium nitroprusside, combined with 
amino acid provision have been shown to increase postprandial muscle protein synthesis rates 
in older subjects [28]. However, whether dietary NO3− co-ingestion with a protein meal can be 
used as a nutritional strategy to augment the postprandial muscle protein synthetic response 
remains to be assessed. 
In particular, dietary NO3− may serve as an effective nutritional strategy to counteract the age-
related anabolic resistance of muscle protein synthesis to protein ingestion through NO-
mediated increases in skeletal muscle microvascular perfusion. In the current investigation, we 
hypothesized that a single dose of dietary NO3− co-ingested with protein increases amino acid 
delivery to skeletal muscle tissue and, subsequently, enhances the postprandial muscle protein 
synthetic response. 
   
 
 
M ETHO DS 
Subjects 
Twenty-four older (72±1 yr), type 2 diabetes patients (body mass index = 26.7±1.4 m·kg-2, 
HbA1C = 7.3±0.4%) were randomly assigned to two groups: a group that ingested protein with 
NaCl (PRO) or a group that ingested protein with NaNO3− (PRONO3). Subjects' characteristics 
are presented in Table 1. All subjects were using oral blood glucose-lowering medication and 
continued their habitual medication. Diabetes patients had been diagnosed with type 2 
diabetes 2–18 yr prior to screening. One subject in the PRO group was unable to complete the 
trial and was, therefore, excluded from analysis. Subjects were informed of the nature and 
possible risks of the experimental procedures prior to providing written informed consent. The 
trial, conducted between August 2011 and July 2012 at Maastricht University, was part of a 
larger project investigating the impact of protein feeding on muscle metabolism in older, type 
2 diabetes patients [29]. The study was approved by the Medical Ethical Committee of the 
Maastricht University Medical Centre and conformed to standards for the use of human 
subjects in research as outlined in the latest version of the Declaration of Helsinki.  
Pretesting 
All subjects participated in a prescreening session to assess their HbA1C, glucose tolerance (by 
a 2-h oral glucose tolerance test [30]), blood pressure, weight, height, and body composition 
[by dual-energy X-ray absorptiometry (Discovery A, Hologic, Bedford, MA)]. The subjects were 
deemed healthy on the basis of their responses to a medical questionnaire and screening 
results. All subjects were instructed to refrain from strenuous physical activity and to maintain 
their diet as constant as possible for 2 days prior to the experimental infusions. On the evening 
before the trial, the subjects consumed a standardized meal (2.38 MJ, 31.7±1.1 kJ·kg-1 body 
wt) composed of 15 energy percent (En%) protein, 55 En% carbohydrate, and 30 En% fat.  
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Table 1 | Subjects’ characteristics 
 PRO (n = 11) PRONO3 (n = 12) 
Age (y) 71±1 73±1 
Weight (kg) 80.4±1.6 83.0±1.8 
BMI (kg·m-2) 26.2±0.5 27.3±0.6 
Lean body mass (kg) 60.6±1.0 60.8±1.4 
Appendicular lean mass (kg) 25.8±0.6 (32%) 25.1±0.8 (30%) 
Skeletal mass index (kg·m-2) 8.4±0.2 8.3±0.3 
Fat (%) 21.8±0.8 23.8±0.8 
Basal plasma glucose (mmol·L-1) 9.6±0.9 9.6±0.6 
Plasma glucose OGTT t= 120 min (mmol·L-1) 16.3±0.9 17.9±0.9 
Basal plasma insulin (mU·L-1) 16.8±2.4 17.4±1.6 
Plasma insulin OGTT t= 120 min (mU·L-1) 45.6±8.0 42.3±7.1 
HbA1C (%) 7.1±0.3 7.6±0.2 
OGIS (mL·min-1·m-2) 286±11 260±9 
HOMA-IR 2.5±0.3 2.5±0.2 
Values are mean±SEM. HbA1C: glycosylated hemoglobin; OGTT: oral glucose tolerance test; OGIS: oral glucose 
insulin sensitivity, HOMA: homeostasis model assessment. Data were analyzed by unpai red Student’s t-test.  
Experimental protocol 
At 0800, after an overnight fast, subjects arrived at the laboratory by car or public transport. 
Upon the subjects' arrival at the laboratory, a Teflon catheter was inserted into an antecubital 
vein for infusion and a second cannula was inserted into the dorsal hand vein of the 
contralateral arm, which was placed in a hot box (60°C) for arterialized blood sampling [31]. 
After baseline blood collection (−210 min), the plasma phenylalanine, tyrosine, and leucine 
pools were primed with a single intravenous (priming) dose of L-[ring-2H5]-phenylalanine (2 
μmol·kg−1), L-[ring-3,5-2H2]-tyrosine (0.615 μmol·kg−1), and L-[1-13C]-leucine (4.0 μmol·kg−1). 
Subsequently, the continuous infusion (0.05 μmol·kg−1·min−1 for L-[ring-2H5]-phenylalanine, 
0.015 μmol·kg−1·min−1 for L-[ring-2H2]-tyrosine, and 0.100 μmol·kg−1·min−1 for L-[1-13C]-
leucine) was initiated and maintained for 8.5 h. At −120 min, subjects ingested a single bolus 
of NaNO3− [(0.15 mmol·kg−1 body wt, which provided NO3− at 9.3 mg· kg-1 body wt (PRONO3 
group; BASF, Ludwigshafen, Germany)] or an equimolar amount of NaCl dissolved in 250 mL 
of water (PRO group; Glacia British salt, United Kingdom) dissolved in 250 mL of water. We 
provided a single dose of dietary NO3− at 2 h prior to protein ingestion to ensure that the 
increase in NO3−/NO2− concentrations would correspond with the postprandial increase in 
 
 
plasma amino acid concentrations [32]. Blood samples were collected during the infusion at 
−120, −90, −60, −30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, and 300 min relative to 
the intake of the protein drink. Blood samples were collected into EDTA-containing tubes and 
centrifuged at 1,000 g at 4°C for 10 min. Aliquots of plasma were frozen in liquid nitrogen and 
stored at −80°C. Muscle biopsies were collected for determination of postabsorptive muscle 
protein synthesis rates (−120 and 0 min). Immediately after the second biopsy, subjects 
ingested a single bolus of 20 g of intrinsically L-[1-13C]-phenylalanine- and L-[1-13C]-leucine-
labeled casein protein dissolved in water that was flavored with 1.5 mL of vanilla (IMCD 
Benelux, Rotterdam, the Netherlands). Additional biopsies (from the contralateral leg) were 
collected at 120 and 300 min for measurement of postprandial muscle protein synthesis rates. 
The Bergström needle technique [33] was used to collect muscle biopsies from the middle 
region of the vastus lateralis (15 cm above the patella). All biopsy samples were freed from 
visible adipose tissue and blood, immediately frozen in liquid nitrogen, and stored at −80°C 
until subsequent analysis.  
Production of intrinsically labeled protein 
Intrinsically L-[1-13C]-phenylalanine- and L-[1-13C]-leucine-labeled casein was obtained by 
infusion of a lactating Holstein cow with L-[1-13C]-phenylalanine (455 μmol·min-1) and L-[1-
13C]-leucine (200 μmol·min-1), collection of the milk, and purification of the casein fraction, as 
described previously [34-36]. Enrichments of L-[1-13C]-phenylalanine and L-[1-13C]-leucine in 
the casein were 38.7 and 9.3 mole percent excess (MPE), respectively. Participants received a 
beverage containing 20 g of casein (containing 1.54 g of leucine) in a total volume of 350 mL. 
The casein protein met all chemical and bacteriological specifications for human consumption.  
Plasma analyses 
Plasma NO3− and NO2− were analyzed by gas-phase chemiluminescence analysis, which has 
been described previously [37]. Briefly, plasma NO3− and NO2− concentrations are determined 
by their reduction to NO. The spectral emission of electronically excited nitrogen dioxide, from 
the NO reaction with ozone, is detected by a thermoelectrically cooled, red-sensitive 
photomultiplier tube, housed in a gas-phase chemiluminescence NO analyzer (Sievers NOA 
280i, Analytix). Plasma glucose and insulin concentrations were analyzed using commercially 
available kits [GLUC3 (catalog no. 05168791 190, Roche) and Immunologic (catalog no. 
12017547 122, Roche), respectively]. Plasma amino acid concentrations and enrichments were 
determined by gas chromatography-mass spectrometry (GC-MS) analysis (model 
7890A/GC/5975C/MSD, Agilent, Little Falls, VA). Specifically, internal standards of [U-13C6]-
leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-tyrosine were added to the samples, which 
were deproteinized on ice with dry 5-sulfosalicylic acid. Free amino acids were purified using 
cation-exchange chromatography (AG 50W-X8 resin, 100- to 200-μm dry mesh; Bio-Rad 
Laboratories, Hercules, CA) and converted to their tert-butyl dimethylsilyl (t-BDMS) derivative 
before GC-MS analysis. The amino acid concentrations were determined using electron impact 
ionization by monitoring ions at mass-to-charge ratios (m/z) of 302 and 308 for unlabeled and 
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Basal plasma insulin (mU·L-1) 16.8±2.4 17.4±1.6 
Plasma insulin OGTT t= 120 min (mU·L-1) 45.6±8.0 42.3±7.1 
HbA1C (%) 7.1±0.3 7.6±0.2 
OGIS (mL·min-1·m-2) 286±11 260±9 
HOMA-IR 2.5±0.3 2.5±0.2 
Values are mean±SEM. HbA1C: glycosylated hemoglobin; OGTT: oral glucose tolerance test; OGIS: oral glucose 
insulin sensitivity, HOMA: homeostasis model assessment. Data were analyzed by unpai red Student’s t-test.  
Experimental protocol 
At 0800, after an overnight fast, subjects arrived at the laboratory by car or public transport. 
Upon the subjects' arrival at the laboratory, a Teflon catheter was inserted into an antecubital 
vein for infusion and a second cannula was inserted into the dorsal hand vein of the 
contralateral arm, which was placed in a hot box (60°C) for arterialized blood sampling [31]. 
After baseline blood collection (−210 min), the plasma phenylalanine, tyrosine, and leucine 
pools were primed with a single intravenous (priming) dose of L-[ring-2H5]-phenylalanine (2 
μmol·kg−1), L-[ring-3,5-2H2]-tyrosine (0.615 μmol·kg−1), and L-[1-13C]-leucine (4.0 μmol·kg−1). 
Subsequently, the continuous infusion (0.05 μmol·kg−1·min−1 for L-[ring-2H5]-phenylalanine, 
0.015 μmol·kg−1·min−1 for L-[ring-2H2]-tyrosine, and 0.100 μmol·kg−1·min−1 for L-[1-13C]-
leucine) was initiated and maintained for 8.5 h. At −120 min, subjects ingested a single bolus 
of NaNO3− [(0.15 mmol·kg−1 body wt, which provided NO3− at 9.3 mg· kg-1 body wt (PRONO3 
group; BASF, Ludwigshafen, Germany)] or an equimolar amount of NaCl dissolved in 250 mL 
of water (PRO group; Glacia British salt, United Kingdom) dissolved in 250 mL of water. We 
provided a single dose of dietary NO3− at 2 h prior to protein ingestion to ensure that the 
increase in NO3−/NO2− concentrations would correspond with the postprandial increase in 
 
 
plasma amino acid concentrations [32]. Blood samples were collected during the infusion at 
−120, −90, −60, −30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, and 300 min relative to 
the intake of the protein drink. Blood samples were collected into EDTA-containing tubes and 
centrifuged at 1,000 g at 4°C for 10 min. Aliquots of plasma were frozen in liquid nitrogen and 
stored at −80°C. Muscle biopsies were collected for determination of postabsorptive muscle 
protein synthesis rates (−120 and 0 min). Immediately after the second biopsy, subjects 
ingested a single bolus of 20 g of intrinsically L-[1-13C]-phenylalanine- and L-[1-13C]-leucine-
labeled casein protein dissolved in water that was flavored with 1.5 mL of vanilla (IMCD 
Benelux, Rotterdam, the Netherlands). Additional biopsies (from the contralateral leg) were 
collected at 120 and 300 min for measurement of postprandial muscle protein synthesis rates. 
The Bergström needle technique [33] was used to collect muscle biopsies from the middle 
region of the vastus lateralis (15 cm above the patella). All biopsy samples were freed from 
visible adipose tissue and blood, immediately frozen in liquid nitrogen, and stored at −80°C 
until subsequent analysis.  
Production of intrinsically labeled protein 
Intrinsically L-[1-13C]-phenylalanine- and L-[1-13C]-leucine-labeled casein was obtained by 
infusion of a lactating Holstein cow with L-[1-13C]-phenylalanine (455 μmol·min-1) and L-[1-
13C]-leucine (200 μmol·min-1), collection of the milk, and purification of the casein fraction, as 
described previously [34-36]. Enrichments of L-[1-13C]-phenylalanine and L-[1-13C]-leucine in 
the casein were 38.7 and 9.3 mole percent excess (MPE), respectively. Participants received a 
beverage containing 20 g of casein (containing 1.54 g of leucine) in a total volume of 350 mL. 
The casein protein met all chemical and bacteriological specifications for human consumption.  
Plasma analyses 
Plasma NO3− and NO2− were analyzed by gas-phase chemiluminescence analysis, which has 
been described previously [37]. Briefly, plasma NO3− and NO2− concentrations are determined 
by their reduction to NO. The spectral emission of electronically excited nitrogen dioxide, from 
the NO reaction with ozone, is detected by a thermoelectrically cooled, red-sensitive 
photomultiplier tube, housed in a gas-phase chemiluminescence NO analyzer (Sievers NOA 
280i, Analytix). Plasma glucose and insulin concentrations were analyzed using commercially 
available kits [GLUC3 (catalog no. 05168791 190, Roche) and Immunologic (catalog no. 
12017547 122, Roche), respectively]. Plasma amino acid concentrations and enrichments were 
determined by gas chromatography-mass spectrometry (GC-MS) analysis (model 
7890A/GC/5975C/MSD, Agilent, Little Falls, VA). Specifically, internal standards of [U-13C6]-
leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-tyrosine were added to the samples, which 
were deproteinized on ice with dry 5-sulfosalicylic acid. Free amino acids were purified using 
cation-exchange chromatography (AG 50W-X8 resin, 100- to 200-μm dry mesh; Bio-Rad 
Laboratories, Hercules, CA) and converted to their tert-butyl dimethylsilyl (t-BDMS) derivative 
before GC-MS analysis. The amino acid concentrations were determined using electron impact 
ionization by monitoring ions at mass-to-charge ratios (m/z) of 302 and 308 for unlabeled and 
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[U-13C6]-labeled leucine, respectively, m/z 336 and 346 for unlabeled and [U-13C915N]-labeled 
phenylalanine, respectively, and m/z 466 and 476 for unlabeled and [U-13C915N]-labeled 
tyrosine, respectively. The plasma phenylalanine and tyrosine 13C and 2H enrichments were 
determined using selective ion monitoring at m/z 336, 337, and 341 for unlabeled and labeled 
(1-13C and ring-2H5)-phenylalanine, respectively, and m/z 466, 467, 468, and 470 for unlabeled 
and labeled (1-13C, ring-3,5-2H2, and ring-2H4)-tyrosine, respectively. For L-[1-13C]-
leucine, m/z 302 (m + 0) and m/z 303 (m + 1) were monitored. Standard regression curves 
were applied from a series of known standard enrichment values against the measured values 
to assess the linearity of the mass spectrometer and to account for any isotope fractionation 
that may have occurred during the analysis. Phenylalanine and tyrosine enrichments were 
corrected for the presence of the 13C and 2H isotopes. Plasma isotopic enrichment of the t-
BDMS derivative of α-[13C]-ketoisocaproate (KIC) was measured by GC-MS analysis for use as 
a surrogate for leucyl-tRNA labeling [38]. 
Muscle analyses 
The muscle intracellular free amino acids were extracted from ∼50 mg of wet muscle tissue. 
The muscle was homogenized on ice with a Teflon-coated pestle using ice-cold 2% perchloric 
acid (7 μl × wet weight) and then centrifuged at 10,000 g and 4°C for 5 min. The supernatant 
was collected, and this process was repeated twice. The supernatant was taken as the muscle 
intracellular free amino acid pool and processed in the same manner as the plasma samples 
for isotopic enrichment by GC-MS analysis. Myofibrillar protein-enriched fractions were 
extracted from a separate ∼50mg piece of wet muscle tissue by hand-homogenization on ice 
using a pestle (Teflon) in a standard extraction buffer (7.5 μl·mg-1) [39]. The samples were spun 
at 1,500 g and 4°C for 10 min. The supernatants containing sarcoplasmic proteins were 
removed. The remaining myofibrillar and collagen pellets were washed with 500 μl of 
extraction buffer and spun at 700 g and 4°C for 10 min. The myofibrillar protein was solubilized 
by addition of 1.5 ml of 0.3 M NaOH and heating at 50°C for 30 min, with vortex mixing every 
10 min. Samples were centrifuged at 10,000 g and 4°C for 5 min, and the supernatant 
containing the myofibrillar-enriched fraction was collected and the collagen pellet was 
discarded. Myofibrillar proteins were precipitated by addition of 1 ml of 1 M perchloric acid 
and spinning at 700 g and 4°C for 10 min. The myofibrillar protein was washed twice with 70% 
ethanol. Amino acids were liberated by addition of 2 ml of 6 M HCl and heating at 110°C for 
24 h. The hydrolyzed myofibrillar protein fraction was dried under a nitrogen stream while 
being heated to 120°C and, subsequently, dissolved in a 25% acetic acid solution and passed 
over a Dowex exchange resin (AG 50W-X8, 100- to 200-μm mesh hydrogen form; Bio-Rad 
Laboratories). The free amino acids were eluted with 2 M NH4OH and dried, and the purified 
amino acids were derivatized into N-tert-butylmethylsilyl-N-methyltrifluoroacetamide-
phenylethylamines [40, 41] for measurement of l-[ring-2H5]phenylalanine labeling using GC-
MS analysis, as described previously [42]. To reduce the signal-to-noise ratio during GC-MS 
analysis at low tracer enrichments, the phenylalanine from the myofibrillar protein 
hydrolysates was enzymatically decarboxylated to phenylethylamine [41] prior to MTBSTFA 
 
 
derivatization [40, 43]. Enrichments of the protein-bound samples were determined by 
selected ion monitoring for phenylalanine m/z 183 (m + 5) to m/z 180 (m + 2) and a single 
linear standard curve (to avoid slope influences on the measured tracer-to-tracee ratio) from 
mixtures of known m + 5 to m + 0 ratios. To avoid saturation of the mass spectrometer and 
eliminate bias due to any potential concentration dependencies (22), the split ratio was 
adjusted prior to the injection of each sample, so that nearly equal amounts of phenylalanine 
were injected for all samples and standards. The derivatized amino acids were separated on a 
30 m × 0.25 mm × 0.50 μm HP-5MS column (temperature program: 80°C for 1 min, 30°C·min-
1 ramp to 300°C, hold for 10 min). Separate aliquots of the purified amino acids were also 
converted to their N(O,S)-ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate for 
determination of the l-[1-13C]phenylalanine and l-[1-13C]leucine labeling of the myofibrillar 
proteins by gas chromatography combustion-isotope ratio mass spectrometry analysis (GC-I-
RMS Trace GC Ultra, model MAT 253, Thermo Scientific, Bremen, Germany). Standard 
regression curves were applied from a series of known standard enrichment values against the 
measured values to assess the linearity of the mass spectrometer and to account for any 
isotope fractionation that may have occurred during the analysis.  
Calculations 
Whole body amino acid kinetics in non-steady-state conditions were calculated from ingestion 
of L-[1-13C]-phenylalanine-labeled protein, intravenous infusion of L-[ring-2H5]-phenylalanine 
and L-[ring-3,5-2H2]-tyrosine, and arterialized venous blood sampling. Total, exogenous, and 
endogenous phenylalanine appearance rates (Ra, in μmol Phe·kg−1·min−1) and plasma 
phenylalanine availability [i.e., the fraction of dietary protein-derived phenylalanine that 
appeared in the systemic circulation (Pheplasma)] were calculated using modified Steele's 
equations [44-46].  
 Total Ra =  
𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
      (1) 
Total phenylalanine Ra was calculated using Eq. 1, where Fiv is the intravenous tracer infusion 
rate (in μmol·kg−1·min−1) and pV is the distribution volume for phenylalanine (0.125 L·kg-1) 
[44]. (C(t) is the mean plasma phenylalanine concentration between two consecutive time 
points, and dEiv/dt represents the time-dependent change in plasma phenylalanine 
enrichment derived from the intravenous tracer and Eiv(t) is the mean plasma phenylalanine 
enrichment from the intravenous tracer between 2 consecutive time points.  
 Exogenous Ra =  
𝑇𝑇𝑇𝑇𝑡𝑡𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎∙𝐸𝐸𝑝𝑝𝑝𝑝 (𝑡𝑡)+[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑝𝑝𝑝𝑝
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
    (2) 
Exogenous phenylalanine Ra (Eq. 2; Exo Ra) represents the plasma entry rate of dietary protein-
derived phenylalanine. Epo(t) is the mean plasma phenylalanine enrichment of the oral tracer, 
dEpo/dt represents the time-dependent change in plasma phenylalanine enrichment derived 
from the oral tracer, and Eprot is the enrichment of L-[1-13C]-phenylalanine in the dietary 
protein.  
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[U-13C6]-labeled leucine, respectively, m/z 336 and 346 for unlabeled and [U-13C915N]-labeled 
phenylalanine, respectively, and m/z 466 and 476 for unlabeled and [U-13C915N]-labeled 
tyrosine, respectively. The plasma phenylalanine and tyrosine 13C and 2H enrichments were 
determined using selective ion monitoring at m/z 336, 337, and 341 for unlabeled and labeled 
(1-13C and ring-2H5)-phenylalanine, respectively, and m/z 466, 467, 468, and 470 for unlabeled 
and labeled (1-13C, ring-3,5-2H2, and ring-2H4)-tyrosine, respectively. For L-[1-13C]-
leucine, m/z 302 (m + 0) and m/z 303 (m + 1) were monitored. Standard regression curves 
were applied from a series of known standard enrichment values against the measured values 
to assess the linearity of the mass spectrometer and to account for any isotope fractionation 
that may have occurred during the analysis. Phenylalanine and tyrosine enrichments were 
corrected for the presence of the 13C and 2H isotopes. Plasma isotopic enrichment of the t-
BDMS derivative of α-[13C]-ketoisocaproate (KIC) was measured by GC-MS analysis for use as 
a surrogate for leucyl-tRNA labeling [38]. 
Muscle analyses 
The muscle intracellular free amino acids were extracted from ∼50 mg of wet muscle tissue. 
The muscle was homogenized on ice with a Teflon-coated pestle using ice-cold 2% perchloric 
acid (7 μl × wet weight) and then centrifuged at 10,000 g and 4°C for 5 min. The supernatant 
was collected, and this process was repeated twice. The supernatant was taken as the muscle 
intracellular free amino acid pool and processed in the same manner as the plasma samples 
for isotopic enrichment by GC-MS analysis. Myofibrillar protein-enriched fractions were 
extracted from a separate ∼50mg piece of wet muscle tissue by hand-homogenization on ice 
using a pestle (Teflon) in a standard extraction buffer (7.5 μl·mg-1) [39]. The samples were spun 
at 1,500 g and 4°C for 10 min. The supernatants containing sarcoplasmic proteins were 
removed. The remaining myofibrillar and collagen pellets were washed with 500 μl of 
extraction buffer and spun at 700 g and 4°C for 10 min. The myofibrillar protein was solubilized 
by addition of 1.5 ml of 0.3 M NaOH and heating at 50°C for 30 min, with vortex mixing every 
10 min. Samples were centrifuged at 10,000 g and 4°C for 5 min, and the supernatant 
containing the myofibrillar-enriched fraction was collected and the collagen pellet was 
discarded. Myofibrillar proteins were precipitated by addition of 1 ml of 1 M perchloric acid 
and spinning at 700 g and 4°C for 10 min. The myofibrillar protein was washed twice with 70% 
ethanol. Amino acids were liberated by addition of 2 ml of 6 M HCl and heating at 110°C for 
24 h. The hydrolyzed myofibrillar protein fraction was dried under a nitrogen stream while 
being heated to 120°C and, subsequently, dissolved in a 25% acetic acid solution and passed 
over a Dowex exchange resin (AG 50W-X8, 100- to 200-μm mesh hydrogen form; Bio-Rad 
Laboratories). The free amino acids were eluted with 2 M NH4OH and dried, and the purified 
amino acids were derivatized into N-tert-butylmethylsilyl-N-methyltrifluoroacetamide-
phenylethylamines [40, 41] for measurement of l-[ring-2H5]phenylalanine labeling using GC-
MS analysis, as described previously [42]. To reduce the signal-to-noise ratio during GC-MS 
analysis at low tracer enrichments, the phenylalanine from the myofibrillar protein 
hydrolysates was enzymatically decarboxylated to phenylethylamine [41] prior to MTBSTFA 
 
 
derivatization [40, 43]. Enrichments of the protein-bound samples were determined by 
selected ion monitoring for phenylalanine m/z 183 (m + 5) to m/z 180 (m + 2) and a single 
linear standard curve (to avoid slope influences on the measured tracer-to-tracee ratio) from 
mixtures of known m + 5 to m + 0 ratios. To avoid saturation of the mass spectrometer and 
eliminate bias due to any potential concentration dependencies (22), the split ratio was 
adjusted prior to the injection of each sample, so that nearly equal amounts of phenylalanine 
were injected for all samples and standards. The derivatized amino acids were separated on a 
30 m × 0.25 mm × 0.50 μm HP-5MS column (temperature program: 80°C for 1 min, 30°C·min-
1 ramp to 300°C, hold for 10 min). Separate aliquots of the purified amino acids were also 
converted to their N(O,S)-ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate for 
determination of the l-[1-13C]phenylalanine and l-[1-13C]leucine labeling of the myofibrillar 
proteins by gas chromatography combustion-isotope ratio mass spectrometry analysis (GC-I-
RMS Trace GC Ultra, model MAT 253, Thermo Scientific, Bremen, Germany). Standard 
regression curves were applied from a series of known standard enrichment values against the 
measured values to assess the linearity of the mass spectrometer and to account for any 
isotope fractionation that may have occurred during the analysis.  
Calculations 
Whole body amino acid kinetics in non-steady-state conditions were calculated from ingestion 
of L-[1-13C]-phenylalanine-labeled protein, intravenous infusion of L-[ring-2H5]-phenylalanine 
and L-[ring-3,5-2H2]-tyrosine, and arterialized venous blood sampling. Total, exogenous, and 
endogenous phenylalanine appearance rates (Ra, in μmol Phe·kg−1·min−1) and plasma 
phenylalanine availability [i.e., the fraction of dietary protein-derived phenylalanine that 
appeared in the systemic circulation (Pheplasma)] were calculated using modified Steele's 
equations [44-46].  
 Total Ra =  
𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
      (1) 
Total phenylalanine Ra was calculated using Eq. 1, where Fiv is the intravenous tracer infusion 
rate (in μmol·kg−1·min−1) and pV is the distribution volume for phenylalanine (0.125 L·kg-1) 
[44]. (C(t) is the mean plasma phenylalanine concentration between two consecutive time 
points, and dEiv/dt represents the time-dependent change in plasma phenylalanine 
enrichment derived from the intravenous tracer and Eiv(t) is the mean plasma phenylalanine 
enrichment from the intravenous tracer between 2 consecutive time points.  
 Exogenous Ra =  
𝑇𝑇𝑇𝑇𝑡𝑡𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎∙𝐸𝐸𝑝𝑝𝑝𝑝 (𝑡𝑡)+[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑝𝑝𝑝𝑝
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
    (2) 
Exogenous phenylalanine Ra (Eq. 2; Exo Ra) represents the plasma entry rate of dietary protein-
derived phenylalanine. Epo(t) is the mean plasma phenylalanine enrichment of the oral tracer, 
dEpo/dt represents the time-dependent change in plasma phenylalanine enrichment derived 
from the oral tracer, and Eprot is the enrichment of L-[1-13C]-phenylalanine in the dietary 
protein.  
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 Endogenous Ra =  Total𝑅𝑅𝑎𝑎 –  Exo𝑅𝑅𝑎𝑎 – 𝐹𝐹𝑖𝑖𝑖𝑖      (3) 
Endogenous phenylalanine Ra (Eq. 3; Endo Ra) represents the plasma entry rate of 
phenylalanine derived from whole body protein breakdown.  
 Pheplasma = [𝐴𝐴𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
𝑃𝑃ℎ𝑒𝑒𝑝𝑝𝑝𝑝𝐸𝐸𝑝𝑝
] ∙ BW ∙ 100%    (4) 
Pheplasma was calculated using Eq. 4. AUCExoRa is the area under the curve (AUC) of Exo Ra, BW 
is the body weight of the subject (in kg), and Pheprot is the amount of dietary phenylalanine 
that is ingested.  
Total phenylalanine rate of disappearance (Eq. 5; Rd, in μmol Phe·kg−1·min−1) equals the rate 
of phenylalanine hydroxylation (the 1st step in phenylalanine oxidation) and utilization for 
protein synthesis. These parameters are calculated as follows  
 Total Rd = 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 −  𝑝𝑝𝑝𝑝 ∙ 𝑑𝑑𝐴𝐴𝑑𝑑𝑑𝑑      (5) 
 Phe hydroxylation = 𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 ∙
𝐸𝐸𝑝𝑝𝑡𝑡𝑝𝑝(𝑑𝑑)
𝐸𝐸𝑝𝑝ℎ𝑒𝑒(𝑑𝑑)
 ∙
𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑
(𝐹𝐹𝑃𝑃ℎ𝑒𝑒+𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑 )
    (6) 
 Protein synthesis = Total Rd – Phe hydroxylation   (7) 
 Phe net balance = Protein synthesis – Endo Ra   (8) 
Tyr Ra is the total rate of tyrosine appearance based on the L-[ring-3,5-2H2]-tyrosine infusion 
and plasma enrichment. ETyr(t) and EPhe(t) represent the mean plasma L-[ring-2H4]-tyrosine 
and L-[ring-2H5]-phenylalanine enrichment between two consecutive time points, 
respectively. FPhe is the intravenous infusion rate of L-[ring-2H5]-phenylalanine (in 
μmol·kg−1·min−1). 
Myofibrillar protein fractional synthesis rates (FSR) were calculated using the standard 
precursor-product equation 
 𝐹𝐹𝐹𝐹𝑅𝑅 = 𝛥𝛥𝐸𝐸𝛥𝛥
𝐸𝐸𝑝𝑝𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝐸𝐸𝑝𝑝 ∙ 𝑑𝑑
 ∙ 100%     (9)  
where ΔEp is the increment in myofibrillar protein-bound L-[ring-2H5]-phenylalanine or L-[1-
13C]-leucine enrichments after an incorporation period (in mole percent excess; MPE). 
Eprecursor is the average plasma L-[ring-2H5]-phenylalanine or α-[1-13C]-KIC enrichment during 
the tracer incorporation period (in MPE), and t is the incorporation period (in hours). For basal 
FSR, muscle biopsies at −120 and 0 min were used; for postprandial FSR, biopsies at 0, 120, 
and 300 min were used to calculate the early (0–2 h) and late (2–5 h) postprandial muscle 
protein synthetic response.  
Statistics 
Values are means±SE. Differences in baseline values were determined using an unpaired, two-
tailed Student's t-test. Incremental AUC (iAUC), peak value, and time to peak were calculated 
for all plasma time curves, and differences were determined using an unpaired, two-tailed 
 
 
Student's t-test. Two-way ANOVA with time as the within-group factor and intervention as the 
between-group factor was used to compare differences over time in plasma glucose, insulin, 
NO3−, NO2−, amino acid concentrations and enrichments, whole body phenylalanine Ra, and 
FSR. In case of significant interaction between time and intervention, Bonferroni's post hoc 
test was applied. Differences between intervention groups in muscle free and protein-bound 
amino acid enrichments were analyzed with an unpaired, two-tailed Student's t-test. For all 
analyses, statistical significance was set at P<0.05. All calculations were performed using IBM 
SPSS Statistics (version 21). 
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 Endogenous Ra =  Total𝑅𝑅𝑎𝑎 –  Exo𝑅𝑅𝑎𝑎 – 𝐹𝐹𝑖𝑖𝑖𝑖      (3) 
Endogenous phenylalanine Ra (Eq. 3; Endo Ra) represents the plasma entry rate of 
phenylalanine derived from whole body protein breakdown.  
 Pheplasma = [𝐴𝐴𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸
𝑃𝑃ℎ𝑒𝑒𝑝𝑝𝑝𝑝𝐸𝐸𝑝𝑝
] ∙ BW ∙ 100%    (4) 
Pheplasma was calculated using Eq. 4. AUCExoRa is the area under the curve (AUC) of Exo Ra, BW 
is the body weight of the subject (in kg), and Pheprot is the amount of dietary phenylalanine 
that is ingested.  
Total phenylalanine rate of disappearance (Eq. 5; Rd, in μmol Phe·kg−1·min−1) equals the rate 
of phenylalanine hydroxylation (the 1st step in phenylalanine oxidation) and utilization for 
protein synthesis. These parameters are calculated as follows  
 Total Rd = 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 −  𝑝𝑝𝑝𝑝 ∙ 𝑑𝑑𝐴𝐴𝑑𝑑𝑑𝑑      (5) 
 Phe hydroxylation = 𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 ∙
𝐸𝐸𝑝𝑝𝑡𝑡𝑝𝑝(𝑑𝑑)
𝐸𝐸𝑝𝑝ℎ𝑒𝑒(𝑑𝑑)
 ∙
𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑
(𝐹𝐹𝑃𝑃ℎ𝑒𝑒+𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑 )
    (6) 
 Protein synthesis = Total Rd – Phe hydroxylation   (7) 
 Phe net balance = Protein synthesis – Endo Ra   (8) 
Tyr Ra is the total rate of tyrosine appearance based on the L-[ring-3,5-2H2]-tyrosine infusion 
and plasma enrichment. ETyr(t) and EPhe(t) represent the mean plasma L-[ring-2H4]-tyrosine 
and L-[ring-2H5]-phenylalanine enrichment between two consecutive time points, 
respectively. FPhe is the intravenous infusion rate of L-[ring-2H5]-phenylalanine (in 
μmol·kg−1·min−1). 
Myofibrillar protein fractional synthesis rates (FSR) were calculated using the standard 
precursor-product equation 
 𝐹𝐹𝐹𝐹𝑅𝑅 = 𝛥𝛥𝐸𝐸𝛥𝛥
𝐸𝐸𝑝𝑝𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝐸𝐸𝑝𝑝 ∙ 𝑑𝑑
 ∙ 100%     (9)  
where ΔEp is the increment in myofibrillar protein-bound L-[ring-2H5]-phenylalanine or L-[1-
13C]-leucine enrichments after an incorporation period (in mole percent excess; MPE). 
Eprecursor is the average plasma L-[ring-2H5]-phenylalanine or α-[1-13C]-KIC enrichment during 
the tracer incorporation period (in MPE), and t is the incorporation period (in hours). For basal 
FSR, muscle biopsies at −120 and 0 min were used; for postprandial FSR, biopsies at 0, 120, 
and 300 min were used to calculate the early (0–2 h) and late (2–5 h) postprandial muscle 
protein synthetic response.  
Statistics 
Values are means±SE. Differences in baseline values were determined using an unpaired, two-
tailed Student's t-test. Incremental AUC (iAUC), peak value, and time to peak were calculated 
for all plasma time curves, and differences were determined using an unpaired, two-tailed 
 
 
Student's t-test. Two-way ANOVA with time as the within-group factor and intervention as the 
between-group factor was used to compare differences over time in plasma glucose, insulin, 
NO3−, NO2−, amino acid concentrations and enrichments, whole body phenylalanine Ra, and 
FSR. In case of significant interaction between time and intervention, Bonferroni's post hoc 
test was applied. Differences between intervention groups in muscle free and protein-bound 
amino acid enrichments were analyzed with an unpaired, two-tailed Student's t-test. For all 
analyses, statistical significance was set at P<0.05. All calculations were performed using IBM 
SPSS Statistics (version 21). 
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R ESULTS  
Plasma analyses 
Plasma NO3− and NO2− concentrations are presented in Figure 1. Plasma 
NO3− concentrations (Figure 1A) did not differ at baseline (−210 min) between intervention 
groups and increased following NaNO3− ingestion (P<0.001). Throughout the experiment, 
NO3− concentrations were significantly higher in the PRONO3 than the PRO group (P<0.001, 
time × intervention interaction P<0.001, iAUC P<0.001), reaching peak values of 663±22 and 
39±2 μmol·L-1 in the PRONO3 and PRO groups, respectively (P<0.001). Plasma 
NO2− concentrations (Figure 1B) increased significantly following NaNO3− ingestion in the 
PRONO3 group only (time effect P<0.01, group effect P<0.05, time × intervention 
interaction P<0.01), reaching peak values of 788±138 and 389±55 mmol·L-1 the PRONO3 and 
PRO groups, respectively (peak values P<0.05, iAUC P<0.01). 
 
Figure 1 | Plasma nitrate (NO3−, A) and nitrite (NO2−, B) concentrations in older, type 2 diabetes patients following 
protein ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Vertical lines indicate ingestion 
of the drinks: dotted lines, NaNO3− or NaCl; dashed lines, 20 g protein. Inset: integrated area under the curve 
(iAUC). Values are means±SE. Data were analyzed with repeated-measures (time × intervention) ANOVA.                   
* Significant difference between groups, P<0.01.  
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Plasma glucose and insulin concentrations are shown in Figure 2. Plasma glucose 
concentrations (Figure 2A) did not differ between interventions throughout the experimental 
trial. Plasma insulin concentrations (Figure 2B) increased following protein ingestion 
(P<0.001), but to a greater extent in the PRO than the PRONO3 group (time × intervention 
interaction P<0.001, iAUC P=0.4).  
 
Figure 2 | Plasma glucose (A) and insulin (B) concentrations in older, type 2 diabetes patients following protein 
ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Vertical lines indicate ingestion of the 
drinks: dotted lines, NaNO3− or NaCl; dashed lines, 20 g protein. Values are means±SE. Data were analyzed with 
repeated-measures (time × intervention) ANOVA.  
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concentrations (Figure 2A) did not differ between interventions throughout the experimental 
trial. Plasma insulin concentrations (Figure 2B) increased following protein ingestion 
(P<0.001), but to a greater extent in the PRO than the PRONO3 group (time × intervention 
interaction P<0.001, iAUC P=0.4).  
 
Figure 2 | Plasma glucose (A) and insulin (B) concentrations in older, type 2 diabetes patients following protein 
ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Vertical lines indicate ingestion of the 
drinks: dotted lines, NaNO3− or NaCl; dashed lines, 20 g protein. Values are means±SE. Data were analyzed with 
repeated-measures (time × intervention) ANOVA.  
  
Glucose
-120 -60 0 60 120 180 240 300
0
2
4
6
8
10
Pla
sm
a c
on
ce
nt
ra
tio
n (
m
m
ol
L-
1 )
Insulin
-120 -60 0 60 120 180 240 300
0
5
10
15
20
25
PRO
PRONO3
Time (min)
Pla
sm
a c
on
ce
nt
ra
tio
n (
m
U
L-
1 )
B
0
500
1000
1500
iA
UC
A
 144
 
 
Plasma amino acid concentrations (Figure 3) increased after protein ingestion (P<0.001), with 
no differences between groups for phenylalanine (Figure 3A) and leucine (Figure 3C) 
concentrations. Plasma tyrosine concentrations (Figure 3B) were higher in the PRO group 
during the postprandial period (intervention effect P<0.05, iAUC P=0.3). 
Plasma amino acid enrichments are presented in Figure 4. Plasma L-[ring-2H5]-phenylalanine 
(Figure 4A) and L-[1-13C]-leucine (Figure 4C) enrichments did not differ between 
interventions in the basal and postprandial periods. Plasma L-[1-13C]-phenylalanine 
enrichments (Figure 4B) increased following protein ingestion in both intervention groups 
(P<0.001), reaching peak values of 12.3±0.7 MPE at 72±12 min and 11.8±0.8 MPE at 86±24 
min in the PRO and PRONO3 groups, respectively, and did not differ between groups 
(intervention effect P=0.7, iAUC P=0.8).  
 
 
 
Figure 3 | Plasma phenylalanine (A), tyrosine (B), and leucine (C) concentrations in older, type 2 diabetes patients 
following protein ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Vertical lines indicate 
ingestion of the drinks: dotted lines, NaNO3− or NaCl; dashed lines, 20 g protein. Inset: iAUC. Values are means±SE. 
Data were analyzed with repeated-measures (time × intervention) ANOVA. 
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Figure 4 | Plasma L-[ring-2H5]-phenylalanine (A), L-[1-13C]-phenylalanine (B), and L-[1-13C]-leucine (C) 
enrichments [mole percent excess (MPE)] in older, type 2 diabetes patients following protein ingestion with 
(PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Vertical lines indicate ingestion of the drinks: dotted 
lines, NaNO3− or NaCl; dashed lines, 20 g protein. Inset: iAUC. Values are means±SE. Data were analyzed with 
repeated-measures (time × intervention) ANOVA. 
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Whole body phenylalanine kinetics 
Whole body phenylalanine Ra values are presented in Figure 5. Exogenous phenylalanine Ra 
(Figure 5A) increased rapidly following protein ingestion (P<0.001) and did not differ between 
groups. The fraction of dietary protein-derived phenylalanine that was released in the plasma 
over the 5h postprandial period was 55±2% and 53±2% in the PRO and PRONO3 groups, 
respectively. Endogenous phenylalanine Ra (Figure 5B) decreased following protein ingestion 
and did not differ between intervention groups. No differences were detected between 
interventions in total plasma phenylalanine Ra (Figure 5C) and Rd (Figure 5D). 
 
Figure 5 | Exogenous rate of appearance (Ra, A), endogenous Ra (B), total Ra (C), and total rate of disappearance 
(Rd, D) in older, type 2 diabetes patients following protein ingestion with (PRONO3, n = 12) or without (PRO, n = 
11) dietary NO3−. Vertical lines indicate ingestion of the drinks: dotted lines, NaNO3− or NaCl; dashed lines, 20 g 
protein. Values are means±SE. Data were analyzed with repeated-measures (time × intervention) ANOVA. 
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groups. The fraction of dietary protein-derived phenylalanine that was released in the plasma 
over the 5h postprandial period was 55±2% and 53±2% in the PRO and PRONO3 groups, 
respectively. Endogenous phenylalanine Ra (Figure 5B) decreased following protein ingestion 
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Postabsorptive and postprandial whole body protein breakdown, synthesis, oxidation, and net 
balance are presented in Figure 6. Whole body protein breakdown rates decreased following 
protein ingestion (P<0.001). Whole body protein synthesis rates increased after protein 
ingestion (P<0.001), with no differences between groups (P=0.3). Whole body protein 
oxidation rates were significantly higher in the PRO than the PRONO3 group in the basal and 
postprandial periods (P<0.05). Whole body protein net balance in the postabsorptive phase 
was significantly higher in the PRONO3 than the PRO group (0.66±0.10 vs. 1.04±0.12 
μmol·kg·h−1, P<0.05) and increased in the postprandial phase (7.71±0.33 and 7.80±0.53 
μmol·kg·h−1 in PRO and PRONO3, respectively, P<0.001), with no differences between groups 
(P=0.8). 
 
Figure 6 | Whole body protein metabolism during basal and postprandial periods in older, type 2 diabetes patients 
following 20 g protein ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Values are 
means±SE. Data were analyzed with unpaired Student's t-test (between groups) and repeated-measures (time × 
intervention) ANOVA. Whole body protein breakdown rates: time effect  P<0.001; whole body protein synthesis 
rates: time effect P<0.001; whole body protein oxidation rates: time effect P<0.001, basal between-groups P=0.01, 
postprandial between-groups P=0.04; whole body protein net balance: time effect P<0.001, basal between-
groups P=0.02. * Significant time effect, P<0.01. #Significant difference between groups, P<0.05. 
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Muscle protein synthesis  
Myofibrillar protein synthesis rates, expressed as FSR, are presented in Figure 7. 
Postabsorptive myofibrillar FSR based on the L-[ring-2H5]-phenylalanine tracer (Figure 7A), 
with plasma L-[ring-2H5]-phenylalanine enrichments used as precursor pool, did not differ 
between interventions (P=0.6). After protein ingestion, myofibrillar protein synthesis rates in 
the PRO and PRONO3 groups averaged 0.025±0.004 and 0.021±0.007 %·h-1, respectively, in 
the early (0–2 h) postprandial phase and 0.032±0.004 and 0.030±0.003 %·h-1, respectively, in 
the late (2–5 h) postprandial phase, with no differences between groups (time effect P<0.05, 
intervention effect P=0.7). Postabsorptive myofibrillar FSR based on the L-[1-13C]-leucine 
tracer (Figure 7B), with plasma α-[1-13C]-KIC enrichments used as precursor pool, did not 
differ between groups (P=0.8). After protein ingestion, early and late postprandial muscle 
protein synthesis rates in PRO and PRONO3 groups averaged 0.039±0.007 and 0.040±0.011 
%·h-1 and 0.046±0.008 and 0.038±0.007 %·h-1, respectively, with no differences between 
groups (time effect P=0.7, intervention effect P=0.7).  
 
Figure 7 | Myofibrillar muscle protein fractional synthesis rates (FSR) in older, type 2 diabetes patients 
intravenously infused with L-[ring-2H5]-phenylalanine (A) and L-[1-13C]-leucine (B) following 20 g protein 
ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Values are means±SE. Data were analyzed 
with unpaired Student's t-test (between groups) and repeated-measures (time × intervention) ANOVA. FSR based 
on L-[ring-2H5]-phenylalanine enrichments: time effect P=0.03, intervention effect P=0.7; FSR based on L-[1-13C]-
leucine enrichments: time effect P=0.7, intervention effect P=0.7. * Significant time effect, P<0.05. 
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Postabsorptive and postprandial whole body protein breakdown, synthesis, oxidation, and net 
balance are presented in Figure 6. Whole body protein breakdown rates decreased following 
protein ingestion (P<0.001). Whole body protein synthesis rates increased after protein 
ingestion (P<0.001), with no differences between groups (P=0.3). Whole body protein 
oxidation rates were significantly higher in the PRO than the PRONO3 group in the basal and 
postprandial periods (P<0.05). Whole body protein net balance in the postabsorptive phase 
was significantly higher in the PRONO3 than the PRO group (0.66±0.10 vs. 1.04±0.12 
μmol·kg·h−1, P<0.05) and increased in the postprandial phase (7.71±0.33 and 7.80±0.53 
μmol·kg·h−1 in PRO and PRONO3, respectively, P<0.001), with no differences between groups 
(P=0.8). 
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%·h-1 and 0.046±0.008 and 0.038±0.007 %·h-1, respectively, with no differences between 
groups (time effect P=0.7, intervention effect P=0.7).  
 
Figure 7 | Myofibrillar muscle protein fractional synthesis rates (FSR) in older, type 2 diabetes patients 
intravenously infused with L-[ring-2H5]-phenylalanine (A) and L-[1-13C]-leucine (B) following 20 g protein 
ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Values are means±SE. Data were analyzed 
with unpaired Student's t-test (between groups) and repeated-measures (time × intervention) ANOVA. FSR based 
on L-[ring-2H5]-phenylalanine enrichments: time effect P=0.03, intervention effect P=0.7; FSR based on L-[1-13C]-
leucine enrichments: time effect P=0.7, intervention effect P=0.7. * Significant time effect, P<0.05. 
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Myofibrillar protein-bound L-[1-13C]-phenylalanine enrichments in PRO and PRONO3 groups 
averaged 0.0051±0.0011 and 0.0061±0.0013 MPE, respectively, at 2 h and 0.0155±0.0020 and 
0.0135±0.0022 MPE, respectively, at 5 h, with no differences between groups (time 
effect P<0.001, intervention effect P=0.8). 
 
Figure 8 | Myofibrillar protein-bound L-[1-13C]-phenylalanine enrichments in older, type 2 diabetes patients 
following 20 g protein ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Values are 
means±SE. Data were analyzed with unpaired Student's t-test (between groups) and repeated-measures (time × 
intervention) ANOVA. Time effect P<0.001, intervention effect P=0.8. * Significant time effect, P<0.001. 
Muscle tissue free L-[ring-2H5]-phenylalanine, L-[1-13C]-leucine, and L-[1-13C]-phenylalanine 
enrichments did not differ between groups (Table 2). Similar observations were observed 
when myofibrillar protein synthesis rates were calculated based on use of muscle free 
phenylalanine enrichments as precursor pool (data not shown). 
Table 2 | Muscle tissue-free enrichments 
  -2h 0h 2h 5h 
L-[ring-2H5]-
phenylalanine (MPE) 
PRO (n=11) 4.37±0.42 5.50±0.38 5.00±0.26 5.91±0.20 
PRONO3 (n 
=12) 4.40±0.44 5.31±0.48 5.14±0.28 5.87±0.33 
L-[1-13C]-leucine (MPE) 
PRO (n=11) 3.51±0.28 4.64±0.20 5.68±0.26 5.74±0.17 
PRONO3 
(n=12) 3.47±0.23 4.34±0.28 5.69±0.29 5.85±0.21 
L-[1-13C]-phenylalanine 
(MPE) 
PRO (n=11) N/A N/A 5.44±0.68 3.10±0.33 
PRONO3 
(n=12) N/A N/A 5.06±0.77 3.59±0.23 
Values are means±SE. MPE, mole percent excess; NA, not available. Data were analyzed by repeated-measures 
(time × intervention) ANOVA.  
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D ISCUSSION  
This is the first study to assess if a single dose of dietary NO3− ingested with protein increases 
amino acid delivery to skeletal muscle tissue and, subsequently, augments the postprandial 
muscle protein synthetic response in older, type 2 diabetes patients. The ingestion of 20 g of 
protein increased plasma amino acid availability (Figures 3–5), stimulated whole body protein 
synthesis (Figure 6), increased myofibrillar protein synthesis rates (Figure 7), and enhanced 
the use of dietary protein-derived amino acids for de novo muscle protein synthesis (Figure 
8). However, co-ingestion of a single dose of dietary NO3− with the same amount of protein 
did not modulate postprandial protein handling in older men with type 2 diabetes. 
Reductions in vascular function in response to aging and/or diabetes may be due in part to 
reductions in NO synthesis and a reduced NO-mediated vasodilatory response to feeding-
induced hyperinsulinemia [19]. Consequently, a reduction in NO-mediated vascular function 
may attenuate postprandial plasma amino acid delivery to tissues, thereby having a negative 
impact on normal feeding-mediated increases in postprandial muscle protein synthesis rates. 
Current evidence suggests that the ingestion of dietary NO3− can substantially increase NO 
availability, which may be of particular importance in pathological conditions associated with 
a disrupted NO synthase (NOS)-NO pathway, as in the case of aging or diabetes [22, 47]. 
Inorganic NO3− is converted to NO2− by NO3− reductase-expressing bacteria, which naturally 
reside in the oral cavity. Once salivary NO2− is swallowed, some of it enters the systemic 
circulation, where it is chemically reduced to NO. A recent study by Wylie and co-workers [32] 
showed that changes in plasma NO2− occur 2–3 h after ingestion of beetroot juice (a 
concentrated source of dietary NO3−). Therefore, we provided a single dose of dietary NO3− at 
2 h prior to protein ingestion, so that increased NO2− concentrations would temporally 
correspond with increased postprandial plasma amino acid concentrations. The ingestion of 
NaNO3− increased plasma NO3− concentrations, which remained elevated for up to 7 h (Figure 
1). Moreover, plasma NO2− increased following the ingestion of NaNO3−, reaching peak 
concentrations of ∼800 mmol·l-1 at 30 min after protein ingestion. These findings indicate an 
intact enterosalivary circuit in older, type 2 diabetes patients. 
After protein ingestion, plasma amino acid concentrations increased in both groups (Figure 
3). By combining the ingestion of intrinsically L-[1-13C]-phenylalanine-labeled protein with a 
primed continuous L-[ring-2H5]-phenylalanine infusion, we were able to measure protein-
derived L-[1-13C]-phenylalanine enrichments (Figure 4) and quantify the Ra of dietary protein-
derived amino acids into the circulation (Figure 5) [36, 48]. Plasma L-[1-13C]-phenylalanine 
enrichments increased directly following protein ingestion in both groups, reaching peak 
values of 12.3±0.7 and 11.8±0.8 MPE in the PRO and PRONO3 groups, respectively. In total, 
55±2% and 53±2% of the ingested protein became available in the circulation during the 5-h 
postprandial period in the PRO and PRONO3 groups, respectively. Despite previous reports 
that dietary strategies augmenting NO metabolism may alter gut and organ tissue perfusion 
[49, 50], the greater plasma NO2− availability in the PRONO3 group did not modulate dietary 
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Myofibrillar protein-bound L-[1-13C]-phenylalanine enrichments in PRO and PRONO3 groups 
averaged 0.0051±0.0011 and 0.0061±0.0013 MPE, respectively, at 2 h and 0.0155±0.0020 and 
0.0135±0.0022 MPE, respectively, at 5 h, with no differences between groups (time 
effect P<0.001, intervention effect P=0.8). 
 
Figure 8 | Myofibrillar protein-bound L-[1-13C]-phenylalanine enrichments in older, type 2 diabetes patients 
following 20 g protein ingestion with (PRONO3, n = 12) or without (PRO, n = 11) dietary NO3−. Values are 
means±SE. Data were analyzed with unpaired Student's t-test (between groups) and repeated-measures (time × 
intervention) ANOVA. Time effect P<0.001, intervention effect P=0.8. * Significant time effect, P<0.001. 
Muscle tissue free L-[ring-2H5]-phenylalanine, L-[1-13C]-leucine, and L-[1-13C]-phenylalanine 
enrichments did not differ between groups (Table 2). Similar observations were observed 
when myofibrillar protein synthesis rates were calculated based on use of muscle free 
phenylalanine enrichments as precursor pool (data not shown). 
Table 2 | Muscle tissue-free enrichments 
  -2h 0h 2h 5h 
L-[ring-2H5]-
phenylalanine (MPE) 
PRO (n=11) 4.37±0.42 5.50±0.38 5.00±0.26 5.91±0.20 
PRONO3 (n 
=12) 4.40±0.44 5.31±0.48 5.14±0.28 5.87±0.33 
L-[1-13C]-leucine (MPE) 
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PRONO3 
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PRONO3 
(n=12) N/A N/A 5.06±0.77 3.59±0.23 
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D ISCUSSION  
This is the first study to assess if a single dose of dietary NO3− ingested with protein increases 
amino acid delivery to skeletal muscle tissue and, subsequently, augments the postprandial 
muscle protein synthetic response in older, type 2 diabetes patients. The ingestion of 20 g of 
protein increased plasma amino acid availability (Figures 3–5), stimulated whole body protein 
synthesis (Figure 6), increased myofibrillar protein synthesis rates (Figure 7), and enhanced 
the use of dietary protein-derived amino acids for de novo muscle protein synthesis (Figure 
8). However, co-ingestion of a single dose of dietary NO3− with the same amount of protein 
did not modulate postprandial protein handling in older men with type 2 diabetes. 
Reductions in vascular function in response to aging and/or diabetes may be due in part to 
reductions in NO synthesis and a reduced NO-mediated vasodilatory response to feeding-
induced hyperinsulinemia [19]. Consequently, a reduction in NO-mediated vascular function 
may attenuate postprandial plasma amino acid delivery to tissues, thereby having a negative 
impact on normal feeding-mediated increases in postprandial muscle protein synthesis rates. 
Current evidence suggests that the ingestion of dietary NO3− can substantially increase NO 
availability, which may be of particular importance in pathological conditions associated with 
a disrupted NO synthase (NOS)-NO pathway, as in the case of aging or diabetes [22, 47]. 
Inorganic NO3− is converted to NO2− by NO3− reductase-expressing bacteria, which naturally 
reside in the oral cavity. Once salivary NO2− is swallowed, some of it enters the systemic 
circulation, where it is chemically reduced to NO. A recent study by Wylie and co-workers [32] 
showed that changes in plasma NO2− occur 2–3 h after ingestion of beetroot juice (a 
concentrated source of dietary NO3−). Therefore, we provided a single dose of dietary NO3− at 
2 h prior to protein ingestion, so that increased NO2− concentrations would temporally 
correspond with increased postprandial plasma amino acid concentrations. The ingestion of 
NaNO3− increased plasma NO3− concentrations, which remained elevated for up to 7 h (Figure 
1). Moreover, plasma NO2− increased following the ingestion of NaNO3−, reaching peak 
concentrations of ∼800 mmol·l-1 at 30 min after protein ingestion. These findings indicate an 
intact enterosalivary circuit in older, type 2 diabetes patients. 
After protein ingestion, plasma amino acid concentrations increased in both groups (Figure 
3). By combining the ingestion of intrinsically L-[1-13C]-phenylalanine-labeled protein with a 
primed continuous L-[ring-2H5]-phenylalanine infusion, we were able to measure protein-
derived L-[1-13C]-phenylalanine enrichments (Figure 4) and quantify the Ra of dietary protein-
derived amino acids into the circulation (Figure 5) [36, 48]. Plasma L-[1-13C]-phenylalanine 
enrichments increased directly following protein ingestion in both groups, reaching peak 
values of 12.3±0.7 and 11.8±0.8 MPE in the PRO and PRONO3 groups, respectively. In total, 
55±2% and 53±2% of the ingested protein became available in the circulation during the 5-h 
postprandial period in the PRO and PRONO3 groups, respectively. Despite previous reports 
that dietary strategies augmenting NO metabolism may alter gut and organ tissue perfusion 
[49, 50], the greater plasma NO2− availability in the PRONO3 group did not modulate dietary 
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protein digestion, amino acid absorption, or the amount of protein-derived amino acids that 
became available within the circulation after the ingestion of 20 g of protein in these older, 
type 2 diabetes patients. 
Protein ingestion increased postprandial whole body protein synthesis and decreased whole 
body protein breakdown rates, resulting in a positive postprandial whole body protein net 
balance. However, ingestion of dietary NO3− did not modulate postprandial whole body 
protein turnover rates (Figure 6). Our results seem to agree with previous observations by 
Thibault and colleagues [51], who were unable to detect an effect of citrulline, a substrate for 
NOS-mediated NO synthesis, on whole body protein turnover. In addition to measuring whole 
body protein turnover rates, we also measured the impact of dietary NO3− ingestion on the 
postprandial myofibrillar protein synthetic response. The ingestion of a meal-like amount of 
protein increased postprandial myofibrillar protein synthesis rates; however, co-ingestion of 
dietary NO3− did not further increase postprandial myofibrillar protein synthesis rates (Figure 
7). In addition to determining the postprandial myofibrillar protein synthesis rates, we used 
highly enriched (38.7 MPE), intrinsically L-[1-13C]-phenylalanine-labeled protein to assess the 
metabolic fate of the ingested protein by measuring the incorporation of dietary protein-
derived L-[1-13C]-phenylalanine into de novo muscle tissue (Figure 8). Protein ingestion 
resulted in a substantial increase in myofibrillar protein-bound L-[1-13C]-phenylalanine 
enrichments at 2 and 5 h, but no additional effect of dietary NO3− co-ingestion was observed. 
Reductions in NO synthesis in older adults may be partly responsible for diminished NO-
mediated capillary recruitment and the blunted muscle protein synthetic response to the 
postprandial rise in plasma amino acid concentrations. In support of this notion, 
pharmacological strategies utilizing NO donors (i.e., sodium nitroprusside or methacholine) 
have been shown to effectively increase blood flow and microvascular perfusion and augment 
the muscle protein synthetic response to amino acid administration [52, 53]. However, practical 
dietary interventions providing precursors for endothelial NOS-mediated NO synthesis, such 
as citrulline [54] and/or arginine [55] co-ingested with protein, have not been effective in 
increasing the postprandial rise in muscle protein synthesis rates. In the present study, dietary 
NO3− was provided as a practical nutritional strategy to increase NO availability through a 
separate pathway that does not require endothelial NOS. Supplementation of dietary 
NO3− has been shown to have significant effects on endothelial function [25], blood pressure 
[26, 32, 56], and O2 consumption during exercise [32] in young and older subjects. However, 
despite the established effects of NO3− on vascular function, our results demonstrate that co-
ingestion of NO3− with a meal-like amount of protein does not augment postprandial plasma 
amino acid availability, modulate whole body protein metabolism, increase skeletal muscle 
protein synthesis rates, or stimulate incorporation of dietary protein-derived amino acids into 
de novo myofibrillar protein. These data are the first to demonstrate that acute 
NO3− supplementation does not represent an effective nutritional strategy to enhance 
postprandial protein handling in vivo in humans. As acute dietary interventions to restore 
vascular function do not appear to increase postprandial muscle protein synthesis rates [54, 
55, 57], longer-term intervention studies involving chronic supplementation of NO substrates 
 
 
may be necessary to enhance vascular function and augment the anabolic response to protein 
ingestion [58-60]. Furthermore, more clinically compromised subpopulations suffering from 
macro- and/or microvascular complications may present greater benefits from the use of 
dietary NO3− ingestion. 
In conclusion, co-ingestion of dietary NO3− with a single meal-like amount of protein increases 
plasma NO3− and NO2− concentrations but does not modulate protein digestion and amino 
acid absorption, augment postprandial whole body or skeletal muscle protein synthesis rates, 
or stimulate incorporation of dietary protein-derived amino acids into de novo muscle protein 
in older, type 2 diabetes patients. Therefore, acute dietary NO3−supplementation does not 
represent an effective nutritional strategy to restore or enhance NO metabolism and improve 
postprandial protein handling in older, type 2 diabetes patients. 
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protein digestion, amino acid absorption, or the amount of protein-derived amino acids that 
became available within the circulation after the ingestion of 20 g of protein in these older, 
type 2 diabetes patients. 
Protein ingestion increased postprandial whole body protein synthesis and decreased whole 
body protein breakdown rates, resulting in a positive postprandial whole body protein net 
balance. However, ingestion of dietary NO3− did not modulate postprandial whole body 
protein turnover rates (Figure 6). Our results seem to agree with previous observations by 
Thibault and colleagues [51], who were unable to detect an effect of citrulline, a substrate for 
NOS-mediated NO synthesis, on whole body protein turnover. In addition to measuring whole 
body protein turnover rates, we also measured the impact of dietary NO3− ingestion on the 
postprandial myofibrillar protein synthetic response. The ingestion of a meal-like amount of 
protein increased postprandial myofibrillar protein synthesis rates; however, co-ingestion of 
dietary NO3− did not further increase postprandial myofibrillar protein synthesis rates (Figure 
7). In addition to determining the postprandial myofibrillar protein synthesis rates, we used 
highly enriched (38.7 MPE), intrinsically L-[1-13C]-phenylalanine-labeled protein to assess the 
metabolic fate of the ingested protein by measuring the incorporation of dietary protein-
derived L-[1-13C]-phenylalanine into de novo muscle tissue (Figure 8). Protein ingestion 
resulted in a substantial increase in myofibrillar protein-bound L-[1-13C]-phenylalanine 
enrichments at 2 and 5 h, but no additional effect of dietary NO3− co-ingestion was observed. 
Reductions in NO synthesis in older adults may be partly responsible for diminished NO-
mediated capillary recruitment and the blunted muscle protein synthetic response to the 
postprandial rise in plasma amino acid concentrations. In support of this notion, 
pharmacological strategies utilizing NO donors (i.e., sodium nitroprusside or methacholine) 
have been shown to effectively increase blood flow and microvascular perfusion and augment 
the muscle protein synthetic response to amino acid administration [52, 53]. However, practical 
dietary interventions providing precursors for endothelial NOS-mediated NO synthesis, such 
as citrulline [54] and/or arginine [55] co-ingested with protein, have not been effective in 
increasing the postprandial rise in muscle protein synthesis rates. In the present study, dietary 
NO3− was provided as a practical nutritional strategy to increase NO availability through a 
separate pathway that does not require endothelial NOS. Supplementation of dietary 
NO3− has been shown to have significant effects on endothelial function [25], blood pressure 
[26, 32, 56], and O2 consumption during exercise [32] in young and older subjects. However, 
despite the established effects of NO3− on vascular function, our results demonstrate that co-
ingestion of NO3− with a meal-like amount of protein does not augment postprandial plasma 
amino acid availability, modulate whole body protein metabolism, increase skeletal muscle 
protein synthesis rates, or stimulate incorporation of dietary protein-derived amino acids into 
de novo myofibrillar protein. These data are the first to demonstrate that acute 
NO3− supplementation does not represent an effective nutritional strategy to enhance 
postprandial protein handling in vivo in humans. As acute dietary interventions to restore 
vascular function do not appear to increase postprandial muscle protein synthesis rates [54, 
55, 57], longer-term intervention studies involving chronic supplementation of NO substrates 
 
 
may be necessary to enhance vascular function and augment the anabolic response to protein 
ingestion [58-60]. Furthermore, more clinically compromised subpopulations suffering from 
macro- and/or microvascular complications may present greater benefits from the use of 
dietary NO3− ingestion. 
In conclusion, co-ingestion of dietary NO3− with a single meal-like amount of protein increases 
plasma NO3− and NO2− concentrations but does not modulate protein digestion and amino 
acid absorption, augment postprandial whole body or skeletal muscle protein synthesis rates, 
or stimulate incorporation of dietary protein-derived amino acids into de novo muscle protein 
in older, type 2 diabetes patients. Therefore, acute dietary NO3−supplementation does not 
represent an effective nutritional strategy to restore or enhance NO metabolism and improve 
postprandial protein handling in older, type 2 diabetes patients. 
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ABST RACT  
Background:  The loss of skeletal muscle mass with aging has been attributed to the 
blunted anabolic response to protein intake. Presleep protein ingestion has 
been suggested as an effective strategy to compensate for such anabolic 
resistance. 
Objective:  We assessed the efficacy of presleep protein ingestion on dietary protein 
digestion and absorption kinetics and overnight muscle protein synthesis 
rates in older men. 
Methods:  In a randomized, double-blind, parallel design, 48 older men (mean±SEM 
age: 72±1 y) ingested 40 g casein (PRO40), 20 g casein (PRO20), 20 g casein 
plus 1.5 g leucine (PRO20+LEU), or a placebo before sleep. Ingestion of 
intrinsically L-[1-13C]-phenylalanine and L-[1-13C]-leucine–labeled protein 
was combined with intravenous L-[ring-2H5]-phenylalanine and L-[1-13C]-
leucine infusions during sleep. Muscle and blood samples were collected 
throughout overnight sleep. 
Results:  Exogenous phenylalanine appearance rates increased after protein 
ingestion, but to a greater extent in PRO40 than in PRO20 and PRO20+LEU 
(P<0.05). Overnight myofibrillar protein synthesis rates (based on L-[ring-
2H5]-phenylalanine) were 0.033±0.002 %·h-1, 0.037±0.003 %·h-1, 0.039±0.002 
%·h-1, and 0.044±0.003 %·h-1 in placebo, PRO20, PRO20+LEU, and PRO40, 
respectively, and were higher in PRO40 than in placebo (P=0.02). 
Observations were similar based on L-[1-13C]-leucine tracer (placebo: 
0.047±0.004 %·h-1 and PRO40: 0.058±0.003 %·h-1, P=0.08). More protein-
derived amino acids (L-[1-13C]-phenylalanine) were incorporated into 
myofibrillar protein in PRO40 than in PRO20 (0.033±0.002 and 0.019±0.002 
MPE, respectively, P<0.001) and tended to be higher than in PRO20+LEU 
(0.025±0.002 MPE, P=0.06). 
Conclusions:  Protein ingested before sleep is properly digested and absorbed throughout 
the night, providing precursors for myofibrillar protein synthesis during 
sleep in healthy older men. Ingestion of 40 g protein before sleep increases 
myofibrillar protein synthesis rates during overnight sleep. These findings 
provide the scientific basis for a novel nutritional strategy to support muscle 
mass preservation in aging and disease.    
 
 
IN TRODU CTION  
Age-related changes in skeletal muscle mass are attributed to a disruption in the regulation 
of muscle protein synthesis and breakdown rates. Protein ingestion stimulates muscle protein 
synthesis and forms an important factor in maintaining skeletal muscle mass over the lifespan 
[1]. The ingestion of 20 g protein increases muscle protein synthesis rates by ∼75% in young 
individuals [2-4], whereas ∼40 g protein seems to be required to allow a similar postprandial 
rise in muscle protein synthesis rates in the older population [5-8]. Besides ingesting larger 
amounts of protein, fortifying lower amounts of protein with free leucine has been shown to 
increase postprandial muscle protein synthesis rates [9-11]. Instead of increasing the anabolic 
response to a single meal, we recently proposed the overnight period as a window of 
opportunity to stimulate muscle protein synthesis. In a first proof-of-concept study, we 
showed that 40 g protein administered via a nasogastric tube during sleep is rapidly digested 
and absorbed, with dietary protein–derived amino acids being used for de novo muscle protein 
synthesis during overnight sleep [12]. Intragastric feeding during sleep may represent an 
interesting clinical strategy to preserve skeletal muscle mass in hospitalized patients but does 
not represent a feasible dietary strategy to support muscle mass maintenance in healthy or 
less clinically compromised older individuals. We therefore propose presleep protein ingestion 
as a nutritional strategy to augment muscle protein synthesis rates during the overnight period 
to support muscle mass preservation in the older population. 
The present study (registered at www.trialregister.nl as NTR3885) assessed the effect of varying 
amounts of protein ingested before sleep on overnight muscle protein synthesis during a 7.5-
h postprandial period. In contrast to typical postprandial periods of 4–6 h [5-8], such an 
extended overnight period should allow the ingested protein dose to be fully digested and 
absorbed throughout the night. We hypothesized that ingesting 40 g protein before sleep 
would increase overnight plasma amino acid availability, thereby stimulating overnight muscle 
protein synthesis in older individuals. Because smaller amounts of protein would be more 
practical to ingest, we evaluated the effect of ingesting 20 g protein on overnight muscle 
protein synthesis rates. We also assessed whether fortifying the lower 20-g protein dose with 
1.5 g free leucine (providing the same amount of leucine as 40 g protein) can further augment 
the overnight muscle protein synthetic response compared with the presleep ingestion of 20 
g protein.  
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M ETHO DS 
Subjects 
A total of 48 healthy, normoglycemic, older men [mean±SEM age: 72±1 y; BMI (in kg·m-2): 
25.4±0.3; glycated hemoglobin: 5.5±0.1%] participated in this study. Subjects’ characteristics 
are presented in Table 1. After pretesting, subjects were randomly assigned to 1 of 4 groups: 
40 g casein (PRO40), 20 g casein (PRO20), 20 g casein plus 1.5 g of crystalline leucine 
(PRO20+LEU), or placebo. Randomization was computer generated, and all procedures and 
analysis were performed in a double-blind manner. The trial was conducted between April 
2013 and October 2013 at Maastricht University Medical Centre+, Maastricht, Netherlands. All 
participants were informed about the purpose of the study, the experimental procedures, and 
possible risks before providing written consent. This study is part of a greater project 
investigating the effect of presleep protein ingestion on overnight muscle protein synthesis. 
Data from the PRO40 group were published in recent work that assessed the effect of physical 
activity performed in the evening on overnight muscle protein synthesis [13]. The present 
study was approved by the Maastricht University Medical Centre+ Medical Ethical Committee, 
Maastricht, Netherlands, and conformed to the latest version of the Declaration of Helsinki.  
Table 1 | Subjects’ characteristics 
 PLA PRO20 PRO20+LEU PRO40 
Age (y) 71±2 72±1 74±2 70±1 
Weight (kg) 76.5±2.9 76.9±2.1 76.5±1.7 79.4±2.2 
BMI (kg·m-2) 24.4±0.6 25.3±0.5 26.0±0.5 25.7±0.6 
Fat (%) 19.7±0.7 20.9±0.9 22.6±1.2 20.8±0.9 
Lean body mass (kg) 58.9±2.1 58.7±1.8 57.1±1.1 60.6±1.4 
Appendicular lean mass (kg) 25.6±1.1 25.5±0.9 24.5±0.5 26.2±0.7 
Skeletal muscle mass index (kg·m-2) 8.2±0.2 8.4±0.3 8.3±0.1 8.5±0.1 
Basal plasma glucose (mmol·L-1) 5.4±0.1 5.8±0.2 5.7±0.2 5.8±0.2 
Plasma glucose 2 h OGTT (mmol·L-1) 6.3±0.4 6.8±0.6 7.0±0.5 6.5±0.3 
Glycated hemoglobin (%) 5.6±0.1 5.6±0.1 5.5±0.1 5.3±0.1 
Values are mean±SEM. n = 12/treatment group. OGTT, oral glucose tolerance test; PLA, placebo; PRO20, 20 g 
dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary protein. 
  
 
 
Pretesting 
After an overnight fast, participants arrived at the laboratory at 08:30 by car or public transport. 
All participants underwent a medical screening to assess glycated hemoglobin, glucose 
tolerance, blood pressure, weight, height, and body composition (DXA, Discovery A; Hologic). 
Plasma glucose and insulin concentrations were measured at baseline and 2 h after a 75 g 
glucose load was ingested to determine oral glucose intolerance or the presence of type 2 
diabetes according to 2006 American Diabetes Association guidelines [14]. Inclusion criteria 
were male sex, age ≥65 y, and a BMI from 20 to 30. Subjects were excluded if any comorbidities 
or use of medication affecting muscle metabolism and mobility of the limbs, interfering with 
gastrointestinal function, neurologic or renal diseases, diagnosed diabetes mellitus, smoking, 
and weight loss >3 kg in the last 3 mo, the use of protein supplements, participation in an 
exercise program, or coagulation diseases were present. All subjects were deemed healthy 
before the experimental trial. See Figure 1 for the Consolidated Standards of Reporting Trials 
flow diagram. The pretesting and experimental trials were separated by a period of ≥7 d. 
 
 
Figure 1 | Flow diagram of participants’ enrollment procedure according to the CONSORT (Consolidated 
Standards of Reporting Trials). PLA: placebo, PRO20: 20 g dietary protein, PRO20+LEU: 20 g dietary protein + 1.5 
g crystalline leucine, PRO40: 40 g dietary protein. 
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Diet and physical activity control 
All volunteers refrained from any exhaustive physical activity and kept their diet as constant 
as possible 48 h before the trial. On the day of the experiment, a standardized diet (3 meals 
and 2 snacks) was consumed that provided 9.3±0.6 MJ total energy, 55±2 energy% (En%) 
carbohydrate, 27±2 En% fat, and 16±0.2 En% protein. The energy content of the standardized 
diet was based on individual energy requirements (Harris-Benedict equation) and adjusted 
with the use of a physical activity factor of 1.4 to ensure ample energy intake. Dietary protein 
intake averaged 1.1±0.01 g·kg-1 body weight, with 35±1% of the protein provided at dinner 
(i.e., containing 29±2 g protein). A visual analog scale (VAS) was used to assess hunger ratings 
before and in the morning after the intervention [15]. In the morning after the experimental 
trial, subjects were invited to an ad libitum breakfast where food intake was recorded.  
Experimental protocol 
At 17:30, participants reported to the laboratory where 2 catheters were inserted into an 
antecubital vein of both arms. After basal blood collection at 18:30 (t = −300 min relative to 
drink ingestion), subjects consumed a standardized dinner under supervision (2.6±0.1 MJ, 
providing 62 En% carbohydrate, 19 En% protein, and 19 En% fat). Subjects rested until the 
initiation of the tracer infusion protocol at 2100. The plasma phenylalanine, tyrosine, and 
leucine pools were primed with a single intravenous dose of L-[ring-2H5]-phenylalanine (2.0 
μmol·kg-1), L-[ring-3,5-2H2]-tyrosine (0.6 μmol·kg-1), and L-[1-13C]-leucine (4.0 μmol·kg-1). 
Thereafter, a continuous stable isotope infusion was initiated (t = −150 min) at an infusion rate 
of 0.050 μmol⋅kg−1⋅min−1 for L-[ring-2H5]-phenylalanine, 0.015 μmol⋅kg−1⋅min−1 for L-[ring-
3,5-2H2]-tyrosine, and 0.100 μmol⋅kg−1⋅min−1 for L-[1-13C]-leucine. Participants rested supine 
for 2.5 h. At 23:30 (t = 0 min), a skeletal muscle biopsy was taken. Subjects then ingested the 
beverage that contained 0, 20, or 40 g casein intrinsically labeled with L-[1-13C]-phenylalanine 
and L-[1-13C]-leucine (placebo, PRO20, PRO20+LEU, or PRO40, respectively) within 5 min and 
went to sleep afterward at ∼00:00. During the night, blood samples (10 ml) were collected 
without waking the subjects at t = 30, 60, 90, 150, 210, 270, 330, 390, and 450 min relative to 
the drink ingestion. A second muscle biopsy was obtained from the contralateral leg 7.5 h later 
at ∼07:00 (t = 450 min). Blood samples were collected in tubes containing EDTA and 
centrifuged at 1000 × g for 10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen 
and stored at −80°C. The percutaneous needle biopsy technique was used to obtain muscle 
biopsy samples from the middle region of the vastus lateralis, 15 cm above the patella and ~4 
cm below entry through the fascia [16]. Muscle samples were dissected carefully, freed from 
any visible non-muscle material, and were immediately frozen in liquid nitrogen and stored at 
−80°C until further analysis. 
  
 
 
Production of intrinsically labeled protein and tracer infusion  
Details on the production and experimental use of intrinsically L-[1-13C]-phenylalanine and L-
[1-13C]-leucine–labeled casein have been reported previously [17-19]. The L-[1-13C]-
phenylalanine and L-[1-13C]-leucine enrichments in casein averaged 38.7 and 9.3 mole percent 
excess (MPE), respectively. The micellar casein met all chemical and bacteriologic specifications 
for human consumption. Micellar casein protein was selected for this study because it 
represents the more slowly digestible protein source and should thus allow for a more 
sustained release of amino acids throughout overnight sleep [20] and was the only intrinsically 
labeled protein available in our laboratory at the time. All test beverages contained 450 mL 
water, with 149 or 298 g micellar casein concentrate containing 20 or 40 g protein, respectively, 
and were flavored and matched for taste by adding 1.5 mL noncaloric vanilla flavor (Dr. 
Oetker). In the PRO20+LEU treatment, 1.5 g crystalline leucine (99.95% L-leucine; Frutarom 
Ltd.) was added to the beverage, matching the leucine content of the PRO40 treatment. The 
placebo treatment consisted of 450 mL water with 1.5 mL vanilla flavor. The stable isotope 
tracers L-[ring-2H5]-phenylalanine, L-[ring-3,5-2H2]-tyrosine, and L-[1-13C]-leucine were 
purchased from Cambridge Isotopes and dissolved in 0.9% saline before infusion (Basic 
Pharma). Continuous intravenous infusions were performed with the use of a calibrated IVAC 
598 Volumetric Infusion Pump (Cardinal Health). 
Sleep quality assessment 
The Pittsburgh Sleep Quality Index (Sleep Medicine Institute, University of Pittsburgh) was 
used to assess habitual sleep quality during pretesting, before randomization [21]. Pittsburgh 
Sleep Quality Index scoring (0–21 points) was used to classify subjects as “very good,” “good,” 
“poor,” or “very poor” sleepers. Subjects that scored >5 (“poor” or “very poor” sleepers) were 
excluded from participation. Sleep behavior during the night was monitored with wrist activity 
monitors and analyzed with Actiware software (Philips Respironics) [22]. Time was scored as 
awake unless the following conditions were met simultaneously: 1) participant was lying down 
attempting to sleep and 2) the activity counts from the monitor were sufficiently low to 
indicate that the participant was immobile. Start and end time of sleep were also recorded 
throughout the trial. The following variables were derived from sleep records and activity 
monitors: bedtime (clock time), get-up time (clock time), time in bed (the amount spent in bed 
attempting to sleep between bedtime and get-up time), sleep onset latency (the period 
between bedtime and sleep start), sleep duration (in hours), sleep efficiency (percentage of 
sleep duration expressed as a percentage of time in bed), and total sleep time (in hours: the 
sum of the sleep obtained at night). 
Plasma analyses 
Plasma glucose and insulin concentrations were analyzed with the use of commercially 
available kits (GLUC3, Ref: 05168791 190, and Immunologic, Ref: 12017547 122, respectively, 
Roche). Plasma amino acid concentrations and enrichments were determined by GC-MS 
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(i.e., containing 29±2 g protein). A visual analog scale (VAS) was used to assess hunger ratings 
before and in the morning after the intervention [15]. In the morning after the experimental 
trial, subjects were invited to an ad libitum breakfast where food intake was recorded.  
Experimental protocol 
At 17:30, participants reported to the laboratory where 2 catheters were inserted into an 
antecubital vein of both arms. After basal blood collection at 18:30 (t = −300 min relative to 
drink ingestion), subjects consumed a standardized dinner under supervision (2.6±0.1 MJ, 
providing 62 En% carbohydrate, 19 En% protein, and 19 En% fat). Subjects rested until the 
initiation of the tracer infusion protocol at 2100. The plasma phenylalanine, tyrosine, and 
leucine pools were primed with a single intravenous dose of L-[ring-2H5]-phenylalanine (2.0 
μmol·kg-1), L-[ring-3,5-2H2]-tyrosine (0.6 μmol·kg-1), and L-[1-13C]-leucine (4.0 μmol·kg-1). 
Thereafter, a continuous stable isotope infusion was initiated (t = −150 min) at an infusion rate 
of 0.050 μmol⋅kg−1⋅min−1 for L-[ring-2H5]-phenylalanine, 0.015 μmol⋅kg−1⋅min−1 for L-[ring-
3,5-2H2]-tyrosine, and 0.100 μmol⋅kg−1⋅min−1 for L-[1-13C]-leucine. Participants rested supine 
for 2.5 h. At 23:30 (t = 0 min), a skeletal muscle biopsy was taken. Subjects then ingested the 
beverage that contained 0, 20, or 40 g casein intrinsically labeled with L-[1-13C]-phenylalanine 
and L-[1-13C]-leucine (placebo, PRO20, PRO20+LEU, or PRO40, respectively) within 5 min and 
went to sleep afterward at ∼00:00. During the night, blood samples (10 ml) were collected 
without waking the subjects at t = 30, 60, 90, 150, 210, 270, 330, 390, and 450 min relative to 
the drink ingestion. A second muscle biopsy was obtained from the contralateral leg 7.5 h later 
at ∼07:00 (t = 450 min). Blood samples were collected in tubes containing EDTA and 
centrifuged at 1000 × g for 10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen 
and stored at −80°C. The percutaneous needle biopsy technique was used to obtain muscle 
biopsy samples from the middle region of the vastus lateralis, 15 cm above the patella and ~4 
cm below entry through the fascia [16]. Muscle samples were dissected carefully, freed from 
any visible non-muscle material, and were immediately frozen in liquid nitrogen and stored at 
−80°C until further analysis. 
  
 
 
Production of intrinsically labeled protein and tracer infusion  
Details on the production and experimental use of intrinsically L-[1-13C]-phenylalanine and L-
[1-13C]-leucine–labeled casein have been reported previously [17-19]. The L-[1-13C]-
phenylalanine and L-[1-13C]-leucine enrichments in casein averaged 38.7 and 9.3 mole percent 
excess (MPE), respectively. The micellar casein met all chemical and bacteriologic specifications 
for human consumption. Micellar casein protein was selected for this study because it 
represents the more slowly digestible protein source and should thus allow for a more 
sustained release of amino acids throughout overnight sleep [20] and was the only intrinsically 
labeled protein available in our laboratory at the time. All test beverages contained 450 mL 
water, with 149 or 298 g micellar casein concentrate containing 20 or 40 g protein, respectively, 
and were flavored and matched for taste by adding 1.5 mL noncaloric vanilla flavor (Dr. 
Oetker). In the PRO20+LEU treatment, 1.5 g crystalline leucine (99.95% L-leucine; Frutarom 
Ltd.) was added to the beverage, matching the leucine content of the PRO40 treatment. The 
placebo treatment consisted of 450 mL water with 1.5 mL vanilla flavor. The stable isotope 
tracers L-[ring-2H5]-phenylalanine, L-[ring-3,5-2H2]-tyrosine, and L-[1-13C]-leucine were 
purchased from Cambridge Isotopes and dissolved in 0.9% saline before infusion (Basic 
Pharma). Continuous intravenous infusions were performed with the use of a calibrated IVAC 
598 Volumetric Infusion Pump (Cardinal Health). 
Sleep quality assessment 
The Pittsburgh Sleep Quality Index (Sleep Medicine Institute, University of Pittsburgh) was 
used to assess habitual sleep quality during pretesting, before randomization [21]. Pittsburgh 
Sleep Quality Index scoring (0–21 points) was used to classify subjects as “very good,” “good,” 
“poor,” or “very poor” sleepers. Subjects that scored >5 (“poor” or “very poor” sleepers) were 
excluded from participation. Sleep behavior during the night was monitored with wrist activity 
monitors and analyzed with Actiware software (Philips Respironics) [22]. Time was scored as 
awake unless the following conditions were met simultaneously: 1) participant was lying down 
attempting to sleep and 2) the activity counts from the monitor were sufficiently low to 
indicate that the participant was immobile. Start and end time of sleep were also recorded 
throughout the trial. The following variables were derived from sleep records and activity 
monitors: bedtime (clock time), get-up time (clock time), time in bed (the amount spent in bed 
attempting to sleep between bedtime and get-up time), sleep onset latency (the period 
between bedtime and sleep start), sleep duration (in hours), sleep efficiency (percentage of 
sleep duration expressed as a percentage of time in bed), and total sleep time (in hours: the 
sum of the sleep obtained at night). 
Plasma analyses 
Plasma glucose and insulin concentrations were analyzed with the use of commercially 
available kits (GLUC3, Ref: 05168791 190, and Immunologic, Ref: 12017547 122, respectively, 
Roche). Plasma amino acid concentrations and enrichments were determined by GC-MS 
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analysis (Agilent 7890A GC/5975C; mass selective detector, Agilent Technologies). Specifically, 
internal standards of [U-13C6]-leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-tyrosine 
were added to the plasma samples. Plasma samples were deproteinized with dry 5-
sulfosalicylic acid. Free amino acids were purified using cation exchange chromatography (AG 
50W-X8 resin, mesh size: 100–200 µm, ionic form: hydrogen; Bio-Rad Laboratories, Hercules, 
USA). The purified amino acids were converted into tert-butyldimethylsilyl (tert-BDMS) 
derivatives with MTBSTFA before analysis by GC-MS. The amino acid concentrations were 
determined using electron impact ionization by monitoring ions at mass/charge (m/z) 302 and 
308 for unlabeled and [U-13C6]-labeled-leucine, 336 and 346 for unlabeled and [U-13C915N]-
labeled-phenylalanine respectively, and 466 and 476 for unlabeled and [U-13C915N] tyrosine, 
respectively. The plasma leucine, phenylalanine, and tyrosine 13C and 2H enrichments were 
determined using selective ion monitoring at m/z 302 and 303 for unlabeled and labeled L-
[1-13C]-leucine, respectively; m/z 336, 337, and 341 for unlabeled and labeled L-[1-13C]-
phenylalanine and L-[ring-2H5]-phenylalanine, respectively; m/z 466, 467, 468, and 470 for 
unlabeled and labeled L-[1-13C]-tyrosine, L-[ring-3,5-2H2]-tyrosine and L-[ring-2H4]-tyrosine, 
respectively. Standard regression curves were applied from a series of known standard 
enrichment values against the measured values to assess the linearity of the mass 
spectrometer and to account for any isotope fractionation. 
Muscle analyses 
Myofibrillar protein–enriched fractions were extracted from ∼60 mg wet muscle tissue by 
hand-homogenizing on ice with a pestle in a standard extraction buffer (7 μL·mg-1) [23]. 
Myofibrillar protein–bound L-[ring-2H5]-phenylalanine enrichments were determined by GC-
MS, and myofibrillar protein–bound L-[1-13C]-phenylalanine enrichments were measured by 
gas chromatography-combustion isotope ratio mass spectrometry (GC-CIRMS) (Trace GC 
Ultra, IRMS model MAT 253; Thermo Scientific) with the use of a DB-5ms column (no. 122-
5532; Agilent J+W Scientific GC Column, GC Isolink). The samples were spun at 2500g and 4˚C 
for 5 min. The pellet was washed with 500 µL ddH2O and centrifuged at 250g and 4ºC for 10 
min. The myofibrillar protein was solubilized by adding 1 mL of 0.3 м NaOH and heating at 
50ºC for 30 min with vortex mixing every 10 min. Samples were centrifuged at 9500g and 4˚C 
for 5 min, the supernatant containing the myofibrillar proteins was collected and the collagen 
pellet was discarded. Myofibrillar proteins were precipitated by the addition of 1 mL of 1 м 
PCA and spinning at 700g and 4˚C for 10 min. The myofibrillar protein pellet was washed twice 
with 70% ethanol and hydrolyzed overnight in 2 mL of 6 м HCL at 110˚C. The free amino acids 
from the hydrolyzed myofibrillar protein pellet were dried under nitrogen stream while being 
heated to 120˚C. The free amino acids were then dissolved in 25% acetic acid solution, passed 
over cation exchange AG 50W-X8 resin columns (mesh size: 100-200, ionic form: hydrogen; 
Bio-Rad Laboratories, Hercules, USA), and eluted with 2 м NH4OH. The purified amino acids 
were divided into 2 aliquots to determine the L-[ring-2H5]-phenylalanine enrichments by GC-
MS analysis and the L-[1-13C]-phenylalanine and L-[1-13C]-leucine enrichments by gas 
chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) analysis. To 
 
 
reduce the signal-to-noise ratio during GC-MS analysis at low tracer enrichments, the 
phenylalanine from the myofibrillar protein hydrolysates was enzymatically decarboxylated to 
β-phenylethylamine prior to derivatization with MTBSTFA. To determine myofibrillar L-[1-13C]-
phenylalanine and L-[1-13C]-leucine enrichments by GC-C-IRMS analysis, the purified amino 
acids were converted into N-ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate 
(ECF). The derivatives were then measured by GC-C-IRMS (Finnigan MAT 253, Bremen, 
Germany) using a DB5-MS-column (no. 122-5532; Agilent J+W scientific GC Column, GC 
Isolink), and monitoring of ion masses 44, 45 and 46. Standard regression curves were applied 
to assess the linearity of the mass spectrometer and to account for isotopic fractionation. 
Calculations 
Ingestion of L-[1-13C]-phenylalanine-labeled protein, intravenous infusion of L-[ring-2H5]-
phenylalanine and L-[ring-3,5-2H2]-tyrosine, and venous blood sampling were used to assess 
whole-body amino acid kinetics in non–steady-state conditions. Modified Steele's equations 
were used to calculate total, exogenous, and endogenous phenylalanine rates of appearance 
(expressed as μmol phenylalanine⋅kg−1⋅min−1) as well as plasma availability of dietary protein–
derived phenylalanine that appeared in the systemic circulation as a fraction of total amount 
of phenylalanine that was ingested [24-26]. 
 Total Ra =  
 𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
      (1) 
 Exogenous Ra =  
 𝑇𝑇𝑇𝑇𝑡𝑡𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎∙𝐸𝐸𝑝𝑝𝑝𝑝(𝑑𝑑) +[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑑𝑑)∙
𝑑𝑑𝐸𝐸𝑝𝑝𝑝𝑝
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
    (2) 
 Endogenous Ra =  𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑅𝑅𝑇𝑇 –  𝐸𝐸𝐸𝐸𝑇𝑇𝑅𝑅𝑇𝑇 – 𝐹𝐹𝑖𝑖𝑖𝑖      (3) 
 Pheplasma =  [ 𝐴𝐴𝐴𝐴𝐶𝐶𝐸𝐸𝐸𝐸𝑝𝑝𝐸𝐸𝑎𝑎
𝑃𝑃ℎ𝑒𝑒𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
] ∙ BW ∙ 100%    (4) 
Fiv is the intravenous tracer infusion rate (in µmol·kg-1·min-1); pV is the distribution volume for 
phenylalanine (0.125 L·kg-1) [24]; C(t) is the mean plasma phenylalanine concentration between 
two consecutive time points; dEiv/dt represents the time-dependent variations of plasma 
phenylalanine enrichment derived from the intravenous tracer; and Eiv(t) is the mean plasma 
phenylalanine enrichment from the intravenous tracer between two consecutive time points. 
Exogenous phenylalanine rate of appearance (ExoRa) represents the plasma entry rate of 
dietary protein-derived phenylalanine. Epo(t) is the mean plasma phenylalanine enrichment 
from the oral tracer between two consecutive time points; dEpo/dt represents the time-
dependent variations of plasma phenylalanine enrichment derived from the oral tracer; and 
Eprot is the L-[1-13C]-phenylalanine enrichment in the dietary protein. Endogenous 
phenylalanine Ra (Endo Ra) represents the rate at which phenylalanine derived from whole-
body protein breakdown enters the circulation. The fraction of dietary phenylalanine taken up 
in the systemic circulation was calculated as a fraction of the total amount of phenylalanine 
that was ingested, Pheplasma. AUCExoRa is the area under the curve (AUC) of Exo Ra, which 
corresponds to the amount of dietary protein-derived phenylalanine that appeared in the 
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analysis (Agilent 7890A GC/5975C; mass selective detector, Agilent Technologies). Specifically, 
internal standards of [U-13C6]-leucine, [U-13C915N]-phenylalanine, and [U-13C915N]-tyrosine 
were added to the plasma samples. Plasma samples were deproteinized with dry 5-
sulfosalicylic acid. Free amino acids were purified using cation exchange chromatography (AG 
50W-X8 resin, mesh size: 100–200 µm, ionic form: hydrogen; Bio-Rad Laboratories, Hercules, 
USA). The purified amino acids were converted into tert-butyldimethylsilyl (tert-BDMS) 
derivatives with MTBSTFA before analysis by GC-MS. The amino acid concentrations were 
determined using electron impact ionization by monitoring ions at mass/charge (m/z) 302 and 
308 for unlabeled and [U-13C6]-labeled-leucine, 336 and 346 for unlabeled and [U-13C915N]-
labeled-phenylalanine respectively, and 466 and 476 for unlabeled and [U-13C915N] tyrosine, 
respectively. The plasma leucine, phenylalanine, and tyrosine 13C and 2H enrichments were 
determined using selective ion monitoring at m/z 302 and 303 for unlabeled and labeled L-
[1-13C]-leucine, respectively; m/z 336, 337, and 341 for unlabeled and labeled L-[1-13C]-
phenylalanine and L-[ring-2H5]-phenylalanine, respectively; m/z 466, 467, 468, and 470 for 
unlabeled and labeled L-[1-13C]-tyrosine, L-[ring-3,5-2H2]-tyrosine and L-[ring-2H4]-tyrosine, 
respectively. Standard regression curves were applied from a series of known standard 
enrichment values against the measured values to assess the linearity of the mass 
spectrometer and to account for any isotope fractionation. 
Muscle analyses 
Myofibrillar protein–enriched fractions were extracted from ∼60 mg wet muscle tissue by 
hand-homogenizing on ice with a pestle in a standard extraction buffer (7 μL·mg-1) [23]. 
Myofibrillar protein–bound L-[ring-2H5]-phenylalanine enrichments were determined by GC-
MS, and myofibrillar protein–bound L-[1-13C]-phenylalanine enrichments were measured by 
gas chromatography-combustion isotope ratio mass spectrometry (GC-CIRMS) (Trace GC 
Ultra, IRMS model MAT 253; Thermo Scientific) with the use of a DB-5ms column (no. 122-
5532; Agilent J+W Scientific GC Column, GC Isolink). The samples were spun at 2500g and 4˚C 
for 5 min. The pellet was washed with 500 µL ddH2O and centrifuged at 250g and 4ºC for 10 
min. The myofibrillar protein was solubilized by adding 1 mL of 0.3 м NaOH and heating at 
50ºC for 30 min with vortex mixing every 10 min. Samples were centrifuged at 9500g and 4˚C 
for 5 min, the supernatant containing the myofibrillar proteins was collected and the collagen 
pellet was discarded. Myofibrillar proteins were precipitated by the addition of 1 mL of 1 м 
PCA and spinning at 700g and 4˚C for 10 min. The myofibrillar protein pellet was washed twice 
with 70% ethanol and hydrolyzed overnight in 2 mL of 6 м HCL at 110˚C. The free amino acids 
from the hydrolyzed myofibrillar protein pellet were dried under nitrogen stream while being 
heated to 120˚C. The free amino acids were then dissolved in 25% acetic acid solution, passed 
over cation exchange AG 50W-X8 resin columns (mesh size: 100-200, ionic form: hydrogen; 
Bio-Rad Laboratories, Hercules, USA), and eluted with 2 м NH4OH. The purified amino acids 
were divided into 2 aliquots to determine the L-[ring-2H5]-phenylalanine enrichments by GC-
MS analysis and the L-[1-13C]-phenylalanine and L-[1-13C]-leucine enrichments by gas 
chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) analysis. To 
 
 
reduce the signal-to-noise ratio during GC-MS analysis at low tracer enrichments, the 
phenylalanine from the myofibrillar protein hydrolysates was enzymatically decarboxylated to 
β-phenylethylamine prior to derivatization with MTBSTFA. To determine myofibrillar L-[1-13C]-
phenylalanine and L-[1-13C]-leucine enrichments by GC-C-IRMS analysis, the purified amino 
acids were converted into N-ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate 
(ECF). The derivatives were then measured by GC-C-IRMS (Finnigan MAT 253, Bremen, 
Germany) using a DB5-MS-column (no. 122-5532; Agilent J+W scientific GC Column, GC 
Isolink), and monitoring of ion masses 44, 45 and 46. Standard regression curves were applied 
to assess the linearity of the mass spectrometer and to account for isotopic fractionation. 
Calculations 
Ingestion of L-[1-13C]-phenylalanine-labeled protein, intravenous infusion of L-[ring-2H5]-
phenylalanine and L-[ring-3,5-2H2]-tyrosine, and venous blood sampling were used to assess 
whole-body amino acid kinetics in non–steady-state conditions. Modified Steele's equations 
were used to calculate total, exogenous, and endogenous phenylalanine rates of appearance 
(expressed as μmol phenylalanine⋅kg−1⋅min−1) as well as plasma availability of dietary protein–
derived phenylalanine that appeared in the systemic circulation as a fraction of total amount 
of phenylalanine that was ingested [24-26]. 
 Total Ra =  
 𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
      (1) 
 Exogenous Ra =  
 𝑇𝑇𝑇𝑇𝑡𝑡𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎∙𝐸𝐸𝑝𝑝𝑝𝑝(𝑑𝑑) +[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑑𝑑)∙
𝑑𝑑𝐸𝐸𝑝𝑝𝑝𝑝
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
    (2) 
 Endogenous Ra =  𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑅𝑅𝑇𝑇 –  𝐸𝐸𝐸𝐸𝑇𝑇𝑅𝑅𝑇𝑇 – 𝐹𝐹𝑖𝑖𝑖𝑖      (3) 
 Pheplasma =  [ 𝐴𝐴𝐴𝐴𝐶𝐶𝐸𝐸𝐸𝐸𝑝𝑝𝐸𝐸𝑎𝑎
𝑃𝑃ℎ𝑒𝑒𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑
] ∙ BW ∙ 100%    (4) 
Fiv is the intravenous tracer infusion rate (in µmol·kg-1·min-1); pV is the distribution volume for 
phenylalanine (0.125 L·kg-1) [24]; C(t) is the mean plasma phenylalanine concentration between 
two consecutive time points; dEiv/dt represents the time-dependent variations of plasma 
phenylalanine enrichment derived from the intravenous tracer; and Eiv(t) is the mean plasma 
phenylalanine enrichment from the intravenous tracer between two consecutive time points. 
Exogenous phenylalanine rate of appearance (ExoRa) represents the plasma entry rate of 
dietary protein-derived phenylalanine. Epo(t) is the mean plasma phenylalanine enrichment 
from the oral tracer between two consecutive time points; dEpo/dt represents the time-
dependent variations of plasma phenylalanine enrichment derived from the oral tracer; and 
Eprot is the L-[1-13C]-phenylalanine enrichment in the dietary protein. Endogenous 
phenylalanine Ra (Endo Ra) represents the rate at which phenylalanine derived from whole-
body protein breakdown enters the circulation. The fraction of dietary phenylalanine taken up 
in the systemic circulation was calculated as a fraction of the total amount of phenylalanine 
that was ingested, Pheplasma. AUCExoRa is the area under the curve (AUC) of Exo Ra, which 
corresponds to the amount of dietary protein-derived phenylalanine that appeared in the 
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circulation over the 7.5 h postprandial period; Pheprot is the amount of dietary phenylalanine 
ingested; and BW is the participants’ body weight. 
Total phenylalanine rate of disappearance (Rd in µmol Phe·kg-1·min-1) equals the rate of 
phenylalanine hydroxylation (first step in phenylalanine oxidation) plus the rate of 
phenylalanine utilization for protein synthesis. Because whole-body Rd comprises the rate of 
phenylalanine disappearance from the free amino acid pool in the blood due to protein 
synthesis and oxidation, whole-body protein synthesis can be calculated as Rd minus oxidation. 
Whole-body phenylalanine oxidation can be determined from the conversion (hydroxylation) 
of L-[ring-2H5]-phenylalanine to L-[ring-2H4]-tyrosine. These parameters are calculated as 
follows: 
 Total Rd = 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 −  𝑝𝑝𝑝𝑝 ∙ 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑      [5] 
 Phe hydroxylation = 𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 ∙
𝐸𝐸𝑡𝑡𝑡𝑡𝑡𝑡(𝑑𝑑)
𝐸𝐸𝑝𝑝ℎ𝑒𝑒(𝑑𝑑)
 ∙
𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑
(𝐹𝐹𝑖𝑖𝑖𝑖+𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑 )
    (6) 
 Protein synthesis = Total Rd – Phe hydroxylation   (7) 
 Protein net balance = Protein synthesis – Endo Ra   (8) 
TyrRa is the total rate of tyrosine appearance based on the L-[ring-3,5-2H2]-tyrosine infusion 
and plasma enrichments. Etyr(t) and Ephe(t) represent the mean plasma L-[ring-2H4]-tyrosine and 
L-[ring-2H5]-phenylalanine enrichment between 2 consecutive time points, respectively; and 
Fiv is the intravenous infusion rate of L-[ring-2H5]-phenylalanine. Whole-body protein net 
balance was calculated as the AUC over the 7.5-h postprandial phase (t = 0-450 min) by using 
whole-body protein synthesis minus the endogenous rate of appearance.  
The fractional synthesis rate (FSR in %·h-1) of myofibrillar protein was calculated using the 
standard precursor-product equation: 
 𝐹𝐹𝐹𝐹𝑅𝑅 =  𝛥𝛥𝐸𝐸𝛥𝛥
𝐸𝐸𝑝𝑝𝑡𝑡𝑒𝑒𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝𝑡𝑡 ∙𝑑𝑑
 ∙ 100%     (9) 
ΔEp is the increment in myofibrillar protein-bound L-[ring-2H5]-phenylalanine or L-[1-13C]-
leucine enrichment between two muscle biopsies (in tracer to tracee ratio: TTR); Eprecursor is the 
weighted mean plasma L-[ring-2H5]-phenylalanine or plasma L-[1-13C]-leucine enrichment 
during the tracer incorporation period (TTR); and t (h) is the incorporation period between 
muscle biopsies. 
Statistics 
All data are expressed as mean±SEM. Baseline characteristics between treatment groups were 
compared by using 1-factor ANOVA. Plasma metabolite concentrations, plasma amino acid 
enrichments, and whole-body protein kinetics measured over time were analyzed by 2-factor 
repeated-measures ANOVA with time as the within-subjects factor and treatment group as 
the between-subjects factor. The analysis was done for the period starting at the time of 
protein ingestion, between t = 0 and t = 450 min. In case of significant time × treatment group 
 
 
interactions, separate analyses were performed to determine time effects for each treatment 
group (1-factor repeated-measures ANOVA) and treatment effects for each time point (1-
factor ANOVA). In addition, 1-factor ANOVA was used to determine differences between 
treatment groups for peak plasma values as well as the incremental AUC and differences in 
whole-body protein turnover rates and myofibrillar protein synthesis. In case of significant 
main effects of treatment group, a Tukey's post hoc test was applied to locate group 
differences. Results from our previous work [12] were used to calculate a sample size (G*Power 
3.1.9.2 software; Heinrich-Heine-University, Dusseldorf, Germany) by using an FSR of 
0.029±0.0052 %·h-1 for the placebo group and a clinically relevant difference in FSR of ∼30% 
[5, 12]. With a power of 80%, a 2-sided significance level of 0.01 (to adjust for multiple post 
hoc testing), and a dropout rate of 10%, the final number of participants to be included after 
screening was calculated as n = 12/group. No dropouts occurred in the 4 treatment groups. 
Statistical significance was set at P<0.05. All calculations were performed with SPSS Statistics 
24.0 software (IBM Corp.).   
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circulation over the 7.5 h postprandial period; Pheprot is the amount of dietary phenylalanine 
ingested; and BW is the participants’ body weight. 
Total phenylalanine rate of disappearance (Rd in µmol Phe·kg-1·min-1) equals the rate of 
phenylalanine hydroxylation (first step in phenylalanine oxidation) plus the rate of 
phenylalanine utilization for protein synthesis. Because whole-body Rd comprises the rate of 
phenylalanine disappearance from the free amino acid pool in the blood due to protein 
synthesis and oxidation, whole-body protein synthesis can be calculated as Rd minus oxidation. 
Whole-body phenylalanine oxidation can be determined from the conversion (hydroxylation) 
of L-[ring-2H5]-phenylalanine to L-[ring-2H4]-tyrosine. These parameters are calculated as 
follows: 
 Total Rd = 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 −  𝑝𝑝𝑝𝑝 ∙ 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑      [5] 
 Phe hydroxylation = 𝑇𝑇𝑇𝑇𝑇𝑇 𝑅𝑅𝑎𝑎 ∙
𝐸𝐸𝑡𝑡𝑡𝑡𝑡𝑡(𝑑𝑑)
𝐸𝐸𝑝𝑝ℎ𝑒𝑒(𝑑𝑑)
 ∙
𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑
(𝐹𝐹𝑖𝑖𝑖𝑖+𝑃𝑃ℎ𝑒𝑒𝑅𝑅𝑑𝑑 )
    (6) 
 Protein synthesis = Total Rd – Phe hydroxylation   (7) 
 Protein net balance = Protein synthesis – Endo Ra   (8) 
TyrRa is the total rate of tyrosine appearance based on the L-[ring-3,5-2H2]-tyrosine infusion 
and plasma enrichments. Etyr(t) and Ephe(t) represent the mean plasma L-[ring-2H4]-tyrosine and 
L-[ring-2H5]-phenylalanine enrichment between 2 consecutive time points, respectively; and 
Fiv is the intravenous infusion rate of L-[ring-2H5]-phenylalanine. Whole-body protein net 
balance was calculated as the AUC over the 7.5-h postprandial phase (t = 0-450 min) by using 
whole-body protein synthesis minus the endogenous rate of appearance.  
The fractional synthesis rate (FSR in %·h-1) of myofibrillar protein was calculated using the 
standard precursor-product equation: 
 𝐹𝐹𝐹𝐹𝑅𝑅 =  𝛥𝛥𝐸𝐸𝛥𝛥
𝐸𝐸𝑝𝑝𝑡𝑡𝑒𝑒𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝𝑡𝑡 ∙𝑑𝑑
 ∙ 100%     (9) 
ΔEp is the increment in myofibrillar protein-bound L-[ring-2H5]-phenylalanine or L-[1-13C]-
leucine enrichment between two muscle biopsies (in tracer to tracee ratio: TTR); Eprecursor is the 
weighted mean plasma L-[ring-2H5]-phenylalanine or plasma L-[1-13C]-leucine enrichment 
during the tracer incorporation period (TTR); and t (h) is the incorporation period between 
muscle biopsies. 
Statistics 
All data are expressed as mean±SEM. Baseline characteristics between treatment groups were 
compared by using 1-factor ANOVA. Plasma metabolite concentrations, plasma amino acid 
enrichments, and whole-body protein kinetics measured over time were analyzed by 2-factor 
repeated-measures ANOVA with time as the within-subjects factor and treatment group as 
the between-subjects factor. The analysis was done for the period starting at the time of 
protein ingestion, between t = 0 and t = 450 min. In case of significant time × treatment group 
 
 
interactions, separate analyses were performed to determine time effects for each treatment 
group (1-factor repeated-measures ANOVA) and treatment effects for each time point (1-
factor ANOVA). In addition, 1-factor ANOVA was used to determine differences between 
treatment groups for peak plasma values as well as the incremental AUC and differences in 
whole-body protein turnover rates and myofibrillar protein synthesis. In case of significant 
main effects of treatment group, a Tukey's post hoc test was applied to locate group 
differences. Results from our previous work [12] were used to calculate a sample size (G*Power 
3.1.9.2 software; Heinrich-Heine-University, Dusseldorf, Germany) by using an FSR of 
0.029±0.0052 %·h-1 for the placebo group and a clinically relevant difference in FSR of ∼30% 
[5, 12]. With a power of 80%, a 2-sided significance level of 0.01 (to adjust for multiple post 
hoc testing), and a dropout rate of 10%, the final number of participants to be included after 
screening was calculated as n = 12/group. No dropouts occurred in the 4 treatment groups. 
Statistical significance was set at P<0.05. All calculations were performed with SPSS Statistics 
24.0 software (IBM Corp.).   
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R ESULTS  
Plasma glucose concentrations declined overnight in all treatment groups (main time 
effect, P=0.005) and differed between treatment groups (main treatment group 
effect, P<0.05; Figure 2A). Plasma insulin concentrations increased rapidly after protein 
ingestion but not after placebo (time × treatment group interaction, P<0.001) and were higher 
during the overnight period in PRO20+LEU and PRO40 than in placebo (P<0.001, Figure 2B). 
A main treatment group effect (P<0.001) showed that peak plasma insulin concentrations were 
higher in all protein groups than in the placebo group (all P<0.05). 
 
Figure 2 | Plasma glucose (A) and insulin (B) concentrations during overnight sleep in 48 healthy older men who 
ingested placebo or supplemental protein before sleep. PLA: placebo, PRO20: 20 g dietary protein, PRO20+LEU: 
20 g dietary protein + 1.5 g crystalline leucine, PRO40: 40 g dietary protein. The dotted line represents the 
ingestion of the treatment. Values are mean±SEM, n = 12 per treatment group.  
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Plasma amino acid concentrations are shown in Figures 3 and 4. Significant time × treatment 
group interactions were observed for all plasma amino acid concentrations (all P<0.001). 
Plasma phenylalanine concentrations increased after protein ingestion (main time effects in all 
protein groups, all P<0.001) and were elevated throughout the night in the protein groups 
compared with the placebo group (P<0.001; Figure 3A). Plasma tyrosine concentrations 
increased after protein ingestion (main time effects in all protein groups, all P<0.001; Figure 
3B) and were higher than in the placebo group (P<0.001).  
 
Figure 3 | Plasma phenylalanine (A) and tyrosine (B) concentrations during overnight sleep in 48 healthy older 
men who ingested PLA or supplemental protein before sleep. The dotted line represents the ingest ion of the 
treatment. Values are mean±SEM, n = 12/treatment group. PLA, placebo; PRO20, 20 g dietary protein; 
PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary protein.  
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Plasma amino acid concentrations are shown in Figures 3 and 4. Significant time × treatment 
group interactions were observed for all plasma amino acid concentrations (all P<0.001). 
Plasma phenylalanine concentrations increased after protein ingestion (main time effects in all 
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Plasma leucine concentrations increased rapidly after protein ingestion (main time effects in 
all protein groups, P<0.001; Figure 4A), but to a greater extent in PRO20+LEU (peak values: 
396±20 μmol·L-1) than in PRO40 and PRO20 (316±19 and 269±10 μmol·L-1, 
respectively, P<0.001). The incremental AUC (Figure 4B) did not differ between PRO20+LEU 
and PRO40 (P=0.56), but both were higher than in PRO20 and placebo (both P<0.001), and 
PRO20 was higher than in placebo (P<0.001).  
 
Figure 4 | Plasma leucine concentrations during overnight sleep (A) and expressed as the incremental AUC (B) in 
48 healthy older men who ingested PLA or supplemental protein before sleep. The dotted line represents the 
ingestion of the treatment. Values are mean±SEM, n = 12/treatment group. Labeled bars without a common letter 
differ, P<0.001. PLA, placebo; PRO20, 20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystall ine 
leucine; PRO40, 40 g dietary protein. 
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Plasma amino acid enrichments 
Significant time × treatment group interactions were observed for all plasma amino acid 
enrichments (all P<0.05). Plasma L-[1-13C]-phenylalanine enrichments increased after protein 
ingestion (main time effects in all protein groups, all P<0.001; Figure 5A), and peak values 
were different between groups (main treatment group effect, P<0.001), with higher 
enrichments observed in PRO40 (12.9±0.7 MPE) than in PRO20 and PRO20+LEU (10.8±0.4 and 
10.1±0.5 MPE, respectively, both P<0.05). Plasma amino acid availability, as a fraction from the 
ingested amount of protein, differed between treatment groups (main treatment group 
effect, P<0.001) and was higher in PRO20 and PRO20+LEU (69±1% and 64±2%, respectively) 
than in PRO40 (53±3%, both P<0.001). The absolute amount of dietary protein derived from 
the drink that appeared in the circulation during the 7.5-h overnight postprandial period 
differed between groups (main treatment group effect, P<0.001; Figure 5B) and was higher 
in PRO40 (21.3±1.2 g) than in PRO20 and PRO20+LEU (13.8±0.3 and 12.8±0.4 g, respectively, 
both P<0.001), with no differences between PRO20 and PRO20+LEU (P=0.70; Figure 3B).  
 
Figure 5 | Plasma L-[1-13C]-phenylalanine enrichments during overnight sleep (A) and plasma amino acid 
availability from the ingested protein drink during the 7.5-h overnight period (B) in 48 healthy older men who 
ingested PLA or supplemental protein before sleep. The dotted line represents the ingestion of the treatment. 
Values are mean ± SEM, n = 12/treatment group. Labeled bars without a common letter differ,  P<0.001. MPE, 
mole percent excess; PLA, placebo; PRO20, 20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g 
crystalline leucine; PRO40, 40 g dietary protein. 
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Plasma leucine concentrations increased rapidly after protein ingestion (main time effects in 
all protein groups, P<0.001; Figure 4A), but to a greater extent in PRO20+LEU (peak values: 
396±20 μmol·L-1) than in PRO40 and PRO20 (316±19 and 269±10 μmol·L-1, 
respectively, P<0.001). The incremental AUC (Figure 4B) did not differ between PRO20+LEU 
and PRO40 (P=0.56), but both were higher than in PRO20 and placebo (both P<0.001), and 
PRO20 was higher than in placebo (P<0.001).  
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leucine; PRO40, 40 g dietary protein. 
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Plasma amino acid enrichments 
Significant time × treatment group interactions were observed for all plasma amino acid 
enrichments (all P<0.05). Plasma L-[1-13C]-phenylalanine enrichments increased after protein 
ingestion (main time effects in all protein groups, all P<0.001; Figure 5A), and peak values 
were different between groups (main treatment group effect, P<0.001), with higher 
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the drink that appeared in the circulation during the 7.5-h overnight postprandial period 
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in PRO40 (21.3±1.2 g) than in PRO20 and PRO20+LEU (13.8±0.3 and 12.8±0.4 g, respectively, 
both P<0.001), with no differences between PRO20 and PRO20+LEU (P=0.70; Figure 3B).  
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Plasma L-[ring-2H5]-phenylalanine enrichments were higher in the placebo group than in the 
PRO groups (P<0.001; Figure 6A). Plasma L-[1-13C]-leucine enrichments were higher in PRO40 
than in placebo (P<0.05; Figure 6B). 
 
Figure 6 | Plasma L-[ring2H5]-phenylalanine (A) and L-[1- 13C]-leucine (B) enrichments during overnight sleep in 
48 healthy older men who ingested placebo or supplemental protein before sleep (n = 12 per treatment group). 
PLA: placebo, PRO20: 20 g dietary protein, PRO20+LEU: 20 g dietary protein + 1.5 g crystalline leucine, PRO40: 40 
g dietary protein. MPE, mole percent excess. The dotted line represents the ingestion of the treatment. Values are 
mean±SEM. 
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Whole-body amino acids kinetics 
Whole-body protein kinetics are displayed in Figure 7. A significant time × treatment group 
interaction (P<0.001) showed an increase in exogenous phenylalanine rates of appearance 
after protein intake in all groups (P<0.001), which was higher in PRO40 (peak values: 0.26±0.02 
μmol phenylalanine⋅kg−1⋅min−1) than in PRO20 and PRO20+LEU (0.22±0.01 and 0.18±0.01 
μmol phenylalanine⋅kg−1⋅min−1, respectively, both P<0.05; Figure 7A). Endogenous 
phenylalanine rates of appearance decreased in all groups (main time effect, P<0.001) with no 
differences between groups (time × treatment group interaction, P=0.30; Figure 7B). 
Significant time × treatment group interactions were observed for total phenylalanine rates of 
appearance and disappearance (both P<0.001). Follow-up analyses showed a decrease in all 
groups in total phenylalanine rates of appearance (P<0.001), and higher values in the protein 
groups than in the placebo group (P<0.001; Figure 7C). Total phenylalanine rates of 
disappearance were higher in all protein groups than in the placebo group (P<0.05; Figure 
7D).  
 
Figure 7 | Exogenous Ra (A), endogenous Ra (B), total Ra (C), and total Rd (D) during overnight sleep in 48 healthy 
older men who ingested PLA or supplemental protein before sleep. The dotted line represents the ingestion of 
the treatment. Values are mean±SEM, n = 12/treatment group. PLA, placebo; PRO20, 20 g dietary protein; 
PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary protein; R a, rate of appearance; 
Rd, rate of disappearance.  
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Plasma L-[ring-2H5]-phenylalanine enrichments were higher in the placebo group than in the 
PRO groups (P<0.001; Figure 6A). Plasma L-[1-13C]-leucine enrichments were higher in PRO40 
than in placebo (P<0.05; Figure 6B). 
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48 healthy older men who ingested placebo or supplemental protein before sleep (n = 12 per treatment group). 
PLA: placebo, PRO20: 20 g dietary protein, PRO20+LEU: 20 g dietary protein + 1.5 g crystalline leucine, PRO40: 40 
g dietary protein. MPE, mole percent excess. The dotted line represents the ingestion of the treatment. Values are 
mean±SEM. 
  
0 60 120 180 240 300 360 420 480
0
2
4
6
8
10
12
14
Time x treatment interaction P<0.001
PLA
PRO20+LEU
PRO20
PRO40
Time (min)
Pla
sm
a
L-
[ri
ng
-2
H 5
]-P
he
(M
PE
)
0 60 120 180 240 300 360 420 480
0
2
4
6
8
10
12
14
Time x treatment interaction P<0.05
Time (min)
Pla
sm
a
L-
[1-
13
C]
-L
eu
(M
PE
)
B
A
 
 
Whole-body amino acids kinetics 
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μmol phenylalanine⋅kg−1⋅min−1, respectively, both P<0.05; Figure 7A). Endogenous 
phenylalanine rates of appearance decreased in all groups (main time effect, P<0.001) with no 
differences between groups (time × treatment group interaction, P=0.30; Figure 7B). 
Significant time × treatment group interactions were observed for total phenylalanine rates of 
appearance and disappearance (both P<0.001). Follow-up analyses showed a decrease in all 
groups in total phenylalanine rates of appearance (P<0.001), and higher values in the protein 
groups than in the placebo group (P<0.001; Figure 7C). Total phenylalanine rates of 
disappearance were higher in all protein groups than in the placebo group (P<0.05; Figure 
7D).  
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Whole-body protein metabolism is shown in Figure 8. Whole-body protein synthesis rates 
differed between groups (main treatment group effect, P<0.001), and were higher in PRO20, 
PRO20+LEU, and PRO40 than in placebo (all P<0.05). Whole-body protein breakdown rates 
did not differ between treatments (P=0.26). Whole-body protein oxidation rates were different 
between treatments (main treatment group effect, P<0.001) and were higher in PRO40 and 
PRO20 than in placebo (both P<0.05), and in PRO40 than in PRO20 and PRO20+LEU 
(both P<0.05). Whole-body protein net balance differed between treatments (main treatment 
group effect, P<0.001) and was higher in all PRO groups than in the placebo group 
(all P<0.001) and in PRO40 than in PRO20 and PRO20+LEU (both P<0.001). 
 
Figure 8 | Rates of whole-body protein synthesis, breakdown, oxidation, and net balance during the 7.5-h 
overnight period in 48 healthy older men who ingested PLA or supplemental protein before sleep. Values are 
mean±SEM, n = 12/treatment group. Labelled bars without a common letter differ, P<0.05. PLA, placebo; PRO20, 
20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary protein.  
Myofibrillar protein synthesis rates and protein-bound enrichments 
Myofibrillar protein FSRs based on L-[ring-2H5]-phenylalanine and FSRs based on L-[1-13C]-
leucine are displayed in Figure 9. FSR values calculated from L-[ring-2H5]-phenylalanine 
enrichments differed between treatment groups and were a mean of 0.033±0.002 %·h-1in 
placebo, 0.037±0.003 %·h-1 in PRO20, 0.039±0.002 %·h-1 in PRO20+LEU, and 0.044±0.003 %· 
h-1 in PRO40 (main treatment group effect, P=0.03; Figure 9A). Post hoc analyses showed that 
myofibrillar FSRs were higher in PRO40 than in placebo (P=0.02). No differences were 
observed in FSR values for PRO20 (P=0.73) and PRO20+LEU (P=0.42) compared with placebo 
or between PRO20+LEU and PRO20 (P=0.96). In accordance, myofibrillar protein synthesis 
rates based on L-[1-13C]-leucine enrichments were different between treatment groups and 
were a mean of 0.047±0.004 %·h-1 in placebo, 0.046±0.004%·h-1 in PRO20, 0.056±0.002 %·h-1 
in PRO20+LEU, and 0.058±0.003 %·h-1 in PRO40 (main treatment group effect, P=0.02; Figure 
9B).  
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Post hoc analyses showed that FSRs in PRO40 tended to be higher than in placebo (P=0.08) 
and PRO20 (P=0.06). PRO20 (P=0.99) and PRO20+LEU (P=0.19) did not differ compared with 
placebo. No differences were observed in FSR values between PRO20+LEU and PRO20 
(P=0.16). 
 
Figure 9 | Myofibrillar protein fractional synthetic rates using intravenous L-[ring-2H5]-phenylalanine infusion (A) 
and intravenous and dietary protein-derived muscle protein–bound L-[1-13C]-leucine (B) during overnight sleep 
in 48 healthy older men who ingested PLA or supplemental protein before sleep. Values are mean±SEM, n = 12/ 
treatment group. Labeled bars without a common letter differ,  P<0.05. FSR, fractional synthesis rates; PLA, 
placebo; PRO20, 20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g 
dietary protein. 
  
0.00
0.01
0.02
0.03
0.04
0.05 b
a
a,b a,b
Main treatment effect P=0.03
PRO40 vs PLA P=0.02
PLA PRO20 PRO20+LEU PRO40
0-7.5 h
M
yo
fib
rill
ar
 L-
[ri
ng
-2
H 5
]-P
he
 FS
R 
(%
h-
1 )
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07 Main treatment effect P=0.02
PRO40 vs PLA P=0.08
PRO40 vs PRO20 P=0.06
PLA PRO20 PRO20+LEU PRO40
0-7.5 h
M
yo
fib
rill
ar
 L-
[1-
13
C]
-L
eu
 FS
R 
(%
h-
1 )
A
B
   
   
  C
HA
PT
ER
 S
EV
EN
 
177
                Protein ingestion prior to sleep   
 
 
Whole-body protein metabolism is shown in Figure 8. Whole-body protein synthesis rates 
differed between groups (main treatment group effect, P<0.001), and were higher in PRO20, 
PRO20+LEU, and PRO40 than in placebo (all P<0.05). Whole-body protein breakdown rates 
did not differ between treatments (P=0.26). Whole-body protein oxidation rates were different 
between treatments (main treatment group effect, P<0.001) and were higher in PRO40 and 
PRO20 than in placebo (both P<0.05), and in PRO40 than in PRO20 and PRO20+LEU 
(both P<0.05). Whole-body protein net balance differed between treatments (main treatment 
group effect, P<0.001) and was higher in all PRO groups than in the placebo group 
(all P<0.001) and in PRO40 than in PRO20 and PRO20+LEU (both P<0.001). 
 
Figure 8 | Rates of whole-body protein synthesis, breakdown, oxidation, and net balance during the 7.5-h 
overnight period in 48 healthy older men who ingested PLA or supplemental protein before sleep. Values are 
mean±SEM, n = 12/treatment group. Labelled bars without a common letter differ, P<0.05. PLA, placebo; PRO20, 
20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary protein.  
Myofibrillar protein synthesis rates and protein-bound enrichments 
Myofibrillar protein FSRs based on L-[ring-2H5]-phenylalanine and FSRs based on L-[1-13C]-
leucine are displayed in Figure 9. FSR values calculated from L-[ring-2H5]-phenylalanine 
enrichments differed between treatment groups and were a mean of 0.033±0.002 %·h-1in 
placebo, 0.037±0.003 %·h-1 in PRO20, 0.039±0.002 %·h-1 in PRO20+LEU, and 0.044±0.003 %· 
h-1 in PRO40 (main treatment group effect, P=0.03; Figure 9A). Post hoc analyses showed that 
myofibrillar FSRs were higher in PRO40 than in placebo (P=0.02). No differences were 
observed in FSR values for PRO20 (P=0.73) and PRO20+LEU (P=0.42) compared with placebo 
or between PRO20+LEU and PRO20 (P=0.96). In accordance, myofibrillar protein synthesis 
rates based on L-[1-13C]-leucine enrichments were different between treatment groups and 
were a mean of 0.047±0.004 %·h-1 in placebo, 0.046±0.004%·h-1 in PRO20, 0.056±0.002 %·h-1 
in PRO20+LEU, and 0.058±0.003 %·h-1 in PRO40 (main treatment group effect, P=0.02; Figure 
9B).  
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Post hoc analyses showed that FSRs in PRO40 tended to be higher than in placebo (P=0.08) 
and PRO20 (P=0.06). PRO20 (P=0.99) and PRO20+LEU (P=0.19) did not differ compared with 
placebo. No differences were observed in FSR values between PRO20+LEU and PRO20 
(P=0.16). 
 
Figure 9 | Myofibrillar protein fractional synthetic rates using intravenous L-[ring-2H5]-phenylalanine infusion (A) 
and intravenous and dietary protein-derived muscle protein–bound L-[1-13C]-leucine (B) during overnight sleep 
in 48 healthy older men who ingested PLA or supplemental protein before sleep. Values are mean±SEM, n = 12/ 
treatment group. Labeled bars without a common letter differ,  P<0.05. FSR, fractional synthesis rates; PLA, 
placebo; PRO20, 20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g 
dietary protein. 
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The incorporation of dietary protein–derived amino acids (L-[1-13C]-phenylalanine 
enrichments) into de novo myofibrillar protein was 0.019±0.002, 0.025±0.002, and 0.033±0.002 
MPE in PRO20, PRO20+LEU, and PRO40, respectively, and differed between treatment groups 
(main treatment group effect, P<0.001; Figure 10). Post hoc analyses showed that L-[1-13C]-
phenylalanine myofibrillar protein–bound enrichments were higher in PRO40, PRO20+LEU, 
and PRO20 than in placebo (P<0.001). Enrichments were also higher in PRO40 than in PRO20 
(P<0.001) and tended to be higher than in PRO20+LEU (P=0.06). No differences were observed 
in MPE values between PRO20+LEU and PRO20 (P=0.17). 
 
Figure 10 | Diet-derived myofibrillar protein–bound L-[1-13C]-phenylalanine enrichments after overnight sleep in 
48 healthy older men who ingested PLA or supplemental protein before sleep. Values are mean±SEM,  n = 12/ 
treatment group. Labeled bars without a common letter differ,  P<0.05. MPE, mole percent excess; PLA, placebo; 
PRO20, 20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary 
protein. 
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Sleep quality 
There were no differences in VAS tiredness scores between groups taken before sleep or in 
the morning (main treatment group effect, both P>0.05; data not shown). Sleep analyses data 
are presented in Table 2. The treatment groups were similar in bedtime, get-up time, sleep 
onset latency (the time between bedtime and falling asleep), sleep duration (in hours), and 
sleep efficiency (percentage of sleep duration expressed as a percentage of time in bed) (main 
treatment group effect, all P>0.05). 
Table 2 | Sleep analyses  
 PLA PRO20 PRO20+LEU PRO40 mean SEM 
Bed time (hh:mm:ss) 23:56:45 23:47:00 23:55:09 23:55:24 23:53:34 0:01:59 
Wake time 
(hh:mm:ss) 7:01:38 7:01:50 6:55:34 7:01:00 7:00:00 0:01:20 
Time to fall asleep 
(hh:mm:ss) 0:08:22 0:10:40 0:09:43 0:06:12 0:08:44 0:00:52 
Sleep duration 
(hh:mm:ss) 6:08:15 6:21:40 6:16:17 5:46:48 6:08:15 0:06:51 
Sleep efficiency (%) 87 88 89 81 86 2 
Sleep analyses in 48 healthy older men who ingested placebo or supplemental protein before sleep. Values are 
mean, n = 12 per treatment group. PLA: placebo, PRO20: 20 g dietary protein, PRO20+LEU: 20 g dietary protein 
+ 1.5 g crystalline leucine, PRO40: 40 g dietary protein. No significant differences between treatment groups were 
observed (P<0.05). 
Hunger and satiety in the morning 
There were no differences between groups in the VAS hunger and satiety scores taken before 
protein ingestion or after the overnight period before ad libitum breakfast ingestion (main 
treatment group effect, both P>0.05; data not shown). Energy intake at breakfast was 
2.53±0.11 MJ total energy, containing 46±1 En% carbohydrate, 38±1 En% fat, and 14±1 En% 
protein, with no differences between treatment groups (main treatment group effect, 
all P>0.05).  
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The incorporation of dietary protein–derived amino acids (L-[1-13C]-phenylalanine 
enrichments) into de novo myofibrillar protein was 0.019±0.002, 0.025±0.002, and 0.033±0.002 
MPE in PRO20, PRO20+LEU, and PRO40, respectively, and differed between treatment groups 
(main treatment group effect, P<0.001; Figure 10). Post hoc analyses showed that L-[1-13C]-
phenylalanine myofibrillar protein–bound enrichments were higher in PRO40, PRO20+LEU, 
and PRO20 than in placebo (P<0.001). Enrichments were also higher in PRO40 than in PRO20 
(P<0.001) and tended to be higher than in PRO20+LEU (P=0.06). No differences were observed 
in MPE values between PRO20+LEU and PRO20 (P=0.17). 
 
Figure 10 | Diet-derived myofibrillar protein–bound L-[1-13C]-phenylalanine enrichments after overnight sleep in 
48 healthy older men who ingested PLA or supplemental protein before sleep. Values are mean±SEM,  n = 12/ 
treatment group. Labeled bars without a common letter differ,  P<0.05. MPE, mole percent excess; PLA, placebo; 
PRO20, 20 g dietary protein; PRO20+LEU, 20 g dietary protein plus 1.5 g crystalline leucine; PRO40, 40 g dietary 
protein. 
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Sleep quality 
There were no differences in VAS tiredness scores between groups taken before sleep or in 
the morning (main treatment group effect, both P>0.05; data not shown). Sleep analyses data 
are presented in Table 2. The treatment groups were similar in bedtime, get-up time, sleep 
onset latency (the time between bedtime and falling asleep), sleep duration (in hours), and 
sleep efficiency (percentage of sleep duration expressed as a percentage of time in bed) (main 
treatment group effect, all P>0.05). 
Table 2 | Sleep analyses  
 PLA PRO20 PRO20+LEU PRO40 mean SEM 
Bed time (hh:mm:ss) 23:56:45 23:47:00 23:55:09 23:55:24 23:53:34 0:01:59 
Wake time 
(hh:mm:ss) 7:01:38 7:01:50 6:55:34 7:01:00 7:00:00 0:01:20 
Time to fall asleep 
(hh:mm:ss) 0:08:22 0:10:40 0:09:43 0:06:12 0:08:44 0:00:52 
Sleep duration 
(hh:mm:ss) 6:08:15 6:21:40 6:16:17 5:46:48 6:08:15 0:06:51 
Sleep efficiency (%) 87 88 89 81 86 2 
Sleep analyses in 48 healthy older men who ingested placebo or supplemental protein before sleep. Values are 
mean, n = 12 per treatment group. PLA: placebo, PRO20: 20 g dietary protein, PRO20+LEU: 20 g dietary protein 
+ 1.5 g crystalline leucine, PRO40: 40 g dietary protein. No significant differences between treatment groups were 
observed (P<0.05). 
Hunger and satiety in the morning 
There were no differences between groups in the VAS hunger and satiety scores taken before 
protein ingestion or after the overnight period before ad libitum breakfast ingestion (main 
treatment group effect, both P>0.05; data not shown). Energy intake at breakfast was 
2.53±0.11 MJ total energy, containing 46±1 En% carbohydrate, 38±1 En% fat, and 14±1 En% 
protein, with no differences between treatment groups (main treatment group effect, 
all P>0.05).  
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D ISCUSSION   
In the present study we show that protein ingested before sleep was properly digested and 
absorbed throughout the night, thereby increasing overnight plasma amino acid availability 
and facilitating myofibrillar protein synthesis during sleep in healthy older men. Ingestion of 
40 g protein before sleep increased overnight muscle protein synthesis rates (0.044±0.003 
%·h-1) compared with the placebo treatment (0.033±0.002 %·h-1; P=0.02). Ingesting a smaller 
(20 g) dose of protein, with or without additional leucine, did not significantly increase 
overnight muscle protein synthesis rates compared with the placebo intervention. 
Because gut motility and gastric acid secretion are affected by circadian oscillations, the pH of 
the stomach has been speculated to change during sleep, which may affect digestion and 
absorption (i.e. clotting of the casein) [27]. By combining the ingestion of intrinsically L-[1-
13C]-phenylalanine–labeled protein with primed continuous infusions of L-[ring-2H5]-
phenylalanine we were able to quantify the rate of appearance of dietary protein–derived 
amino acids during overnight sleep [17, 18]. Presleep protein ingestion increased overnight 
plasma amino acid availability with 53±3%, 69±1%, and 64±2% of protein-derived amino acids 
being released into the systemic circulation during the 7.5-h overnight period in PRO40, 
PRO20, and PRO20+LEU treatments, respectively (Figure 5B). As expected, more dietary 
protein–derived amino acids were released after the ingestion of 40 g than after 20 g protein, 
with greater exogenous amino acid appearance rates in the PRO40 treatment up into the later 
stages of overnight sleep (Figure 7A). These data tend to be in line with our previous work 
[12] showing 58±4% of the protein-derived amino acids becoming available in the circulation 
after the administration of 40 g protein during sleep via a nasogastric tube. The present study 
extends this prior work by showing that protein ingested before sleep is properly digested 
and absorbed during subsequent overnight sleep, with postprandial plasma amino acid 
availability being similar to nasogastric tube feeding during sleep. 
The release of dietary protein–derived amino acids into the circulation stimulated whole-body 
protein synthesis rates during the overnight phase. This resulted in a positive whole-body 
protein net balance during overnight sleep in all protein groups compared with a zero net 
balance that was observed in the placebo group (Figure 8). Because plasma amino acid 
kinetics do not necessarily reflect changes in skeletal muscle protein turnover [28], we also 
obtained skeletal muscle biopsy samples before and after overnight sleep and measured the 
L-[1-13C]-phenylalanine, L-[ring-2H5]-phenylalanine, and L-[1-13C]-leucine incorporation into 
myofibrillar protein. Consequently, this allowed us to quantify the effect of protein ingestion 
on overnight muscle protein synthesis rates (Figure 9) and assess the direct incorporation of 
dietary protein–derived amino acids into de novo myofibrillar protein (Figure 10). 
The ingestion of 40 g protein before sleep increased overnight muscle protein synthesis rates 
by ∼33% above values observed in the placebo group (based on the L-[ring-2H5]-
phenylalanine tracer, P=0.02; Figure 6). Likewise, a ∼25% higher FSR was observed in PRO40 
than in placebo based on the L-[1-13C]-leucine tracer, although this difference did not reach 
 
 
statistical significance (P=0.08). These findings are in line with our first proof-of-concept study 
where we reported a similar increase in overnight muscle protein synthesis rates after the 
nasogastric administration of 40 g protein during sleep in older men [12]. We extend this work 
by showing that ingesting protein before sleep increases overnight amino acid availability, 
thereby increasing myofibrillar protein synthesis rates during sleep in healthy older men. 
Ingestion of 20 g compared with 40 g protein did not increase overnight muscle protein 
synthesis rates (Figure 9), confirming our hypothesis that more protein is required to stimulate 
muscle protein synthesis during the extended postprandial overnight period (7.5 h) in healthy 
older men. Because we anticipated a lower muscle protein synthetic response after the 
ingestion of 20 g protein compared with 40 g protein, we assessed whether overnight muscle 
protein synthesis rates could be further increased by ingesting 20 g protein fortified with free 
leucine. Previous work has shown that increasing the leucine content in a dose of protein or 
amino acids can augment the postprandial muscle protein synthetic response in older 
individuals [9-11].  
Despite the greater plasma leucine availability after leucine co-ingestion (Figure 4), we 
observed no substantial increase in overnight muscle protein synthesis rates. The absence of 
a stimulating effect after leucine co-ingestion could be attributed to the absence of a robust 
insulin response during the overnight period, the lack of sufficient amino acids as precursors 
for muscle protein synthesis during the relatively long overnight period, or simply that the 
stimulating properties of leucine are less evident during sleep. We conclude that only 
increasing the leucine content of a 20-g protein dose is not sufficient to drive a similar 
overnight muscle protein synthetic response to the levels observed after the presleep 
ingestion of 40 g protein. These data suggest that the greater plasma amino acid availability 
after ingestion of 40 g compared with 20 g protein during the longer overnight period may 
be required to allow a measurable increase in muscle protein synthesis rates. 
We applied highly enriched (∼39 MPE), intrinsically L-[1-13C]-phenylalanine–labeled casein to 
allow assessment of the metabolic fate of the ingested protein by measuring the incorporation 
of dietary protein–derived amino acids into de novo myofibrillar protein. Protein ingested 
before sleep resulted in a substantial increase in myofibrillar protein–bound L-[1-13C]-
phenylalanine enrichments, with more dietary protein–derived amino acids being 
incorporated after the ingestion of 40 g compared with 20 g protein (P<0.001; Figure 10). 
Despite the absence of a measurable increase in overnight muscle protein synthesis rates after 
ingestion of 20 g protein, these data clearly show that protein ingested before sleep provides 
ample precursors that are being used to support overnight muscle protein synthesis. Co-
ingestion of free leucine with 20 g protein was not effective in further increasing the overnight 
deposition of dietary protein–derived amino acids into de novo myofibrillar protein 
(P=0.17; Figure 10). 
Here, we show that presleep protein ingestion increases overnight muscle protein synthesis 
rates, even in a setting where substantial amounts (1.1±0.01 g⋅kg−1⋅d−1) of protein are already 
consumed throughout the day, with a normal protein-rich dinner (29±2 g protein) ingested 
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D ISCUSSION   
In the present study we show that protein ingested before sleep was properly digested and 
absorbed throughout the night, thereby increasing overnight plasma amino acid availability 
and facilitating myofibrillar protein synthesis during sleep in healthy older men. Ingestion of 
40 g protein before sleep increased overnight muscle protein synthesis rates (0.044±0.003 
%·h-1) compared with the placebo treatment (0.033±0.002 %·h-1; P=0.02). Ingesting a smaller 
(20 g) dose of protein, with or without additional leucine, did not significantly increase 
overnight muscle protein synthesis rates compared with the placebo intervention. 
Because gut motility and gastric acid secretion are affected by circadian oscillations, the pH of 
the stomach has been speculated to change during sleep, which may affect digestion and 
absorption (i.e. clotting of the casein) [27]. By combining the ingestion of intrinsically L-[1-
13C]-phenylalanine–labeled protein with primed continuous infusions of L-[ring-2H5]-
phenylalanine we were able to quantify the rate of appearance of dietary protein–derived 
amino acids during overnight sleep [17, 18]. Presleep protein ingestion increased overnight 
plasma amino acid availability with 53±3%, 69±1%, and 64±2% of protein-derived amino acids 
being released into the systemic circulation during the 7.5-h overnight period in PRO40, 
PRO20, and PRO20+LEU treatments, respectively (Figure 5B). As expected, more dietary 
protein–derived amino acids were released after the ingestion of 40 g than after 20 g protein, 
with greater exogenous amino acid appearance rates in the PRO40 treatment up into the later 
stages of overnight sleep (Figure 7A). These data tend to be in line with our previous work 
[12] showing 58±4% of the protein-derived amino acids becoming available in the circulation 
after the administration of 40 g protein during sleep via a nasogastric tube. The present study 
extends this prior work by showing that protein ingested before sleep is properly digested 
and absorbed during subsequent overnight sleep, with postprandial plasma amino acid 
availability being similar to nasogastric tube feeding during sleep. 
The release of dietary protein–derived amino acids into the circulation stimulated whole-body 
protein synthesis rates during the overnight phase. This resulted in a positive whole-body 
protein net balance during overnight sleep in all protein groups compared with a zero net 
balance that was observed in the placebo group (Figure 8). Because plasma amino acid 
kinetics do not necessarily reflect changes in skeletal muscle protein turnover [28], we also 
obtained skeletal muscle biopsy samples before and after overnight sleep and measured the 
L-[1-13C]-phenylalanine, L-[ring-2H5]-phenylalanine, and L-[1-13C]-leucine incorporation into 
myofibrillar protein. Consequently, this allowed us to quantify the effect of protein ingestion 
on overnight muscle protein synthesis rates (Figure 9) and assess the direct incorporation of 
dietary protein–derived amino acids into de novo myofibrillar protein (Figure 10). 
The ingestion of 40 g protein before sleep increased overnight muscle protein synthesis rates 
by ∼33% above values observed in the placebo group (based on the L-[ring-2H5]-
phenylalanine tracer, P=0.02; Figure 6). Likewise, a ∼25% higher FSR was observed in PRO40 
than in placebo based on the L-[1-13C]-leucine tracer, although this difference did not reach 
 
 
statistical significance (P=0.08). These findings are in line with our first proof-of-concept study 
where we reported a similar increase in overnight muscle protein synthesis rates after the 
nasogastric administration of 40 g protein during sleep in older men [12]. We extend this work 
by showing that ingesting protein before sleep increases overnight amino acid availability, 
thereby increasing myofibrillar protein synthesis rates during sleep in healthy older men. 
Ingestion of 20 g compared with 40 g protein did not increase overnight muscle protein 
synthesis rates (Figure 9), confirming our hypothesis that more protein is required to stimulate 
muscle protein synthesis during the extended postprandial overnight period (7.5 h) in healthy 
older men. Because we anticipated a lower muscle protein synthetic response after the 
ingestion of 20 g protein compared with 40 g protein, we assessed whether overnight muscle 
protein synthesis rates could be further increased by ingesting 20 g protein fortified with free 
leucine. Previous work has shown that increasing the leucine content in a dose of protein or 
amino acids can augment the postprandial muscle protein synthetic response in older 
individuals [9-11].  
Despite the greater plasma leucine availability after leucine co-ingestion (Figure 4), we 
observed no substantial increase in overnight muscle protein synthesis rates. The absence of 
a stimulating effect after leucine co-ingestion could be attributed to the absence of a robust 
insulin response during the overnight period, the lack of sufficient amino acids as precursors 
for muscle protein synthesis during the relatively long overnight period, or simply that the 
stimulating properties of leucine are less evident during sleep. We conclude that only 
increasing the leucine content of a 20-g protein dose is not sufficient to drive a similar 
overnight muscle protein synthetic response to the levels observed after the presleep 
ingestion of 40 g protein. These data suggest that the greater plasma amino acid availability 
after ingestion of 40 g compared with 20 g protein during the longer overnight period may 
be required to allow a measurable increase in muscle protein synthesis rates. 
We applied highly enriched (∼39 MPE), intrinsically L-[1-13C]-phenylalanine–labeled casein to 
allow assessment of the metabolic fate of the ingested protein by measuring the incorporation 
of dietary protein–derived amino acids into de novo myofibrillar protein. Protein ingested 
before sleep resulted in a substantial increase in myofibrillar protein–bound L-[1-13C]-
phenylalanine enrichments, with more dietary protein–derived amino acids being 
incorporated after the ingestion of 40 g compared with 20 g protein (P<0.001; Figure 10). 
Despite the absence of a measurable increase in overnight muscle protein synthesis rates after 
ingestion of 20 g protein, these data clearly show that protein ingested before sleep provides 
ample precursors that are being used to support overnight muscle protein synthesis. Co-
ingestion of free leucine with 20 g protein was not effective in further increasing the overnight 
deposition of dietary protein–derived amino acids into de novo myofibrillar protein 
(P=0.17; Figure 10). 
Here, we show that presleep protein ingestion increases overnight muscle protein synthesis 
rates, even in a setting where substantial amounts (1.1±0.01 g⋅kg−1⋅d−1) of protein are already 
consumed throughout the day, with a normal protein-rich dinner (29±2 g protein) ingested 
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5h before sleep. Presleep protein ingestion provides a window of opportunity to stimulate 
muscle protein synthesis during a period where muscle protein synthesis rates are typically 
low [12, 29]. Moreover, we show that protein ingestion before sleep provides amino acids as 
precursors for de novo overnight muscle protein synthesis. This nutritional strategy may be of 
relevance for older individuals aiming to maintain skeletal muscle mass and also sarcopenic 
individuals who have already lost substantial amounts of muscle mass and strength. 
Several studies have reported increases in lean body mass after prolonged protein 
supplementation in various older populations [30-32], whereas others have failed to show 
measurable increases in muscle mass or strength [33-36]. A proper distribution of protein 
intake over the main meals has been proposed to increase muscle protein synthesis rates 
throughout the day [37-39] and is associated with higher lean mass in older adults [40]. 
However, whether a more balanced protein distribution also increases skeletal muscle mass 
and strength should be evaluated in long-term intervention studies. We believe that a proper 
distribution (both timing and quantity) of protein intake is essential to allow protein 
supplementation to increase muscle mass, strength, and function, which includes presleep 
protein ingestion. Besides optimizing the protein content with every meal, we recently showed 
that physical activity performed in the evening can further enhance the overnight muscle 
protein synthetic response to presleep protein ingestion in older subjects [13]. As such, 
combining presleep protein ingestion with physical activity may serve as an effective strategy 
to preserve skeletal muscle mass with aging. Interestingly, we showed that daily presleep 
protein ingestion increases the gains in muscle mass and strength after 3 mo of resistance-
type exercise training in young men who were already consuming ample amounts of protein 
in their diet (1.3 g⋅kg−1⋅d−1) [41]. Future work should establish the effect of long-term 
intervention programs using presleep protein ingestion (combined with physical activity) on 
lean mass and functional capacity in healthy or clinically compromised older populations. 
More work is needed on the effect of protein intake distribution and overnight muscle protein 
synthesis rates in older individuals. Although ∼40 g high-quality protein seems to be required 
to maximize postprandial muscle protein synthesis rates in older individuals [42], a definite 
upper threshold remains to be established. Also, previous work has shown greater stimulation 
of postprandial FSR after whey ingestion than after casein ingestion [20]. Yet, the anabolic 
response to whey protein ingestion has also been shown to be relatively short lived. Which 
protein source would be preferred to stimulate muscle protein synthesis throughout overnight 
sleep clearly remains to be determined. In addition, more work is warranted to assess the effect 
of reducing the amount of time spent in a fasting state not only on whole-body and tissue-
specific protein turnover but also on overall metabolism [43-46]. Finally, we need to evaluate 
how overnight muscle protein metabolism modulates protein metabolism during the day, and 
vice versa. 
In conclusion, the ingestion of 40 g casein before sleep is followed by proper protein digestion 
and amino acid absorption throughout the night, thereby increasing overnight plasma amino 
acid availability and stimulating overnight muscle protein synthesis in healthy older men. 
Presleep ingestion of smaller doses of protein (20 g), with or without additional free leucine, 
 
 
do not seem sufficient to increase overnight muscle protein synthesis rates but do provide 
amino acids as precursors for myofibrillar protein synthesis during overnight sleep in healthy 
older men. The present study introduces presleep protein ingestion as a practical and effective 
dietary strategy to stimulate overnight muscle protein accretion and, as such, may help to 
attenuate or prevent muscle loss in both health and disease. 
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how overnight muscle protein metabolism modulates protein metabolism during the day, and 
vice versa. 
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and amino acid absorption throughout the night, thereby increasing overnight plasma amino 
acid availability and stimulating overnight muscle protein synthesis in healthy older men. 
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ABST RACT  
Background:  The age-related decline in skeletal muscle mass is partly attributed to 
anabolic resistance to food intake. Dietary protein ingestion before sleep 
could be used as a nutritional strategy to compensate for anabolic 
resistance. 
Objective:  The present study assessed whether physical activity performed in the 
evening can augment the overnight muscle protein synthetic response to 
presleep protein ingestion in older men. 
Methods:  In a parallel group design, 23 healthy older men (mean±SEM age: 71±1 y) 
were randomly assigned to ingest 40 g protein intrinsically labeled with L-
[1-13C]-phenylalanine and L-[1-13C]-leucine before going to sleep with 
(PRO+EX) or without (PRO) performing physical activity earlier in the 
evening. Overnight protein digestion and absorption kinetics and 
myofibrillar protein synthesis rates were assessed by combining primed, 
continuous infusions of L-[ring-2H5]-phenylalanine, L-[1-13C]-leucine, and L-
[ring-2H2]-tyrosine with the ingestion of intrinsically labeled casein protein. 
Muscle and blood samples were collected throughout overnight sleep. 
Results:  Protein ingested before sleep was normally digested and absorbed, with 
54±2% of the protein-derived amino acids appearing in the circulation 
throughout overnight sleep. Overnight myofibrillar protein synthesis rates 
were 31% (0.058±0.002 %·h-1 compared with 0.044±0.003 %·h-1; P<0.01; 
based on L-[ring-2H5]-phenylalanine) and 27% (0.074±0.004 %·h-1 compared 
with 0.058±0.003 %·h-1; P<0.01; based on L-[1-13C]-leucine) higher in the 
PRO+EX than in the PRO treatment. More dietary protein-derived amino 
acids were incorporated into de novo myofibrillar protein during overnight 
sleep in PRO+EX than in PRO treatment (0.042±0.002 compared with 
0.033±0.002 MPE; P<0.05). 
Conclusions:  Physical activity performed in the evening augments the overnight muscle 
protein synthetic response to presleep protein ingestion and allows more of 
the ingested protein-derived amino acids to be used for de novo muscle 
protein synthesis during overnight sleep in older men.  
  
 
 
IN TRODU CTION  
The age-related decline in muscle mass and strength, termed sarcopenia, is accompanied by 
impairments in functional capacity and an increased risk of developing chronic metabolic 
diseases[1, 2]. With no apparent differences in basal, postabsorptive muscle protein synthesis 
rates between young and older individuals [3, 4], many research groups have started to 
investigate the muscle protein synthetic response to the main anabolic stimuli, such as food 
intake and physical activity. This has led to the observation of an attenuated muscle protein 
synthetic response to food intake in older individuals [5, 6], a condition that has been 
coined anabolic resistance [7]. 
Effective strategies are needed to augment the muscle protein synthetic response to feeding 
as a means to compensate for the presence of anabolic resistance. Therefore, our laboratory 
and many others are investigating nutritional strategies to increase the muscle protein 
synthetic response to meal ingestion. Such interventions may include modulating the amount 
[8-10], type [11-13], and timing [14, 15] of protein ingestion, as well as combining protein 
ingestion with various food compounds [16, 17]. Besides enhancing the muscle protein 
synthetic response to the main meals (i.e., breakfast, lunch, and dinner), we have proposed the 
ingestion of dietary protein before sleep with the aim of providing dietary-derived amino acids 
to support an increase in overnight muscle protein synthesis [18, 19]. In a proof-of-principle 
study, Groen et al. [19] found that enteral administration of 40 g protein during sleep via a 
nasogastric tube was followed by proper protein digestion and absorption, thereby increasing 
overnight amino acid availability and stimulating overnight muscle protein synthesis rates in 
older individuals. Therefore, we proposed dietary protein ingestion before sleep as a practical 
and effective strategy to improve overnight protein balance and to stimulate overnight muscle 
protein synthesis.  
Physical activity is an important factor responsible for the degree of anabolic resistance [7, 20]. 
Previous work has established that physical activity or exercise can robustly increase muscle 
protein synthesis rates [21-24]. Moreover, physical activity augments the postprandial muscle 
protein synthetic response to protein feeding, thereby compensating for anabolic resistance 
[9, 10, 22]. Here, we hypothesized that physical activity performed during the evening would 
augment the overnight muscle protein synthetic response to presleep protein ingestion, 
allowing more of the ingested protein to be used for de novo myofibrillar protein accretion 
during sleep. To test our hypothesis that physical activity can augment the impact of presleep 
protein ingestion on overnight muscle protein synthesis, we selected 23 older men (71±1 y) 
who ingested 40 g casein protein intrinsically labeled with L-[1-13C]-phenylalanine and L-[1-
13C]-leucine before going to sleep with (PRO+EX; n = 11) or without (PRO; n = 12) a bout of 
physical activity being performed earlier in the evening. By combining the ingestion of 
specifically produced casein intrinsically labeled with L-[1-13C]-phenylalanine and L-[1-13C]-
leucine with the administration of primed continuous infusions of L-[ring-2H5]-phenylalanine, 
L-[1-13C]-leucine, and L-[ring-2H2]-tyrosine we were able to assess overnight protein digestion 
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and amino acid absorption kinetics, whole-body protein metabolism, muscle protein synthesis 
rates, and the metabolic fate of the dietary protein-derived amino acids during overnight 
sleep. 
  
 
 
M ETHO DS 
Subjects 
A total of 24 healthy, normoglycemic, older men (71±1 y) were selected to participate in the 
present study. Subject characteristics of the study participants are presented in Table 1. 
Subjects were randomly assigned to the PRO+EX (n = 11) or the PRO (n = 12) presleep 
treatment group. One subject randomly assigned to the PRO+EX group did not complete the 
physical activity session and was therefore excluded from all analyses. All subjects were 
informed of the nature and possible risks of the experimental procedures before their written 
informed consent was obtained. The study was approved by the Medical Ethical Committee 
of the Maastricht University Medical Centre, Netherlands, and conformed to standards for the 
use of human subjects in research as outlined in the most recent version of the Helsinki 
Declaration. The study was registered at Nederlands Trial Register as NTR3885. 
Table 1 | Subjects’ characteristics of healthy older men who ingested 40 g protein prior to sleep after either 
completing a session of resistance exercise or remaining at rest.  
 PRO PRO+EX P-value 
Age, y 70±1 71±1 0.48 
Body weight, kg 79.4±2.2 79.0±2.2 0.88 
Body mass index, kg·m-2 25.7±0.6 26.0±0.7 0.71 
Body fat, % 20.8±0.9 20.9±1.3 0.92 
Lean body mass, kg 60.6±1.4 60.1±1.8 0.84 
Appendicular lean mass, kg 26.2±0.7 25.9±0.9 0.78 
Leg volume, L 8.4±0.5 8.1± 0.5 0.70 
HbA1c, % 5.3±0.1 5.5±0.1 0.43 
Basal plasma glucose, mmol·L-1 6.4±0.3 5.8±0.2 0.08 
Basal plasma insulin, mU·L-1 10.6±1.3 8.5±1.1 0.24 
HOMA-IR 2.2±0.3 3.1±0.4 0.09 
1RM Leg Press, kg - 170±8 - 
1RM Leg Extension, kg - 77±5 - 
PSQI Score 2.3±0.3 2.8±0.5 0.48 
Values are expressed as means±SEMs. No differences were observed between treatment groups. HbA1c, glycated 
hemoglobin; PRO, 40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise; PSQI, Pittsburg 
Sleep Quality Index; 1RM, 1 repetition maximum. 
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Pretesting 
Participants arrived at the laboratory at 08:30 by car or public transport in an overnight fasted 
state. On arrival, body weight, body composition, and bone mineral content were measured 
with DXA (Discovery A; Hologic). Thereafter, all participants performed an oral-glucose-
tolerance test. Plasma glucose and insulin concentrations were measured to determine oral 
glucose intolerance and/or the presence of type 2 diabetes according to 2006 guidelines from 
the American Diabetes Association [25]. All subjects were screened on medical issues and were 
excluded if any gastrointestinal, neurologic, or renal diseases were present. 
Subjects randomly assigned to the PRO+EX treatment were cleared to perform physical 
activity by a cardiologist who examined electrocardiograms measured at rest and during 
submaximal cycling (performed at 70% of age-predicted heart rate maximum). The subjects 
were then familiarized with the exercise equipment and physical activity protocol. Subjects 
first performed a 10-min cycling warm-up at 70% of their age-predicted heart rate maximum 
before completing an estimation of their 1 repetition maximum (1RM) on the leg press and 
leg extension exercises with the use of the multiple repetitions testing procedure [26]. For each 
exercise, subjects performed 10 submaximal, or warm-up, repetitions to become familiarized 
with the equipment and to have lifting technique critiqued and corrected. Subjects then 
performed sets at progressively increasing loads until failing to complete a valid repetition, 
judged by their inability to complete the full range of motion for an exercise. Ideally, subjects 
failed within 3–6 repetitions during the last and heaviest set. A 2-min resting period between 
subsequent attempts was allowed. The pretesting and experimental trials were separated by 
a period of ≥7 d. 
Diet and physical activity  
All volunteers were instructed to refrain from any exhaustive physical activity and to keep their 
diet as consistent as possible 48 h before the trial. On the day of the experiment, a 
standardized diet (3 meals and 2 snacks) was consumed that provided 9.3±0.6 MJ, with 55±2% 
of energy as carbohydrate, 27±2% of energy as fat, and 16±0.2% of energy as protein. The 
energy content of the standardized diet was based on individual energy requirements 
calculated with the Harris-Benedict equation and adjusted with a physical activity factor of 1.4 
to ensure ample energy intake. The mean ± SEM dietary protein intake was 1.1±0.01 g·kg-1 
bodyweight, with 35±1% of the protein consumed at dinner.  
Experimental protocol 
At 17:30, participants reported to the laboratory and had Teflon catheters inserted into the 
antecubital veins of each arm. At 18:30 (t = −300 min), all subjects consumed the same 
standardized dinner meal under supervision (2.5 ± 0.1 MJ, providing 62±0.2% of energy as 
carbohydrate, 19±0.1% of energy as fat, and 19±0.1% of energy as protein). Subjects in the 
PRO+EX group performed a single physical activity session between 19:45 and 20:45. After the 
physical activity session, and at 21:00 (t = −150 min), a background blood sample was taken 
before the initiation of the tracer infusion protocol. The plasma and intracellular phenylalanine 
and leucine pools were primed with a single intravenous dose (priming dose) of L-[ring-2H5]-
phenylalanine (2.0 µmol·kg-1), L-[ring-2H2]-tyrosine (0.615 µmol·kg-1), and L-[1-13C]-leucine 
(4.0 µmol·kg-1). Once primed, the continuous stable isotope infusion was initiated (infusion 
rate: 0.05 μmol·kg−1·min−1 L-[ring-2H5]-phenylalanine, 0.015 μmol·kg−1·min−1 L-[ring-2H2]-
tyrosine, and 0.1 μmol·kg−1·min−1 L-[1-13C]-leucine; Cambridge Isotopes Laboratories). 
Participants rested for 2.5 h until 23:30 (t = 0 min), when the first muscle biopsy sample was 
taken. Subsequently, subjects ingested within 5 min a 450-mL beverage that contained 40 g 
casein intrinsically labeled with L-[1-13C]-phenylalanine and L-[1-13C]-leucine and 1.5 mL 
vanilla extract, added to improve palatability (Dr. Oetker, Amersfoort, Netherlands). Subjects 
went to sleep at 00:00. During the night, blood samples (10 mL) were taken without waking 
the subjects at t = 30, 60, 90, 150, 210, 270, 330, 390, 450 min relative to the intake of the 
protein drink. A second muscle biopsy was obtained from the contralateral leg 7.5 h later at 
07:00 (t = 450 min).  
Blood samples were collected in EDTA-containing tubes and were centrifuged at 1000 g for 
10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen and stored at −80°C. Muscle 
biopsies were obtained from the middle region of the M. vastus lateralis, 15 cm above the 
patella and ∼4 cm below entry through the fascia, using the percutaneous needle biopsy 
technique [27]. Muscle samples were dissected carefully and freed from any visible non-muscle 
material. The muscle samples were immediately frozen in liquid nitrogen and stored at −80°C 
until further analysis. A graphical representation of the experimental protocol is shown 
in Figure 1. 
Figure 1 | Graphical representation of the experimental protocol. 
Physical activity protocol 
The physical activity protocol consisted of 60 min of moderate-intensity, lower-body, 
resistance-type exercise. After 15 min of self-paced cycling at 100 W with a cadence of 60–80 
rpm, subjects performed 6 sets of 10 repetitions on the horizontal leg press machine 
(Technogym BV) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV). 
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Pretesting 
Participants arrived at the laboratory at 08:30 by car or public transport in an overnight fasted 
state. On arrival, body weight, body composition, and bone mineral content were measured 
with DXA (Discovery A; Hologic). Thereafter, all participants performed an oral-glucose-
tolerance test. Plasma glucose and insulin concentrations were measured to determine oral 
glucose intolerance and/or the presence of type 2 diabetes according to 2006 guidelines from 
the American Diabetes Association [25]. All subjects were screened on medical issues and were 
excluded if any gastrointestinal, neurologic, or renal diseases were present. 
Subjects randomly assigned to the PRO+EX treatment were cleared to perform physical 
activity by a cardiologist who examined electrocardiograms measured at rest and during 
submaximal cycling (performed at 70% of age-predicted heart rate maximum). The subjects 
were then familiarized with the exercise equipment and physical activity protocol. Subjects 
first performed a 10-min cycling warm-up at 70% of their age-predicted heart rate maximum 
before completing an estimation of their 1 repetition maximum (1RM) on the leg press and 
leg extension exercises with the use of the multiple repetitions testing procedure [26]. For each 
exercise, subjects performed 10 submaximal, or warm-up, repetitions to become familiarized 
with the equipment and to have lifting technique critiqued and corrected. Subjects then 
performed sets at progressively increasing loads until failing to complete a valid repetition, 
judged by their inability to complete the full range of motion for an exercise. Ideally, subjects 
failed within 3–6 repetitions during the last and heaviest set. A 2-min resting period between 
subsequent attempts was allowed. The pretesting and experimental trials were separated by 
a period of ≥7 d. 
Diet and physical activity  
All volunteers were instructed to refrain from any exhaustive physical activity and to keep their 
diet as consistent as possible 48 h before the trial. On the day of the experiment, a 
standardized diet (3 meals and 2 snacks) was consumed that provided 9.3±0.6 MJ, with 55±2% 
of energy as carbohydrate, 27±2% of energy as fat, and 16±0.2% of energy as protein. The 
energy content of the standardized diet was based on individual energy requirements 
calculated with the Harris-Benedict equation and adjusted with a physical activity factor of 1.4 
to ensure ample energy intake. The mean ± SEM dietary protein intake was 1.1±0.01 g·kg-1 
bodyweight, with 35±1% of the protein consumed at dinner.  
Experimental protocol 
At 17:30, participants reported to the laboratory and had Teflon catheters inserted into the 
antecubital veins of each arm. At 18:30 (t = −300 min), all subjects consumed the same 
standardized dinner meal under supervision (2.5 ± 0.1 MJ, providing 62±0.2% of energy as 
carbohydrate, 19±0.1% of energy as fat, and 19±0.1% of energy as protein). Subjects in the 
PRO+EX group performed a single physical activity session between 19:45 and 20:45. After the 
physical activity session, and at 21:00 (t = −150 min), a background blood sample was taken 
before the initiation of the tracer infusion protocol. The plasma and intracellular phenylalanine 
and leucine pools were primed with a single intravenous dose (priming dose) of L-[ring-2H5]-
phenylalanine (2.0 µmol·kg-1), L-[ring-2H2]-tyrosine (0.615 µmol·kg-1), and L-[1-13C]-leucine 
(4.0 µmol·kg-1). Once primed, the continuous stable isotope infusion was initiated (infusion 
rate: 0.05 μmol·kg−1·min−1 L-[ring-2H5]-phenylalanine, 0.015 μmol·kg−1·min−1 L-[ring-2H2]-
tyrosine, and 0.1 μmol·kg−1·min−1 L-[1-13C]-leucine; Cambridge Isotopes Laboratories). 
Participants rested for 2.5 h until 23:30 (t = 0 min), when the first muscle biopsy sample was 
taken. Subsequently, subjects ingested within 5 min a 450-mL beverage that contained 40 g 
casein intrinsically labeled with L-[1-13C]-phenylalanine and L-[1-13C]-leucine and 1.5 mL 
vanilla extract, added to improve palatability (Dr. Oetker, Amersfoort, Netherlands). Subjects 
went to sleep at 00:00. During the night, blood samples (10 mL) were taken without waking 
the subjects at t = 30, 60, 90, 150, 210, 270, 330, 390, 450 min relative to the intake of the 
protein drink. A second muscle biopsy was obtained from the contralateral leg 7.5 h later at 
07:00 (t = 450 min).  
Blood samples were collected in EDTA-containing tubes and were centrifuged at 1000 g for 
10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen and stored at −80°C. Muscle 
biopsies were obtained from the middle region of the M. vastus lateralis, 15 cm above the 
patella and ∼4 cm below entry through the fascia, using the percutaneous needle biopsy 
technique [27]. Muscle samples were dissected carefully and freed from any visible non-muscle 
material. The muscle samples were immediately frozen in liquid nitrogen and stored at −80°C 
until further analysis. A graphical representation of the experimental protocol is shown 
in Figure 1. 
Figure 1 | Graphical representation of the experimental protocol. 
Physical activity protocol 
The physical activity protocol consisted of 60 min of moderate-intensity, lower-body, 
resistance-type exercise. After 15 min of self-paced cycling at 100 W with a cadence of 60–80 
rpm, subjects performed 6 sets of 10 repetitions on the horizontal leg press machine 
(Technogym BV) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV). 
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The first 2 sets of both exercises were performed at 55% and 65% 1RM, respectively, and sets 
3–6 were performed at 75% 1RM. Subjects were allowed to rest for 2 min between all sets. 
Sleep quality assessment 
The Pittsburg Sleep Quality Index (Sleep Medicine Institute, University of Pittsburgh) was used 
to assess habitual sleep quality during pretesting [28]. Pittsburg Sleep Quality Index scoring 
(global scores 0–21 points) was used to classify all subjects to very good, good, poor, or very 
poor sleepers. Subjects that scored >5 (poor sleepers) were not included in the trial. Sleep 
behavior during the test night was monitored with wrist activity monitors and analyzed with 
Actiware software (Philips Respironics). Time was scored as awake unless the following 2 
conditions were met simultaneously: participant was lying down attempting to sleep and the 
activity counts from the monitor were sufficiently low to indicate that the participant was 
immobile. In addition, the start and end times of sleep were recorded throughout the trial. The 
following variables were derived from sleep records and activity monitors: bed time (clock 
time), get up time (clock time), sleep onset latency (the period of time between bedtime and 
sleep start), sleep duration (h), time awake/light sleep (h), sleep efficiency (sleep duration 
expressed as a percentage of time in bed), and wake bouts 
Preparation of tracer and production of intrinsically labeled protein  
The stable isotope tracers L-[ring-2H5]-phenylalanine, L-[1-13C]-leucine, and L-[ring-2H2]-
tyrosine were purchased from Cambridge Isotopes and were dissolved in 0.9% saline before 
infusion (Basic Pharma). Continuous intravenous infusions were performed with a calibrated 
IVAC 598 pump. Casein protein intrinsically labeled with L-[1-13C]-phenylalanine and L-[1-13C]-
leucine was extracted from whole milk obtained during the constant infusion of L-[1-13C]-
phenylalanine (455 µmol·min-1) and L-[1-13C]-leucine (200 µmol·min-1) for 96 h in a lactating 
dairy cow. The milk was collected, processed, and fractionated into the casein protein 
concentrate as previously described [16, 18, 29]. The L-[1-13C]-phenylalanine and L-[1-13C]-
leucine enrichments in casein protein were measured by gas chromatography–combustion 
isotope ratio mass spectrometry (MAT 252; Finnigan) and averaged 38.7 mole percent excess 
(MPE) and 9.3 MPE, respectively. The proteins met all chemical and bacteriologic specifications 
for human consumption 
Plasma analysis 
Plasma glucose and insulin concentrations were analyzed using commercially available kits 
(GLUC3, Roche, Ref: 05168791 190, and Immunologic, Roche, Ref: 12017547 122, respectively). 
Plasma amino acid concentrations and enrichments were determined by gas chromatography-
mass spectrometry analysis (GC-MS; Agilent 7890A GC/5975C; MSD, Wilmington, Delaware, 
USA). Specifically, internal standards of [U-13C6]-leucine, [U-13C915N]-phenylalanine, and [U-
13C915N]-tyrosine were added to the plasma samples. Plasma samples were deproteinized with 
dry 5-sulfosalicylic acid. Free amino acids were purified using cation exchange 
 
 
chromatography (AG 50W-X8 resin, mesh size: 100–200 µm, ionic form: hydrogen; Bio-Rad 
Laboratories, Hercules, CA). The purified amino acids were converted into tert-
butyldimethylsilyl (tert-BDMS) derivatives with MTBSTFA before analysis by GC-MS. The amino 
acid concentrations were determined using electron impact ionization by monitoring ions at 
mass/charge (m/z) 302 and 308 for unlabeled and [U-13C6]-labeled-leucine, 336 and 346 for 
unlabeled and [U-13C915N] labelled phenylalanine respectively, and 466 and 476 for unlabeled 
and [U-13C915N]-labeled tyrosine, respectively. The plasma leucine, phenylalanine, and tyrosine 
13C and 2H enrichments were determined using selective ion monitoring at m/z 302 and 303 
for unlabeled and labeled (1-13C)-leucine, respectively; m/z 336, 337, and 341 for unlabeled 
and labeled (1-13C and ring-2H5)-phenylalanine, respectively; m/z 466, 467, 468, and 470 for 
unlabeled and labeled (1-13C, ring-3,5-2H2, and ring-2H4)-tyrosine, respectively. Standard 
regression curves were applied from a series of known standard enrichment values against the 
measured values to assess the linearity of the mass spectrometer and to account for any 
isotope fractionation. 
Muscle analyses 
Myofibrillar protein-bound L-[ring-2H5]-phenylalanine enrichments were determined by gas 
chromatography–mass spectrometry analysis, whereas the L-[1-13C]-phenylalanine and L-[1-
13C]-leucine enrichments were determined by gas chromatography–combustion isotope ratio 
mass spectrometry analysis (Trace GC Ultra, IRMS model MAT 253; Thermo Scientific). 
Myofibrillar protein-enriched fractions were extracted from ~60 mg of wet muscle tissue by 
hand-homogenizing on ice using a pestle in a standard extraction buffer (7 L·mg-1) [19]. The 
samples were spun at 2500 g and 4 ºC for 5 min. The pellet was washed with 500 µL ddH2O 
and centrifuged at 250 g and 4 ºC for 10 min. The myofibrillar protein was solubilized by 
adding 1 mL of 0.3 M NaOH and heating at 50 ºC for 30 min with vortex mixing every 10 min. 
Samples were centrifuged at 9500 g and 4 ºC for 5 min, the supernatant containing the 
myofibrillar proteins was collected and the collagen pellet was discarded. Myofibrillar proteins 
were precipitated by the addition of 1 mL of 1 M PCA and spinning at 700 g and 4 ºC for 10 
min. The myofibrillar protein was washed twice with 70% ethanol and hydrolyzed overnight in 
2 mL of 6 M HCL at 110˚C. The free amino acids from the hydrolyzed myofibrillar protein pellet 
were dried under a nitrogen stream while being heated to 120 ºC. The free amino acids were 
then dissolved in 25% acetic acid solution, passed over cation exchange AG 50W-X8 resin 
columns (mesh size: 100-200, ionic form: hydrogen; Bio-Rad Laboratories, Hercules, CA), and 
eluted with 2 M NH4OH. The purified amino acids were divided into 2 aliquots to determine 
the L-[ring-2H5]-phenylalanine enrichments by GC-MS analysis and the L-[1-13C]-
phenylalanine and L-[1-13C]-leucine enrichments by gas chromatography-combustion-
isotope ratio mass spectrometry (GC-C-IRMS) analysis. To reduce the signal-to-noise ratio 
during GC-MS analysis at low tracer enrichments, the phenylalanine from the myofibrillar 
protein hydrolysates was enzymatically decarboxylated to β-phenylethylamine prior to 
derivatization with MTBSTFA. To determine myofibrillar protein L-[1-13C]-phenylalanine and L-
[1-13C]-leucine enrichments by GC-C-IRMS analysis, the purified amino acids were converted 
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The first 2 sets of both exercises were performed at 55% and 65% 1RM, respectively, and sets 
3–6 were performed at 75% 1RM. Subjects were allowed to rest for 2 min between all sets. 
Sleep quality assessment 
The Pittsburg Sleep Quality Index (Sleep Medicine Institute, University of Pittsburgh) was used 
to assess habitual sleep quality during pretesting [28]. Pittsburg Sleep Quality Index scoring 
(global scores 0–21 points) was used to classify all subjects to very good, good, poor, or very 
poor sleepers. Subjects that scored >5 (poor sleepers) were not included in the trial. Sleep 
behavior during the test night was monitored with wrist activity monitors and analyzed with 
Actiware software (Philips Respironics). Time was scored as awake unless the following 2 
conditions were met simultaneously: participant was lying down attempting to sleep and the 
activity counts from the monitor were sufficiently low to indicate that the participant was 
immobile. In addition, the start and end times of sleep were recorded throughout the trial. The 
following variables were derived from sleep records and activity monitors: bed time (clock 
time), get up time (clock time), sleep onset latency (the period of time between bedtime and 
sleep start), sleep duration (h), time awake/light sleep (h), sleep efficiency (sleep duration 
expressed as a percentage of time in bed), and wake bouts 
Preparation of tracer and production of intrinsically labeled protein  
The stable isotope tracers L-[ring-2H5]-phenylalanine, L-[1-13C]-leucine, and L-[ring-2H2]-
tyrosine were purchased from Cambridge Isotopes and were dissolved in 0.9% saline before 
infusion (Basic Pharma). Continuous intravenous infusions were performed with a calibrated 
IVAC 598 pump. Casein protein intrinsically labeled with L-[1-13C]-phenylalanine and L-[1-13C]-
leucine was extracted from whole milk obtained during the constant infusion of L-[1-13C]-
phenylalanine (455 µmol·min-1) and L-[1-13C]-leucine (200 µmol·min-1) for 96 h in a lactating 
dairy cow. The milk was collected, processed, and fractionated into the casein protein 
concentrate as previously described [16, 18, 29]. The L-[1-13C]-phenylalanine and L-[1-13C]-
leucine enrichments in casein protein were measured by gas chromatography–combustion 
isotope ratio mass spectrometry (MAT 252; Finnigan) and averaged 38.7 mole percent excess 
(MPE) and 9.3 MPE, respectively. The proteins met all chemical and bacteriologic specifications 
for human consumption 
Plasma analysis 
Plasma glucose and insulin concentrations were analyzed using commercially available kits 
(GLUC3, Roche, Ref: 05168791 190, and Immunologic, Roche, Ref: 12017547 122, respectively). 
Plasma amino acid concentrations and enrichments were determined by gas chromatography-
mass spectrometry analysis (GC-MS; Agilent 7890A GC/5975C; MSD, Wilmington, Delaware, 
USA). Specifically, internal standards of [U-13C6]-leucine, [U-13C915N]-phenylalanine, and [U-
13C915N]-tyrosine were added to the plasma samples. Plasma samples were deproteinized with 
dry 5-sulfosalicylic acid. Free amino acids were purified using cation exchange 
 
 
chromatography (AG 50W-X8 resin, mesh size: 100–200 µm, ionic form: hydrogen; Bio-Rad 
Laboratories, Hercules, CA). The purified amino acids were converted into tert-
butyldimethylsilyl (tert-BDMS) derivatives with MTBSTFA before analysis by GC-MS. The amino 
acid concentrations were determined using electron impact ionization by monitoring ions at 
mass/charge (m/z) 302 and 308 for unlabeled and [U-13C6]-labeled-leucine, 336 and 346 for 
unlabeled and [U-13C915N] labelled phenylalanine respectively, and 466 and 476 for unlabeled 
and [U-13C915N]-labeled tyrosine, respectively. The plasma leucine, phenylalanine, and tyrosine 
13C and 2H enrichments were determined using selective ion monitoring at m/z 302 and 303 
for unlabeled and labeled (1-13C)-leucine, respectively; m/z 336, 337, and 341 for unlabeled 
and labeled (1-13C and ring-2H5)-phenylalanine, respectively; m/z 466, 467, 468, and 470 for 
unlabeled and labeled (1-13C, ring-3,5-2H2, and ring-2H4)-tyrosine, respectively. Standard 
regression curves were applied from a series of known standard enrichment values against the 
measured values to assess the linearity of the mass spectrometer and to account for any 
isotope fractionation. 
Muscle analyses 
Myofibrillar protein-bound L-[ring-2H5]-phenylalanine enrichments were determined by gas 
chromatography–mass spectrometry analysis, whereas the L-[1-13C]-phenylalanine and L-[1-
13C]-leucine enrichments were determined by gas chromatography–combustion isotope ratio 
mass spectrometry analysis (Trace GC Ultra, IRMS model MAT 253; Thermo Scientific). 
Myofibrillar protein-enriched fractions were extracted from ~60 mg of wet muscle tissue by 
hand-homogenizing on ice using a pestle in a standard extraction buffer (7 L·mg-1) [19]. The 
samples were spun at 2500 g and 4 ºC for 5 min. The pellet was washed with 500 µL ddH2O 
and centrifuged at 250 g and 4 ºC for 10 min. The myofibrillar protein was solubilized by 
adding 1 mL of 0.3 M NaOH and heating at 50 ºC for 30 min with vortex mixing every 10 min. 
Samples were centrifuged at 9500 g and 4 ºC for 5 min, the supernatant containing the 
myofibrillar proteins was collected and the collagen pellet was discarded. Myofibrillar proteins 
were precipitated by the addition of 1 mL of 1 M PCA and spinning at 700 g and 4 ºC for 10 
min. The myofibrillar protein was washed twice with 70% ethanol and hydrolyzed overnight in 
2 mL of 6 M HCL at 110˚C. The free amino acids from the hydrolyzed myofibrillar protein pellet 
were dried under a nitrogen stream while being heated to 120 ºC. The free amino acids were 
then dissolved in 25% acetic acid solution, passed over cation exchange AG 50W-X8 resin 
columns (mesh size: 100-200, ionic form: hydrogen; Bio-Rad Laboratories, Hercules, CA), and 
eluted with 2 M NH4OH. The purified amino acids were divided into 2 aliquots to determine 
the L-[ring-2H5]-phenylalanine enrichments by GC-MS analysis and the L-[1-13C]-
phenylalanine and L-[1-13C]-leucine enrichments by gas chromatography-combustion-
isotope ratio mass spectrometry (GC-C-IRMS) analysis. To reduce the signal-to-noise ratio 
during GC-MS analysis at low tracer enrichments, the phenylalanine from the myofibrillar 
protein hydrolysates was enzymatically decarboxylated to β-phenylethylamine prior to 
derivatization with MTBSTFA. To determine myofibrillar protein L-[1-13C]-phenylalanine and L-
[1-13C]-leucine enrichments by GC-C-IRMS analysis, the purified amino acids were converted 
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into N-ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate (ECF). The derivatives 
were then measured by GC-C-IRMS (Finnigan MAT 253, Bremen, Germany) using a DB5-MS-
column (no. 122-5532; Agilent J+W scientific GC Column, GC Isolink) and monitoring of ion 
masses 44, 45 and 46. Standard regression curves were applied to assess the linearity of the 
mass spectrometer and to account for isotopic fractionation. 
Calculations 
Ingestion of L-[1-13C]-phenylalanine–labeled protein, intravenous infusion of L-[ring-2H5]-
phenylalanine, and blood sample enrichment values were used to assess whole-body amino 
acid kinetics in non–steady state conditions. Total, exogenous, and endogenous phenylalanine 
rate of appearance (Ra) and rate of plasma availability of dietary protein-derived phenylalanine 
that appeared in the systemic circulation as a fraction of total amount of phenylalanine that 
was ingested were calculated with modified Steele's equations [30-32]. 
 These parameters were calculated as follows: 
 Total𝑅𝑅𝑎𝑎  =   
 𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
      (1) 
 Exo𝑅𝑅𝑎𝑎 =
Total 𝑅𝑅𝑎𝑎 ⋅ 𝐸𝐸𝑝𝑝𝑜𝑜(𝑡𝑡) +[𝑝𝑝𝑝𝑝 ⋅𝐶𝐶(𝑡𝑡) ∙ 
𝑑𝑑𝐸𝐸𝑝𝑝𝑜𝑜
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑜𝑜𝑑𝑑
                         (2)     
 Endo𝑅𝑅𝑎𝑎 =  Total𝑅𝑅𝑎𝑎 –  Exo𝑅𝑅𝑎𝑎 –  𝐹𝐹𝑖𝑖𝑖𝑖     (3) 
 Pheplasma = (AUCExoRa
Pheprot
) ∙ 100     (4) 
where Fiv is the intravenous tracer infusion rate (µmol∙kg-1∙min-1), pV (0.125 L∙kg-1) is the 
distribution volume for phenylalanine (3). C(t) is the mean plasma phenylalanine concentration 
between 2 consecutive time points. dEiv/dt represents the time-dependent variations of plasma 
phenylalanine enrichment derived from the intravenous tracer and Eiv (t) is the mean plasma 
phenylalanine enrichment from the intravenous tracer between 2 consecutive time points. 
ExoRa represents the plasma entry rate of dietary phenylalanine, Epo (t) is the mean plasma 
phenylalanine enrichment for the ingested tracer, dEpo/dt represents the time-dependent 
variations of plasma phenylalanine enrichment derived from the oral tracer and Eprot is the L-
[1-13C]-phenylalanine enrichment in the dietary protein. Pheplasma is the percentage of ingested 
dietary phenylalanine that becomes available in the plasma and is calculated using PheProt and 
AUCExoRa. PheProt is the amount of dietary phenylalanine ingested and AUCExoRa represents the 
area under the curve (AUC) of ExoRa, which corresponds to the amount of dietary 
phenylalanine that appeared in the blood over a 7.5 h period following ingestion. 
Total rate of disappearance of phenylalanine (TotalRd) equals the rate of phenylalanine 
hydroxylation (first step in phenylalanine oxidation) and utilization for protein synthesis. This 
parameter is calculated as follows: 
 Rd = TotalRa-pV ∙ dCdt       (5) 
 
 
Whole body phenylalanine oxidation can be determined from the conversion (hydroxylation) 
of L-[ring-2H5]-phenylalanine to L-[ring-2H4]-tyrosine. The rate of phenylalanine hydroxylation 
was calculated by using the following formula: 
 Pheℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 = Tyr𝑅𝑅𝑦𝑦 ∙ Et(t)Ep(t) ∙
PheR𝑑𝑑
(Fiv + PheR𝑑𝑑)
   (6) 
Because whole body Rd comprises the rate of phenylalanine disappearance from the free 
amino acid pool in the blood due to protein synthesis (S) and oxidation, whole body protein 
synthesis can be calculated as Rd minus Phehydroxylation (oxidation). TyrRa represents the rate of 
appearance of L-[ring-2H4]-tyrosine; Et(t) and Ep(t) are the L-[ring-2H4]-tyrosine and L-[ring-
2H5]-phenylalanine enrichments in plasma between 2 consecutive time points, respectively and 
Fiv is the infusion rate of phenylalanine. Whole body protein synthesis was calculated using: 
 𝑆𝑆 = 𝑅𝑅𝑦𝑦 − Pheℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦      (7)  
Whole body protein net balance was calculated as AUC over the 7.5 h post-prandial phase 
using whole body protein synthesis minus endogenous Ra.   
 𝑃𝑃ℎ𝑒𝑒𝑦𝑦𝑛𝑛𝑦𝑦 𝑏𝑏𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑏𝑏𝑛𝑛 =  𝑆𝑆 − 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑅𝑅𝑦𝑦      (8) 
Myofibrillar protein fractional synthetic rate (FSR) was calculated with the standard precursor-
product method. The FSR of myofibrillar protein was calculated by dividing the increment in 
enrichment in the product, i.e. protein-bound L-[1-13C]-leucine or L-[ring-2H5]-phenylalanine, 
by the enrichment of the respective precursor amino acid enrichments (i.e., plasma free amino 
acids). Weighted mean plasma L-[ring-2H5]-phenylalanine and L-[1-13C]-leucine enrichments 
were used as the preferred precursor pools to estimate myofibrillar protein fractional synthesis 
rates from the continuously infused L-[ring-2H5]-phenylalanine, and L-[1-13C]-leucine tracers. 
Consequently, myofibrillar FSR was calculated as follows (4): 
 𝐹𝐹𝑆𝑆𝑅𝑅 =  E𝐵𝐵(𝑦𝑦)− E𝐵𝐵(0)
∫ E𝐹𝐹(𝑦𝑦)∙ ∆𝑦𝑦
𝑡𝑡1
𝑡𝑡0
 ∙ 100                                (9) 
where EB(t) - EB(0) represents muscle protein bound L-[ring-2H5]-phenylalanine or L-[1-13C]-
leucine. EF represent the average plasma L-[ring-2H5]-phenylalanine or L-[1-13C]-leucine 
enrichment during the tracer incorporation period. ∆t indicates the time interval (h) between 
biopsies. 
Statistics 
All data are expressed as means±SEMs. Baseline characteristics between groups were 
compared with a Student's unpaired t test. A 2-factor repeated-measures ANOVA (time × 
treatment) with time as within-subjects factor and treatment group as between-subjects factor 
was performed for the analysis of plasma amino acid concentrations, plasma tracer 
enrichments, whole-body protein kinetics, and glucose and insulin concentrations. The 
analysis was performed for the period that started at the time of protein administration, 
between t = 0 and 450 min. On identification of a statistically significant time × treatment 
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into N-ethoxycarbonyl ethyl ester derivatives with ethyl chloroformate (ECF). The derivatives 
were then measured by GC-C-IRMS (Finnigan MAT 253, Bremen, Germany) using a DB5-MS-
column (no. 122-5532; Agilent J+W scientific GC Column, GC Isolink) and monitoring of ion 
masses 44, 45 and 46. Standard regression curves were applied to assess the linearity of the 
mass spectrometer and to account for isotopic fractionation. 
Calculations 
Ingestion of L-[1-13C]-phenylalanine–labeled protein, intravenous infusion of L-[ring-2H5]-
phenylalanine, and blood sample enrichment values were used to assess whole-body amino 
acid kinetics in non–steady state conditions. Total, exogenous, and endogenous phenylalanine 
rate of appearance (Ra) and rate of plasma availability of dietary protein-derived phenylalanine 
that appeared in the systemic circulation as a fraction of total amount of phenylalanine that 
was ingested were calculated with modified Steele's equations [30-32]. 
 These parameters were calculated as follows: 
 Total𝑅𝑅𝑎𝑎  =   
 𝐹𝐹𝑖𝑖𝑖𝑖−[𝑝𝑝𝑝𝑝∙𝐶𝐶(𝑡𝑡)∙
𝑑𝑑𝐸𝐸𝑖𝑖𝑖𝑖
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑖𝑖𝑖𝑖(𝑡𝑡)
      (1) 
 Exo𝑅𝑅𝑎𝑎 =
Total 𝑅𝑅𝑎𝑎 ⋅ 𝐸𝐸𝑝𝑝𝑜𝑜(𝑡𝑡) +[𝑝𝑝𝑝𝑝 ⋅𝐶𝐶(𝑡𝑡) ∙ 
𝑑𝑑𝐸𝐸𝑝𝑝𝑜𝑜
𝑑𝑑𝑑𝑑
]
𝐸𝐸𝑝𝑝𝑝𝑝𝑜𝑜𝑑𝑑
                         (2)     
 Endo𝑅𝑅𝑎𝑎 =  Total𝑅𝑅𝑎𝑎 –  Exo𝑅𝑅𝑎𝑎 –  𝐹𝐹𝑖𝑖𝑖𝑖     (3) 
 Pheplasma = (AUCExoRa
Pheprot
) ∙ 100     (4) 
where Fiv is the intravenous tracer infusion rate (µmol∙kg-1∙min-1), pV (0.125 L∙kg-1) is the 
distribution volume for phenylalanine (3). C(t) is the mean plasma phenylalanine concentration 
between 2 consecutive time points. dEiv/dt represents the time-dependent variations of plasma 
phenylalanine enrichment derived from the intravenous tracer and Eiv (t) is the mean plasma 
phenylalanine enrichment from the intravenous tracer between 2 consecutive time points. 
ExoRa represents the plasma entry rate of dietary phenylalanine, Epo (t) is the mean plasma 
phenylalanine enrichment for the ingested tracer, dEpo/dt represents the time-dependent 
variations of plasma phenylalanine enrichment derived from the oral tracer and Eprot is the L-
[1-13C]-phenylalanine enrichment in the dietary protein. Pheplasma is the percentage of ingested 
dietary phenylalanine that becomes available in the plasma and is calculated using PheProt and 
AUCExoRa. PheProt is the amount of dietary phenylalanine ingested and AUCExoRa represents the 
area under the curve (AUC) of ExoRa, which corresponds to the amount of dietary 
phenylalanine that appeared in the blood over a 7.5 h period following ingestion. 
Total rate of disappearance of phenylalanine (TotalRd) equals the rate of phenylalanine 
hydroxylation (first step in phenylalanine oxidation) and utilization for protein synthesis. This 
parameter is calculated as follows: 
 Rd = TotalRa-pV ∙ dCdt       (5) 
 
 
Whole body phenylalanine oxidation can be determined from the conversion (hydroxylation) 
of L-[ring-2H5]-phenylalanine to L-[ring-2H4]-tyrosine. The rate of phenylalanine hydroxylation 
was calculated by using the following formula: 
 Pheℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 = Tyr𝑅𝑅𝑦𝑦 ∙ Et(t)Ep(t) ∙
PheR𝑑𝑑
(Fiv + PheR𝑑𝑑)
   (6) 
Because whole body Rd comprises the rate of phenylalanine disappearance from the free 
amino acid pool in the blood due to protein synthesis (S) and oxidation, whole body protein 
synthesis can be calculated as Rd minus Phehydroxylation (oxidation). TyrRa represents the rate of 
appearance of L-[ring-2H4]-tyrosine; Et(t) and Ep(t) are the L-[ring-2H4]-tyrosine and L-[ring-
2H5]-phenylalanine enrichments in plasma between 2 consecutive time points, respectively and 
Fiv is the infusion rate of phenylalanine. Whole body protein synthesis was calculated using: 
 𝑆𝑆 = 𝑅𝑅𝑦𝑦 − Pheℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦      (7)  
Whole body protein net balance was calculated as AUC over the 7.5 h post-prandial phase 
using whole body protein synthesis minus endogenous Ra.   
 𝑃𝑃ℎ𝑒𝑒𝑦𝑦𝑛𝑛𝑦𝑦 𝑏𝑏𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑏𝑏𝑛𝑛 =  𝑆𝑆 − 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑅𝑅𝑦𝑦      (8) 
Myofibrillar protein fractional synthetic rate (FSR) was calculated with the standard precursor-
product method. The FSR of myofibrillar protein was calculated by dividing the increment in 
enrichment in the product, i.e. protein-bound L-[1-13C]-leucine or L-[ring-2H5]-phenylalanine, 
by the enrichment of the respective precursor amino acid enrichments (i.e., plasma free amino 
acids). Weighted mean plasma L-[ring-2H5]-phenylalanine and L-[1-13C]-leucine enrichments 
were used as the preferred precursor pools to estimate myofibrillar protein fractional synthesis 
rates from the continuously infused L-[ring-2H5]-phenylalanine, and L-[1-13C]-leucine tracers. 
Consequently, myofibrillar FSR was calculated as follows (4): 
 𝐹𝐹𝑆𝑆𝑅𝑅 =  E𝐵𝐵(𝑦𝑦)− E𝐵𝐵(0)
∫ E𝐹𝐹(𝑦𝑦)∙ ∆𝑦𝑦
𝑡𝑡1
𝑡𝑡0
 ∙ 100                                (9) 
where EB(t) - EB(0) represents muscle protein bound L-[ring-2H5]-phenylalanine or L-[1-13C]-
leucine. EF represent the average plasma L-[ring-2H5]-phenylalanine or L-[1-13C]-leucine 
enrichment during the tracer incorporation period. ∆t indicates the time interval (h) between 
biopsies. 
Statistics 
All data are expressed as means±SEMs. Baseline characteristics between groups were 
compared with a Student's unpaired t test. A 2-factor repeated-measures ANOVA (time × 
treatment) with time as within-subjects factor and treatment group as between-subjects factor 
was performed for the analysis of plasma amino acid concentrations, plasma tracer 
enrichments, whole-body protein kinetics, and glucose and insulin concentrations. The 
analysis was performed for the period that started at the time of protein administration, 
between t = 0 and 450 min. On identification of a statistically significant time × treatment 
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interaction, Bonferroni post hoc testing was used to identify time points in which the 
treatments differed. Non–time-dependent variables (i.e., whole-body protein metabolism, FSR 
values, L-[1-13C]-phenylalanine myofibrillar enrichments) were compared between treatment 
groups with the use of Student's unpaired t test. Statistical significance was set at P<0.05. All 
calculations were performed with SPSS 21.0 (SPSS Inc.)  
 
 
R ESULTS  
Plasma analysis 
Overnight plasma glucose (Figure 2A) and insulin (Figure 2B) concentrations after presleep 
protein ingestion did not differ between the PRO and PRO+EX groups (P≥0.05). Plasma insulin 
concentrations increased after protein ingestion in both treatments, reaching peak 
concentrations after 30 min. 
Plasma concentrations of phenylalanine (Figure 3A), leucine (Figure 3B), and tyrosine (Figure 
3C) increased over time, with peak concentrations being reached 210 min after protein 
ingestion, which did not differ between treatments (P≥0.05). 
 
Figure 2 | Overnight plasma glucose (A, mmol·L-1) and insulin concentrations (B, mU·L-1) following pre-sleep 
protein ingestion with (PRO+EX; n = 11) and without (PRO; n = 12) prior exercise in older men. The data were 
analyzed with a two-way repeated-measures (treatment x time) ANOVA.  
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interaction, Bonferroni post hoc testing was used to identify time points in which the 
treatments differed. Non–time-dependent variables (i.e., whole-body protein metabolism, FSR 
values, L-[1-13C]-phenylalanine myofibrillar enrichments) were compared between treatment 
groups with the use of Student's unpaired t test. Statistical significance was set at P<0.05. All 
calculations were performed with SPSS 21.0 (SPSS Inc.)  
 
 
R ESULTS  
Plasma analysis 
Overnight plasma glucose (Figure 2A) and insulin (Figure 2B) concentrations after presleep 
protein ingestion did not differ between the PRO and PRO+EX groups (P≥0.05). Plasma insulin 
concentrations increased after protein ingestion in both treatments, reaching peak 
concentrations after 30 min. 
Plasma concentrations of phenylalanine (Figure 3A), leucine (Figure 3B), and tyrosine (Figure 
3C) increased over time, with peak concentrations being reached 210 min after protein 
ingestion, which did not differ between treatments (P≥0.05). 
 
Figure 2 | Overnight plasma glucose (A, mmol·L-1) and insulin concentrations (B, mU·L-1) following pre-sleep 
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Figure 3 | Overnight plasma concentrations of phenylalanine (A), leucine (B), and tyrosine (C) after PRO+EX (n = 
11) or PRO (n = 12) presleep treatment in older men. The dotted line represents the ingestion of the beverage. 
Values are means±SEMs. Data were analyzed with a 2-factor repeated-measures (treatment × time) ANOVA. PRO, 
40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise. 
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Plasma enrichments from infused L-[ring-2H5]-phenylalanine (Figure 4A), infused and 
ingested L-[1-13C]-leucine (Figure 2B), and ingested L-[1-13C]-phenylalanine (Figure 4C) did 
not differ between treatments before ingesting the protein (t = 0 min; P≥0.05). Plasma L-[ring-
2H5]-phenylalanine enrichments declined after protein ingestion; plasma L-[1-13C]-leucine 
enrichment increased before reaching a steady state for the duration of the trial. After protein 
ingestion, plasma L-[1-13C]-phenylalanine enrichments, originating from the ingested protein, 
increased in both groups, reaching maximal values at t = 210 min in the PRO group and t = 
150 min in the PRO+EX group and remained elevated for the duration of the night. A main 
effect for time was detected across groups (P<0.05), but no significant interaction effects were 
found for treatment × time.  
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Figure 3 | Overnight plasma concentrations of phenylalanine (A), leucine (B), and tyrosine (C) after PRO+EX (n = 
11) or PRO (n = 12) presleep treatment in older men. The dotted line represents the ingestion of the beverage. 
Values are means±SEMs. Data were analyzed with a 2-factor repeated-measures (treatment × time) ANOVA. PRO, 
40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise. 
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Plasma enrichments from infused L-[ring-2H5]-phenylalanine (Figure 4A), infused and 
ingested L-[1-13C]-leucine (Figure 2B), and ingested L-[1-13C]-phenylalanine (Figure 4C) did 
not differ between treatments before ingesting the protein (t = 0 min; P≥0.05). Plasma L-[ring-
2H5]-phenylalanine enrichments declined after protein ingestion; plasma L-[1-13C]-leucine 
enrichment increased before reaching a steady state for the duration of the trial. After protein 
ingestion, plasma L-[1-13C]-phenylalanine enrichments, originating from the ingested protein, 
increased in both groups, reaching maximal values at t = 210 min in the PRO group and t = 
150 min in the PRO+EX group and remained elevated for the duration of the night. A main 
effect for time was detected across groups (P<0.05), but no significant interaction effects were 
found for treatment × time.  
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Figure 4 | Overnight plasma L-[ring-2H5]-phenylalanine (A), L-[1-13C]-leucine (B), and L-[1-13C]-phenylalanine (C) 
enrichments after PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older men. The dotted line represents 
the ingestion of the beverage. Values are means±SEMs. Data were analyzed with 2-factor repeated-measures 
(treatment × time) ANOVA. MPE, mole percent excess; PRO, 40 g protein in rested state; PRO+EX, 40 g protein 
after resistance-type exercise. 
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Whole-body amino acid kinetics 
Exogenous phenylalanine Ra (Figure 5A) increased after protein ingestion with peak rates 
being reached at t = 150 min in the PRO and PRO+EX treatment groups (P≥0.05). As a result 
of increased exogenous Ra, endogenous phenylalanine Ra (Figure 5B) declined after protein 
ingestion in both groups, with no differences detected (P≥0.05). The ingested dietary protein-
bound phenylalanine that appeared in the circulation over the entire 7.5-h postprandial period 
did not differ between groups (P≥0.05) and was 54±2% overall. 
 
Figure 5 | Exogenous phenylalanine Ra (A), endogenous phenylalanine Ra (B), total phenylalanine Ra (C), and total 
phenylalanine Rd (D) after PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older men. Values are 
means±SEMs. Data were analyzed with 2-factor repeated-measures (treatment × time) ANOVA. PRO, 40 g protein 
in rested state; PRO+EX, 40 g protein after resistance-type exercise; Ra, rate of appearance; Rd, rate of 
disappearance. 
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Figure 4 | Overnight plasma L-[ring-2H5]-phenylalanine (A), L-[1-13C]-leucine (B), and L-[1-13C]-phenylalanine (C) 
enrichments after PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older men. The dotted line represents 
the ingestion of the beverage. Values are means±SEMs. Data were analyzed with 2-factor repeated-measures 
(treatment × time) ANOVA. MPE, mole percent excess; PRO, 40 g protein in rested state; PRO+EX, 40 g protein 
after resistance-type exercise. 
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Whole-body amino acid kinetics 
Exogenous phenylalanine Ra (Figure 5A) increased after protein ingestion with peak rates 
being reached at t = 150 min in the PRO and PRO+EX treatment groups (P≥0.05). As a result 
of increased exogenous Ra, endogenous phenylalanine Ra (Figure 5B) declined after protein 
ingestion in both groups, with no differences detected (P≥0.05). The ingested dietary protein-
bound phenylalanine that appeared in the circulation over the entire 7.5-h postprandial period 
did not differ between groups (P≥0.05) and was 54±2% overall. 
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Protein ingestion before sleep resulted in positive overnight whole-body protein net balance 
(Figure 6), with no differences observed between treatment groups (P≥0.05). Furthermore, 
physical activity did not appear to further influence any other variables of whole-body protein 
metabolism: synthesis rates (P≥0.05), breakdown rates (P≥0.05), oxidation rates (P≥0.05). 
 
Figure 6 | Calculated rates of whole-body protein synthesis, breakdown, oxidation, and net protein balance after 
PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older men. Values are means±SEMs. Data were analyzed 
with an unpaired Student's t test. No significant differences were detected. PRO, 40 g protein in rested state; 
PRO+EX, 40 g protein after resistance-type exercise. 
Myofibrillar fractional synthesis rates and protein-bound enrichments 
Myofibrillar L-[ring-2H5]-phenylalanine and L-[1-13C]-leucine enrichments were measured in 
muscle samples collected immediately before protein ingestion and immediately after waking. 
The mean postprandial increase in myofibrillar protein-bound L-[ring-2H5]-phenylalanine and 
L-[1-13C]-leucine enrichments was 0.0230±0.0015 compared with 0.0294±0.0010 MPE and 
0.0334±0.0020 compared with 0.0417±0.0018 MPE in PRO compared with PRO+EX, 
respectively (P<0.05). Myofibrillar protein FSR (in %·h-1) was calculated with L-[ring-2H5]-
phenylalanine plasma (Figure 7A) and muscle protein-bound enrichments and with L-[1-13C]-
leucine (Figure 7B) plasma and muscle protein-bound enrichments. PRO+EX resulted in 
greater stimulation of overnight myofibrillar FSR than PRO, calculated from L-[ring-2H5]-
phenylalanine (P<0.05) and L-[1-13C]-leucine (P<0.05). Overnight FSR was 31% and 27% higher 
in the PRO+EX treatment group than in the PRO treatment group, based on L-[ring-2H5]-
phenylalanine and L-[1-13C]-leucine infusion, respectively. Myofibrillar L-[1-13C]-phenylalanine 
(Figure 8) protein-bound enrichment (MPE) was 28% higher after the ingestion of protein 
intrinsically labeled with L-[1-13C]-phenylalanine in the PRO+EX treatment group than in the 
PRO treatment group (P<0.05) 
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Figure 7 | Overnight myofibrillar protein FSRs after PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older 
men as calculated with L-[ring-2H5]-phenylalanine (A) or L-[1-13C]-leucine (B) as tracer. Values are means±SEMs. 
Data were analyzed with an unpaired Student's t test. * Different from PRO, P<0.01. FSR, fractional synthetic rate; 
PRO, 40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise. 
 
Figure 8 | Overnight L-[1-13C]-phenylalanine incorporation into myofibrillar protein after PRO+EX (n = 11) or PRO 
(n = 12) presleep treatment with intrinsically labeled L-[1-13C]-phenylalanine in older men. Values are 
means±SEMs. Data were analyzed with an unpaired Student's  t test. * Different from PRO, P<0.01. MPE, mole 
percent excess; PRO, 40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise.  
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Protein ingestion before sleep resulted in positive overnight whole-body protein net balance 
(Figure 6), with no differences observed between treatment groups (P≥0.05). Furthermore, 
physical activity did not appear to further influence any other variables of whole-body protein 
metabolism: synthesis rates (P≥0.05), breakdown rates (P≥0.05), oxidation rates (P≥0.05). 
 
Figure 6 | Calculated rates of whole-body protein synthesis, breakdown, oxidation, and net protein balance after 
PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older men. Values are means±SEMs. Data were analyzed 
with an unpaired Student's t test. No significant differences were detected. PRO, 40 g protein in rested state; 
PRO+EX, 40 g protein after resistance-type exercise. 
Myofibrillar fractional synthesis rates and protein-bound enrichments 
Myofibrillar L-[ring-2H5]-phenylalanine and L-[1-13C]-leucine enrichments were measured in 
muscle samples collected immediately before protein ingestion and immediately after waking. 
The mean postprandial increase in myofibrillar protein-bound L-[ring-2H5]-phenylalanine and 
L-[1-13C]-leucine enrichments was 0.0230±0.0015 compared with 0.0294±0.0010 MPE and 
0.0334±0.0020 compared with 0.0417±0.0018 MPE in PRO compared with PRO+EX, 
respectively (P<0.05). Myofibrillar protein FSR (in %·h-1) was calculated with L-[ring-2H5]-
phenylalanine plasma (Figure 7A) and muscle protein-bound enrichments and with L-[1-13C]-
leucine (Figure 7B) plasma and muscle protein-bound enrichments. PRO+EX resulted in 
greater stimulation of overnight myofibrillar FSR than PRO, calculated from L-[ring-2H5]-
phenylalanine (P<0.05) and L-[1-13C]-leucine (P<0.05). Overnight FSR was 31% and 27% higher 
in the PRO+EX treatment group than in the PRO treatment group, based on L-[ring-2H5]-
phenylalanine and L-[1-13C]-leucine infusion, respectively. Myofibrillar L-[1-13C]-phenylalanine 
(Figure 8) protein-bound enrichment (MPE) was 28% higher after the ingestion of protein 
intrinsically labeled with L-[1-13C]-phenylalanine in the PRO+EX treatment group than in the 
PRO treatment group (P<0.05) 
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Figure 7 | Overnight myofibrillar protein FSRs after PRO+EX (n = 11) or PRO (n = 12) presleep treatment in older 
men as calculated with L-[ring-2H5]-phenylalanine (A) or L-[1-13C]-leucine (B) as tracer. Values are means±SEMs. 
Data were analyzed with an unpaired Student's t test. * Different from PRO, P<0.01. FSR, fractional synthetic rate; 
PRO, 40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise. 
 
Figure 8 | Overnight L-[1-13C]-phenylalanine incorporation into myofibrillar protein after PRO+EX (n = 11) or PRO 
(n = 12) presleep treatment with intrinsically labeled L-[1-13C]-phenylalanine in older men. Values are 
means±SEMs. Data were analyzed with an unpaired Student's  t test. * Different from PRO, P<0.01. MPE, mole 
percent excess; PRO, 40 g protein in rested state; PRO+EX, 40 g protein after resistance-type exercise.  
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Sleep data 
Sleep onset latency and sleep efficiency data collected during the overnight sleep test are 
displayed in Table 2. Sleep onset latency, a measure of the time taken to fall asleep, was 
6min12s±2min4s compared with 7min±2min9s in the PRO compared with the PRO+EX 
treatment groups, respectively (P≥0.05). The amount of time that subjects spent awake or in 
light sleep throughout the sleeping period was 1h12s±11min28s compared with 
38min15s±6min45 s in the PRO and PRO+EX treatment groups, respectively (P≥0.05). Sleep 
efficiency, a measure of sleep quality throughout the night, also did not differ between 
treatment groups (81.4±3.1% compared with 82.3±8.7% in the PRO and PRO+EX groups, 
respectively; P≥0.05). 
Table 2 | Sleep quality data collected with wrist activity monitors worn during sleep 
 PRO PRO+EX P-value 
Bed Time, hh:mm 23:55 23:55 0.99 
Get up Time, hh:mm 7:01 7:04 0.64 
Sleep onset latency, mm:ss 06:12±02:04 07:00±02:09 0.81 
Sleep Duration, hh:mm 05:46±00:14 05:53±00:37 0.75 
Time Awake/Light Sleep, hh:mm 01:00±00:11 00:38±00:06 0.13 
Sleep Efficiency, % 81.4±3.1 82.3±8.7 0.83 
Wake Bouts 17±2 12±2 0.09 
Values are expressed as means±SEM. PRO treatment, n = 10; PRO+EX treatment, n = 8. No significant differences 
were observed between treatment groups. 
  
 
 
D ISCUSSION   
In the present study, we assessed whether physical activity performed in the evening after a 
full day of standardized dietary intake and physical activity could augment the overnight 
muscle protein synthetic response to presleep protein ingestion in older men. We observed 
that protein ingested before sleep was normally digested and absorbed, with 54±2% of the 
ingested protein-derived amino acids appearing in the circulation throughout overnight sleep. 
Myofibrillar protein synthesis rates during overnight sleep were substantially higher when 
physical activity was performed earlier that evening, with 28% more of the presleep dietary 
protein-derived amino acids being directed toward de novo overnight muscle protein 
synthesis. 
We administered a primed, continuous intravenous infusion of L-[ring-2H5]-phenylalanine and 
L-[1-13C]-leucine throughout the night and provided all participants with 40 g casein protein 
intrinsically labeled with L-[1-13C]-phenylalanine before sleep. With this experimental protocol, 
we were able to assess overnight protein digestion and amino acid absorption kinetics, whole-
body protein metabolism, myofibrillar protein synthesis, and the specific utilization of dietary 
protein-derived amino acids for de novo muscle protein synthesis [16, 33]. On protein 
ingestion, we observed a rapid rise in circulating plasma amino acids (Figure 3) and L-[1-13C]-
phenylalanine enrichments (Figure 4C), indicating proper protein digestion and subsequent 
amino acid absorption during sleep. Exogenous dietary protein-derived phenylalanine 
Ra remained elevated throughout overnight sleep (Figure 5A). Over the entire 7.5-h overnight 
period, 53±2% of the ingested protein-derived amino acids appeared in the circulation, with 
the other 47±2% of the protein-derived amino acids being retained in the gut to support 
turnover of splanchnic tissues. These data are in line with previous work that quantified first-
pass amino acid extraction conducted during the day time [8, 22, 34] and extend on these 
findings with the observation that physical activity performed earlier during the evening does 
not modulate overnight protein digestion and amino acid absorption after presleep protein 
ingestion. 
Protein ingestion before sleep has previously been shown to improve whole-body protein 
synthesis and to reduce whole-body protein breakdown, allowing for a positive net protein 
balance during overnight sleep (18, 19). In the present study, we confirmed our previous 
findings by showing that presleep protein ingestion resulted in a (more) positive overnight 
whole-body protein balance (Figure 6). Physical activity performed earlier that day did not 
seem to have a substantial impact on overnight whole-body protein synthesis, breakdown, 
amino acid oxidation, or net balance (Figure 6). However, note that whole-body protein 
metabolism does not necessarily reflect skeletal muscle protein turnover. Because we aimed 
to assess the impact of physical activity on the overnight muscle protein synthetic response, 
we collected muscle biopsies immediately before and after overnight sleep.  
With the present amino acid tracer method, we were able to assess rates of muscle protein 
synthesis under steady state (L-[1-13C]-leucine) and non–steady state (L-[ring-2H5]-
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intrinsically labeled with L-[1-13C]-phenylalanine before sleep. With this experimental protocol, 
we were able to assess overnight protein digestion and amino acid absorption kinetics, whole-
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protein-derived amino acids for de novo muscle protein synthesis [16, 33]. On protein 
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pass amino acid extraction conducted during the day time [8, 22, 34] and extend on these 
findings with the observation that physical activity performed earlier during the evening does 
not modulate overnight protein digestion and amino acid absorption after presleep protein 
ingestion. 
Protein ingestion before sleep has previously been shown to improve whole-body protein 
synthesis and to reduce whole-body protein breakdown, allowing for a positive net protein 
balance during overnight sleep (18, 19). In the present study, we confirmed our previous 
findings by showing that presleep protein ingestion resulted in a (more) positive overnight 
whole-body protein balance (Figure 6). Physical activity performed earlier that day did not 
seem to have a substantial impact on overnight whole-body protein synthesis, breakdown, 
amino acid oxidation, or net balance (Figure 6). However, note that whole-body protein 
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to assess the impact of physical activity on the overnight muscle protein synthetic response, 
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With the present amino acid tracer method, we were able to assess rates of muscle protein 
synthesis under steady state (L-[1-13C]-leucine) and non–steady state (L-[ring-2H5]-
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phenylalanine) precursor conditions [33]. As hypothesized, myofibrillar protein synthesis rates 
were 31% (L-[ring-2H5]-phenylalanine; Figure 7A) and 27% (L-[1-13C]-leucine; Figure 7B) 
higher with the PRO+EX treatment than with the PRO treatment. These findings extend on our 
previous work showing that administration of 40 g protein before sleep increases overnight 
muscle protein synthesis rates compared with a placebo [19]. Furthermore, these findings are 
in line with previous work that investigated the impact of physical activity or exercise on the 
postprandial muscle protein synthetic response to protein or meal feeding after an overnight 
fast, showing that physical activity further augments the postprandial rise in muscle protein 
synthesis rate by ∼25% [22, 35]. This supports the concept that physical activity increases the 
sensitivity of skeletal muscle tissue to the anabolic properties of protein ingestion and that 
this response may extend into overnight sleep. In the present study, we combined continuous 
infusions of L-[ring-2H5]-phenylalanine and L-[1-13C]-leucine with the ingestion of protein 
intrinsically labeled with L-[1-13C]-phenylalanine [29, 33]. Because this specifically produced 
protein is highly enriched (>35 MPE), we are able to directly assess the metabolic fate of the 
dietary protein-derived amino acids. Here, we demonstrate that the ingested protein was used 
for de novo skeletal muscle protein synthesis throughout overnight sleep (Figure 8). 
Substantially more (28%) of the dietary protein-derived phenylalanine was incorporated into 
skeletal muscle protein when physical activity was performed earlier in the day. Therefore, 
physical activity throughout the day increases the efficiency by which protein-derived amino 
acids provided before sleep are directed toward overnight de novo muscle protein synthesis. 
Consequently, the combination of physical activity or exercise with presleep protein ingestion 
can augment the overnight muscle protein synthetic response and increase the efficacy by 
which presleep protein supplementation may help to preserve muscle mass and strength in 
the older population. In support, we recently reported greater gains in skeletal muscle mass 
and strength after 3 mo of evening resistance-type exercise training in young men when 
subjects were provided with additional protein before sleep [36]. 
It is well established that the anabolic response to protein ingestion is impaired in older [5, 7, 
37] and/or more clinically compromised [20, 37-39] populations. Previous work from our 
group [8] and from others [9, 10] has shown that increasing protein intake can compensate 
for anabolic resistance. However, ingesting larger protein doses may not be feasible or 
practical in all older and/or clinically compromised populations. Protein ingestion before sleep 
may represent an effective nutritional strategy to preserve muscle mass by stimulating and 
supporting muscle protein accretion during overnight sleep. The current data extend on 
previous observations and are the first, to our knowledge, to show that physical activity 
performed throughout the day increases the efficiency by which dietary protein ingested 
before sleep is directed toward de novo muscle protein synthesis in older individuals. 
Therefore, older individuals who are unable to ingest large amounts of protein can still benefit 
from ingesting smaller amounts of protein (<40 g) before sleep by performing physical activity 
beforehand. As such, a physical activity program should be implemented in combination with 
presleep protein ingestion to benefit from the synergy between physical activity and protein 
to increase overnight muscle protein accretion to support healthy aging. 
 
 
In conclusion, physical activity performed in the evening augments the overnight muscle 
protein synthetic response to presleep protein ingestion and allows more of the ingested 
protein-derived amino acids to be used for de novo muscle protein synthesis during overnight 
sleep in older men. Combining presleep protein ingestion with physical activity may aid in 
preserving skeletal muscle mass and, as such, support healthy aging. 
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group [8] and from others [9, 10] has shown that increasing protein intake can compensate 
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performed throughout the day increases the efficiency by which dietary protein ingested 
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Therefore, older individuals who are unable to ingest large amounts of protein can still benefit 
from ingesting smaller amounts of protein (<40 g) before sleep by performing physical activity 
beforehand. As such, a physical activity program should be implemented in combination with 
presleep protein ingestion to benefit from the synergy between physical activity and protein 
to increase overnight muscle protein accretion to support healthy aging. 
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GENE RAL  DIS CUSSI ON  
In view of the ever-increasing number of elderly individuals in our society, the age-related loss 
of skeletal muscle mass and function has received increased attention over the past years. A 
blunted response to the main anabolic stimuli of muscle mass regulation, i.e., dietary protein 
ingestion and physical activity, has been postulated to represent one of the driving factors 
explaining this generalized age-related muscle loss. More specifically, this “anabolic 
resistance” may play a key role in the accelerated loss of muscle mass observed in various 
(clinical) conditions. Anabolic resistance may reside on various levels, from protein digestion 
and amino acid absorption, to amino acid uptake in muscle tissue, and subsequent stimulation 
of muscle protein synthesis. Various factors have been identified to contribute to anabolic 
resistance, including physical inactivity, obesity, insulin resistance, medication use, and 
inflammation. Particularly in older, compromised clinical populations, acute changes in 
habitual physical activity level and food intake - often resulting from the development of 
various health issues - are likely the main cause of the development of anabolic resistance, 
inducing accelerated loss of muscle mass. Importantly, muscle loss during short periods of 
inactivity or hospitalization due to sickness, injury, and/or (elective) surgery is now believed to 
be a key contributor to the progressive age-related decline in muscle mass and strength, as 
older patients are generally unable to regain muscle tissue lost during successive periods of 
such muscle disuse.  
In the present thesis, we aimed to gain further insight in the different factors that regulate 
muscle mass maintenance in older individuals, with a focus on nutritional aspects and clinical 
populations. In the first study, we show that even a short period of hospitalization can result 
in a substantial loss of skeletal muscle mass in older patients (chapter 2) which is likely 
associated with the concomitant decrease in physical activity level and habitual food intake. In 
accordance, in chapter 3, we show that actual energy and protein consumption are largely 
insufficient in older hospitalized patients with 40% of the provided food not being consumed. 
Using stable isotope tracer methodology, we assessed post-absorptive and postprandial 
muscle protein synthesis rates to determine potential alterations herein in older and 
compromised clinical populations (chapter 4 and 5). Finally, we investigated several 
interventional strategies to increase the muscle protein synthetic response to protein intake 
in older individuals (chapter 6, 7, and 8). In this discussion section, we address the findings of 
the previous chapters, while focusing on different nutritional and physical activity intervention 
strategies to attenuate muscle mass and strength loss in older and more clinically 
compromised populations. We propose potential strategies to preserve skeletal muscle mass 
and strength to be implemented before, during, and after hospitalization. 
Before hospitalization  
Having a low muscle mass at an older age increases the risk for hospitalization [1-3]. Moreover, 
patients with low muscle mass at the time of hospital admission have an increased risk of 
 
 
functional decline [3, 4], experience longer length of hospital stay [5-8], show a worsened 
prognosis of disease [5, 7, 8], and have higher mortality rates during hospitalization [1, 5-7, 9-
11]. On average, 5–40% of the older patients report at the hospital with existing sarcopenia [1, 
5, 7]. Importantly though, even a few days of hospitalization, immobilization, or bed rest leads 
to a significant loss of muscle mass, strength, and function [12-20], further compromising 
muscle mass in both sarcopenic and non-sarcopenic patients [21]. Experimental models 
investigating muscle disuse generally report ~0.5% loss of appendicular muscle mass per day 
during limb immobilization or bed rest [12, 18, 22, 23]. We observed that only 5 days of 
hospitalization can lead to as much as 3–4% loss of muscle mass in older patients, even when 
physical therapy and nutritional support are provided throughout hospital stay (chapter 2). 
Likely, the impact of surgery, associated physical and mental stress, and reduced food intake 
during hospitalization further augment disuse-induced loss of skeletal muscle mass and 
function in clinical practice. Improving pre-hospital nutritional and functional status may be 
effective to attenuate the impact of hospitalization on overall muscle mass and function and, 
as such, improve clinical outcome.  
Already before hospital admission, up to 50% of the older patients experience a loss of physical 
functioning [24] which is a result of, among other things, a decrease in habitual physical activity 
level [24, 25]. Exercise therapy prior to hospital admission has been shown to be an effective 
strategy to improve pre-operative muscle strength and physical function in various patient 
populations [26-32]. As such, the waiting period prior to surgery represents a particularly 
suitable opportunity to optimize pre-operative functional capacity and muscle mass in older 
patients, which seems especially applicable in case of elective hospital admission. Indeed, pre-
operative exercise training 2-3 months prior to surgery has been shown to improve physical 
function up to 30% (e.g. improvements in Short Physical Performance Battery (SPPB) and 6-
min walk test) in patients waiting for elective cardiac [28, 33, 34], major abdominal and thoracic 
[26, 27, 31, 35, 36], and knee and hip replacement surgery [37, 38]. In addition, short-term pre-
operative high-intensity interval training (HIIT) has been proposed as an effective strategy to 
rapidly improve aerobic capacity in patients waiting for surgery [39, 40] and combined with 
resistance type exercise to increase muscle strength during chemotherapy [41]. As such, any 
(combined) form of resistance, endurance, HIIT, and/or concurrent exercise training could be 
applied to improve physical function and muscle mass in the pre-operative period. Despite 
the fact that the actual period of hospitalization still induces a reduction in muscle mass and 
function, the level of functioning will be better when compared to a situation where no pre-
operative training was implemented. In addition, such ‘pre-conditioning’ has been shown to 
improve post-operative clinical outcomes [42-44].  
Considering that pre-operative exercise training is cheap, well tolerated, and clinically relevant 
in various patient groups, there is a high potential for the implementation in health care. In 
the Netherlands, clinical home-based concepts like ‘Better In, Better Out’, ‘Strong for Surgery’, 
and ‘Fit4surgery’ have been developed and are now being implemented in several hospitals. 
Studies so far have mostly tested generalized, low-to-moderate intensity exercise programs 
and their clinical effectiveness on changes in muscle mass and strength have not been 
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In view of the ever-increasing number of elderly individuals in our society, the age-related loss 
of skeletal muscle mass and function has received increased attention over the past years. A 
blunted response to the main anabolic stimuli of muscle mass regulation, i.e., dietary protein 
ingestion and physical activity, has been postulated to represent one of the driving factors 
explaining this generalized age-related muscle loss. More specifically, this “anabolic 
resistance” may play a key role in the accelerated loss of muscle mass observed in various 
(clinical) conditions. Anabolic resistance may reside on various levels, from protein digestion 
and amino acid absorption, to amino acid uptake in muscle tissue, and subsequent stimulation 
of muscle protein synthesis. Various factors have been identified to contribute to anabolic 
resistance, including physical inactivity, obesity, insulin resistance, medication use, and 
inflammation. Particularly in older, compromised clinical populations, acute changes in 
habitual physical activity level and food intake - often resulting from the development of 
various health issues - are likely the main cause of the development of anabolic resistance, 
inducing accelerated loss of muscle mass. Importantly, muscle loss during short periods of 
inactivity or hospitalization due to sickness, injury, and/or (elective) surgery is now believed to 
be a key contributor to the progressive age-related decline in muscle mass and strength, as 
older patients are generally unable to regain muscle tissue lost during successive periods of 
such muscle disuse.  
In the present thesis, we aimed to gain further insight in the different factors that regulate 
muscle mass maintenance in older individuals, with a focus on nutritional aspects and clinical 
populations. In the first study, we show that even a short period of hospitalization can result 
in a substantial loss of skeletal muscle mass in older patients (chapter 2) which is likely 
associated with the concomitant decrease in physical activity level and habitual food intake. In 
accordance, in chapter 3, we show that actual energy and protein consumption are largely 
insufficient in older hospitalized patients with 40% of the provided food not being consumed. 
Using stable isotope tracer methodology, we assessed post-absorptive and postprandial 
muscle protein synthesis rates to determine potential alterations herein in older and 
compromised clinical populations (chapter 4 and 5). Finally, we investigated several 
interventional strategies to increase the muscle protein synthetic response to protein intake 
in older individuals (chapter 6, 7, and 8). In this discussion section, we address the findings of 
the previous chapters, while focusing on different nutritional and physical activity intervention 
strategies to attenuate muscle mass and strength loss in older and more clinically 
compromised populations. We propose potential strategies to preserve skeletal muscle mass 
and strength to be implemented before, during, and after hospitalization. 
Before hospitalization  
Having a low muscle mass at an older age increases the risk for hospitalization [1-3]. Moreover, 
patients with low muscle mass at the time of hospital admission have an increased risk of 
 
 
functional decline [3, 4], experience longer length of hospital stay [5-8], show a worsened 
prognosis of disease [5, 7, 8], and have higher mortality rates during hospitalization [1, 5-7, 9-
11]. On average, 5–40% of the older patients report at the hospital with existing sarcopenia [1, 
5, 7]. Importantly though, even a few days of hospitalization, immobilization, or bed rest leads 
to a significant loss of muscle mass, strength, and function [12-20], further compromising 
muscle mass in both sarcopenic and non-sarcopenic patients [21]. Experimental models 
investigating muscle disuse generally report ~0.5% loss of appendicular muscle mass per day 
during limb immobilization or bed rest [12, 18, 22, 23]. We observed that only 5 days of 
hospitalization can lead to as much as 3–4% loss of muscle mass in older patients, even when 
physical therapy and nutritional support are provided throughout hospital stay (chapter 2). 
Likely, the impact of surgery, associated physical and mental stress, and reduced food intake 
during hospitalization further augment disuse-induced loss of skeletal muscle mass and 
function in clinical practice. Improving pre-hospital nutritional and functional status may be 
effective to attenuate the impact of hospitalization on overall muscle mass and function and, 
as such, improve clinical outcome.  
Already before hospital admission, up to 50% of the older patients experience a loss of physical 
functioning [24] which is a result of, among other things, a decrease in habitual physical activity 
level [24, 25]. Exercise therapy prior to hospital admission has been shown to be an effective 
strategy to improve pre-operative muscle strength and physical function in various patient 
populations [26-32]. As such, the waiting period prior to surgery represents a particularly 
suitable opportunity to optimize pre-operative functional capacity and muscle mass in older 
patients, which seems especially applicable in case of elective hospital admission. Indeed, pre-
operative exercise training 2-3 months prior to surgery has been shown to improve physical 
function up to 30% (e.g. improvements in Short Physical Performance Battery (SPPB) and 6-
min walk test) in patients waiting for elective cardiac [28, 33, 34], major abdominal and thoracic 
[26, 27, 31, 35, 36], and knee and hip replacement surgery [37, 38]. In addition, short-term pre-
operative high-intensity interval training (HIIT) has been proposed as an effective strategy to 
rapidly improve aerobic capacity in patients waiting for surgery [39, 40] and combined with 
resistance type exercise to increase muscle strength during chemotherapy [41]. As such, any 
(combined) form of resistance, endurance, HIIT, and/or concurrent exercise training could be 
applied to improve physical function and muscle mass in the pre-operative period. Despite 
the fact that the actual period of hospitalization still induces a reduction in muscle mass and 
function, the level of functioning will be better when compared to a situation where no pre-
operative training was implemented. In addition, such ‘pre-conditioning’ has been shown to 
improve post-operative clinical outcomes [42-44].  
Considering that pre-operative exercise training is cheap, well tolerated, and clinically relevant 
in various patient groups, there is a high potential for the implementation in health care. In 
the Netherlands, clinical home-based concepts like ‘Better In, Better Out’, ‘Strong for Surgery’, 
and ‘Fit4surgery’ have been developed and are now being implemented in several hospitals. 
Studies so far have mostly tested generalized, low-to-moderate intensity exercise programs 
and their clinical effectiveness on changes in muscle mass and strength have not been 
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assessed. As these programs were not designed towards specific patient cohorts, more 
targeted exercise programs have to be developed and evaluated in different patient 
populations in the pre-hospitalization phase. To better tailor pre-habilitation programs to the 
patient, studies specifically investigating the exercise type, frequency, intensity, and duration 
of pre-habilitation programs in various patient populations should be conducted. In addition, 
detailed information on ‘baseline’ physical and functional status of the patient should be 
collected in the pre-hospitalization phase, by implementing more functional measures such 
as body composition (e.g. DXA or BIA), aerobic capacity, and muscle strength in the physical 
screening prior to hospitalization and assess the improvement of these clinical outcomes 
during pre-conditioning. As such, pre-habilitation programs can be better designed for the 
individual patient and specifically target clinical improvements. 
Apart from physical activity, food intake (mainly protein intake) represents another important 
factor for maintenance of skeletal muscle mass and function. Longitudinal studies show 
associations between a low protein intake over several years and lower muscle mass and 
strength, as well as greater declines in muscle mass over time [45-49]. In addition, not only 
protein quantity, but also protein source and quality [45, 50], and protein intake distribution 
pattern [49, 51] have been shown to affect muscle mass and strength. Since nutritional status 
has been shown to affect clinical outcome during hospitalization, screening for energy and 
protein malnutrition has become part of usual health care to identify patients at nutritional 
risk [52]. At present, up to 30% of the older patients in Western-European hospitals are 
malnourished upon hospital admission [52-56]. The supplementation of energy and/or protein 
can improve nutritional status in the pre-hospitalization phase and improve post-operative 
outcomes [57-61]. However, these studies have focused on patients with a high nutritional risk 
such as (elective) major abdominal surgery and (head- and neck) cancer patients, as these 
patients are often malnourished in the pre-hospitalization period [57-59, 62]. Besides the 
benefits of pre-operative oral nutritional supplements (ONS) or enteral nutrition in patients 
undergoing major surgery requiring hospitalization, a large body of data demonstrates that 
the provision of high-protein ONS prior to- and during hospitalization reduces mortality rates, 
complications, hospital readmissions, length of stay, and hospital costs [63-66]. However, to 
what extent nutritional interventions implemented in the pre-hospitalization period can 
improve clinical outcome parameters such as muscle mass, strength, and function in other 
patient groups (not necessarily at risk for malnutrition) remains to be established. In line with 
the support of pre-hospitalization exercise training, pre-hospitalization nutritional 
interventions would benefit from including standardized measurements of these clinical 
parameters prior to- and throughout subsequent hospitalization. Besides assessing the impact 
of these nutritional interventions on clinically relevant outcomes in standardized clinical care, 
the physiological relevance of nutritional supplementation in the pre-hospitalization phase 
needs to be further investigated. The assessment of muscle mass (by CT-scans or muscle 
biopsies for research purposes) seems particularly applicable in the pre-operative period, since 
the surgery itself can serve as an easy way to collect muscle tissue and combine clinical care 
(i.e. scans for medical purposes) with the assessment of more physiologically relevant outcome 
 
 
measurements. Additionally, the application of deuterated water is a feasible tool to measure 
muscle protein synthesis rates over consecutive days or weeks and, as such, can provide more 
in depth information on the capacity of nutritional and/or exercise training interventions to 
modulate muscle protein synthesis during pre-habilitation. In conclusion, nutritional 
intervention studies that translate research findings from bench to bedside are warranted to 
further understand the effect of nutrition during pre-habilitation and support the 
implementation in health care. 
As discussed above, pre-habilitation exercise training seems to be effective to improve pre-
hospital functional status and physical capacity. Nutritional support has been shown to further 
increase the gains in muscle mass and strength during exercise training in older frail as well as 
in diseased populations [36, 67]. Therefore, the combination of pre-operative exercise training 
and nutritional support are key to further support increases in skeletal muscle mass and 
strength prior to hospitalization. So far, only a handful of studies have assessed the effect of 
multimodal exercise and nutrition pre-habilitation programs, showing improvements in 
functional capacity and lean body mass in the pre-operative phase when individualized 
nutritional counselling, protein supplementation, and exercise therapy were combined [36, 68-
70]. To be successful, combined pre-habilitation exercise and nutritional interventions require 
a timeline that needs to start early in the pre-hospitalization phase to ensure patient 
engagement and should extend into the peri- and post-hospitalization periods. As such, the 
mind-set of both patients as well as medical staff needs to shift to pre-emptive rather than 
reactive exercise and nutritional therapies. Therefore, a drastic change towards a more 
multimodal approach in integrated care is needed to establish the successful execution of pre-
habilitation programs in older and clinically compromised populations.  
Strategies to prevent muscle loss during hospitalization 
Although the benefits of physical activity as well as the detrimental effects of physical inactivity 
have been well-established during hospitalization, even hospitalized patients who are not 
bed-ridden spend ~80% of their day in bed [71, 72]. During hospitalization, bed rest should 
be minimalized whenever possible [23, 73]. By simply looking at a typical hospital room, small 
adjustments such as changing the place of the television from above the bed to a common 
living room, and serving the food not in bed but at a table in a communal dining room, may 
already increase physical activity levels. On a broader level, creating an attractive environment 
with walking routes and gardens will encourage patients to perform physical activity during 
hospitalization. Besides these factors that are important to increase overall physical activity 
levels during hospitalization, resistance type exercise training in the pre- and post- 
hospitalization phase is likely a more robust stimulus to suffice in muscle mass and strength 
(re)gain. Implementation of (functional) resistance type exercise training is often compromised 
in most hospitalized settings. In addition, since overall food intake reduces dramatically upon 
hospitalization, this forms another major aspect to improve.  
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assessed. As these programs were not designed towards specific patient cohorts, more 
targeted exercise programs have to be developed and evaluated in different patient 
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collected in the pre-hospitalization phase, by implementing more functional measures such 
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screening prior to hospitalization and assess the improvement of these clinical outcomes 
during pre-conditioning. As such, pre-habilitation programs can be better designed for the 
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Apart from physical activity, food intake (mainly protein intake) represents another important 
factor for maintenance of skeletal muscle mass and function. Longitudinal studies show 
associations between a low protein intake over several years and lower muscle mass and 
strength, as well as greater declines in muscle mass over time [45-49]. In addition, not only 
protein quantity, but also protein source and quality [45, 50], and protein intake distribution 
pattern [49, 51] have been shown to affect muscle mass and strength. Since nutritional status 
has been shown to affect clinical outcome during hospitalization, screening for energy and 
protein malnutrition has become part of usual health care to identify patients at nutritional 
risk [52]. At present, up to 30% of the older patients in Western-European hospitals are 
malnourished upon hospital admission [52-56]. The supplementation of energy and/or protein 
can improve nutritional status in the pre-hospitalization phase and improve post-operative 
outcomes [57-61]. However, these studies have focused on patients with a high nutritional risk 
such as (elective) major abdominal surgery and (head- and neck) cancer patients, as these 
patients are often malnourished in the pre-hospitalization period [57-59, 62]. Besides the 
benefits of pre-operative oral nutritional supplements (ONS) or enteral nutrition in patients 
undergoing major surgery requiring hospitalization, a large body of data demonstrates that 
the provision of high-protein ONS prior to- and during hospitalization reduces mortality rates, 
complications, hospital readmissions, length of stay, and hospital costs [63-66]. However, to 
what extent nutritional interventions implemented in the pre-hospitalization period can 
improve clinical outcome parameters such as muscle mass, strength, and function in other 
patient groups (not necessarily at risk for malnutrition) remains to be established. In line with 
the support of pre-hospitalization exercise training, pre-hospitalization nutritional 
interventions would benefit from including standardized measurements of these clinical 
parameters prior to- and throughout subsequent hospitalization. Besides assessing the impact 
of these nutritional interventions on clinically relevant outcomes in standardized clinical care, 
the physiological relevance of nutritional supplementation in the pre-hospitalization phase 
needs to be further investigated. The assessment of muscle mass (by CT-scans or muscle 
biopsies for research purposes) seems particularly applicable in the pre-operative period, since 
the surgery itself can serve as an easy way to collect muscle tissue and combine clinical care 
(i.e. scans for medical purposes) with the assessment of more physiologically relevant outcome 
 
 
measurements. Additionally, the application of deuterated water is a feasible tool to measure 
muscle protein synthesis rates over consecutive days or weeks and, as such, can provide more 
in depth information on the capacity of nutritional and/or exercise training interventions to 
modulate muscle protein synthesis during pre-habilitation. In conclusion, nutritional 
intervention studies that translate research findings from bench to bedside are warranted to 
further understand the effect of nutrition during pre-habilitation and support the 
implementation in health care. 
As discussed above, pre-habilitation exercise training seems to be effective to improve pre-
hospital functional status and physical capacity. Nutritional support has been shown to further 
increase the gains in muscle mass and strength during exercise training in older frail as well as 
in diseased populations [36, 67]. Therefore, the combination of pre-operative exercise training 
and nutritional support are key to further support increases in skeletal muscle mass and 
strength prior to hospitalization. So far, only a handful of studies have assessed the effect of 
multimodal exercise and nutrition pre-habilitation programs, showing improvements in 
functional capacity and lean body mass in the pre-operative phase when individualized 
nutritional counselling, protein supplementation, and exercise therapy were combined [36, 68-
70]. To be successful, combined pre-habilitation exercise and nutritional interventions require 
a timeline that needs to start early in the pre-hospitalization phase to ensure patient 
engagement and should extend into the peri- and post-hospitalization periods. As such, the 
mind-set of both patients as well as medical staff needs to shift to pre-emptive rather than 
reactive exercise and nutritional therapies. Therefore, a drastic change towards a more 
multimodal approach in integrated care is needed to establish the successful execution of pre-
habilitation programs in older and clinically compromised populations.  
Strategies to prevent muscle loss during hospitalization 
Although the benefits of physical activity as well as the detrimental effects of physical inactivity 
have been well-established during hospitalization, even hospitalized patients who are not 
bed-ridden spend ~80% of their day in bed [71, 72]. During hospitalization, bed rest should 
be minimalized whenever possible [23, 73]. By simply looking at a typical hospital room, small 
adjustments such as changing the place of the television from above the bed to a common 
living room, and serving the food not in bed but at a table in a communal dining room, may 
already increase physical activity levels. On a broader level, creating an attractive environment 
with walking routes and gardens will encourage patients to perform physical activity during 
hospitalization. Besides these factors that are important to increase overall physical activity 
levels during hospitalization, resistance type exercise training in the pre- and post- 
hospitalization phase is likely a more robust stimulus to suffice in muscle mass and strength 
(re)gain. Implementation of (functional) resistance type exercise training is often compromised 
in most hospitalized settings. In addition, since overall food intake reduces dramatically upon 
hospitalization, this forms another major aspect to improve.  
 222
 
 
Food intake during a period of hospitalization generally decreases due to periods of fasting, 
adverse effects of medication, strict timing of food provision, reduced appetite, and/or pain 
and discomfort [74-76]. Such reduced food intake often results in a negative energy and/or 
protein balance, leading to a greater loss of lean body mass, muscle strength, and impairments 
in functional capacity [77-79]. In the present thesis we show that dietary protein intake during 
hospitalization is dramatically low (merely ~0.6 g·kg-1·d-1) in relatively healthy older patients 
admitted for elective orthopedic surgery (chapter 3). In fact, 35-40% of the provided hospital 
food is not consumed, resulting in extremely low energy and protein intake levels during 
hospital stay (chapter 3 and [80-83]). Recently updated guidelines suggest that a protein 
intake of 1.2-1.5 g·kg-1·d-1 is needed for older individuals suffering from acute or chronic 
diseases in order to maintain muscle mass during hospitalization [84, 85]. Strikingly though, 
only one out of four older hospitalized patients meets these increased protein intake 
recommendation levels [80, 81]. Habitual protein intake levels in the older community-
dwelling population have been reported to range between 0.9 and 1.1 g·kg-1·d-1 [45, 49, 86, 
87], which is fairly consistent with nutritional recommendations for healthy older individuals 
[84, 88]. Given the increased protein recommendations for older individuals during 
hospitalization, the drastic decline in energy and protein consumption levels during (short) 
periods of hospitalization, disease, or bed rest likely contributes substantially to the 
concomitant accelerated muscle loss (chapter 2-3 and [77-79]). Therefore, increasing protein 
intake while simultaneously achieving energy balance during hospitalization are proposed to 
attenuate muscle loss during hospitalization [84, 89]. So far, most studies have been unable to 
establish a benefit of protein supplementation to attenuate muscle disuse atrophy in older 
individuals when habitual protein intake exceeds 1.0 g·kg-1·d-1 [13, 90]. However, these studies 
have been conducted in healthy older individuals during experimentally-induced 
immobilization. This obviously represents a different situation compared with the energy and 
protein deficiency observed in a clinical setting.  
When aiming to maintain habitual protein intake levels, the often used supplementation of 
energy-dense ONS may not represent the best strategy. In Figure 1, food consumption from 
hospital meals, protein-rich snacks, and provided ONS in n = 102 older, hospitalized patients 
at nutritional risk is presented (unpublished data). Self-selected hospital meals provided 
patients with ~1.0 g protein·kg-1·d-1, while actual protein consumption averaged ~0.7 g·kg-1· 
d-1. The provision of ONS was ineffective in increasing protein intake during hospitalization, 
as 40% of the provided ONS was not consumed. In addition, since ONS is energy-dense and 
contains all macronutrients this is likely not an effective strategy to increase absolute protein 
intake. As an alternative strategy, we suggest to specifically increase the protein density of the 
diet to allow maintenance of habitual (absolute) protein intake levels during a period of 
hospitalization. As depicted in Figure 1, providing a more protein-dense diet will increase 
protein intake levels without necessarily increasing absolute energy intake, shown by the 
dotted line. Given the reduced appetite in older, hospitalized patients, this may represent a 
much more feasible strategy to reach increased protein recommendation levels [84, 89]. In 
terms of hospital meal provision, simply increasing the amount of food provided will not be 
 
 
an effective strategy since ~30% of the hospital food is not consumed [75, 80, 82, 83]. 
Providing a more protein-dense diet should translate into regular consumption of ~25 g 
protein per meal, thereby optimizing the anabolic response to each meal (chapter 5-7). Of 
course, in certain situations in which total energy intake is so low, the energy deficiency will 
need to be resolved as well. Definitely, the effect of providing a more protein-dense diet on 
muscle mass maintenance in older patients during hospitalization remains to be established.  
 
Figure 1 | The association between energy and protein intake levels measured in n = 102 older, hospitalized 
patients at nutritional risk (unpublished data). Providing a more protein-dense diet will shift the association line 
between energy and protein intake upwards (dotted line). In this study, the provision of ONS was ineffective at 
increasing protein intake. Consumption of more protein-dense meals may be more effective to increase daily 
protein intake in older hospitalized patients. 
Various nutritional strategies in the hospital setting have been proposed to increase protein 
intake levels such as providing protein-rich foods in the diet, food fortification, supplementing 
with ONS, and/or adjusting the timing of protein-rich snacks [80, 82, 91, 92]. Factors such as 
medication, dysphagia, cognitive impairment, nausea, loss of appetite, (obligated) periods of 
fasting, change of social environment, inactivity, social aspects of eating, dislike of the food 
available, the food presentation, and/or a lack of feeding assistance can strongly impact food 
intake during hospitalization. To improve the attractiveness of food and increase overall food 
intake in hospitals, several meal-service concepts have been implemented such as room 
service, buffet-style meals, order meals upon request, mealtime assistance, and providing 
restaurant-style meals [82, 93-95]. For example, room service dining has been shown to 
increase food intake, improve patient satisfaction, and reduce food waste [82, 93, 95, 96]. While 
these strategies provide interesting opportunities to decrease waste, more specific strategies 
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Food intake during a period of hospitalization generally decreases due to periods of fasting, 
adverse effects of medication, strict timing of food provision, reduced appetite, and/or pain 
and discomfort [74-76]. Such reduced food intake often results in a negative energy and/or 
protein balance, leading to a greater loss of lean body mass, muscle strength, and impairments 
in functional capacity [77-79]. In the present thesis we show that dietary protein intake during 
hospitalization is dramatically low (merely ~0.6 g·kg-1·d-1) in relatively healthy older patients 
admitted for elective orthopedic surgery (chapter 3). In fact, 35-40% of the provided hospital 
food is not consumed, resulting in extremely low energy and protein intake levels during 
hospital stay (chapter 3 and [80-83]). Recently updated guidelines suggest that a protein 
intake of 1.2-1.5 g·kg-1·d-1 is needed for older individuals suffering from acute or chronic 
diseases in order to maintain muscle mass during hospitalization [84, 85]. Strikingly though, 
only one out of four older hospitalized patients meets these increased protein intake 
recommendation levels [80, 81]. Habitual protein intake levels in the older community-
dwelling population have been reported to range between 0.9 and 1.1 g·kg-1·d-1 [45, 49, 86, 
87], which is fairly consistent with nutritional recommendations for healthy older individuals 
[84, 88]. Given the increased protein recommendations for older individuals during 
hospitalization, the drastic decline in energy and protein consumption levels during (short) 
periods of hospitalization, disease, or bed rest likely contributes substantially to the 
concomitant accelerated muscle loss (chapter 2-3 and [77-79]). Therefore, increasing protein 
intake while simultaneously achieving energy balance during hospitalization are proposed to 
attenuate muscle loss during hospitalization [84, 89]. So far, most studies have been unable to 
establish a benefit of protein supplementation to attenuate muscle disuse atrophy in older 
individuals when habitual protein intake exceeds 1.0 g·kg-1·d-1 [13, 90]. However, these studies 
have been conducted in healthy older individuals during experimentally-induced 
immobilization. This obviously represents a different situation compared with the energy and 
protein deficiency observed in a clinical setting.  
When aiming to maintain habitual protein intake levels, the often used supplementation of 
energy-dense ONS may not represent the best strategy. In Figure 1, food consumption from 
hospital meals, protein-rich snacks, and provided ONS in n = 102 older, hospitalized patients 
at nutritional risk is presented (unpublished data). Self-selected hospital meals provided 
patients with ~1.0 g protein·kg-1·d-1, while actual protein consumption averaged ~0.7 g·kg-1· 
d-1. The provision of ONS was ineffective in increasing protein intake during hospitalization, 
as 40% of the provided ONS was not consumed. In addition, since ONS is energy-dense and 
contains all macronutrients this is likely not an effective strategy to increase absolute protein 
intake. As an alternative strategy, we suggest to specifically increase the protein density of the 
diet to allow maintenance of habitual (absolute) protein intake levels during a period of 
hospitalization. As depicted in Figure 1, providing a more protein-dense diet will increase 
protein intake levels without necessarily increasing absolute energy intake, shown by the 
dotted line. Given the reduced appetite in older, hospitalized patients, this may represent a 
much more feasible strategy to reach increased protein recommendation levels [84, 89]. In 
terms of hospital meal provision, simply increasing the amount of food provided will not be 
 
 
an effective strategy since ~30% of the hospital food is not consumed [75, 80, 82, 83]. 
Providing a more protein-dense diet should translate into regular consumption of ~25 g 
protein per meal, thereby optimizing the anabolic response to each meal (chapter 5-7). Of 
course, in certain situations in which total energy intake is so low, the energy deficiency will 
need to be resolved as well. Definitely, the effect of providing a more protein-dense diet on 
muscle mass maintenance in older patients during hospitalization remains to be established.  
 
Figure 1 | The association between energy and protein intake levels measured in n = 102 older, hospitalized 
patients at nutritional risk (unpublished data). Providing a more protein-dense diet will shift the association line 
between energy and protein intake upwards (dotted line). In this study, the provision of ONS was ineffective at 
increasing protein intake. Consumption of more protein-dense meals may be more effective to increase daily 
protein intake in older hospitalized patients. 
Various nutritional strategies in the hospital setting have been proposed to increase protein 
intake levels such as providing protein-rich foods in the diet, food fortification, supplementing 
with ONS, and/or adjusting the timing of protein-rich snacks [80, 82, 91, 92]. Factors such as 
medication, dysphagia, cognitive impairment, nausea, loss of appetite, (obligated) periods of 
fasting, change of social environment, inactivity, social aspects of eating, dislike of the food 
available, the food presentation, and/or a lack of feeding assistance can strongly impact food 
intake during hospitalization. To improve the attractiveness of food and increase overall food 
intake in hospitals, several meal-service concepts have been implemented such as room 
service, buffet-style meals, order meals upon request, mealtime assistance, and providing 
restaurant-style meals [82, 93-95]. For example, room service dining has been shown to 
increase food intake, improve patient satisfaction, and reduce food waste [82, 93, 95, 96]. While 
these strategies provide interesting opportunities to decrease waste, more specific strategies 
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to increase the protein content, source, taste, appearance, and timing of the meals are 
essential to increase the protein-density of the diet.  
We propose to apply more specific nutritional strategies throughout different phases of 
hospitalization to improve overall food intake, as presented in Figure 2. For instance, it can be 
argued that achieving energy balance and diminishing the protein deficit by the use of high-
protein ONS, protein-rich snacks, or peri-operative nutrition is especially relevant on the day 
of surgery, since food intake on that day is extremely low (chapter 2 and 3) and periods of 
fasting have been associated with insulin resistance, slower wound healing, and impaired 
response to treatments [61, 62]. Subsequently, nutritional strategies such as food fortification, 
provision of protein-dense meals, and/or an adding an extra meal are likely more effective 
throughout the later days of hospitalization to specifically increase and evenly distribute 
protein intake. In chapter 7, we assessed the impact of pre-sleep protein ingestion on 
overnight muscle protein synthesis rates. We show that the ingestion of 40 g protein prior to 
sleep increases overnight plasma amino acid availability and stimulates overnight muscle 
protein synthesis throughout overnight sleep (chapter 7 and [97]). Based on these findings, 
we propose that the ingestion of an additional protein meal prior to sleep may be an effective 
strategy to improve protein intake throughout hospitalization. In addition, pre-sleep protein 
ingestion the evening before elective surgery may be especially relevant to reduce the period 
of fasting and stimulate muscle protein synthesis up into the peri-operative period (Figure 2).  
 
Figure 2 | Conceptual nutritional strategy to improve protein intake during hospitalization in elective surgery 
patients by; specifically improving nutritional intake with peri-operative nutrition on the day of surgery (e.g., ONS), 
the provision of protein-dense meals during the following days of hospitalization, and the ingestion of pre-sleep 
protein on the day prior to surgery and on hospitalization days to improve overall protein intake. The dark grey 
bars represent protein intake data assessed in chapter 3. 
Previous studies providing protein fortified foods (such as bread, yogurt, cake, fruit juice, and 
soup) or using more protein-dense foods have been effective in improving absolute protein 
intake during hospitalization [80, 82, 91]. In Dutch hospitals, concepts like “At Your Request” 
and “FoodforCare” have been developed that provide a restaurant-style menu with room 
service and advice from a nutritional assistant [82, 93]. Dijxhoorn et al. showed that the 
provision of 6-protein-rich meals per day, directly at the bedside and combined with proactive 
advice from a nutritional assistant, resulted in a 20% higher protein intake during 
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hospitalization when compared with the traditional meal service [82]. In addition, Munck et al. 
provided a protein-supplemented meal service in older hospitalized patients and showed 
increased energy and protein intakes when compared with standard meal service during 2 
weeks of hospitalization [95]. These studies provide interesting evidence that establishing a 
more attractive protein-rich meal service is definitely possible within the framework of the 
hospital. However, current interventional studies are not designed to investigate the effect of 
meal services on more functional outcomes such as skeletal muscle mass, strength, and/or 
physical performance during hospitalization. Therefore, more work is needed that assesses 
clinically relevant physiological and/or functional outcome measures in various patient 
populations when protein-dense meal services are implemented. In addition, a proper baseline 
assessment of absolute protein intake levels and consumption patterns throughout 
hospitalization needs to be included in order to apply more specific nutritional strategies. 
Lastly, issues including the logistics, training of personnel, education towards patients, and 
economical evaluations of specific meal service programs all need to be taken into account 
when aiming to implement more effective strategies in the clinical (hospital) setting. 
Notably, physical activity in combination with protein intake has a synergistic anabolic effect 
(chapter 8). In accordance, specific nutritional interventions such as whey protein, (essential) 
amino acids (EAA), HMB, vitamin D, and/or n-3 fatty acids in combination with resistance type 
exercise training have been shown to improve muscle mass, strength, and/or function in 
healthy and clinically compromised older individuals [67, 98-102]. During hospitalization, whey 
protein or EAA supplementation combined with daily in-hospital resistance type and 
functional exercises has been shown to attenuate the loss of skeletal muscle mass and strength 
in patients following elective knee arthroplasty [103], admitted for geriatric rehabilitative care 
[104], and during chemotherapy for chronic liver disease [105]. While there are only a few 
studies that have assessed the effect of a combined protein supplementation with resistance 
type exercise training program on skeletal muscle mass and strength in older hospitalized 
patients [104, 106], more studies in hospital settings are currently ongoing [107, 108]. Though 
a certain amount of exercise can be applied in nearly all patients, some conditions do not allow 
exercise interventions. In a setting of limb immobilization, hemiplegia, or coma, exercise 
mimetics may be applied effectively during hospitalization. Neuromuscular electrical 
stimulation (NMES) has been shown to further enhance the muscle protein synthetic response 
to food intake [109, 110]. As such, the combination of exercise mimetics combined with 
adequate nutritional support are likely an effective strategy to reduce muscle atrophy during 
hospitalization [109, 111, 112]. Overall, during hospitalization, focus should be placed on 
effectively combining physical activity and nutritional support. Apart from implementing 
specific exercise programs, this can already be partly accomplished by, for example, providing 
protein-dense snacks after physical therapy, and stimulating to perform physical activity 
around the meal times. 
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to increase the protein content, source, taste, appearance, and timing of the meals are 
essential to increase the protein-density of the diet.  
We propose to apply more specific nutritional strategies throughout different phases of 
hospitalization to improve overall food intake, as presented in Figure 2. For instance, it can be 
argued that achieving energy balance and diminishing the protein deficit by the use of high-
protein ONS, protein-rich snacks, or peri-operative nutrition is especially relevant on the day 
of surgery, since food intake on that day is extremely low (chapter 2 and 3) and periods of 
fasting have been associated with insulin resistance, slower wound healing, and impaired 
response to treatments [61, 62]. Subsequently, nutritional strategies such as food fortification, 
provision of protein-dense meals, and/or an adding an extra meal are likely more effective 
throughout the later days of hospitalization to specifically increase and evenly distribute 
protein intake. In chapter 7, we assessed the impact of pre-sleep protein ingestion on 
overnight muscle protein synthesis rates. We show that the ingestion of 40 g protein prior to 
sleep increases overnight plasma amino acid availability and stimulates overnight muscle 
protein synthesis throughout overnight sleep (chapter 7 and [97]). Based on these findings, 
we propose that the ingestion of an additional protein meal prior to sleep may be an effective 
strategy to improve protein intake throughout hospitalization. In addition, pre-sleep protein 
ingestion the evening before elective surgery may be especially relevant to reduce the period 
of fasting and stimulate muscle protein synthesis up into the peri-operative period (Figure 2).  
 
Figure 2 | Conceptual nutritional strategy to improve protein intake during hospitalization in elective surgery 
patients by; specifically improving nutritional intake with peri-operative nutrition on the day of surgery (e.g., ONS), 
the provision of protein-dense meals during the following days of hospitalization, and the ingestion of pre-sleep 
protein on the day prior to surgery and on hospitalization days to improve overall protein intake. The dark grey 
bars represent protein intake data assessed in chapter 3. 
Previous studies providing protein fortified foods (such as bread, yogurt, cake, fruit juice, and 
soup) or using more protein-dense foods have been effective in improving absolute protein 
intake during hospitalization [80, 82, 91]. In Dutch hospitals, concepts like “At Your Request” 
and “FoodforCare” have been developed that provide a restaurant-style menu with room 
service and advice from a nutritional assistant [82, 93]. Dijxhoorn et al. showed that the 
provision of 6-protein-rich meals per day, directly at the bedside and combined with proactive 
advice from a nutritional assistant, resulted in a 20% higher protein intake during 
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hospitalization when compared with the traditional meal service [82]. In addition, Munck et al. 
provided a protein-supplemented meal service in older hospitalized patients and showed 
increased energy and protein intakes when compared with standard meal service during 2 
weeks of hospitalization [95]. These studies provide interesting evidence that establishing a 
more attractive protein-rich meal service is definitely possible within the framework of the 
hospital. However, current interventional studies are not designed to investigate the effect of 
meal services on more functional outcomes such as skeletal muscle mass, strength, and/or 
physical performance during hospitalization. Therefore, more work is needed that assesses 
clinically relevant physiological and/or functional outcome measures in various patient 
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protein or EAA supplementation combined with daily in-hospital resistance type and 
functional exercises has been shown to attenuate the loss of skeletal muscle mass and strength 
in patients following elective knee arthroplasty [103], admitted for geriatric rehabilitative care 
[104], and during chemotherapy for chronic liver disease [105]. While there are only a few 
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exercise interventions. In a setting of limb immobilization, hemiplegia, or coma, exercise 
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stimulation (NMES) has been shown to further enhance the muscle protein synthetic response 
to food intake [109, 110]. As such, the combination of exercise mimetics combined with 
adequate nutritional support are likely an effective strategy to reduce muscle atrophy during 
hospitalization [109, 111, 112]. Overall, during hospitalization, focus should be placed on 
effectively combining physical activity and nutritional support. Apart from implementing 
specific exercise programs, this can already be partly accomplished by, for example, providing 
protein-dense snacks after physical therapy, and stimulating to perform physical activity 
around the meal times. 
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Rehabilitation in the post-hospitalization period  
As described above, there is growing evidence of the beneficial effects of (combined) exercise 
and nutritional programs both before and during hospitalization in older patients. Yet, such 
programs are certainly not common practice yet and the long-term functional benefits remain 
to be elucidated. In contrast, after a period of hospitalization, various rehabilitation training 
programs including conditioning, ambulatory training, transfer and balance training, and in-
patient multidisciplinary programs are already applied in the older population to facilitate 
recovery and further improve functional status. Once immediate recovery from surgery is 
established and patients can safely be discharged, it also becomes more feasible to 
progressively increase training intensities. In general, resistance type exercise training 
represents the most effective method to induce skeletal muscle hypertrophy and increase 
muscle strength and functional performance in the older population [98, 102, 113]. In support, 
Suetta and co-workers showed that resistance type exercise in a clinical setting is more 
effective to regain muscle mass, strength, muscle fiber size, and functional performance when 
compared with standard rehabilitation therapy (i.e. functional exercises) or NMES in older 
patients following total hip replacement surgery [114, 115]. Nevertheless, studies have showed 
that though exercise mimetics can be applied effectively to attenuate muscle mass loss during 
immobilization, they do not preserve muscle strength [14, 114, 115]. Thus, although NMES can 
support the recovery of mobility in older and clinically compromised patients [115, 116] and, 
as such, serve as an adjuvant training modality when exercise training is not feasible, the 
implementation of prolonged resistance type exercise programs in the post-hospitalization 
period should still form a cornerstone in the functional recovery of older patients.  
In terms of nutrition, most rehabilitative exercise training programs do not implement 
concomitant nutritional support. As in professional sports, a proper exercise training program 
should be combined with a diet that provides all the required nutrients to support muscle 
mass and strength conditioning. Increasing protein intake during 24 weeks of intense 
resistance type exercise training in frail older individuals has been shown to further increase 
muscle mass and strength [98]. So far, several studies have assessed the surplus value of 
targeted nutritional supplementation during rehabilitative exercise training to increase muscle 
mass, strength, and/or functional capacity [103, 117-123]. In a rehabilitative setting, some 
studies applying ambulatory recovery with dietary protein supplementation seem ineffective 
in increasing muscle mass and strength [103, 122], while other studies applying more 
progressive resistance type exercise training programs show greater increases in muscle mass, 
muscle strength, and/or greater functional recovery when nutritional support is provided 
during rehabilitative exercise training [107, 117, 118, 121, 123]. Since muscle atrophy following 
a period of hospitalization and bed rest cannot be fully restored in the older population [21, 
23, 124], long-term rehabilitation is of importance to regain (most of) the functional status 
when compared to pre-hospitalization levels. Interestingly, nutritional strategies that are 
applied to improve protein intake during hospitalization may also be suitable to extend to the 
(home-based) post-hospitalization phase. For example, Beelen et al. recently showed that the 
provision of protein-enriched foods and drinks during 3 months after hospital release 
 
 
improved habitual protein intake above adequate intake levels in older geriatric patients [125]. 
As such, the provision of protein-enriched meals and/or the use of protein supplementation 
can serve as an effective strategy to increase protein intake levels both at home, as well as in 
rehabilitation care [125-127].  
Though it is clear that combined exercise and nutrition rehabilitation programs are likely more 
effective in regaining muscle mass and strength, little research has been done. Future studies 
should include proper evidence-based nutritional strategies applying an adequate protein 
dose, source, and timing in long-term rehabilitation programs and assess the effect on muscle 
mass maintenance using physiological and clinical relevant outcomes, during consecutive time 
points, in older and more clinical compromised patients. In addition, knowledge in sports 
nutrition should be more readily applied to the healthcare setting where a proper diet and 
specific applied supplementation can further augment the benefits of intense rehabilitation 
exercise training. Moreover, it is essential to combine nutritional support, education, 
physiotherapy, and implementation in the social situation in patients to improve activities of 
daily living and lifestyle at home. The multimodal approach is key to create a nutritional 
support team including medical doctors, nurses, dietitians, nutritional assistants, pharmacists, 
physical therapists, occupational therapists, and speech-language pathologists. 
Future research and proposed interventions 
In this last paragraph, we suggest future directions for interventional studies aimed at 
supporting muscle mass maintenance in older and more clinically compromised populations. 
There is still little evidence for pre-habilitation training to improve clinical outcome following 
hospitalization. Yet, the waiting period prior to surgery or hospitalization provides a window-
of-opportunity to improve both nutritional as well as physical status. Therefore, intervention 
studies should focus on the combination of pre-habilitation training combined with nutritional 
support to augment muscle mass and strength prior to hospitalization. Since malnutrition 
during hospitalization is still present for >40% of the patients, strategies need to be developed 
to improve nutritional status and, thereby, attenuate muscle loss during hospitalization. The 
provision of high-protein ONS may compensate for the energy and protein intake deficit 
during the acute pre- and peri-operative surgery period, whilst the provision of more protein-
dense meals and pre-sleep protein ingestion may represent feasible nutritional strategies on 
the subsequent days of recovery from surgery. Pre-sleep protein ingestion the evening before 
surgery may also represent an effective strategy to increase overnight muscle protein synthesis 
rates up until actual surgery, and, as such, cover the nutritional deficit in the peri-operative 
state. In order to obtain clinical evidence for the efficacy of such nutritional interventions, 
research studies need to assess more clinical and physiologically relevant outcome 
measurements. The measurement of tissue protein synthesis rates over several days before or 
after surgery may be helpful to elucidate the impact of the afore-mentioned interventions on 
a tissue level. The use of deuterated water is a novel and applicable strategy to assess muscle 
tissue protein synthesis rates on consecutive days or even weeks. Particularly in a clinical 
setting, this provides a valuable tool to measure muscle protein synthesis rates during 
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hospitalization, illness, and in response to nutritional and/or physical activity interventions. In 
the pre-, post, and hospitalization phase, we need to assess skeletal muscle mass, using 
available techniques such as DEXA, MRI, or CT, to quantitatively assess net changes in muscle 
mass during hospitalization or in response to pre- and post-hospitalization interventions [128]. 
In the post-hospitalization period, we need to consider how to implement rehabilitation 
strategies on the longer term, as well as build the evidence-base for the overall benefits of 
(combined) nutritional and exercise interventions to maintain muscle mass and function, 
increase independence, and improve quality of life in older patients. In the end, changes in 
lifestyle regarding proper nutrition and physical activity need to be implemented in integrated 
care and sustained to support active aging and prevent the loss of muscle mass and strength.  
To develop more effective interventional strategies to preserve muscle mass and strength in 
older and clinically compromised populations several questions need to be resolved: 
o What is the impact of the protein dose, source, and/or specific (E)AA on the muscle 
protein synthetic response in hospitalized (older) patients; 
o What is the muscle protein synthetic response to the consumption of a full meal 
when compared to its protein equivalent; 
o What is the impact of the food intake distribution on daily muscle protein balance; 
o What is the effect of meal preparation and mastication on postprandial protein 
handling and the subsequent muscle protein synthetic response; 
o What is the impact of pre-operative protein ingestion on muscle (and other) tissue 
protein turnover rates; 
o Is pre-sleep protein ingestion during hospitalization a valid means to attenuate 
muscle loss during hospitalization; 
o Does the ingestion of more protein-dense meals increase protein intake in 
hospitalized patients and attenuate the loss of skeletal muscle mass and strength;  
o What is the minimal amount of physical activity that is required to preserve muscle 
mass during hospitalization; 
o What is the effect of combined resistance type exercise and protein supplementation 
in various older patient populations during the pre- or post- hospitalization period 
on skeletal muscle mass, strength, and functional outcomes; 
o Do the acute changes of combined training and nutrition interventions in the pre-, 
post-, and hospitalization phase translate to benefits in clinical outcomes on the 
longer term;  
o How can multimodal training and nutrition (p)rehabilitation programs be 
implemented in integrated health care? 
 
 
In conclusion, to attenuate skeletal muscle mass and strength loss before, during, and after 
hospitalization, nutritional and physical activity intervention strategies are essential in older 
and clinically compromised populations. Apart from future work that should further determine 
the effects of nutrition and exercise in the pre-, post-, and hospitalization phase, there is 
currently enough insight to innovate current health care and apply a more pro-active approach 
with the pre- and post-hospitalization reconditioning of older patients. 
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VALOR IZAT ION  
“Knowledge valorization refers to the process of creating value from knowledge, by making 
knowledge suitable and/or available for social (and/or economic) use and by making knowledge 
suitable for translation into competitive products, services, processes, and new commercial 
activities” (National Valorization Committee 2011:8). 
Relevance 
Due to the progressive aging of the population and the greater longevity, the subpopulation 
of older individuals is currently the fastest growing population in the developed world [1]. In 
the Netherlands, most recent predictions show that 33% of the population will be older than 
60 in 2050, and nearly 10% aged over 80 years old [2, 3]. The increasing aging population can 
be seen as a success for public health policies and socioeconomic development, but it also 
challenges society to improve health and functional capacity in older people and stimulate 
their social participation. Moreover, with the rise in the aged population there will be an 
increase in health care costs to cover the prevention, treatment, and hospitalization-associated 
costs of non-communicable and age-related diseases [2]. 
Hospitalization, often required due to illness or surgery, is associated with increased health 
care costs. For example, the cost of one hospital bed per day in the Netherlands is 500 euro, 
based on primary, secondary, and tertiary hospitals [4]. At present, the average hospitalization 
duration is 5 days [5]. However, the length of hospitalization increases with an advancing age 
from the age of 40 [5]. Short periods of bedrest or hospitalization have been shown to induce 
substantial muscle loss (chapter 2 and [6, 7]). The amount of muscle tissue at time of hospital 
admission as well as the amount of muscle tissue lost during hospitalization predict mortality 
and clinical outcomes [8-10]. In addition, following a period of hospitalization, muscle disuse 
atrophy often carries over at home during the subsequent period of recovery. Importantly, it 
has been shown that recovery in older individuals is impaired when compared with younger 
individuals [11]. Subsequent (short) periods of muscle disuse atrophy in older individuals are 
therefore suggested to contribute to the age-related loss in muscle mass and strength, termed 
sarcopenia [6]. From 2016, sarcopenia has been recognized as a disease entity and has been 
given an ICD-10-CM code, meaning that there will be a demand for the availability of 
diagnostic tools, treatments, and intervention strategies to prevent and treat the emergence 
of sarcopenia. 
Health care implementation 
Nowadays, hospitals in the Netherlands have more daycare patients than in-patients. 
Moreover, patients are dismissed earlier, as evidenced by the reduction of average hospital 
length of stay from 7.5 days in 2003 to 5.2 days in 2013 [5]. This places a higher burden on the 
responsibility and the self-direction of the patient for recovery at home or in rehabilitation 
 
 
centers, as well as a multimodal approach for the integrated care to supervise patients from 
home, troughout hospitalization, back to home. Since more of the current health care is 
shifting from primary care towards secondary and tertiary health services, an efficient, 
multidisciplinary, integrated health care system is essential. Recently, more programs have 
been developed to prepare patients prior to a period of hospitalization by pre-habilitation 
training and nutritional support; examples of this are ‘Fit4surgery’ and ‘Better in better out’ 
concepts. Such a pre-habilitation program is not only an effective tool to increase physical and 
nutritional status of the patient; it also puts more accountability and motivation on patients. 
In addition, hospitals have introduced fast track surgeries and more daycare treatments for 
the fittest patients in order to be treated faster, on times outside regular hours, and to be 
dismissed earlier. This requests direct supervision during pre-habilitation and recovery in the 
home-based setting, including medical, nutritional, physical, social, and psychological support. 
Education towards the patients is essential in this case and all health care workers will have to 
carry out the same message in order to support integrated care. 
This thesis provides insight in the absolute amount of muscle mass loss and nutritional intake 
during merely a few days of hospitalization in older patients (chapter 2 and 3). Even though 
there is an increasing amount of evidence on the negative health consequences of 
hospitalization in the older population, our findings have not yet been generalized and 
translated to the general public. Therefore, awareness amongst patients on the relevance of 
nutrition and physical activity should be created. Secondly, it is the task of physicians and 
health care workers to educate their patients on this. During hospital stay, patients spend 
about 80% of their day in bed, their food is served at the bedside, and appointments with 
physicians and health care workers take place in the patients’ room [12, 13]. Indeed, older 
patients during hospitalization spend a mere 43 minutes per day standing or walking [12-14], 
and there is a clear role here for policy makers and the logistics in hospitals to encourage 
physical activity during hospitalization. Some hospitals in the Netherlands have started with 
creating attractive walking routes, gardens, and outside training equipment, which will be 
continued in more hospitals and nursing homes. The intrinsic motivation and patients’ journey 
throughout hospitalization differs per patient, which does not require a one-size-fits-all advice 
and treatment. Therefore, a proper assessment of motivation, functional, and nutritional status 
in the pre- to post- clinical phase is essential to improve the treatment and supervision of the 
patient.  
Products and meal services 
The present thesis discusses several nutritional strategies to increase protein intake in older 
and clinically compromised individuals (chapter 6-8). The ingestion of dietary protein has 
been shown to stimulate muscle protein synthesis, and as such, is a key regulator in the 
maintenance of muscle mass with aging and in clinical populations. Acute changes in food 
intake can dramatically decrease protein intake and contribute to muscle mass and strength 
loss in the older and clinically compromised population.  
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VALOR IZAT ION  
“Knowledge valorization refers to the process of creating value from knowledge, by making 
knowledge suitable and/or available for social (and/or economic) use and by making knowledge 
suitable for translation into competitive products, services, processes, and new commercial 
activities” (National Valorization Committee 2011:8). 
Relevance 
Due to the progressive aging of the population and the greater longevity, the subpopulation 
of older individuals is currently the fastest growing population in the developed world [1]. In 
the Netherlands, most recent predictions show that 33% of the population will be older than 
60 in 2050, and nearly 10% aged over 80 years old [2, 3]. The increasing aging population can 
be seen as a success for public health policies and socioeconomic development, but it also 
challenges society to improve health and functional capacity in older people and stimulate 
their social participation. Moreover, with the rise in the aged population there will be an 
increase in health care costs to cover the prevention, treatment, and hospitalization-associated 
costs of non-communicable and age-related diseases [2]. 
Hospitalization, often required due to illness or surgery, is associated with increased health 
care costs. For example, the cost of one hospital bed per day in the Netherlands is 500 euro, 
based on primary, secondary, and tertiary hospitals [4]. At present, the average hospitalization 
duration is 5 days [5]. However, the length of hospitalization increases with an advancing age 
from the age of 40 [5]. Short periods of bedrest or hospitalization have been shown to induce 
substantial muscle loss (chapter 2 and [6, 7]). The amount of muscle tissue at time of hospital 
admission as well as the amount of muscle tissue lost during hospitalization predict mortality 
and clinical outcomes [8-10]. In addition, following a period of hospitalization, muscle disuse 
atrophy often carries over at home during the subsequent period of recovery. Importantly, it 
has been shown that recovery in older individuals is impaired when compared with younger 
individuals [11]. Subsequent (short) periods of muscle disuse atrophy in older individuals are 
therefore suggested to contribute to the age-related loss in muscle mass and strength, termed 
sarcopenia [6]. From 2016, sarcopenia has been recognized as a disease entity and has been 
given an ICD-10-CM code, meaning that there will be a demand for the availability of 
diagnostic tools, treatments, and intervention strategies to prevent and treat the emergence 
of sarcopenia. 
Health care implementation 
Nowadays, hospitals in the Netherlands have more daycare patients than in-patients. 
Moreover, patients are dismissed earlier, as evidenced by the reduction of average hospital 
length of stay from 7.5 days in 2003 to 5.2 days in 2013 [5]. This places a higher burden on the 
responsibility and the self-direction of the patient for recovery at home or in rehabilitation 
 
 
centers, as well as a multimodal approach for the integrated care to supervise patients from 
home, troughout hospitalization, back to home. Since more of the current health care is 
shifting from primary care towards secondary and tertiary health services, an efficient, 
multidisciplinary, integrated health care system is essential. Recently, more programs have 
been developed to prepare patients prior to a period of hospitalization by pre-habilitation 
training and nutritional support; examples of this are ‘Fit4surgery’ and ‘Better in better out’ 
concepts. Such a pre-habilitation program is not only an effective tool to increase physical and 
nutritional status of the patient; it also puts more accountability and motivation on patients. 
In addition, hospitals have introduced fast track surgeries and more daycare treatments for 
the fittest patients in order to be treated faster, on times outside regular hours, and to be 
dismissed earlier. This requests direct supervision during pre-habilitation and recovery in the 
home-based setting, including medical, nutritional, physical, social, and psychological support. 
Education towards the patients is essential in this case and all health care workers will have to 
carry out the same message in order to support integrated care. 
This thesis provides insight in the absolute amount of muscle mass loss and nutritional intake 
during merely a few days of hospitalization in older patients (chapter 2 and 3). Even though 
there is an increasing amount of evidence on the negative health consequences of 
hospitalization in the older population, our findings have not yet been generalized and 
translated to the general public. Therefore, awareness amongst patients on the relevance of 
nutrition and physical activity should be created. Secondly, it is the task of physicians and 
health care workers to educate their patients on this. During hospital stay, patients spend 
about 80% of their day in bed, their food is served at the bedside, and appointments with 
physicians and health care workers take place in the patients’ room [12, 13]. Indeed, older 
patients during hospitalization spend a mere 43 minutes per day standing or walking [12-14], 
and there is a clear role here for policy makers and the logistics in hospitals to encourage 
physical activity during hospitalization. Some hospitals in the Netherlands have started with 
creating attractive walking routes, gardens, and outside training equipment, which will be 
continued in more hospitals and nursing homes. The intrinsic motivation and patients’ journey 
throughout hospitalization differs per patient, which does not require a one-size-fits-all advice 
and treatment. Therefore, a proper assessment of motivation, functional, and nutritional status 
in the pre- to post- clinical phase is essential to improve the treatment and supervision of the 
patient.  
Products and meal services 
The present thesis discusses several nutritional strategies to increase protein intake in older 
and clinically compromised individuals (chapter 6-8). The ingestion of dietary protein has 
been shown to stimulate muscle protein synthesis, and as such, is a key regulator in the 
maintenance of muscle mass with aging and in clinical populations. Acute changes in food 
intake can dramatically decrease protein intake and contribute to muscle mass and strength 
loss in the older and clinically compromised population.  
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Pre-sleep protein ingestion can likely serve as an effective strategy to increase overall protein 
intake in the older population. We show in chapter 7 that protein ingested prior to sleep is 
effectively digested and absorbed and increases overnight muscle protein synthesis rates. The 
ingestion of 40 g protein significantly increased overnight muscle protein synthesis rates. Since 
40 g of protein (e.g. >1 L of milk) is likely difficult to consume prior to sleep by the general 
elderly population, technological advances towards protein-dense and low-volume products 
are necessary here to develop and improve pre-sleep protein products for healthy and 
diseased older individuals. Moreover, protein intake during hospitalization and 
institutionalization is generally reduced in the majority of the elderly. Still 40% of the patients 
are malnourished during hospitalization and in nursing homes [15, 16]. Pre-sleep protein 
ingestion can serve as an effective strategy to increase overall protein intake or cover energy 
and protein deficits during the first days of illness or in the pre- and peri-operative period. In 
addition, an evening serving round with protein-rich evening snacks can be relatively easily 
implemented in hospitals and nursing homes. However, here lies a call for product developers 
to produce specific pre-sleep nutritional products such as protein-rich snacks and drinks. The 
quality and attractiveness of meal services in hospitals and nursing homes is generally poor. 
New meal service concepts such as room service, buffet-style meals, meal orders upon request, 
mealtime assistance, and restaurant-style meal provisions have been developed [17-20]. Room 
service dining and attractive meals have been shown to increase food intake, improve patient 
satisfaction, and reduce food waste in hospitals [17, 18, 20, 21]. Whilst these strategies provide 
interesting opportunities to decrease waste, more specific strategies to increase the protein 
content, source, taste, appearance, and timing of the meals are essential to increase the 
protein density of the diet. It is crucial that food intake is thoroughly monitored during 
hospitalization. With these new meal service concepts such as ‘ordering upon request’, food 
intake per patient can be directly monitored in order to tailor individualized dietary intake 
plans and directly advise towards the individual patient’s needs and intake of that day. 
Nutritional assistants will have to play a central role in the nutritional support of the patient in 
order to provide patients with attractive meals and monitor nutritional intake.  
Recommendations 
The presented data in this dissertation provide many leads and targets for product 
development and innovations in the nutrition industry and health care. Since parts of this 
thesis have been conducted within the framework of TIFN, a public-private partnership, 
research findings have been shared with industrial partners throughout the last years. As such, 
a transparent platform is already in place for industries to directly implement the research 
findings into innovations.  
To stimulate the implementation in health care, we present 10 key points on a separate flyer 
summarizing the main findings and recommendations from the present thesis. These will be 
distributed to several Dutch hospitals, nutritional companies, and Universities to be used as 
factsheets for health care professionals, patients, nutrition industry, and policy makers.  
 
 
The key recommendations from this thesis include: 
1. Nutritional intervention strategies should be combined with more physical activity 
before, during, and after hospitalization. 
2. Early pre-habilitation interventions that include exercise training and protein 
supplementation should be implemented to improve clinical outcomes during 
hospitalization in older patients. 
3. Since 40% of the provided hospital meals is not consumed, more protein-rich foods 
and attractive meal service concepts need to be provided to the patient to increase 
protein intake.  
4. To reach protein intake recommendation levels of 1.2 g·kg-1·d-1 for older patients, a 
more protein-dense diet will be required. 
5. More specific nutritional interventions throughout hospitalization are needed; 
nutritional supplementation can cover energy and protein deficits in the acute 
(operative) period while the subsequent days will require the focus on the increase in 
protein intake mainly through the diet.  
6. Pre-sleep protein ingestion can be a useful strategy to provide extra protein on the 
evening prior to surgery and during evening rounds on the ward.   
7. An attractive environment using walking routes and gardens could be offered in 
hospitals to encourage patients to be more physically active during hospitalization.  
8. Hospital meals need to be attractive, adequately nutritious, and patient-specific. 
9. Rehabilitation strategies need to be continued on the long term and should combine 
a functional exercise training regimen with proper nutritional support. 
10. A multimodal approach will maximize the intrinsic motivation of the patient. 
Personal perspective 
Throughout my PhD trajectory, it became clear to me that there is an enormous amount of 
scientific research done on nutrition and muscle metabolism, however less is known on the 
practical implementation towards clinical health care. There is a gap between scientific 
research findings on one hand, and clinical bedside applicable research on the other hand. 
The collaboration between academic institutes and health care professionals as well as policy 
makers and nutrition companies is essential to investigate intervention strategies and facilitate 
the practical implementation. I am looking forward to, in the upcoming years, further conduct 
high quality research to gain knowledge on the role of (clinical) nutrition, that can be directly 
translated into practical advice and guidelines to dieticians, health care workers, and patients. 
I believe that dieticians, physicians, and scientists should collaborate to address research 
questions that are directly relevant to health care and patients, where a multimodal approach 
is key. Last but not least, there is currently enough insight to innovate health care and apply a 
more pro-active approach including pre- and post-hospitalization reconditioning of older 
patients. We should start today!  
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SUMMAR Y 
Maintenance of skeletal muscle mass is of great clinical relevance in both health and disease. 
Having a low muscle mass at an older age increases the risk for hospitalization, impairs 
physical function, and results in a longer length of hospital stay, a worsened prognosis of 
disease, and higher mortality rates during hospitalization. A blunted response to the main 
anabolic stimuli of muscle mass regulation (coined anabolic resistance), i.e., dietary protein 
ingestion and physical activity, has been postulated to represent one of the driving factors 
explaining the generalized age-related muscle loss. Particularly in older and compromised 
clinical populations, acute changes in habitual physical activity level and food intake - often 
resulting from the development of various health issues - are likely the main cause of the 
accelerated skeletal muscle mass loss. Intervention strategies to maintain skeletal muscle mass 
are warranted to attenuate muscle loss with aging and during acute and chronic disease. The 
studies described in the present thesis aimed to gain further insight in the different factors 
that regulate muscle mass maintenance in older individuals, with a focus on nutritional aspects 
and clinical populations.  
Older individuals experience multiple successive periods of hospitalization throughout the 
lifespan due to sickness, injury, and/or (elective) surgery. These successive periods likely 
contribute to the age-related loss of muscle mass and strength. To gain insight in the extent 
of muscle loss during a short period of hospitalization, the changes in skeletal muscle mass in 
older patients following elective hip replacement surgery were assessed in chapter 2. On 
average, 6 days of hospitalization resulted in a 3-4% loss of muscle cross-sectional area in 
older patients. Likely, the impact of surgery, associated physical and mental stress, and 
reduced food intake during hospitalization further accelerate disuse-induced loss of skeletal 
muscle mass and function in clinical practice. In chapter 3, food intake in 101 hospitalized, 
older patients was measured and the amount of protein that was provided was compared with 
the amount of protein that was actually consumed in these patients. Protein intake during ~6 
days of hospitalization was dramatically low, i.e. merely ~0.6 g·kg-1·d-1, in relatively healthy, 
older patients admitted for elective orthopedic surgery. In fact, 35-40% of the provided 
hospital food was not consumed, resulting in extremely low energy and protein intake levels 
during hospital stay. Specific nutritional strategies including the provision of more protein-
dense meals, food fortification, supplementing oral nutritional supplements (ONS), and/or 
adjusting the timing of the provision of protein-rich meals and snacks are proposed to increase 
protein intake levels during hospitalization.  
Since there is an accelerated loss of muscle mass in patients with metabolic diseases such as 
obesity, cardiovascular diseases, and type 2 diabetes, the hypothesis that older type 2 diabetes 
patients and obese individuals show impairments in muscle protein metabolism was examined 
in chapter 4 and 5. Using stable isotope tracer methodology, postabsorptive and postprandial 
muscle protein synthesis rates were assessed to determine potential alterations herein. Both 
postabsorptive and postprandial muscle protein synthesis rates following the ingestion of 20 
 
 
g protein did not differ between older individuals with type 2 diabetes and healthy controls 
(chapter 4). As such, the more pronounced loss of skeletal muscle mass and strength in older 
type 2 diabetes patients does not seem to be attributed to a greater level of anabolic 
resistance. Chapter 5 examined postprandial protein handling in middle-aged males with 
morbid obesity and age-matched, lean controls. In contrast to our hypothesis, basal and 
postprandial muscle protein synthesis rates were not impaired in the obese state. We suggest 
that the relatively high level of habitual physical activity observed in the obese subjects may 
have protected from impairments in basal and postprandial muscle protein synthesis rates. 
In chapters 6-8, several nutritional strategies are proposed to further stimulate postprandial 
muscle protein synthesis and, as such, to support muscle mass maintenance in healthy and 
clinically compromised older populations. In view of the recent interest in dietary nitrate as a 
nutritional compound to increase vasodilation and improve muscle tissue perfusion, the 
impact of ingesting a single bolus of dietary nitrate with protein on postprandial muscle 
protein synthesis rates was investigated in older, type 2 diabetes patients in chapter 6. The 
co-ingestion of sodium nitrate with 20 g protein did not result in higher muscle protein 
synthesis rates when compared with protein ingestion only in older individuals with type 2 
diabetes. The ingestion of an additional protein meal prior to sleep provides an alternative 
strategy to stimulate muscle protein synthesis during a period where muscle protein synthesis 
rates are typically low. In chapter 7, the overnight muscle protein synthetic response to 
different amounts of protein ingested prior to sleep was assessed in 48 healthy, older males. 
Protein ingestion before sleep provided amino acids throughout the overnight period and 
subsequently served as precursors for de novo overnight muscle protein synthesis. The 
ingestion of 40 g protein only significantly increased overnight muscle protein synthesis rates 
when compared to a placebo. As physical activity can increase the anabolic response to protein 
intake, we subsequently investigated the surplus effect of physical activity performed in the 
evening to increase overnight muscle protein synthesis rates following pre-sleep protein 
ingestion in chapter 8. Performing physical activity prior to the 40 g pre-sleep protein 
ingestion increased overnight muscle protein synthesis rates to a greater extent. Therefore, we 
suggest that (both daytime and pre-sleep) nutritional strategies in older individuals should be 
combined with a certain amount of physical activity to further increase the muscle protein 
synthetic response to protein intake.  
Finally, chapter 9 discusses different nutritional and physical activity intervention strategies to 
attenuate muscle mass and strength loss in older and clinically compromised populations. The 
pre-hospitalization period provides a window of opportunity to improve both nutritional as 
well as physical activity status and, as such, may improve clinical outcome during and following 
hospitalization. Intervention studies should focus on the combination of pre-habilitation 
training combined with nutritional support to augment muscle mass and strength prior to 
hospitalization. Since malnutrition during hospitalization is still present in >40% of the 
patients, dietary strategies need to be developed to improve nutritional status and, thereby, 
attenuate muscle loss during subsequent hospitalization. The provision of high-protein ONS 
may compensate for the energy and protein intake deficit during the acute surgery period, 
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SUMMAR Y 
Maintenance of skeletal muscle mass is of great clinical relevance in both health and disease. 
Having a low muscle mass at an older age increases the risk for hospitalization, impairs 
physical function, and results in a longer length of hospital stay, a worsened prognosis of 
disease, and higher mortality rates during hospitalization. A blunted response to the main 
anabolic stimuli of muscle mass regulation (coined anabolic resistance), i.e., dietary protein 
ingestion and physical activity, has been postulated to represent one of the driving factors 
explaining the generalized age-related muscle loss. Particularly in older and compromised 
clinical populations, acute changes in habitual physical activity level and food intake - often 
resulting from the development of various health issues - are likely the main cause of the 
accelerated skeletal muscle mass loss. Intervention strategies to maintain skeletal muscle mass 
are warranted to attenuate muscle loss with aging and during acute and chronic disease. The 
studies described in the present thesis aimed to gain further insight in the different factors 
that regulate muscle mass maintenance in older individuals, with a focus on nutritional aspects 
and clinical populations.  
Older individuals experience multiple successive periods of hospitalization throughout the 
lifespan due to sickness, injury, and/or (elective) surgery. These successive periods likely 
contribute to the age-related loss of muscle mass and strength. To gain insight in the extent 
of muscle loss during a short period of hospitalization, the changes in skeletal muscle mass in 
older patients following elective hip replacement surgery were assessed in chapter 2. On 
average, 6 days of hospitalization resulted in a 3-4% loss of muscle cross-sectional area in 
older patients. Likely, the impact of surgery, associated physical and mental stress, and 
reduced food intake during hospitalization further accelerate disuse-induced loss of skeletal 
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older patients was measured and the amount of protein that was provided was compared with 
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dense meals, food fortification, supplementing oral nutritional supplements (ONS), and/or 
adjusting the timing of the provision of protein-rich meals and snacks are proposed to increase 
protein intake levels during hospitalization.  
Since there is an accelerated loss of muscle mass in patients with metabolic diseases such as 
obesity, cardiovascular diseases, and type 2 diabetes, the hypothesis that older type 2 diabetes 
patients and obese individuals show impairments in muscle protein metabolism was examined 
in chapter 4 and 5. Using stable isotope tracer methodology, postabsorptive and postprandial 
muscle protein synthesis rates were assessed to determine potential alterations herein. Both 
postabsorptive and postprandial muscle protein synthesis rates following the ingestion of 20 
 
 
g protein did not differ between older individuals with type 2 diabetes and healthy controls 
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resistance. Chapter 5 examined postprandial protein handling in middle-aged males with 
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impact of ingesting a single bolus of dietary nitrate with protein on postprandial muscle 
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strategy to stimulate muscle protein synthesis during a period where muscle protein synthesis 
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Protein ingestion before sleep provided amino acids throughout the overnight period and 
subsequently served as precursors for de novo overnight muscle protein synthesis. The 
ingestion of 40 g protein only significantly increased overnight muscle protein synthesis rates 
when compared to a placebo. As physical activity can increase the anabolic response to protein 
intake, we subsequently investigated the surplus effect of physical activity performed in the 
evening to increase overnight muscle protein synthesis rates following pre-sleep protein 
ingestion in chapter 8. Performing physical activity prior to the 40 g pre-sleep protein 
ingestion increased overnight muscle protein synthesis rates to a greater extent. Therefore, we 
suggest that (both daytime and pre-sleep) nutritional strategies in older individuals should be 
combined with a certain amount of physical activity to further increase the muscle protein 
synthetic response to protein intake.  
Finally, chapter 9 discusses different nutritional and physical activity intervention strategies to 
attenuate muscle mass and strength loss in older and clinically compromised populations. The 
pre-hospitalization period provides a window of opportunity to improve both nutritional as 
well as physical activity status and, as such, may improve clinical outcome during and following 
hospitalization. Intervention studies should focus on the combination of pre-habilitation 
training combined with nutritional support to augment muscle mass and strength prior to 
hospitalization. Since malnutrition during hospitalization is still present in >40% of the 
patients, dietary strategies need to be developed to improve nutritional status and, thereby, 
attenuate muscle loss during subsequent hospitalization. The provision of high-protein ONS 
may compensate for the energy and protein intake deficit during the acute surgery period, 
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whilst the provision of more protein-dense meals including pre-sleep protein ingestion may 
represent feasible nutritional strategies on the subsequent days of hospitalization. In order to 
obtain clinical evidence for the efficacy of such nutritional interventions, research studies need 
to assess more clinical and physiologically relevant outcome measurements. In the post-
hospitalization period, more evidence-based research is needed to confirm the overall benefits 
of (combined) nutritional and exercise interventions on the maintenance of muscle mass and 
function, overall quality of life in older patients, as well as the implementation of rehabilitation 
strategies in integrated health care.  
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SAMEN VATT ING  
Eén van de grootste uitdagingen in de huidige gezondheidszorg is de afname van spiermassa 
en de afname van fysiek functioneren die gepaard gaat met veroudering, ook wel sarcopenie 
genoemd. Een verlaagde spiermassa op oudere leeftijd vermindert het vermogen om 
dagelijkse activiteiten uit te kunnen voeren, verhoogt het risico op hospitalisatie en leidt 
bovendien tot een verlengde opnameduur, slechtere prognose, en verhoogde mortaliteit bij 
ziekenhuisopname. Spierbehoud wordt grotendeels gereguleerd door anabole stimuli zoals 
inname van eiwit via de voeding en fysieke inspanning. De respons op deze stimuli is echter 
verlaagd op oudere leeftijd (ook wel anabole resistentie genoemd), wat wordt gezien als één 
van de belangrijkste factoren die bijdragen aan het spiermassaverlies met veroudering. Naast 
de algemene afname van fysieke activiteit en voedingsinname met veroudering, krijgen veel 
ouderen te maken met acute klinische situaties waarbij verregaande inactiviteit en 
ondervoeding waarschijnlijk leiden tot een versneld verlies van spiermassa en -functie, 
bijvoorbeeld tijdens ziekenhuisopname. Recente inzichten suggereren dat dergelijke acute 
afnames in spiermassa in sterke mate bij kunnen dragen aan het ontstaan van sarcopenie. 
Interventiestrategieën om spiermassa te behouden zijn van groot belang om het verlies van 
spiermassa bij veroudering en gedurende acute en chronische ziekte te beperken. In dit 
proefschrift worden verschillende factoren beschreven die een rol spelen in de regulatie van 
spiermassa bij ouderen. Daarbij wordt specifieke aandacht besteed aan eiwitrijke voeding en 
verschillende klinische populaties. 
Opeenvolgende periodes van ziekenhuisopname als gevolg van een ziekte, blessure, of 
(geplande) operatie dragen bij aan het leeftijdgerelateerde verlies van spiermassa en 
spierkracht. In hoofdstuk 2 werd het effect van een korte periode van ziekenhuisopname op 
het verlies van spiermassa onderzocht, door veranderingen in spiermassa te meten tijdens 
ziekenhuisopname bij 26 oudere patiënten die een nieuwe heup kregen. Een periode van 
ongeveer 6 dagen ziekenhuisopname resulteerde in een 3-4% verlies van spiermassa bij 
oudere patiënten. Aangezien dit meer is dan de hoeveelheid spiermassa die verloren gaat 
tijdens een periode van fysieke inactiviteit zoals tijdens bedrust of immobilisatie bij gezonde 
mensen, impliceert dit, dat het effect van de operatie, de daaraan gerelateerde fysieke en 
mentale stress en een verminderde voedingsinname gedurende ziekenhuisopname 
waarschijnlijk bijdragen aan het versnelde verlies van spiermassa en -functie in de klinische 
praktijk. In hoofdstuk 3 is de dagelijkse voedingsinname van 101 oudere patiënten tijdens 
ziekenhuisopname voor een geplande knie- of heupoperatie gemeten, en daarbij werd met 
name gekeken naar het verschil tussen de hoeveelheid eiwit die werd aangeboden en datgene 
dat daadwerkelijk geconsumeerd werd. Eiwitconsumptie gedurende 6 dagen 
ziekenhuisopname was gemiddeld slechts 0.6 gram eiwit per kilogram lichaamsgewicht per 
dag, wat beduidend lager was dan de dagelijks aanbevolen hoeveelheid eiwit (0.8 gram per 
kilogram lichaamsgewicht per dag). In totaal werd 35-40% van de aangeboden voeding niet 
geconsumeerd, wat resulteerde in een extreem lage inname van energie en eiwit tijdens 
 
 
ziekenhuisopname. Specifieke voedingsstrategieën zoals het verrijken van de voeding, het 
gebruik van eiwitrijke voedingssupplementen en/of het aanpassen van het tijdstip van inname 
van eiwitrijke maaltijden en snacks zijn waarschijnlijk de meest geschikte strategieën om 
eiwitinname in patiënten tijdens ziekenhuisopname op peil te brengen.  
Ouderen met chronische metabole aandoeningen zoals type 2 diabetes, cardiovasculaire 
ziekten en obesitas verliezen over het algemeen meer spiermassa tijdens veroudering. Daarom 
zijn in hoofdstuk 4 en 5 de hypotheses getest dat oudere patiënten met type 2 diabetes en 
personen met obesitas een verstoord spiereiwitmetabolisme hebben ten opzichte van 
gezonde personen. Door gebruik te maken van stabiele isotopen tracer methodologie kan 
spiereiwitsynthese (de snelheid van aanmaak van spiereiwitten) gemeten worden en de 
mogelijke verschillen tussen groepen worden aangetoond; zowel basaal (nuchter) als na 
inname van voedingseiwit. Zowel de basale spiereiwitsynthese als de spiereiwitsynthese na de 
inname van 20 gram eiwit waren niet verschillend tussen oudere patiënten met type 2 diabetes 
en gezonde ouderen (hoofdstuk 4). Het versnelde spiermassaverlies in ouderen met type 2 
diabetes lijkt dus niet te kunnen worden verklaard door een verstoorde basale spieropbouw 
of een verminderde respons op eiwitinname (zogenaamde ‘anabole resistentie’). In hoofdstuk 
5 is de spieropbouw vergeleken voor en na de inname van 25 g eiwit tussen mannen van 
middelbare leeftijd met obesitas en mannen met een gezond gewicht. In tegenstelling tot de 
hypothese, werd ook in deze studie geen verminderde spiereiwitsynthese gemeten in obese 
proefpersonen in vergelijking met de mannen met een gezond gewicht. Hierdoor wordt 
verondersteld dat de relatief hoge mate van dagelijkse fysieke activiteit in de geïncludeerde 
obese proefpersonen beschermt tegen eventuele verstoringen in de basale en/of 
postprandiale spieropbouw. 
In hoofdstuk 6-8 worden vervolgens verschillende voedingsstrategieën bestudeerd die de 
spiereiwitsynthese stimuleren en daardoor zouden kunnen bijdragen aan het behoud van 
spiermassa bij ouderen en klinische populaties. Nitraat heeft recentelijk veel aandacht 
gekregen als voedingscomponent aangezien het bijdraagt aan vaatverwijding en zodoende 
wellicht de doorbloeding van spierweefsel kan verbeteren. Daarom werd in hoofdstuk 6 het 
effect van de inname van nitraat in combinatie met een eiwitrijke drank op spiereiwitsynthese 
in ouderen met type 2 diabetes onderzocht. De gecombineerde inname van nitraat met 20 g 
eiwit leidde echter niet tot een hogere spiereiwitsynthese in ouderen met type 2 diabetes. Als 
alternatieve strategie om spiereiwitsynthese te stimuleren, in dit geval specifiek tijdens de 
nacht, is vervolgens gekeken naar de toevoeging van een extra eiwitrijke maaltijd voor het 
slapen. In hoofdstuk 7 is het effect van inname van verschillende hoeveelheden eiwit voor het 
slapen gaan in gezonde oudere mannen onderzocht. De inname van een eiwitrijke drank voor 
het slapen gaan zorgde ervoor dat aminozuren uit de drank beschikbaar kwamen in de 
circulatie gedurende de nacht en ook daadwerkelijk fungeerden als bouwstenen voor 
spiereiwitsynthese. Echter, de inname van 40 g eiwit voor het slapen gaan verhoogde de 
spiereiwitsynthese alleen significant ten opzichte van de placebo drank (zonder eiwit). 
Daarnaast is bekend dat fysieke inspanning in combinatie met voedingsinname leidt tot een 
verhoogde anabole respons op voeding. Daarom werd in hoofdstuk 8 het effect van fysieke 
   
   
  C
HA
PT
ER
 T
EN
 
251
                                                             Samenvatting
 
 
SAMEN VATT ING  
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alternatieve strategie om spiereiwitsynthese te stimuleren, in dit geval specifiek tijdens de 
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het slapen gaan zorgde ervoor dat aminozuren uit de drank beschikbaar kwamen in de 
circulatie gedurende de nacht en ook daadwerkelijk fungeerden als bouwstenen voor 
spiereiwitsynthese. Echter, de inname van 40 g eiwit voor het slapen gaan verhoogde de 
spiereiwitsynthese alleen significant ten opzichte van de placebo drank (zonder eiwit). 
Daarnaast is bekend dat fysieke inspanning in combinatie met voedingsinname leidt tot een 
verhoogde anabole respons op voeding. Daarom werd in hoofdstuk 8 het effect van fysieke 
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inspanning voorafgaand aan de inname van 40 g eiwit voor het slapen gaan onderzocht bij 24 
oudere mannen. Fysieke inspanning voorafgaand aan de inname van eiwit voor het slapen 
resulteerde in een hogere spiereiwitsynthese tijdens de nacht in vergelijking met eiwitinname 
alleen. Hieruit wordt geconcludeerd dat voedingsinterventies (in het algemeen als ook voor 
het slapen gaan) gecombineerd zouden moeten worden met fysieke inspanning om zo de 
impact op de spiereiwitsynthese verder te verhogen.  
Dit proefschrift sluit af met een discussie van de onderzoeksresultaten (hoofdstuk 9) en de 
implicaties van verschillende interventiestrategieën op het verlies van spiermassa en 
spierkracht tijdens veroudering en bij klinische populaties. De periode voorafgaande aan 
ziekenhuisopname is een uitermate geschikte periode om zowel de voedingsstatus als fysieke 
status van de patiënt te optimaliseren en zo de klinische uitkomst tijdens en na hospitalisatie 
te verbeteren. Interventiestudies zullen zich allereerst moeten richten op de combinatie van 
pre-habilitatie training in combinatie met optimale voeding om spiermassa en spierkracht te 
verbeteren voorafgaand aan een ziekenhuisopname. Aangezien 40% van de patiënten in het 
ziekenhuis ondervoed zijn, dienen er daarnaast voedingsstrategieën ontwikkeld te worden om 
de voedingsstatus te verbeteren tijdens hospitalisatie, met als doel het spiermassaverlies te 
beperken. Veelbelovende strategieën hiervoor zijn het verstrekken van eiwitrijke 
supplementen op de dagen rondom een operatie of acute opname om het tekort aan energie 
en eiwit aan te vullen. Bovendien zal het aanbieden van eiwitrijke maaltijden in combinatie 
met een eiwitrijke snack voor het slapen gaan geschikt zijn om de voedingsinname te 
verhogen. Om bewijs voor de effectiviteit van bovengenoemde voedingsstrategieën te kunnen 
leveren, zullen interventiestudies zich moeten richten op klinisch en fysiologisch relevante 
uitkomstmaten. Tot slot is er ook in de periode na hospitalisatie meer bewijs nodig van de 
voordelen van gecombineerde voedings- en bewegingsinterventies op het behoud van 
spiermassa en functie, kwaliteit van leven, evenals de mogelijke implementatie van deze 
herstelstrategieën in de ketenzorg. Desalniettemin is de huidige kennis voldoende om 
vandaag al te starten met een verandering in de gezondheidszorg en de richting op te gaan 
naar een meer proactieve benadering in de begeleiding van oudere patiënten voor, tijdens en 
na hospitalisatie. 
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ziekenhuisopname is een uitermate geschikte periode om zowel de voedingsstatus als fysieke 
status van de patiënt te optimaliseren en zo de klinische uitkomst tijdens en na hospitalisatie 
te verbeteren. Interventiestudies zullen zich allereerst moeten richten op de combinatie van 
pre-habilitatie training in combinatie met optimale voeding om spiermassa en spierkracht te 
verbeteren voorafgaand aan een ziekenhuisopname. Aangezien 40% van de patiënten in het 
ziekenhuis ondervoed zijn, dienen er daarnaast voedingsstrategieën ontwikkeld te worden om 
de voedingsstatus te verbeteren tijdens hospitalisatie, met als doel het spiermassaverlies te 
beperken. Veelbelovende strategieën hiervoor zijn het verstrekken van eiwitrijke 
supplementen op de dagen rondom een operatie of acute opname om het tekort aan energie 
en eiwit aan te vullen. Bovendien zal het aanbieden van eiwitrijke maaltijden in combinatie 
met een eiwitrijke snack voor het slapen gaan geschikt zijn om de voedingsinname te 
verhogen. Om bewijs voor de effectiviteit van bovengenoemde voedingsstrategieën te kunnen 
leveren, zullen interventiestudies zich moeten richten op klinisch en fysiologisch relevante 
uitkomstmaten. Tot slot is er ook in de periode na hospitalisatie meer bewijs nodig van de 
voordelen van gecombineerde voedings- en bewegingsinterventies op het behoud van 
spiermassa en functie, kwaliteit van leven, evenals de mogelijke implementatie van deze 
herstelstrategieën in de ketenzorg. Desalniettemin is de huidige kennis voldoende om 
vandaag al te starten met een verandering in de gezondheidszorg en de richting op te gaan 
naar een meer proactieve benadering in de begeleiding van oudere patiënten voor, tijdens en 
na hospitalisatie. 
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Nutritional intervention strategies should be combined with more 
physical activity before, during, and after hospitalization.
Early pre-habilitation interventions that include exercise 
training and protein supplementation should be implemented to 
improve clinical outcomes during hospitalization in older patients.
Since 40% of the provided hospital meals is not consumed, more 
protein-rich foods and attractive meal service concepts need to 
be provided to the patient to increase protein intake. 
To reach protein intake recommendation levels of 1.2 g·kg ·d for 
older patients, a more protein-dense diet will be required.
More specific nutritional interventions throughout 
hospitalization are needed; nutritional supplementation can cover 
energy and protein deficits in the acute (operative) period while 
the subsequent days will require the focus on the increase in 
protein intake mainly through the diet. 
Pre-sleep protein ingestion can be a useful strategy to provide 
extra protein on the evening prior to surgery and during evening 
rounds on the ward.
An attractive environment using walking routes and gardens could 
be offered in hospitals to encourage patients to be more 
physically active during hospitalization. 
  
Hospital meals need to be attractive, adequately nutritious, and 
patient-specific.
Rehabilitation strategies need to be continued on the long term 
and should combine a functional exercise training regimen with 
proper nutritional support.
A multimodal approach will maximize the intrinsic motivation of 
the patient.
1
2
3
4
5
6
7
8
9
10
-1 -1
